<SEC-DOCUMENT>0001655759-23-000041.txt : 20230505
<SEC-HEADER>0001655759-23-000041.hdr.sgml : 20230505
<ACCEPTANCE-DATETIME>20230505085824
ACCESSION NUMBER:		0001655759-23-000041
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		73
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230505
DATE AS OF CHANGE:		20230505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38672
		FILM NUMBER:		23891483

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arvn-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:1f1eeee1-4d1b-4eb9-97f6-83d0702c4de4,g:c3df6ade-21e6-4d49-a1b5-7881af27fa72,d:884cf85f07be4320b5e4857b1da120ed--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:arvn="http://www.arvinas.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arvn-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl8yLTEtMS0xLTY1NDMx_60e4998f-e462-4c41-ac85-f89fd94ef68a">false</ix:nonNumeric><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl8zLTEtMS0xLTY1NDMx_c7a1690b-f606-4131-a00a-a2d563c76681">2023</ix:nonNumeric><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl80LTEtMS0xLTY1NDMx_8bb1d878-9b79-40f9-b5d5-a08f9abf0dee">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl81LTEtMS0xLTY1NDMx_ed9240ac-1f8b-4645-aca0-11c8b0b5a7e5">0001655759</ix:nonNumeric><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl82LTEtMS0xLTY1NDMx_f4313031-1aba-4bf5-8a1c-3cb01834f515">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i6a57f027039d402e89fbc95c1127d3cb_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfMS0xLTEtMS02NTQzMQ_c8ba6401-3d4d-4221-bc59-fa120b3f7830">9</ix:nonNumeric><ix:nonNumeric contextRef="i7e5587709ab9441eb95639b688acbf26_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfMi0xLTEtMS02NTQzMQ_177be2ae-3cb5-4253-bf61-8b7b4e61e305">1</ix:nonNumeric><ix:nonNumeric contextRef="i333fef30c76849dabbf515e19bb3c4dd_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfMy0xLTEtMS02NTQzMQ_2135248f-5fd0-4f2b-a8f4-94e1bde31a5d">1</ix:nonNumeric><ix:nonNumeric contextRef="i64e73ce4a2fb4d8ea4d59c53e7967503_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfNC0xLTEtMS02NTQzMQ_d2635b3d-11f0-4a9d-bc8a-e30fe4d6f99f">1</ix:nonNumeric><ix:nonNumeric contextRef="i5ba9fc908d7b41deaf9a3fd3e31184cb_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfNS0xLTEtMS02NTQzMQ_04cf2725-d0b0-433f-92e7-4e9a065eaa90">1</ix:nonNumeric><ix:nonNumeric contextRef="i6a68588de37d4285a34afb43c82aef31_I20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfNi0xLTEtMS02NTQzMQ_d1a881c5-7b37-4689-af3c-3e0a861fadb9">1</ix:nonNumeric><ix:nonNumeric contextRef="ic6a4b3cb93314f7080a27916d29a1b7c_I20230331" xsi:nil="true" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfNy0xLTEtMS02NTQzMQ_57d237f5-1a2e-43ee-90cd-206505a7ef5d"></ix:nonNumeric><ix:nonNumeric contextRef="i40cf39bc022f4665873ab50b0f55d26f_D20180301-20180331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTczMw_e1a2df49-e8a5-4fa7-9eb4-8efbc048bb75">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arvn-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2e98f70424438bb4719063e8b7d933_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia9c824c6990342a0943fa8aa395e6afd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59fa16591da24cb9adc1d260cd702bec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief60b65dbbed473d990406fe18f4b016_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423be60354244b2b97bcb6297024fc30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i563f01175e814770b8ddb607671d6584_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica93aa257210457588a3dab513ca1281_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b2b0d2b07c477095aa99f00b3e6c9e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41eb626a0ca84eb981b494af99468c57_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91476a3a87b74bfb9daea385c949ed11_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac513c7ce70543009a9875454577f845_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if47c42e24d824e89abf05132bc64e379_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ae605f935c04bc2af190e140938586b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i903857c45a8b454f9d0bd288463f9c45_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6273a26513740c895cd8fe246ea1135_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i228a677a2c5646269e41ad33bcbd8f12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i705af897c9a04f31ab086c30d2b350b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6df2f2c7c5f476fba8a03b362862a96_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90d558a1de93477b87122ce5cd92cc9f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i472c99b27af24b9b91e801b0d2386fd1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebe10aedc0da40bca216552454ea7f4a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd52ecfa49241f8aa987e6cc3468342_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbcae8733b64e3c9cf754f838374162_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6353ac0a26204afa914428ef8c857213_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20e86e77f8c48b79f279e320e800292_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa1890c1439a43ad896af5dfd768c60b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c84844e17f4bfd94a9daafad1c7718_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42ba466978ac4cc992589866c331756a_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16fd9a5fa79d4e9eaa80190af360005c_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryAndSalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief3a7076223347cfbc4892d71334d77b_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3786932f15544cce9cf0079227cdc57b_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcccbc739c0445b2b27349bd42442433_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2695362632e4befb50d084f5a874ac1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ba7e9e46b0c438a8a2acede1d5ac4a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic50dd3e602a14d7c9a8c73c1b9f0f130_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5482ad9db1e14d4db0c6cbc2489c89aa_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf97ed42f0f34c4a8af32817ae8aca05_I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64eaa7a6fadd4ef88cc9a1286c396bbc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1c7c35f0f643bbb3ac71053516932f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25e5433c3b74da39b3c37e3b0ee0ce2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5fab18a22d24d848daaf8e985758c58_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if970016974254601910f92dc80515772_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id250d3ecdba042e2af065ac3f57d8f6b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b3dfdf46ccd4f02aeacc06bab7ab70d_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i934d8ddc1394497d98263e0baef3dfd8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0fa77171342487db29bfb9fd0cd234c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06109f1daf3f44819497e002b80fa05c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2e16ac4423a4e249adbc8e38cfdd227_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i825cb221649b48da99a61c73b128281b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdfdecb591af4d2d9d467b467c44e0d9_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e2b79e3ac2541ffa660c65a665640e6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15ccbabc704747d3912f2887cdca2f5e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ca6fcbbbc8d453cb429124dadde0a44_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378f9a67bc7a479fad0da9c643e33fd7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a57f027039d402e89fbc95c1127d3cb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e5587709ab9441eb95639b688acbf26_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333fef30c76849dabbf515e19bb3c4dd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64e73ce4a2fb4d8ea4d59c53e7967503_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ba9fc908d7b41deaf9a3fd3e31184cb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a68588de37d4285a34afb43c82aef31_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6a4b3cb93314f7080a27916d29a1b7c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2029-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2c16269e704252a73fa8151a039fbe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9a393896693451891e7d053aeeb18be_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e55fd027b044723af517c59364224f0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e3228d892b4e7db62595d4014c6676_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4888c9b0c614731bbdccc05e61bd058_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1de7a0ae0b92460dad81ea74516f18bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b0f02819274e57b2bf846e659c640e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75559e9dfb844d268302204b2976b7f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2563537aad4601938c78056cfd46bb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i870416186c7946d69aba9f21340eedf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c0acd6e5355425eb14e8f4f51b13bc2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43c92c58dac14ec68b6636151c731626_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32031c903a404074b539bf9f44fb8502_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79f9dcb9a8e74e788892552ed47ce8d1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57728ffde72e4b07b7b3bc9db63630f8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i90241bd38fea438fb4cc4148142c1b17_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3420f377cc5416b93dcea5b7709551a_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ic584b3416c774aeca2c48f904781e806_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4cff069a1143b88d3a8e8910d7959f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a4ae741e33e4f4fa646fc2cce479c2d_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c9b7a41f6414722ac66b829dfd54b50_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6dcdbc12c344074b65cede1612dc7bc_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e5965f2e88e4a6da0dccbe7de98fca3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4017a9b524ac448cb97651cbacb79c29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ef3273b7a642339a52f317c1217bf0_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9efa444c10024282a78558891448955e_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aed769f8e3c49e5b63cbed7fce3cc16_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50005b9bf68d4708a6d599e4e722b8e3_I20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4511588e1c85470592130c5c36ee5bfb_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bf0fb8e4f384b26bc23d6ceb6be7d53_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b0bcf64028344e6af483706f401290e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib28dd8ea2b9a41c2971d1c69a31155e1_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a71274815094838ab3c597fb2f26a9a_D20200101-20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9aec8988f694ff0bdcb13df74a26b2b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id759bd76e92c4ede87b28afc4a41b568_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92f1e3b8a73c406baaa7a7de9b0f3308_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc4b7a143d749d3b66e3a8d62fc9739_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40cf39bc022f4665873ab50b0f55d26f_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bbe490912764883b0d0a04c6f91955c_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id11bdfbfc5664070828281a7fc7b86c7_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd1b3df3c405457383f5264958d864d2_I20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f5df6145fa4e158ed350838e5a7e21_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1a047b63716450a86e6886de00be9f1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10eede6b30cc414dbf22a74b29deb8c6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ca05a3c3aa44683a1997583823075d6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10a2301e42b4cbb841833dc0c008446_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabfae107724143078681007be335943e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf44409a8a841bf993b6c95041b34d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied3d963eb80c4cf0821da8185cb0c1b4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc82bdb7f3249e3a8fa6593ba2f1e2f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i349c99c38fd24411a3098e192d5bb289_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c09bc9792f4d4d82779a6ecdfd5cd4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia907332b480c40519a54ef9abc49ebf1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id992f35185d74bae9954007b9459fa21_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c0d5650542472988dfa8a33538b992_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3f89b30e484ddb9d12fd481d56197e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15fe088644044a698fa4be67f06f4289_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b701e816ca846fca1f71db5b8b65b28_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id05b975a531b4a769c53cd848058ea5a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8313eb035f2049c096523de984254655_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4397b2ab6c394deebbeeccdb3d6ef0f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i398833cc0cbe482ca635f3baea15a579_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib19aa9edf1fe4cdebd33b4a75c81c3a7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0298f75c6f440a58c57320fb61d4a0a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2256dbf3cc9e4c8aab20a9ac4ed1d1c6_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11a56379c5434b73ac2a8a2184bf2b26_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice51fdd252534ce4910cdfd6c31f0453_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79495c5a256b4d7db64470507e85fdaf_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec101bcd50d841439204bb45185f462f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia79bc328db4a4707a837e784c470a1b4_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97cfc9c7c575435c98bd43efeb5fb152_I20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7e68f89e4c4b938c8c387fb7a06158_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib401d1efe8db4e449e1330c66a20922b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9edfe32c55049d6b67f5d1ff33010d6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dcee608cf2542be9ac23c358b3e4eae_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b1538561114837a04b610d8fb7d5df_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c7ac62b86294b8d8b81d6270bdf4b43_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b3f861bb3b64d2eb62b4fffd96d22d2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e8d060431b44969048abce12f5e513_D20220604-20220604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:FoundationMedicineIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-04</xbrli:startDate><xbrli:endDate>2022-06-04</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i884cf85f07be4320b5e4857b1da120ed_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQx_779506a3-fdb7-483f-8526-b1b42ba0dee4">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6NzA2OTRkN2ZlMjhkNGU2M2I5OGQ3NTdkMzc1NzkyNDkvdGFibGVyYW5nZTo3MDY5NGQ3ZmUyOGQ0ZTYzYjk4ZDc1N2QzNzU3OTI0OV8wLTAtMS0xLTY1NDMx_969ad9dd-a4c3-457d-b9b3-43f8dbed849c">&#253;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 25.5pt;text-align:left;text-indent:-24.5pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMjE_5bc0536c-06fc-4387-be78-c1525d02e89e">March 31, 2023</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6YmVkZjg0NWUxYjIyNDQ5OWIwNTEzOTI5MzkyY2Y5MTQvdGFibGVyYW5nZTpiZWRmODQ1ZTFiMjI0NDk5YjA1MTM5MjkzOTJjZjkxNF8wLTAtMS0xLTY1NDMx_b1f20ce7-cc3e-4798-a904-45e8169957d0">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQ2_6d3a1054-681c-4a5d-9aa1-3bf54b9e114d">001-38672</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQ3_1c45f7ad-61ff-413f-ba34-9b2b4ff85a5c">ARVINAS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its Charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8wLTAtMS0xLTY1NDMx_97ec3c7f-9a78-47a5-836d-3ac997123a09">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8wLTEtMS0xLTY1NDMx_1656beb5-ebab-41cf-9f5a-c4ae1fed8b46">47-2566120</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">incorporation or organization</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTAtMS0xLTY1NDMxL3RleHRyZWdpb246ODRkOGY4M2YyNTNkNDU5MGFmMDY4ZGM2M2E1YmJkMzhfNQ_1c30830a-0f88-4ce1-994c-cc16c612137c">5 Science Park</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTAtMS0xLTY1NDMxL3RleHRyZWdpb246ODRkOGY4M2YyNTNkNDU5MGFmMDY4ZGM2M2E1YmJkMzhfOQ_f9fea624-9d1c-4d62-97d6-3b6aa87395f9">395 Winchester Ave</ix:nonNumeric>. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTAtMS0xLTY1NDMxL3RleHRyZWdpb246ODRkOGY4M2YyNTNkNDU5MGFmMDY4ZGM2M2E1YmJkMzhfMTQ_fff16694-f2b9-4a57-9aea-75250e162c71">New Haven</ix:nonNumeric>, <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTAtMS0xLTY1NDMxL3RleHRyZWdpb246ODRkOGY4M2YyNTNkNDU5MGFmMDY4ZGM2M2E1YmJkMzhfMTg_3a6ac6fe-dfd0-40d5-9174-ba0f6929d143">Connecticut</ix:nonNumeric> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTEtMS0xLTY1NDMx_fccfb1d1-4377-4d09-9a25-026551df5111">06511</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQy_b5c5957c-68c5-4c5d-b534-bdab841fcc3a">203</ix:nonNumeric>) <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQz_28581221-345d-4e09-9811-d0a976165354">535-1456</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:39.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.896%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.265%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6YTg0ZWQwMTU3ZWQ3NGYzNWI1NmQ2YzI4ZWIwMjJhZTcvdGFibGVyYW5nZTphODRlZDAxNTdlZDc0ZjM1YjU2ZDZjMjhlYjAyMmFlN18xLTAtMS0xLTY1NDMx_f2294647-741c-4f2a-b806-cb9a1a77e003">Common stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6YTg0ZWQwMTU3ZWQ3NGYzNWI1NmQ2YzI4ZWIwMjJhZTcvdGFibGVyYW5nZTphODRlZDAxNTdlZDc0ZjM1YjU2ZDZjMjhlYjAyMmFlN18xLTItMS0xLTY1NDMx_83a3dd50-588c-40f7-bdb2-b8470f743fb2">ARVN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6YTg0ZWQwMTU3ZWQ3NGYzNWI1NmQ2YzI4ZWIwMjJhZTcvdGFibGVyYW5nZTphODRlZDAxNTdlZDc0ZjM1YjU2ZDZjMjhlYjAyMmFlN18xLTQtMS0xLTY1NDMx_08cf07b5-567d-4f23-96f9-29368174409c"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The Nasdaq </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Market LLC</span></ix:nonNumeric></div></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTM4_b84ed4de-c45d-45d5-a688-404d1f7cc84b">Yes</ix:nonNumeric> </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQ0_8a1e6d0f-f803-4af4-9ee1-f419b9a69fd4">Yes</ix:nonNumeric> </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6MzhkMWIyMDRhNzQ5NDg3N2I4OTc4ZDIxNGE1MjU4ZGQvdGFibGVyYW5nZTozOGQxYjIwNGE3NDk0ODc3Yjg5NzhkMjE0YTUyNThkZF8wLTAtMS0xLTY1NDMx_95279753-21ca-4593-ae50-e62dd0f9619f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#253;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6MzhkMWIyMDRhNzQ5NDg3N2I4OTc4ZDIxNGE1MjU4ZGQvdGFibGVyYW5nZTozOGQxYjIwNGE3NDk0ODc3Yjg5NzhkMjE0YTUyNThkZF8xLTMtMS0xLTY1NDMx_8c8a2320-d51c-40c2-889b-ef56222ece4e">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6MzhkMWIyMDRhNzQ5NDg3N2I4OTc4ZDIxNGE1MjU4ZGQvdGFibGVyYW5nZTozOGQxYjIwNGE3NDk0ODc3Yjg5NzhkMjE0YTUyNThkZF8yLTMtMS0xLTY1NDMx_15abbb80-18ee-408b-90c7-a4aa3b4d309c">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQw_a0ad9bc6-8280-417f-a15d-ba447ea36740">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> No </span><span style="background-color:#ffffff;color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of April&#160;28, 2023, the registrant had <ix:nonFraction unitRef="shares" contextRef="i1a2e98f70424438bb4719063e8b7d933_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMDcw_673775b5-06e0-4fa6-b247-30a48bec24e3">53,398,353</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</span></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:12pt;text-align:center"><span><br/></span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_13">PART I.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_13">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_16">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_16">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_19">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_19">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_22">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.15pt;text-indent:-0.15pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_28">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_28">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_31">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_31">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_34">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_88">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_88">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_88">19</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_106">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_106">31</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_109">Item 4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_109">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_109">31</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_112">PART II.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_112">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_112">33</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_115">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_115">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_115">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_118">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_118">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_118">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_121">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_121">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_121">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_124">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_124">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_124">34</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_127">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i884cf85f07be4320b5e4857b1da120ed_127">35</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;goals,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the initiation, timing, progress and results of our current and future clinical trials of vepdegestrant (ARV-471), bavdegalutamide (ARV-110) and ARV-766, including statements regarding the period during which the results of the clinical trials will become available;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the timing of, and our ability to obtain, marketing approval of vepdegestrant (ARV-471), bavdegalutamide (ARV-110) and ARV-766, and the ability of vepdegestrant (ARV-471), bavdegalutamide (ARV-110), ARV-766 and our other product candidates to meet existing or future regulatory standards;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the potential achievement of milestones and receipt of payments under our collaborations, including our collaboration with Pfizer Inc., or Pfizer, entered into in July 2021, or the ARV-471 Collaboration;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our plans to pursue research and development of other product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">our plans to submit Investigational New Drug Applications and/or Clinical Trial Applications;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the potential advantages of our platform technology and our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the extent to which our scientific approach and platform technology may potentially address a broad range of diseases and disease targets;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the potential receipt of revenue from future sales of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our estimates regarding the potential market opportunity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our sales, marketing and distribution capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our ability to establish and maintain arrangements for manufacture of our product candidates;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our ability to enter into additional collaborations with third parties;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our intellectual property position;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the impact of government laws and regulations; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our competitive position.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed on February 23, 2023, and this Quarterly Report on Form 10-Q, particularly in the &#8220;Risk Factors&#8221; sections, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may differ materially from what we expect. We do not assume any obligation to update any forward-looking statements except as required by applicable law.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Quarterly Report on Form 10-Q, references to the &#8220;Company,&#8221; &#8220;Arvinas,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to Arvinas, Inc. and its consolidated subsidiaries, except where the context requires otherwise, or any one or more of them as the context may require, and &#8220;our board of directors&#8221; refers to the board of directors of Arvinas, Inc.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Arvinas name and logo are our trademarks. We also own the service mark and the registered U.S. trademark for PROTAC&#174;. This Quarterly Report on Form 10-Q contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q, including logos, artwork and other visual displays, may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">iii</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_16"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_19"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMy0xLTEtMS02NTQzMQ_877283eb-4f51-4e24-833e-f83ec0a1012e">130.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMy0zLTEtMS02NTQzMQ_8dab89d4-b2b4-4aa3-aeda-6ef18855231b">81.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNC0xLTEtMS02NTQzMQ_d8656e32-08e1-4af9-b8b0-e78d9dc77d77">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNC0zLTEtMS02NTQzMQ_ef35e20e-936b-4152-a2db-0ab8c6d6b4ad">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNS0xLTEtMS02NTQzMQ_17820d3a-b2c0-4896-b7c7-fcae9d527e83">993.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNS0zLTEtMS02NTQzMQ_c0f3e895-052a-440b-8f75-28eccfe8c17a">1,124.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNi0xLTEtMS02NTQzMQ_f474be29-d16c-4359-a532-49a31bfcf0fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNi0zLTEtMS02NTQzMQ_f4a10be1-2d8e-4954-af4a-2274361f93ef">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNy0xLTEtMS02NTQzMQ_eadb57ef-f710-4075-920d-275e0f56ad4e">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNy0zLTEtMS02NTQzMQ_dcc45b3a-ede8-46e8-9227-9a8d836a9c80">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfOC0xLTEtMS02NTQzMQ_05209609-8015-4bda-bd6a-c6a35e637022">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfOC0zLTEtMS02NTQzMQ_cd5aebf2-d057-480a-bc95-a5b67662d6c5">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfOS0xLTEtMS02NTQzMQ_cf40d57b-ffd3-4475-b891-d219da1cc00b">1,148.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfOS0zLTEtMS02NTQzMQ_2bc41e2b-c927-4303-a55e-0293600e4177">1,240.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTAtMS0xLTEtNjU0MzE_48da5f7c-8986-470c-b791-50fe8754b2dc">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTAtMy0xLTEtNjU0MzE_6fdc6476-f20d-46b2-a0b7-5756b3cb1738">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTEtMS0xLTEtNjU0MzE_af6a33c8-0b18-44f0-b986-ab4a34358447">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTEtMy0xLTEtNjU0MzE_cd8a51fb-0711-4b51-88e9-29c421e765ea">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Collaboration contract asset and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTItMS0xLTEtNjU0MzE_68165a87-39d7-4424-93e6-2b9cc59369e9">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTItMy0xLTEtNjU0MzE_112757f3-65db-4a3d-91d8-904364c5db87">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total assets</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTMtMS0xLTEtNjU0MzE_d4047896-9ef6-4f3a-8b39-055fe8cc4c6f">1,175.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTMtMy0xLTEtNjU0MzE_8cf2b183-c458-4667-8e9f-e68424bf6673">1,268.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTYtMS0xLTEtNjU0MzE_00e095bc-04fc-4dc7-ad03-e170388f503e">66.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTYtMy0xLTEtNjU0MzE_01db2b8e-5fa3-4a1b-8695-5753522a0d79">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTctMS0xLTEtNjU0MzE_47788eb8-b735-41af-b87f-7f379cf2b5cc">214.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTctMy0xLTEtNjU0MzE_03097886-85fb-41fc-9574-580bf3b8f1b6">218.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current portion of long term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTgtMS0xLTEtNjk0ODI_4c0dba88-babf-4a0b-8cbc-8bcc6413aeee">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTgtMy0xLTEtNjk0ODI_80261507-78e4-4e9e-84a6-97555550c819">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTgtMS0xLTEtNjU0MzE_d9ec2cc3-9c5a-4d78-87d4-ae1e4999c741">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTgtMy0xLTEtNjU0MzE_410f4b1f-cadd-49dd-810f-739baee9a2a1">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTktMS0xLTEtNjU0MzE_e27c6496-0297-4525-b5ae-f3f575f0baa7">282.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTktMy0xLTEtNjU0MzE_3c85b895-6103-4ee8-8045-19a0eb362f8a">295.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjAtMS0xLTEtNjU0MzE_c8d19186-fb37-42fe-a6d6-3b53e94d6adf">378.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjAtMy0xLTEtNjU0MzE_9e00ae31-1f5f-4a61-8ff8-75be0b42383b">405.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjEtMS0xLTEtNjU0MzE_121cab09-d15e-40d2-a7dc-58cc0639a282">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjEtMy0xLTEtNjU0MzE_a9cfcabf-e3c4-4cf5-a610-5ebd14dac48c">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjItMS0xLTEtNjU0MzE_ccbfbfd2-8f5d-4788-9716-7f2f6b8bc5cd">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjItMy0xLTEtNjU0MzE_95a7cea1-65bb-4ccf-82bf-3172da7f73a1">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjMtMS0xLTEtNjU0MzE_773e8984-dc90-480e-bd07-4234bfbbdefe">664.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjMtMy0xLTEtNjU0MzE_b8f16428-f2e1-4c54-8bf1-970470b210ae">703.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and Contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjQtMS0xLTEtNjU0MzE_924f6b2a-eb71-4c8b-a573-729b047d154c"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjQtMy0xLTEtNjU0MzE_4fc8a865-9060-4d5c-a36d-812a3a4ceab9"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl8xOQ_2150cc16-7cc4-4670-bf69-247e8bb4442b"><ix:nonFraction unitRef="usdPerShare" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl8xOQ_5dcdf6ac-d478-4be6-b0b5-61369083e5e4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl8zMw_541d17f8-7698-4081-9fc6-3cb05b4d9f1e"><ix:nonFraction unitRef="shares" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl8zMw_7edfd7fd-0410-4d6b-9391-14bf3178b3f4">53.4</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl80MA_38921954-8f07-47f8-afcb-3cef7b245e46"><ix:nonFraction unitRef="shares" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl80MA_bf240e75-5a9d-443e-a456-65f1dcbd77c8">53.2</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMS0xLTEtNjU0MzE_68a23f39-65a7-459c-bdd3-99efadc50781">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMy0xLTEtNjU0MzE_1a56f271-89e7-47a1-9d6e-448912b06749">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjctMS0xLTEtNjU0MzE_dce59a62-3e30-45e3-8a32-f7eb3a854c36">1,047.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjctMy0xLTEtNjU0MzE_245dc333-e55f-4390-9190-adcd4cd84029">965.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjgtMS0xLTEtNjU0MzE_6a5b13e7-668d-408d-acf1-0be332f7080c">1,570.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjgtMy0xLTEtNjU0MzE_14197110-d083-4cfe-a549-eda46975b67c">1,549.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjktMS0xLTEtNjU0MzE_a83bf1c4-8866-4d44-83f2-6ecbf8224c24">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjktMy0xLTEtNjU0MzE_84355694-0d1b-4f04-b521-7f117caef06c">19.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMzAtMS0xLTEtNjU0MzE_d1ea0594-5f8a-46e1-b0b1-45102bc73bb4">511.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMzAtMy0xLTEtNjU0MzE_2ee14d63-c92d-44a7-81c0-531538bfb024">564.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMzEtMS0xLTEtNjU0MzE_89423683-0c84-4d7f-9939-6511f53fe82a">1,175.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMzEtMy0xLTEtNjU0MzE_a1774470-29b1-4afe-913f-88f790b42ed4">1,268.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMi0xLTEtMS02NTQzMQ_c2ccbc8b-d328-4b33-8376-5a34efbbd298">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMi0zLTEtMS02NTQzMQ_d6a570ef-d7ea-429f-8657-c53ced19dc23">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNC0xLTEtMS02NTQzMQ_b53697e3-1b81-45bd-9fcd-5b69d08c58f7">95.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNC0zLTEtMS02NTQzMQ_d3d25cdd-cfff-4cc1-81b5-ba36a7b58d69">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNS0xLTEtMS02NTQzMQ_49f112d7-716e-4b97-8459-7d614cd97410">24.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNS0zLTEtMS02NTQzMQ_f5916834-497c-435d-9022-f9aaa57aa008">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNi0xLTEtMS02NTQzMQ_8f42c13c-d27a-4944-ab92-4d6bc25c1515">120.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNi0zLTEtMS02NTQzMQ_af4d6bb3-3bea-40e2-9da0-b55d9dc7deeb">84.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNy0xLTEtMS02NTQzMQ_420f9620-6357-4cb6-bc96-12d6593f7927">87.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNy0zLTEtMS02NTQzMQ_b41d2684-fa41-4a55-b5fe-ab2ca9a1a22d">57.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other income (expenses)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfOS0xLTEtMS02NTQzMQ_26cc7420-32b6-434f-8fe1-261f0911de7c">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfOS0zLTEtMS02NTQzMQ_55ebde09-278d-4805-a8ef-4a141c3a95f6">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTAtMS0xLTEtNjU0MzE_2270be7e-c314-4dd2-87b7-15242649d74c">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTAtMy0xLTEtNjU0MzE_f0126acc-aae3-44d0-8f36-41d979a12e97">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTItMS0xLTEtNjU0MzE_e7d0f4ef-eb77-4c50-814c-56ef02c848ea">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTItMy0xLTEtNjU0MzE_8c6a1bc3-8e18-4111-93c4-71fcca0a480e">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss before income taxes and loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTMtMS0xLTEtNjU0MzE_8617980f-1485-4b1a-b2d3-02bb4d29ba81">81.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTMtMy0xLTEtNjU0MzE_0f51e303-6a8d-4394-bb06-d899cd8472dc">56.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTQtMS0xLTEtNjU0MzE_4fc76848-c502-442b-a20c-b9b4357e127b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTQtMy0xLTEtNjU0MzE_b4395eb0-031f-47ae-a9a6-c62a2e23743f">4.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTUtMS0xLTEtNjYxMzc_444fb160-547b-4265-823f-1e0040171278">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTUtMy0xLTEtNjYxMzc_c2fd0c7a-392c-4188-a282-c107bb985c72">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTUtMS0xLTEtNjU0MzE_c9c51be3-939a-4e73-8c70-738e3e29539c">81.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTUtMy0xLTEtNjU0MzE_3f09a15a-74eb-493f-b4c5-c323e372d68d">63.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss per common share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTYtMS0xLTEtNjU0MzE_37bf92ca-1e2f-4b65-91ba-4c3cac97ccdc"><ix:nonFraction unitRef="usdPerShare" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTYtMS0xLTEtNjU0MzE_7a60d933-0f8f-4e49-8901-c3bdf2e56e98">1.54</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTYtMy0xLTEtNjU0MzE_844d245b-1dd7-4c8a-9f9c-6a1752819502"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTYtMy0xLTEtNjU0MzE_8e59b7f1-82a9-422b-b3c6-4993a1a5234d">1.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted average common shares outstanding, basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTctMS0xLTEtNjU0MzE_38641114-e869-4b1e-9ffa-951c10e9cc24"><ix:nonFraction unitRef="shares" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTctMS0xLTEtNjU0MzE_52671e94-1e89-4265-8ec2-9a40e34d0713">53.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTctMy0xLTEtNjU0MzE_7de70be2-79fa-44c5-b984-c599bb83138a"><ix:nonFraction unitRef="shares" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTctMy0xLTEtNjU0MzE_f2a1906a-f1fb-4e54-96a1-6b9666c4c824">53.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i884cf85f07be4320b5e4857b1da120ed_25"></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfMi0xLTEtMS02NTQzMQ_f2e5a155-0690-469d-85f7-21f9bd79fbe0">81.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfMi0zLTEtMS02NTQzMQ_943dbb66-c9fe-4203-810a-a180c5042cbf">63.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Unrealized gain (loss) on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfNC0xLTEtMS02NTQzMQ_530d128d-322a-48b2-8030-a2ec5b02a98b">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfNC0zLTEtMS02NTQzMQ_4bd8e5c4-24d2-4307-9c08-eabd1e0293d9">14.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfNS0xLTEtMS02NTQzMQ_9144776b-f527-4301-aa64-93c68f53f6c3">75.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfNS0zLTEtMS02NTQzMQ_59bb7722-3c42-414b-9378-3572387c56b6">77.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.027%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Common</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Accumulated <br/>Other <br/>Comprehensive <br/>(Loss) Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Total <br/>Stockholders' <br/>Equity </span></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:115%">For the Three Months Ended March 31, 2023 and 2022</span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i59fa16591da24cb9adc1d260cd702bec_I20221231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi0xLTEtMS02NTQzMQ_2b6a5f12-7de5-41c2-81c4-cb5ab562b865">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i59fa16591da24cb9adc1d260cd702bec_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi0zLTEtMS02NTQzMQ_aa079b89-321c-4ccd-ac7a-3da4b40a2f1d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ief60b65dbbed473d990406fe18f4b016_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi01LTEtMS02NTQzMQ_915bb015-d59b-4faa-b002-0b0d7f1209f8">965.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i423be60354244b2b97bcb6297024fc30_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi03LTEtMS02NTQzMQ_8b8934c9-62d6-4e0b-b1ae-c2b750068e36">1,549.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i563f01175e814770b8ddb607671d6584_I20221231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi05LTEtMS02NTQzMQ_d382deba-f6d2-4258-bb1e-909ab4a5f203">19.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi0xMS0xLTEtNjU0MzE_2ce01421-9368-4d0b-a5dd-8e2bfc342cf2">564.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ica93aa257210457588a3dab513ca1281_D20230101-20230331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMy03LTEtMS02NTQzMQ_3dfb7241-bde6-4bda-99c0-47d755ae58ee">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMy0xMS0xLTEtNjU0MzE_b677487d-b7c6-4af5-82bf-818c5478ad60">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i70b2b0d2b07c477095aa99f00b3e6c9e_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNC01LTEtMS02NTQzMQ_efb0dba2-6649-49e2-b402-b4e523f07428">81.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNC0xMS0xLTEtNjU0MzE_1eb0e25f-796e-411e-acae-f0cf64bddd79">81.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Exercise/ vesting of stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i41eb626a0ca84eb981b494af99468c57_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNi0xLTEtMS02NTQzMQ_3cb2914f-4677-4984-a54d-feb9c7c12d63">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ica93aa257210457588a3dab513ca1281_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNi03LTEtMS02NTQzMQ_cd17687d-7288-4fd2-9882-4f0f104aaadb">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNi0xMS0xLTEtNjU0MzE_1de04f09-6efa-4ecb-aad4-1a56228c47d3">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22.22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i91476a3a87b74bfb9daea385c949ed11_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNy05LTEtMS02NTQzMQ_16524b23-da67-4980-a689-5e3ed3767c44">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNy0xMS0xLTEtNjU0MzE_fd831456-1b34-4065-8443-6c380642e8bf">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of March&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="iac513c7ce70543009a9875454577f845_I20230331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC0xLTEtMS02NTQzMQ_a562015c-0d5d-4521-98d2-42b189fed156">53.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iac513c7ce70543009a9875454577f845_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC0zLTEtMS02NTQzMQ_643746d7-a209-411f-852b-3908911419ee">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="if47c42e24d824e89abf05132bc64e379_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC01LTEtMS02NTQzMQ_2ce0a70b-9960-427d-8a1a-382d794e8ec1">1,047.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7ae605f935c04bc2af190e140938586b_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC03LTEtMS02NTQzMQ_40ef82a0-2a6d-4308-87b7-6fde92b57684">1,570.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i903857c45a8b454f9d0bd288463f9c45_I20230331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC05LTEtMS02NTQzMQ_05c5ce48-0409-43e9-a5fd-8bbde71a94aa">12.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC0xMS0xLTEtNjU0MzE_190892ae-7848-4c42-9521-e4cddc061266">511.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id6273a26513740c895cd8fe246ea1135_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS0xLTEtMS02NTQzMQ_54174ecb-035a-44d5-bda9-6a4c5090ed34">53.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id6273a26513740c895cd8fe246ea1135_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS0zLTEtMS02NTQzMQ_13499e9d-cb01-4554-ae55-9a285e6c0abd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i228a677a2c5646269e41ad33bcbd8f12_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS01LTEtMS02NTQzMQ_8dfbbb24-bd76-4f2a-9ba0-900b4361352e">682.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i705af897c9a04f31ab086c30d2b350b0_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS03LTEtMS02NTQzMQ_f46f9d39-9edc-44c3-b4ab-6a46fa115cb3">1,469.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia6df2f2c7c5f476fba8a03b362862a96_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS05LTEtMS02NTQzMQ_059c2a8e-3c5d-44a5-ba12-453f9e59d296">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS0xMS0xLTEtNjU0MzE_b6242e5d-3466-4083-88d3-8cbdad02be56">781.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i90d558a1de93477b87122ce5cd92cc9f_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTAtNy0xLTEtNjU0MzE_6ae79f61-d36a-4e5f-814e-a986ed1189c6">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTAtMTEtMS0xLTY1NDMx_3ad0f883-3509-4246-bd11-2abc7979239e">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i472c99b27af24b9b91e801b0d2386fd1_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTEtNS0xLTEtNjU0MzE_0b16d11d-87a6-44eb-8553-bf1b101ef90a">63.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTEtMTEtMS0xLTY1NDMx_ecac1593-0697-411a-8b5a-25385809bcf2">63.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Exercise/ vesting of stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="iebe10aedc0da40bca216552454ea7f4a_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTMtMS0xLTEtNjU0MzE_3894c5f1-577e-4649-aa6d-db071e30bb66">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i90d558a1de93477b87122ce5cd92cc9f_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTMtNy0xLTEtNjU0MzE_7bc63ee2-7b4b-490a-8f1e-c0931f9bdbf6">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTMtMTEtMS0xLTY1NDMx_f2d272bc-77af-49e9-a800-c013d3dcd0d1">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Unrealized loss on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="icfd52ecfa49241f8aa987e6cc3468342_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTUtOS0xLTEtNjU0MzE_f0744439-d223-466a-85a4-020400dc44a9">14.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTUtMTEtMS0xLTY1NDMx_2025d5aa-aa95-4471-b3e9-1ae5cd707b16">14.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Balance as of March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="iafbcae8733b64e3c9cf754f838374162_I20220331" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtMS0xLTEtNjU0MzE_3809ffc6-8b87-49dd-8a73-f5f4dcab08d5">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iafbcae8733b64e3c9cf754f838374162_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtMy0xLTEtNjU0MzE_04b1d89d-2d4a-4a1d-a2e6-28ea29a8c830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i6353ac0a26204afa914428ef8c857213_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtNS0xLTEtNjU0MzE_0e55cc72-be78-422b-9329-9b3c687f596b">746.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id20e86e77f8c48b79f279e320e800292_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtNy0xLTEtNjU0MzE_37faf0b4-9f64-4873-925a-cbfb43feb0b7">1,488.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iaa1890c1439a43ad896af5dfd768c60b_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtOS0xLTEtNjU0MzE_e4c6af69-c2a1-4042-81c9-6bb47e1a765c">18.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtMTEtMS0xLTY1NDMx_ab730d97-d5c4-4458-a42d-ab91f23ad327">723.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMy0xLTEtMS02NTQzMQ_68244e1a-b535-4b19-99c6-8baa65e009ec">81.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMy0zLTEtMS02NTQzMQ_4e77d7e2-2fed-432e-b8ef-d90e665ab87d">63.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfNS0xLTEtMS02NTQzMQ_72b51db3-849d-4a94-9475-94caaf233443">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfNS0zLTEtMS02NTQzMQ_1495026d-34ab-446c-94ec-4fdbff5365ef">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net accretion of bond discounts/premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfNi0xLTEtMS02NTQzMQ_ef904022-bf41-4ca9-95bd-f3454298cbef">3.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfNi0zLTEtMS02NTQzMQ_5cdc3884-4549-41a7-a3af-4659804d826c">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loss on sale of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfOC0xLTEtMS02NTQzMQ_3c7b5aaa-5a7e-4845-a132-4d2f19db0af1">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfOC0zLTEtMS02NTQzMQ_78c6f6df-8c25-4903-b559-42d8c996e3cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfOS0xLTEtMS02NTQzMQ_eb47902a-7963-4055-9f1e-6d77e6f5779d">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfOS0zLTEtMS02NTQzMQ_731c490b-4311-4214-be0a-6cabe2ddcedc">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Amortization of collaboration contract asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTAtMS0xLTEtNjU0MzE_d760f376-8562-4a7d-9cd7-1df3306167e1">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTAtMy0xLTEtNjU0MzE_1187a8f4-e359-4e4e-8c97-9adcdd50c1f3">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTItMS0xLTEtNjU0MzE_c05d3233-449a-40d5-b541-df72016ec49a">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTItMy0xLTEtNjU0MzE_b8a4e7d2-8d33-490f-931b-6817bdf4d39d">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTQtMS0xLTEtNjU0MzE_56a8e7eb-4b80-45e6-8be1-8a52d065bd9a">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTQtMy0xLTEtNjU0MzE_fd55c424-8a4c-4b36-9611-005c3c56f755">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTUtMS0xLTEtNjU0MzE_0e3aa7c2-ac7a-4046-8f39-4cedf5cab172">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTUtMy0xLTEtNjU0MzE_0374cd1b-2249-4793-91a5-459b24a4fefd">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTYtMS0xLTEtNjU0MzE_48f28beb-0110-4752-a257-84e4c630fbf4">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTYtMy0xLTEtNjU0MzE_37903b19-2250-41f4-8563-87d43e5cbeca">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTgtMS0xLTEtNjU0MzE_87595073-56d1-49ff-aa8a-73dd37de7f79">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTgtMy0xLTEtNjU0MzE_0b7256c4-6cf6-4fa9-b051-f0f6d4b1b788">15.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTktMS0xLTEtNjU0MzE_465462da-aba6-4fda-b58d-292cbb8ef93c">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTktMy0xLTEtNjU0MzE_47871e22-0124-4667-9de8-a43b06d5ce87">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjAtMS0xLTEtNjU0MzE_5752b750-93f2-4a0f-9285-997d73df54ae">29.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjAtMy0xLTEtNjU0MzE_5ff50af6-52c6-47b3-9fe7-b2c9b9252bfe">21.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjEtMS0xLTEtNjU0MzE_35b106ec-bb2f-48b0-8253-0ac84c248bed">91.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjEtMy0xLTEtNjU0MzE_04000ca1-89a3-46d6-969c-4a898fd4682c">57.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjMtMS0xLTEtNjU0MzE_b8f50e66-d562-4071-ba4f-360df8c85b2b">175.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjMtMy0xLTEtNjU0MzE_b86d1f99-e563-4865-aeaa-ee72d61ba77b">263.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjQtMS0xLTEtNjU0MzE_bd4e9e4d-5bff-4fc0-833f-b88bd71ad182">280.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjQtMy0xLTEtNjU0MzE_73c13831-6001-4e77-bdd0-3cbbcd446137">273.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:ProceedsFromSaleOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjUtMS0xLTEtNjU0MzE_57a7b457-bc0c-4c60-a591-a2906bc4f321">35.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:ProceedsFromSaleOfMarketableSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjUtMy0xLTEtNjU0MzE_87a2d4b2-474d-4a45-bb4e-42da7d4b0514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases of property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjYtMS0xLTEtNjU0MzE_cec92d52-5c16-41fe-b081-50ea7a024913">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjYtMy0xLTEtNjU0MzE_fd1ebf0c-0f58-4f10-9c0e-b23aa8302d14">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjgtMS0xLTEtNjU0MzE_c4f7676c-4c6f-41bf-a5bb-1e1181aca18c">138.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjgtMy0xLTEtNjU0MzE_56cd0015-660b-4a38-a204-737d0ee1afd1">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Proceeds from exercise of stock options and issuance of ESPP shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzItMS0xLTEtNjU0MzE_7a682df4-d686-4f87-ba0c-7751291fd225">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzItMy0xLTEtNjU0MzE_2d3262ac-fbe0-4f42-8a89-5cab04ad187a">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzMtMS0xLTEtNjU0MzE_3aa6e0f9-4686-43e1-8808-d104f225cc62">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzMtMy0xLTEtNjU0MzE_6c40fb5a-9ec1-4d40-a08e-89d111e1251e">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzQtMS0xLTEtNjU0MzE_bf97d84a-7c79-40bc-afdb-e13365b48ced">48.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzQtMy0xLTEtNjU0MzE_446dad33-af0b-447b-8067-b5949a26bb31">46.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzUtMS0xLTEtNjU0MzE_4fa2c5dd-61b1-4506-a26c-fe0287ae997c">86.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzUtMy0xLTEtNjU0MzE_77b40cf3-5030-43fa-866b-d7375709d322">112.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzYtMS0xLTEtNjU0MzE_d2f75d79-b11f-4848-9f1a-3627adfe5c01">135.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzYtMy0xLTEtNjU0MzE_6c93af09-5adb-4b26-ac30-448fed11d731">66.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Purchases of property, equipment and leasehold improvements </span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">unpaid at period end</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzgtMS0xLTEtNjU0MzE_bad871c7-702a-4993-8a7d-8f945c9b95bb">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzgtMy0xLTEtNjU0MzE_5ff72fcf-5c4e-4605-920a-d480dade211f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzMg_407cfcf3-8e94-4da9-bd1b-f2db771d234a" continuedAt="i9419fdbaa37346019c604db81d5dc899" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i9419fdbaa37346019c604db81d5dc899"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its subsidiaries (&#8220;Arvinas&#8221; or the "Company&#8221;) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzMw_d0a8ea24-700c-4808-b092-d5de99d5d9b5" escape="true">The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (&#8220;SEC&#8221;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2022, forming part of Arvinas&#8217; 2022 Annual Report on Form 10-K filed with the SEC on February&#160;23, 2023.</ix:nonNumeric> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzNA_f28f6187-a5e8-41c0-80b8-3175a9e17266" escape="true">The following reclassification has been made to prior period financial information in order to conform with current period presentation: Accounts payable and Accrued expenses have been condensed into Accounts payable and accrued liabilities</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed in the Company's 2022 Annual Report on Form 10-K, the Company revised the accounting for its investment in Oerth Bio LLC ("Oerth Bio"). Accordingly, Arvinas recorded an adjustment to the unaudited condensed consolidated financial statements for the three months ended March 31, 2022 that were previously included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. See Note 12,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity Method Investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzNQ_28f83fff-f19c-473c-a4b6-3d945f075463" escape="true">The preparation of the Company&#8217;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzNg_19c033e3-e221-47d5-80c3-f8c8178c9383" continuedAt="i2148d3c46c9b477182a3a92817b926e3" escape="true">Risks and Uncertainties</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2148d3c46c9b477182a3a92817b926e3">The Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-8" name="arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfMzU1OA_75aff7f2-c953-4d2c-ac75-56484b0c2ac7">1.1</ix:nonFraction> billion as of March&#160;31, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMzY5_833e4547-b359-4652-a977-8f60b5be6f0a" continuedAt="if675d13401844d068764f1af3e7cc07e" escape="true">Accounting Pronouncements and Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="if675d13401844d068764f1af3e7cc07e"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMjc0ODc3OTA3NjA4Ng_2b42784d-22f3-4aa7-a6fc-23aa86411e49" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new accounting standards as issued. As of March&#160;31, 2023, the Company has not identified any new standards that it believes will have a material impact on the Company&#8217;s financial statements.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMjc0ODc3OTA3NjA4NQ_8325360e-6eaa-444f-bf66-60ab62049786" continuedAt="i182c9c573ecf4b499ea1fc533ab762a6" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMjc0ODc3OTA3NjA4Nw_55681459-8d1c-482f-a302-fd73a1167d42" escape="true"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMjc0ODc3OTA3NjA4Nw_f396f305-e182-4aa7-9173-ea2c921f84be" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the condensed consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMi0xLTEtMS02Nzc0Mw_877283eb-4f51-4e24-833e-f83ec0a1012e">130.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMi0zLTEtMS02Nzc0Mw_f361feb2-c8e0-43f5-b4f1-ec0b7aaa6b80">62.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMy0xLTEtMS02Nzc0Mw_d8656e32-08e1-4af9-b8b0-e78d9dc77d77">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMy0zLTEtMS02Nzc0Mw_4a3e39d3-657e-48b9-aacb-d50a819f6365">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMy0xLTEtMS02Nzg1Ng_ccb95cf5-d326-4655-aaf3-30fe9b3a7354">135.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMy0zLTEtMS02Nzg1Ng_d89ac005-615d-44c2-bfd3-68109e43a18c">66.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i182c9c573ecf4b499ea1fc533ab762a6">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.</ix:continuation></span></div></ix:continuation><div id="i884cf85f07be4320b5e4857b1da120ed_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNjI2OA_87ae2d39-673e-41da-9cff-eaee442801a6" continuedAt="ib2bdfb8446164eadae911f78fa691cdb" escape="true">Research Collaboration and License Agreements </ix:nonNumeric></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"><ix:continuation id="ib2bdfb8446164eadae911f78fa691cdb" continuedAt="ib3a2c040230c47d8ada4cb3072e876ed"> </ix:continuation></span></div><ix:continuation id="ib3a2c040230c47d8ada4cb3072e876ed" continuedAt="idb05e159dff2450b84e28a7e685f4b10"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARV-471 Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) (the &#8220;ARV-471 Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound ARV-471 (the &#8220;Licensed Products&#8221;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="i42ba466978ac4cc992589866c331756a_I20210731" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTEw_bbdc86f1-e3ab-4213-9816-59372ad92196">650.0</ix:nonFraction> million. In addition, the Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i16fd9a5fa79d4e9eaa80190af360005c_I20210731" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTgy_a5e30585-cbc2-4e08-8217-732320da767b">1.4</ix:nonFraction> billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $<ix:nonFraction unitRef="usd" contextRef="ief3a7076223347cfbc4892d71334d77b_I20210731" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNzI1_e2adbc62-1922-415b-a9fa-eeadd1a3b07e">400.0</ix:nonFraction> million in regulatory milestones are related to marketing approvals and $<ix:nonFraction unitRef="usd" contextRef="i3786932f15544cce9cf0079227cdc57b_I20210731" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNzky_49219609-ab78-4eac-80ac-dab7d047b9fd">1.0</ix:nonFraction> billion are related to sales-based milestones. There were <ix:nonFraction unitRef="usd" contextRef="ibcccbc739c0445b2b27349bd42442433_D20230101-20230331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTQ5NzU1ODIyMzM2_49084bf9-e986-4daf-ad99-c8e3d05986af"><ix:nonFraction unitRef="usd" contextRef="ic2695362632e4befb50d084f5a874ac1_D20230101-20230331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTQ5NzU1ODIyMzM2_da2b1399-11dd-4c1b-9b40-de05dfdf10e3">no</ix:nonFraction></ix:nonFraction> regulatory or sales-based milestone payments received through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $<ix:nonFraction unitRef="usd" contextRef="i3ba7e9e46b0c438a8a2acede1d5ac4a7_D20230101-20230331" decimals="-5" name="arvn:DirectAndIncrementalCostsIncurredToObtainTheContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTg4NQ_79bdb4ad-96b2-4449-9450-a4835a9e58ea">12.9</ix:nonFraction> million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $<ix:nonFraction unitRef="usd" contextRef="ic50dd3e602a14d7c9a8c73c1b9f0f130_I20230331" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTk4NQ_62c41c05-08b4-42bc-b7e4-414638b0231a">12.9</ix:nonFraction> million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><ix:continuation id="idb05e159dff2450b84e28a7e685f4b10" continuedAt="i9e784aa439da449ca9b870dfe58a88fc"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#8220;Bayer Collaboration Agreement&#8221;) setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras ("PROTAC&#174; targeted protein degraders") that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="i5482ad9db1e14d4db0c6cbc2489c89aa_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMjczNQ_80558201-65a6-43fb-9b9c-08f84b78c7b5">17.5</ix:nonFraction> million in exchange for the use of the Company&#8217;s technology license. Bayer AG is committed to fund an additional $<ix:nonFraction unitRef="usd" contextRef="iaf97ed42f0f34c4a8af32817ae8aca05_I20231231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMjg0MA_9d0bdd22-56d6-4b30-9ba8-83a55bbb6262">12.0</ix:nonFraction> million through 2023, all of which was received as of March&#160;31, 2023, including $<ix:nonFraction unitRef="usd" contextRef="i64eaa7a6fadd4ef88cc9a1286c396bbc_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTA5OTUxMTYzNDQzOA_fe4d36b2-185a-4523-9968-ebfc7934dade">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3f1c7c35f0f643bbb3ac71053516932f_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTA5OTUxMTYzNDQ1Mg_254d3aed-de9e-47ae-b886-6260ae999820">3.0</ix:nonFraction>&#160;million in the three months ended March&#160;31, 2023 and 2022, respectively. These payments are being recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ic25e5433c3b74da39b3c37e3b0ee0ce2_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzA0MA_d0d8c36b-4e45-4b9e-90a8-69641daa4dcf">197.5</ix:nonFraction>&#160;million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="ie5fab18a22d24d848daaf8e985758c58_I20190630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzA4Nw_82dd4013-0913-401a-9c56-f665ad7a7e1f">490.0</ix:nonFraction>&#160;million in sales-based milestone payments for all designated targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="if970016974254601910f92dc80515772_D20230101-20230331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzM3MA_2ca53062-1495-41f3-a8f3-487fb2c25196"><ix:nonFraction unitRef="usd" contextRef="id250d3ecdba042e2af065ac3f57d8f6b_D20230101-20230331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzM3MA_abdc24b9-d8bb-4cf1-aaf5-cf695159c1f8">no</ix:nonFraction></ix:nonFraction> development or sales-based milestone payments or royalties received through March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#8220;Pfizer Research Collaboration Agreement&#8221;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $<ix:nonFraction unitRef="usd" contextRef="i4b3dfdf46ccd4f02aeacc06bab7ab70d_D20180101-20181231" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzgwMw_a376c93d-1984-4418-b35d-e9d319734ef9">28.0</ix:nonFraction> million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i934d8ddc1394497d98263e0baef3dfd8_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDExOQ_83c99100-725c-47a9-ac45-4deaccb4777b">37.5</ix:nonFraction>&#160;million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="ia0fa77171342487db29bfb9fd0cd234c_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDMwMQ_0447095f-ec1b-485c-8bd7-9d0072241b4a">225.0</ix:nonFraction>&#160;million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i06109f1daf3f44819497e002b80fa05c_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDM0OA_a9ca0b2f-6898-4e87-bba9-de7ee5dc2045">550.0</ix:nonFraction>&#160;million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the three months ended March&#160;31, 2023 and 2022, the Company received payments totaling $<ix:nonFraction unitRef="usd" contextRef="ie2e16ac4423a4e249adbc8e38cfdd227_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDU3Nw_4e0811f4-10f9-4951-b065-9546e43d9ac4">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i825cb221649b48da99a61c73b128281b_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTA5OTUxMTYzNDU4Mg_331e8b7f-8e19-44d2-8c65-a3bd68357592">3.5</ix:nonFraction> million which were included in accounts receivable as of December 31, 2022 and 2021, respectively, for additional targets and services which are being recognized as revenue over the total period of performance. There were <ix:nonFraction unitRef="usd" contextRef="ic2695362632e4befb50d084f5a874ac1_D20230101-20230331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDc4NA_c628cad1-2479-43af-9747-4140ccae9919">no</ix:nonFraction> sales-based milestone payments or royalties received through March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genentech Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#8220;Restated Genentech Agreement&#8221;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of $<ix:nonFraction unitRef="usd" contextRef="ibdfdecb591af4d2d9d467b467c44e0d9_D20171101-20171130" decimals="-5" name="us-gaap:ProceedsFromCollaborators" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTIyMg_40bc0719-eea8-4daf-bd29-be2333bfbd1d">34.5</ix:nonFraction> million (in addition to $<ix:nonFraction unitRef="usd" contextRef="ibdfdecb591af4d2d9d467b467c44e0d9_D20171101-20171130" decimals="-5" name="arvn:AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTI0MQ_c6127e2c-afba-4eba-89ab-f6b424b61e06">11.0</ix:nonFraction> million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i2e2b79e3ac2541ffa660c65a665640e6_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTcwMQ_ff4d32ab-f04e-442b-b802-93d0a4126487">44.0</ix:nonFraction>&#160;million per target in development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="i15ccbabc704747d3912f2887cdca2f5e_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTc1MA_91be116d-e979-4019-b574-8bfd1aaf2b2b">52.5</ix:nonFraction>&#160;million in regulatory milestone payments and $<ix:nonFraction unitRef="usd" contextRef="i3ca6fcbbbc8d453cb429124dadde0a44_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTc5MA_b4113909-bdb8-4d01-88c5-f2e8852eabb1">60.0</ix:nonFraction>&#160;million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were <ix:nonFraction unitRef="usd" contextRef="i378f9a67bc7a479fad0da9c643e33fd7_D20230101-20230331" decimals="INF" name="us-gaap:ProceedsFromCollaborators" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTg5Ng_a1155e26-308b-4a01-9d34-2dbf36a4bd65">no</ix:nonFraction> development, regulatory or commercial milestone payments or royalties received through March&#160;31, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><ix:continuation id="i9e784aa439da449ca9b870dfe58a88fc"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNjI2Ng_dead96cf-fe63-4f40-9921-f0c952762044" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances for the three months ended March&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable related to collaborations</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMi0xLTEtMS02NTQzMQ_d7b8632c-3f01-43f1-8aee-1aed74d3a209">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMi0zLTEtMS02NTQzMQ_723d7635-c976-46ed-9bb5-2927775fa0f4">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMy0xLTEtMS02NTQzMQ_0a8143d9-ed68-4495-af3c-807874530a1d">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMy0zLTEtMS02NTQzMQ_0dfb1d19-c0ce-4682-b6e8-0619d9c3fb03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNC0xLTEtMS02NTQzMQ_0f3d228a-ea4d-4d6e-8b3f-9b0701d50ddb">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNC0zLTEtMS02NTQzMQ_77b62c77-4755-4c42-8227-e80842ee72f4">15.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNS0xLTEtMS02NTQzMQ_cd49eac2-baec-4cea-a686-e8609ce102be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNS0zLTEtMS02NTQzMQ_6d3ef6d5-86f5-40bd-8cf2-195b36538ff3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNy0xLTEtMS03MDI4NA_5cb340da-2b81-482e-87d0-17b7e1f7833e">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNy0zLTEtMS03MDI4NA_c85e8999-680f-4b08-8ef1-b3382811b6c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOC0xLTEtMS03MDI4NA_855d104b-66a1-4214-98e0-c9f0543b949a">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentAdditions" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOC0zLTEtMS03MDI4NA_f37b3188-6ea2-4e44-87e1-f68300823733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOS0xLTEtMS03MDI4NA_849f9c96-bcac-4c1e-b556-9415758c1100">5.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentPayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOS0zLTEtMS03MDI4NA_90a8bc9b-96f6-4940-8328-f9e7dee4fb7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTAtMS0xLTEtNzAyODQ_f45d9b40-556b-4769-86fc-8db8bc065486">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTAtMy0xLTEtNzAyODQ_80b62da9-4292-4f60-b7d1-f473dded9653">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNy0xLTEtMS02NTQzMQ_07220e10-24f2-4bae-8366-904c6687813b">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNy0zLTEtMS02NTQzMQ_fb6fd04c-dcfb-4d84-8df4-cdd81e16bdb4">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOC0xLTEtMS02NTQzMQ_5b08d817-7ad3-4d4f-b40e-dd1e5f9bdad0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOC0zLTEtMS02NTQzMQ_569e517f-bb3f-4b05-8574-c319045a2df8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:CapitalizedContractCostAmortizationDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOS0xLTEtMS02NTQzMQ_232c1c17-ff3f-4d8e-8cd0-5fb0413eac51">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:CapitalizedContractCostAmortizationDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOS0zLTEtMS02NTQzMQ_96c625a0-952e-45bf-972d-68d1517cc2a4">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTAtMS0xLTEtNjU0MzE_95ddd0f5-1d28-4f03-b461-fdcd52913456">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTAtMy0xLTEtNjU0MzE_c1383052-d9b6-472f-af9c-a698126adb02">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTItMS0xLTEtNjU0MzE_45ca9049-d3d1-4ced-a759-44888906a052">623.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTItMy0xLTEtNjU0MzE_16c8c816-90f4-4bd6-ac12-8cdf38e1bba0">740.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTMtMS0xLTEtNjU0MzE_f29655bc-5726-40be-9817-0020a9da2ed3">31.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTMtMy0xLTEtNjU0MzE_83f3b6aa-6d26-45dd-aaf3-b3d323e79c44">24.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTQtMS0xLTEtNjU0MzE_2b0020e6-a5bf-4056-ac38-236b6129977f">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTQtMy0xLTEtNjU0MzE_9694cc39-1215-40f5-8a52-40dc272ff8f9">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTUtMS0xLTEtNjU0MzE_1dca20be-aa06-4bc4-817f-e5ebde74d788">593.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTUtMy0xLTEtNjU0MzE_729b6b31-52e0-4589-b092-efa1558e3a12">719.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company recorded cumulative catch-up adjustments from contract modifications totaling $(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTA5OTUxMTYzNTM3Nw_3a4e7536-42ee-4bad-bdf4-6aafe0b1127b">8.2</ix:nonFraction>) million relating to performance obligations which were satisfied in prior periods.</span></div><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNjI2Nw_5a773027-7d8e-4cb7-b61a-fe5c91c2ebf0" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNjIwMQ_6aa1f5bd-f1f6-4ce7-8916-f1c3a9609a3c">593.8</ix:nonFraction> million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6a57f027039d402e89fbc95c1127d3cb_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfMS0xLTEtMS02NTQzMQ_c35a4625-2ae6-4ac6-8485-1eb9f7932be3">163.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7e5587709ab9441eb95639b688acbf26_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfMi0xLTEtMS02NTQzMQ_cc63bfa2-8df5-4155-9810-6770631c8bee">200.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i333fef30c76849dabbf515e19bb3c4dd_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfMy0xLTEtMS02NTQzMQ_970b438d-8b64-430f-946d-749542e628ec">90.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i64e73ce4a2fb4d8ea4d59c53e7967503_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfNC0xLTEtMS02NTQzMQ_adaa2bbf-9a81-4871-b132-6b3a20439fd7">55.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i5ba9fc908d7b41deaf9a3fd3e31184cb_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfNS0xLTEtMS02NTQzMQ_5ae15918-c651-4507-a99d-652100b1e5b6">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6a68588de37d4285a34afb43c82aef31_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfNi0xLTEtMS02NTQzMQ_81c1d0bf-8d84-4a76-9bb1-eb5b29e81c76">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic6a4b3cb93314f7080a27916d29a1b7c_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfNy0xLTEtMS02NTQzMQ_76b41d56-9d70-42c6-95c5-fcaa869519db">38.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfOC0xLTEtMS02NTQzMQ_e76b9c7a-85ec-4039-9797-6013f0249a62">593.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i884cf85f07be4320b5e4857b1da120ed_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RleHRyZWdpb246MDc0ZDZkYzYyMmY2NDRlZTgxZGUyMzc2M2IxMzVhMDRfNTgz_30172cb2-c04d-485c-8a22-6de0d7b65d69" continuedAt="ie4d48b1edde94906b54d7cddf3df77cf" escape="true">Marketable Securities and Fair Value Measurements </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie4d48b1edde94906b54d7cddf3df77cf" continuedAt="i938972f9bde64256804728066c39c207">The Company&#8217;s marketable securities consist of corporate bonds and government securities which are adjusted to fair value as of each balance sheet date based on quoted prices, which are considered Level 2 inputs. </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><ix:continuation id="i938972f9bde64256804728066c39c207"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RleHRyZWdpb246MDc0ZDZkYzYyMmY2NDRlZTgxZGUyMzc2M2IxMzVhMDRfNTg0_00de8ff7-4209-4d53-b4ae-5739d97b6d5a" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifd2c16269e704252a73fa8151a039fbe_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMi02LTEtMS02NTQzMQ_f1cd76f2-d5e1-4266-a458-3fbe8949b660">688.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifd2c16269e704252a73fa8151a039fbe_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMi04LTEtMS02NTQzMQ_7b9c08bd-4c4b-4a92-a00b-2845dd3d68e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ifd2c16269e704252a73fa8151a039fbe_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMi0xMC0xLTEtNjU0MzE_3442a8c5-9444-427f-be64-af04bd4e4b07">6.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ifd2c16269e704252a73fa8151a039fbe_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMi0xMi0xLTEtNjU0MzE_856ee08f-3d6b-4ca1-add6-b3f060febd60">682.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie9a393896693451891e7d053aeeb18be_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMy02LTEtMS02NTQzMQ_b658b138-f4df-4831-8a58-44ad33c6e766">206.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie9a393896693451891e7d053aeeb18be_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMy04LTEtMS02NTQzMQ_6bdf8e57-256e-4247-9afa-9df737a0db29">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ie9a393896693451891e7d053aeeb18be_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMy0xMC0xLTEtNjU0MzE_ffe495c3-7f85-49d9-a120-e6ec69f88c15">6.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ie9a393896693451891e7d053aeeb18be_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMy0xMi0xLTEtNjU0MzE_a95f44de-daa7-4283-83aa-2e1bf68199f0">200.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e55fd027b044723af517c59364224f0_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNC02LTEtMS02NTQzMQ_af1f0ce1-e0a3-42d2-8427-5114c0b32726">56.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e55fd027b044723af517c59364224f0_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNC04LTEtMS02NTQzMQ_c7028ca5-1b65-4599-8697-40244c547027">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i2e55fd027b044723af517c59364224f0_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNC0xMC0xLTEtNjU0MzE_aecf3b2c-480d-4bb5-8924-4a3130bc3bbe">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e55fd027b044723af517c59364224f0_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNC0xMi0xLTEtNjU0MzE_b83430d9-78e8-4168-af34-9da31c1a9955">56.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNS02LTEtMS02NTQzMQ_dd2e1244-b02e-4f94-b4d5-07a1c02d7de3">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNS04LTEtMS02NTQzMQ_74847c9e-768f-40fe-adda-a4e8ef8bea1f">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNS0xMC0xLTEtNjU0MzE_23717a9a-f951-4269-aeed-aaee7683c56b">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNS0xMi0xLTEtNjU0MzE_d8ac0914-515f-4c24-9832-7e7de6c43a0d">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i57e3228d892b4e7db62595d4014c6676_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNi02LTEtMS02NTQzMQ_bc73c7de-5c28-4e89-b460-b2686d0f611d">1,005.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i57e3228d892b4e7db62595d4014c6676_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNi04LTEtMS02NTQzMQ_fec863df-3221-4207-8c68-b118c11f0ba8">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i57e3228d892b4e7db62595d4014c6676_I20230331" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNi0xMC0xLTEtNjU0MzE_59fdb16d-7917-48db-9ee0-d05506a63209">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i57e3228d892b4e7db62595d4014c6676_I20230331" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNi0xMi0xLTEtNjU0MzE_19ebb094-929f-4800-a3c1-6d283eb23dfe">993.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4888c9b0c614731bbdccc05e61bd058_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMi02LTEtMS02NTQzMQ_db78cc81-77a9-4272-a4ab-027f27db855c">802.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4888c9b0c614731bbdccc05e61bd058_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMi04LTEtMS02NTQzMQ_427eff1b-91df-4190-a63f-5a8303dd68b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ic4888c9b0c614731bbdccc05e61bd058_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMi0xMC0xLTEtNjU0MzE_84bb2117-8a27-4f99-8796-0fc0b1aa45a4">9.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ic4888c9b0c614731bbdccc05e61bd058_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMi0xMi0xLTEtNjU0MzE_cad8ddd7-b1d8-4c2c-8268-889f6f8c0b4a">793.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1de7a0ae0b92460dad81ea74516f18bd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMy02LTEtMS02NTQzMQ_33752c20-bdbe-42cc-9f2f-af9ad6cd324e">205.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1de7a0ae0b92460dad81ea74516f18bd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMy04LTEtMS02NTQzMQ_5dbde017-84c6-4d8c-8fcc-49b39763655b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i1de7a0ae0b92460dad81ea74516f18bd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMy0xMC0xLTEtNjU0MzE_25339c9a-8bcc-4a0a-a2e7-f3f25e5d0d3e">9.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i1de7a0ae0b92460dad81ea74516f18bd_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMy0xMi0xLTEtNjU0MzE_351a50ef-b9b8-4b96-8a19-c5dd01cb3472">196.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC02LTEtMS02NzQ2OQ_008e70e5-5087-4235-9989-853e6980a0c5">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC04LTEtMS02Nzg5NA_52463b48-c9d7-48ae-9f2c-494d46938c1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC0xMC0xLTEtNjc0Njk_c096aef7-07f7-4012-88c1-2b3a2367e2bf">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC0xMi0xLTEtNjc0Njk_2dea2ced-c22e-4dec-844d-fe0574e31ad4">61.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i43b0f02819274e57b2bf846e659c640e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC02LTEtMS02NTQzMQ_983cc49b-b92e-4ace-97d8-99e76f851753">73.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i43b0f02819274e57b2bf846e659c640e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC04LTEtMS02NTQzMQ_872150f8-82b9-4315-850a-5fdd628221da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i43b0f02819274e57b2bf846e659c640e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC0xMC0xLTEtNjU0MzE_185879ee-d23a-4835-a828-7c12110bbabf">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i43b0f02819274e57b2bf846e659c640e_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC0xMi0xLTEtNjU0MzE_128fc417-3787-45c5-98f2-cb5d78c1ffe2">73.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i75559e9dfb844d268302204b2976b7f5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNS02LTEtMS02NTQzMQ_083ad3df-f7e5-4d19-93c3-bce2834b52b4">1,143.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i75559e9dfb844d268302204b2976b7f5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNS04LTEtMS02NTQzMQ_ed363f65-9ada-444c-bc94-b84d9d7f426a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i75559e9dfb844d268302204b2976b7f5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNS0xMC0xLTEtNjU0MzE_7bd5861f-a552-4a24-97bd-4d016e1e8e7e">19.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i75559e9dfb844d268302204b2976b7f5_I20221231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNS0xMi0xLTEtNjU0MzE_f1cbbeed-1d0f-4095-876b-b175cacca2fe">1,124.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts receivable and accounts payable and accrued liabilities approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div></ix:continuation><div id="i884cf85f07be4320b5e4857b1da120ed_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RleHRyZWdpb246ZjAxYTY0Mzc4OGJkNDg5MjgwNzIxZTcyNjIzMDUzYzVfMzAz_b58a4b80-9f46-4a1e-830b-c2b3124230c0" continuedAt="i248a0b16f7ba4bb5a28cffcf2a4cd569" escape="true">Property, Equipment and Leasehold Improvements </ix:nonNumeric></span></div><ix:continuation id="i248a0b16f7ba4bb5a28cffcf2a4cd569" continuedAt="i07e27e5fcf514592bd8ba7453b88908e"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RleHRyZWdpb246ZjAxYTY0Mzc4OGJkNDg5MjgwNzIxZTcyNjIzMDUzYzVfMzA0_d4d21279-ae41-4c55-9db3-b00fde5d7882" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7b2563537aad4601938c78056cfd46bb_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMS0xLTEtMS02NTQzMQ_f15bbdb6-54d0-45d3-adb4-4d2b4fe18f24">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i870416186c7946d69aba9f21340eedf7_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMS0zLTEtMS02NTQzMQ_06c4aaea-4981-4140-b138-9ed982fd86dc">17.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i7c0acd6e5355425eb14e8f4f51b13bc2_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMi0xLTEtMS02NTQzMQ_e843ffe8-aaff-4629-a8d4-0957a3bce01f">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i43c92c58dac14ec68b6636151c731626_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMi0zLTEtMS02NTQzMQ_3f31a7ac-5358-4a5a-b105-f5e89a42df3a">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i32031c903a404074b539bf9f44fb8502_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMy0xLTEtMS02NTQzMQ_f9e9e0f8-43c6-45c7-96e2-73a0c99b0c23">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i79f9dcb9a8e74e788892552ed47ce8d1_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMy0zLTEtMS02NTQzMQ_72ca8413-8af8-436b-b8b4-d99412953741">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNC0xLTEtMS02NTQzMQ_fc76550f-8aac-4c88-94c8-90ef08c0796e">31.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNC0zLTEtMS02NTQzMQ_d8082c67-4400-4390-a2d3-99333527b9d3">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNS0xLTEtMS02NTQzMQ_2128eea9-1148-4bb9-a019-c8908e7a7e0c">17.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNS0zLTEtMS02NTQzMQ_4db5ff5b-25eb-46a6-b986-96c1e2af7cf5">16.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNi0xLTEtMS02NTQzMQ_e01b6b60-dfd2-47ae-9dc8-ece631620dd0">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNi0zLTEtMS02NTQzMQ_1ad98752-e70f-4f88-8623-4f197f89ce7d">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i07e27e5fcf514592bd8ba7453b88908e">Depreciation and amortization expense totaled $<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RleHRyZWdpb246ZjAxYTY0Mzc4OGJkNDg5MjgwNzIxZTcyNjIzMDUzYzVfMTgw_44b4b0c7-d8b3-4fed-a573-c6b664b3c942">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RleHRyZWdpb246ZjAxYTY0Mzc4OGJkNDg5MjgwNzIxZTcyNjIzMDUzYzVfMTg3_20b599d3-c8c5-4fe5-b3a8-5d378215a088">1.5</ix:nonFraction> million for the three months ended March&#160;31, 2023 and 2022, respectively</ix:continuation>.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_55"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4OA_ded363b4-a38a-4e99-91a1-690bc0233d16" continuedAt="i9da4fe2398164d41af92820d3820e1ff" escape="true">Right-of-Use Assets and Liabilities</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9da4fe2398164d41af92820d3820e1ff" continuedAt="i07537e15b5954ccf90c57523ebcb83c1">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the condensed consolidated balance sheets.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><ix:continuation id="i07537e15b5954ccf90c57523ebcb83c1"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments, which ranges from <ix:nonFraction unitRef="number" contextRef="i57728ffde72e4b07b7b3bc9db63630f8_I20230331" decimals="3" name="arvn:PercentageOfIncrementalBorrowingForLeasePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfODY2_a4c36e98-4602-462b-8c9d-9261370e7f09">3.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i90241bd38fea438fb4cc4148142c1b17_I20230331" decimals="3" name="arvn:PercentageOfIncrementalBorrowingForLeasePayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfODcx_43d53000-8af8-4db9-971d-13cda34ba0f4">4.1</ix:nonFraction>%. Lease expense is recognized on a straight-line basis over the lease term. The Company considers options to extend or terminate leases in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a lease arrangement, which was amended in August 2022, for approximately <ix:nonFraction unitRef="sqft" contextRef="if3420f377cc5416b93dcea5b7709551a_I20210531" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTMwNg_4908e6be-3d87-4aaf-ae4e-0627fc8ee151">160,000</ix:nonFraction> square feet of laboratory and office space, expected to be occupied in 2025. In connection with the signing of the lease and the related amendment, and at the Company&#8217;s election to increase the landlord&#8217;s contribution to the tenant improvement allowance, the Company initially issued a letter of credit totaling $<ix:nonFraction unitRef="usd" contextRef="ic584b3416c774aeca2c48f904781e806_I20210531" decimals="-5" name="us-gaap:DebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTA5OTUxMTYzMDM1MA_24e37a47-a5b8-4ace-97bc-281a44db419d">4.5</ix:nonFraction>&#160;million, which was subsequently increased to $<ix:nonFraction unitRef="usd" contextRef="i2a4cff069a1143b88d3a8e8910d7959f_I20230331" decimals="-5" name="us-gaap:DebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTU5Ng_abc203f1-beb4-4e37-8fb8-25c7930bedb0">5.5</ix:nonFraction> million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash in the consolidated balance sheets. Once occupied, the base rent will range from $<ix:nonFraction unitRef="usd" contextRef="i6a4ae741e33e4f4fa646fc2cce479c2d_D20210501-20210531" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTc1Ng_21438633-3982-4eff-a240-65ae551a7549">7.7</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i0c9b7a41f6414722ac66b829dfd54b50_D20210501-20210531" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTc2Mg_7e023099-4c2b-4c5e-8b34-9df61838ea10">8.8</ix:nonFraction> million annually over a <ix:nonNumeric contextRef="if6dcdbc12c344074b65cede1612dc7bc_D20210501-20210531" name="arvn:BaseLeaseRentPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4OQ_cc92f66e-e04a-4c59-9845-e48c829521de">ten-year</ix:nonNumeric> lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than January 2026. The leases have a weighted average remaining term of <ix:nonNumeric contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTk4MA_4dd939fa-6740-4a62-b6b7-3c7416f33a09">2.1</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4NQ_c09c6939-24d0-4c88-a5ac-cafa3daaf25c" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOjg2N2Y4ODIyOTQ3YjQ5YjY5ZmU4MWMxMzYzODc0YzFiL3RhYmxlcmFuZ2U6ODY3Zjg4MjI5NDdiNDliNjlmZTgxYzEzNjM4NzRjMWJfMi0xLTEtMS02NTQzMQ_62b066f7-8403-4933-8c53-32795016e947">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOjg2N2Y4ODIyOTQ3YjQ5YjY5ZmU4MWMxMzYzODc0YzFiL3RhYmxlcmFuZ2U6ODY3Zjg4MjI5NDdiNDliNjlmZTgxYzEzNjM4NzRjMWJfMi0zLTEtMS02NTQzMQ_8bc405ab-8846-450c-bae5-a7c13d030de8">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4Ng_965f2ce9-b2d9-4fb0-b2b5-c9eeec981313" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmJkMTgwZDA5YmEwYTQwNGFiOWY3YWI5NjI1NDZhMWI5L3RhYmxlcmFuZ2U6YmQxODBkMDliYTBhNDA0YWI5ZjdhYjk2MjU0NmExYjlfMy0xLTEtMS02NTQzMQ_47f24a94-4214-4a15-a028-ac47c1130488">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmJkMTgwZDA5YmEwYTQwNGFiOWY3YWI5NjI1NDZhMWI5L3RhYmxlcmFuZ2U6YmQxODBkMDliYTBhNDA0YWI5ZjdhYjk2MjU0NmExYjlfMy0zLTEtMS02NTQzMQ_96e05af7-b486-4059-a08f-ee788aa6dc54">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmJkMTgwZDA5YmEwYTQwNGFiOWY3YWI5NjI1NDZhMWI5L3RhYmxlcmFuZ2U6YmQxODBkMDliYTBhNDA0YWI5ZjdhYjk2MjU0NmExYjlfNS0xLTEtMS02NTQzMQ_ad25a848-33ff-4d36-93b9-bbf94956c3d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmJkMTgwZDA5YmEwYTQwNGFiOWY3YWI5NjI1NDZhMWI5L3RhYmxlcmFuZ2U6YmQxODBkMDliYTBhNDA0YWI5ZjdhYjk2MjU0NmExYjlfNS0zLTEtMS02NTQzMQ_f636b2ce-bc79-4e5f-a59f-a735c927a351">2.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4Nw_dab988f3-1613-4786-a2ad-d6d7c7fce80a" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2023, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfMS0xLTEtMS02NTQzMQ_2675e33a-fc0b-431b-99b5-5c095348975c">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfMi0xLTEtMS02NTQzMQ_611086d2-c2e2-4dec-829d-78e46a1370bb">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfMy0xLTEtMS02NTQzMQ_0d224203-c192-4ef0-af17-8f42cd29a452">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfNC0xLTEtMS02NTQzMQ_1b45314f-1d05-49a0-9feb-0a7779ccfce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfOC0xLTEtMS02NTQzMQ_fa7cdd3e-91a8-4785-b78b-a15ba9675774">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfOS0xLTEtMS02NTQzMQ_d88fe2a8-166b-4ed4-beee-f83a28921b9d">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfMTAtMS0xLTEtNjU0MzE_dae3711b-9188-468f-9b8b-07c6ee002585">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RleHRyZWdpb246MmYwODIxZmUyMTliNDQ3M2EyZWRhMTYyYmRjYWVkYjJfMTIw_669ea728-8974-4449-9057-61f30e570654" continuedAt="i7a54effba5af46869febbbb76a8e8dd0" escape="true">Accounts Payable and Accrued Liabilities </ix:nonNumeric></span></div><ix:continuation id="i7a54effba5af46869febbbb76a8e8dd0"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RleHRyZWdpb246MmYwODIxZmUyMTliNDQ3M2EyZWRhMTYyYmRjYWVkYjJfMTE5_5180df01-b42f-4567-9277-1d3c5f927633" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfMS0xLTEtMS02NTQzMQ_103ee4fb-ccbc-428b-8b8c-cb82e76df6be">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfMS0zLTEtMS02NTQzMQ_876892b0-97df-4d6a-82b4-676ef77e6102">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfMy0xLTEtMS02NTQzMQ_fb8d5830-e843-4619-a1c9-0c8ef6017c7d">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfMy0zLTEtMS02NTQzMQ_2a268752-30d3-4223-8953-e9468af81986">35.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0xLTEtMS03MjY4OA_b83fe317-5724-4480-9f45-13e575e7ac67">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0zLTEtMS03MjY4OA_899085b7-459b-4aa7-9b17-eec68f76bf0e">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0xLTEtMS03MjY3Mw_89b60071-e58a-417d-bb39-544189dc2e18">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0zLTEtMS03MjY3Mw_25b05abd-7e1e-4b5f-acc8-be585c8b6953">18.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0xLTEtMS02ODQxOQ_709ef257-175f-46f4-9bee-7cd91d6e0780">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0zLTEtMS02ODQxOQ_10c549b7-d1a4-4cbb-8dc7-2e1fdbb413ee">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNy0xLTEtMS02NTQzMQ_cb0e01b7-b68a-4949-82ef-230984f410a3">66.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNy0zLTEtMS02NTQzMQ_4171c662-5aa6-4065-8367-816cc7674b90">74.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i884cf85f07be4320b5e4857b1da120ed_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMTM5Mg_a3b7e6a0-c29d-49fc-8586-da4529c87263" continuedAt="iddaa60bb16254ee78c243c14607c9279" escape="true">Long-Term Debt</ix:nonNumeric></span></div><ix:continuation id="iddaa60bb16254ee78c243c14607c9279"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMjc0ODc3OTA3MTA0Mw_d819ebfe-dcdf-49b5-b137-ba31c15f2edc" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2e5965f2e88e4a6da0dccbe7de98fca3_I20230331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMS0zLTEtMS02ODIyMQ_eae5ea4b-d1dc-4b6b-b5ff-797a015a3397">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i2e5965f2e88e4a6da0dccbe7de98fca3_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMS01LTEtMS02ODIzNQ_faf885fe-1a00-4099-82fa-8335b6cb9996">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i4017a9b524ac448cb97651cbacb79c29_I20221231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMS03LTEtMS02ODIzNQ_7242be6e-1351-4569-b451-35b1c9e762d0">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMi01LTEtMS02ODMyNw_48688e16-8084-4477-bbb7-fb06f3c376b9">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMi03LTEtMS02ODMyNw_f55eb59d-24b3-4f1d-855d-64661b14ad4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMy01LTEtMS02ODMyNw_36795747-cc1e-4235-8d30-46c02f34d994">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMy03LTEtMS02ODMyNw_2200554b-11c1-448c-bb75-69908880417e">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an additional assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $<ix:nonFraction unitRef="usd" contextRef="i33ef3273b7a642339a52f317c1217bf0_I20180630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMjY2_5685d212-c8c7-4a0a-b680-77df244bfa34">2.0</ix:nonFraction> million under the 2018 Assistance Agreement in September 2018, of which $<ix:nonFraction unitRef="usd" contextRef="i9efa444c10024282a78558891448955e_D20180901-20180930" decimals="-5" name="arvn:DebtInstrumentLoanForgiveness" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMzMz_d50e726b-c121-49ef-8813-53fb8a1fa967">1.0</ix:nonFraction> million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of <ix:nonFraction unitRef="number" contextRef="i33ef3273b7a642339a52f317c1217bf0_I20180630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNDQ5_31f8baf4-0593-41e8-92d7-9492556460c1">3.25</ix:nonFraction>% per annum, with interest-only payments required for the first <ix:nonNumeric contextRef="i9efa444c10024282a78558891448955e_D20180901-20180930" name="arvn:DebtInstrumentInterestPaymentsTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNTE0_134675d1-d40c-4b72-9ec1-7126e935f627">60</ix:nonNumeric> months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="usd" contextRef="i3aed769f8e3c49e5b63cbed7fce3cc16_I20180930" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNzMy_e9fc7885-5ee2-43ea-9631-022f281adf29">2.0</ix:nonFraction> million plus liquidated damages of <ix:nonFraction unitRef="number" contextRef="i9efa444c10024282a78558891448955e_D20180901-20180930" decimals="INF" name="arvn:PercentageOfLiquidatedDamages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNzYy_ae9d9de9-b7b5-412b-8d88-6a029c86c7bd">7.5</ix:nonFraction>% of the total amount of funding received.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an assistance agreement with the State of Connecticut entered into in 2014 under which all the borrowings by the Company were forgiven, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="usd" contextRef="i50005b9bf68d4708a6d599e4e722b8e3_I20141231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMTE5NA_56ee54f5-0635-45f7-b2d8-62c09c3f8030">2.5</ix:nonFraction> million plus liquidated damages of <ix:nonFraction unitRef="number" contextRef="i4511588e1c85470592130c5c36ee5bfb_D20140101-20141231" decimals="INF" name="arvn:PercentageOfLiquidatedDamages" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMTIyNA_11f01b9e-68ca-4aad-95ad-ed7cc6506ff4">7.5</ix:nonFraction>%. </span></div><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMTM5Mw_d83d4d56-59c0-42a8-9531-5b477505d440" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfMS0xLTEtMS02NTQzMQ_c7cf9f2d-c833-4cc8-a8d1-a77d3691fd89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfMi0xLTEtMS02NTQzMQ_33d0c7d3-2903-4d17-859c-85028c126ee3">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfMy0xLTEtMS02NTQzMQ_8c5f25c2-347f-4939-bedf-9320772cf1af">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfNC0xLTEtMS02NTQzMQ_9b3a3c41-fb3a-410e-9781-8d01c8f119a5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfNS0xLTEtMS02NTQzMQ_c0dbf468-b5cb-48a9-b31e-185b026eea29">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="arvn:LongTermDebtMaturityYearSix" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfNi0xLTEtMS02NTQzMQ_406ac45e-1b8b-4c3a-906c-f019a51c28d3">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfNy0xLTEtMS02NTQzMQ_b22a0d83-e355-4642-b815-d5aa586b3776">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, interest expense was <ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNTQ5NzU1ODE1Mjgy_c3849ffd-e7df-49cc-b65e-43c34605495f"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNTQ5NzU1ODE1Mjgy_dc750cea-8b99-4443-8bb8-bfe0eb276556">immaterial</ix:nonFraction></ix:nonFraction>.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTMzNw_845a243b-a6ac-48d7-809b-a9c5eb809b77" continuedAt="iafb3bad171174af9a880351205179cba" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="iafb3bad171174af9a880351205179cba" continuedAt="i82b9564c021549558cfb4af6d3720402"><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $<ix:nonFraction unitRef="usd" contextRef="i7bf0fb8e4f384b26bc23d6ceb6be7d53_I20210831" decimals="-5" name="arvn:MaximumAggregateOfferingPriceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzEy_38ec67e5-6c9d-4ce5-9aac-db9f5b7dfac4">300.0</ix:nonFraction> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the common stock registered under the Company's universal shelf registration statement pursuant to one or more &#8220;at-the-market" offerings. During the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i6b0bcf64028344e6af483706f401290e_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNDg2_51346eef-81eb-4769-8735-82716c28ca96">no</ix:nonFraction> shares were issued under this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="ib28dd8ea2b9a41c2971d1c69a31155e1_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfODYz_9d1885a9-6f77-46ff-9b3c-b6f0f1b9a96f">311,850</ix:nonFraction> shares of the Company&#8217;s common stock. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to <ix:nonFraction unitRef="number" contextRef="i4a71274815094838ab3c597fb2f26a9a_D20200101-20200101" decimals="2" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA3Nw_77c7930d-fdcd-4c77-9d47-c783c2bbf4fa">1</ix:nonFraction>% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="ib9aec8988f694ff0bdcb13df74a26b2b_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTE3OA_627eb118-8b85-47a4-b97d-95dc15338afd">2,495,756</ix:nonFraction> shares remained available for purchase. During the three months ended March&#160;31, 2023 and 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="id759bd76e92c4ede87b28afc4a41b568_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTI3OA_2217032b-35f3-4257-83a8-a9185911d0d5">23,206</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i92f1e3b8a73c406baaa7a7de9b0f3308_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTI4NQ_dc45c735-ca11-4ff3-aa83-d6eb0d4d9ff7">5,749</ix:nonFraction> shares of common stock, respectively, of common stock under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Share Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Fourth Amendment to the Company&#8217;s Incentive Share Plan (the &#8220;Incentive Plan&#8221;) adopted in March 2018, the Company was authorized to issue up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9dc4b7a143d749d3b66e3a8d62fc9739_I20180331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTUyNg_0cf08321-cef3-461d-ad80-09c5af023a5a">6,199,477</ix:nonFraction> incentive units pursuant to the terms of the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTczMw_e1a2df49-e8a5-4fa7-9eb4-8efbc048bb75">one</span> to <ix:nonNumeric contextRef="i4bbe490912764883b0d0a04c6f91955c_D20180301-20180331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTczOQ_6a3bb014-9c2c-480e-8596-1d86b14ea948">four years</ix:nonNumeric>. The Incentive Plan was terminated in September 2018. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) <ix:nonFraction unitRef="shares" contextRef="id11bdfbfc5664070828281a7fc7b86c7_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMjE4NQ_7f59c2f7-14cb-4af0-8841-565c198210b9">4,067,007</ix:nonFraction> shares of common stock; plus (2) the number of shares of common stock (up to <ix:nonFraction unitRef="shares" contextRef="ibd1b3df3c405457383f5264958d864d2_I20180930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMjI2NQ_8fabb737-a9d5-4f57-8f73-03666353cbb9">1,277,181</ix:nonFraction> shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of <ix:nonFraction unitRef="shares" contextRef="id5f5df6145fa4e158ed350838e5a7e21_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMjgzNQ_e3e2bfd3-55c5-4ca2-8c86-c07e32f64421">4,989,593</ix:nonFraction> shares of the Company&#8217;s common stock, <ix:nonFraction unitRef="number" contextRef="ib1a047b63716450a86e6886de00be9f1_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMjg3Ng_8c24360a-9c4c-4661-9073-89c5df7f69c0">4</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of March&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="i10eede6b30cc414dbf22a74b29deb8c6_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzA0NQ_a066cd39-1685-4fcc-9be0-7fdb21fb3d5e">2,115,004</ix:nonFraction> shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered, or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><ix:continuation id="i82b9564c021549558cfb4af6d3720402" continuedAt="i58ba343e88d34bb98b3c2f8d5062a584"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company recognized compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i5ca05a3c3aa44683a1997583823075d6_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzQ0MA_3dcfb208-6d84-4911-aca9-c8d0c7c72549">19.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie10a2301e42b4cbb841833dc0c008446_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzQ0Nw_8507246c-d883-481f-b162-2b3a77ab41f8">16.6</ix:nonFraction> million, respectively, related to the issuance of incentive awards, including $<ix:nonFraction unitRef="usd" contextRef="iabfae107724143078681007be335943e_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzMzQ0MQ_b26f61a0-8a51-467f-82c2-9dcbb3fa0a76">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibbf44409a8a841bf993b6c95041b34d7_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzMzQ1Ng_7d7557b3-1fc7-4766-8df7-cb49ed8495b3">0.1</ix:nonFraction> million, respectively, related to the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="ied3d963eb80c4cf0821da8185cb0c1b4_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzY4OA_3dab7b3c-ab76-442c-8970-1ba472b08ef8">97.7</ix:nonFraction> million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately <ix:nonNumeric contextRef="i5ca05a3c3aa44683a1997583823075d6_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzgwOQ_79b7e098-9358-4a44-b134-66fef2d6b976">1.9</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTMzOA_91dbb67a-ca57-489d-b9fc-86a59a2c1bce" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the three months ended March&#160;31, 2023 and 2022 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMS0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOjM2NmZiMjRkMDVmYjQwZGZhMmExNjZlNjhhZTI4MmJmXzQ_18bbe872-b169-4aef-936d-c8d5de5b4a1c">72.6</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMS0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOjM2NmZiMjRkMDVmYjQwZGZhMmExNjZlNjhhZTI4MmJmXzk_ded94561-2fee-42b6-ac65-11aa32b8718c">74.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMS0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOmRkNzQ5ZDVjMjU5MTRmZGZhOTdkMjg5NjE4YzE0NjQxXzQ_3d94c525-5f7c-4aeb-a5c8-e53c3d5436c3">73.2</ix:nonFraction> - <ix:nonFraction unitRef="number" contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMS0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOmRkNzQ5ZDVjMjU5MTRmZGZhOTdkMjg5NjE4YzE0NjQxXzk_f836ca32-7de7-4f0e-a9b2-11d52f4b8cb9">76.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i1dc82bdb7f3249e3a8fa6593ba2f1e2f_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMi0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOjgwMzAyZmE1ZjgwZDQzZDVhODc0MGEzNmVlN2UyN2QyXzQ_302dfa49-5f09-468d-b145-163304faf5fc">5.6</ix:nonNumeric> - <ix:nonNumeric contextRef="i349c99c38fd24411a3098e192d5bb289_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMi0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOjgwMzAyZmE1ZjgwZDQzZDVhODc0MGEzNmVlN2UyN2QyXzk_12df1f9b-4462-4265-87f3-dfbe31e02342">7.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i12c09bc9792f4d4d82779a6ecdfd5cd4_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMi0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjJiMjY1OTUyMDMzMjQzOGU4YzUyMmVmMjNjMmQ5YmQ5XzQ_80631b43-1cbb-4964-a1cd-5112e4709868">5.6</ix:nonNumeric> - <ix:nonNumeric contextRef="ia907332b480c40519a54ef9abc49ebf1_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMi0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjJiMjY1OTUyMDMzMjQzOGU4YzUyMmVmMjNjMmQ5YmQ5Xzk_dec8849f-618e-4257-9c56-053ab7094d21">7.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMy0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOmI2MjI1YjJmYzNkZDQxZjhhNjY3ODAxNmNiMDY2NDI1XzQ_73091f41-87ca-42dc-9c75-a81e2c3b3d6c">3.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMy0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOmI2MjI1YjJmYzNkZDQxZjhhNjY3ODAxNmNiMDY2NDI1Xzk_14a66fd4-6cea-423b-ac8e-735dfdc44d86">4.2</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMy0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjU0NDNmYjQzZTUwOTRiYWE5NmM3MWE0MDE3MWNhNTk5XzQ_e8921e5a-8da7-4e56-a889-53b8fc59dcc3">1.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMy0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjU0NDNmYjQzZTUwOTRiYWE5NmM3MWE0MDE3MWNhNTk5Xzk_81674d46-ff9b-4ae5-8b68-ad106acafb34">2.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNC0xLTEtMS02NTQzMQ_bfa2c15d-e0a3-4600-adbb-0551552eca23">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="number" contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNC0zLTEtMS02NTQzMQ_f8d4b3ab-37b7-44b6-9db4-494736dd650c">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id992f35185d74bae9954007b9459fa21_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNS0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOmEwYTFlZmNkNTcxODRhZTJiY2EzNjE2MTQ5MTA0OTc0XzQ_95e80405-7b2b-4400-9d99-925e33c8ea2f">30.40</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i34c0d5650542472988dfa8a33538b992_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNS0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOmEwYTFlZmNkNTcxODRhZTJiY2EzNjE2MTQ5MTA0OTc0Xzk_3dafa15b-8901-4f72-aba4-29a41040e6c9">36.27</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1f3f89b30e484ddb9d12fd481d56197e_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNS0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjU0YjI4OTVmYTYzMjQ4ZTBiOWZkNjAwNmQ1MGI1ZTRiXzQ_2c62ef2b-9ceb-4125-9d7e-e0fcd041e714">64.19</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i15fe088644044a698fa4be67f06f4289_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNS0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjU0YjI4OTVmYTYzMjQ4ZTBiOWZkNjAwNmQ1MGI1ZTRiXzk_53f3a8f8-e6f3-4da2-9baf-0097e4aefaf3">78.91</ix:nonFraction></span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the Company&#8217;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. </span></div><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTMzOQ_6b2072e4-a9f1-4458-83e4-12e0b320d0bc" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include stock options granted to employees and directors.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMS0yLTEtMS02NTQzMQ_6d565028-c698-4ab1-a0de-1b16a93c8280">6,814,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMS00LTEtMS02NTQzMQ_06127d19-5b38-40b3-985e-007c6b97740a">49.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i6b701e816ca846fca1f71db5b8b65b28_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMS02LTEtMS03NDM2MQ_972f6476-10d3-47bf-92a6-d9476fb7e107">7.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMS04LTEtMS03NDM0OA_033efd42-c97f-411c-a00f-890842c7e732">34.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMi0yLTEtMS02NTQzMQ_2f02b872-ee38-4f62-863b-b08b3b9fb010">1,470,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMi00LTEtMS02NTQzMQ_ccd957e2-edb7-4ad0-8bf1-5676ab7159db">34.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMy0yLTEtMS02NTQzMQ_688050f7-bb28-4c21-a03b-4251e27e438e">46,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMy00LTEtMS02NTQzMQ_1c01f52e-fa3f-41ab-a441-8d3af34e5f98">17.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNC0yLTEtMS02NTQzMQ_f80a71a7-59c6-47a9-80b1-81c915cd2c1e">41,416</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNC00LTEtMS02NTQzMQ_4a885b14-e882-4288-93b4-2911b0d3790a">63.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNS0yLTEtMS02NTQzMQ_da765ac3-6f4b-471d-9bb1-de9e57f234d5">8,196,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNS00LTEtMS02NTQzMQ_f6a8f875-9ac4-43ed-b623-de3ab95ff5d9">46.51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNS02LTEtMS02NTQzMQ_2a3bf235-c948-4ef5-ab52-fc4fef06dc9c">7.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNS04LTEtMS02NTQzMQ_2582034b-52dc-461a-8c67-adeb9a5181c2">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exercisable as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNi0yLTEtMS02NTQzMQ_323c563b-b280-45ae-b702-9f8cb94147d6">4,114,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNi00LTEtMS02NTQzMQ_20a6bff6-4d8a-489d-b903-3cf7d20ef9b8">40.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNi02LTEtMS02NTQzMQ_a4ceca18-8e1a-49c5-8e52-c2fadbe50e53">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNi04LTEtMS02NTQzMQ_08734aad-6e48-44ee-b385-46a7315b0ccf">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><ix:continuation id="i58ba343e88d34bb98b3c2f8d5062a584"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of options granted during the three months ended March&#160;31, 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNDYxMg_538f6eb3-4c39-4bf4-bed7-b29a699fa565">23.38</ix:nonFraction>. The total intrinsic value of options exercised during the three months ended March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNDY5Nw_f4f9739b-24b6-4a0c-aab4-a7eb66054109">0.5</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="i10eede6b30cc414dbf22a74b29deb8c6_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzMzkwNA_e4eafce6-6a66-4ae0-a30a-e840ab9c363b">67.9</ix:nonFraction> million of unrecognized stock option compensation expense that is expected to be amortized over a weighted average period of approximately <ix:nonNumeric contextRef="i8313eb035f2049c096523de984254655_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzMzkxMg_2ebc59d8-a4e5-472c-a5ce-38aeb3edc895">1.7</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i10eede6b30cc414dbf22a74b29deb8c6_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNDcyMw_6d008cac-ec05-47e3-8a13-b088224f69ed">7,743,483</ix:nonFraction> stock options under the 2018 Plan that have vested or are expected to vest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (RSUs)</span></div><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTM0MQ_19a95008-6acc-463f-afea-8e6fccd1a2ce" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include RSUs granted to employees. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i4397b2ab6c394deebbeeccdb3d6ef0f9_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMS0yLTEtMS02NTQzMQ_fcae7026-e808-4a91-881e-f0cc3d13cf2b">489,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4397b2ab6c394deebbeeccdb3d6ef0f9_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMS00LTEtMS02NTQzMQ_36ecde2f-f313-4045-bca0-7a494856c3d4">51.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMi0yLTEtMS02NTQzMQ_1db9c82f-104d-43a4-80cb-404ec3bb1e70">702,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMi00LTEtMS02NTQzMQ_135f4b0a-1612-4498-88fd-1cd19f92c3e9">34.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMy0yLTEtMS02NTQzMQ_eb26f6a7-aedb-485a-a038-31ef8d029901">81,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMy00LTEtMS02NTQzMQ_62f74853-53b4-4aaa-ae9a-8da9fb72c41e">43.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfNC0yLTEtMS02NTQzMQ_eddd6f8c-b501-4a4f-8477-659e1509e1f4">2,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfNC00LTEtMS02NTQzMQ_34167c1f-950f-4978-80a7-6fb8d3449044">58.13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="i398833cc0cbe482ca635f3baea15a579_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfNS0yLTEtMS02NTQzMQ_a328cbfc-f284-42c6-b588-ec8f363f0fca">1,107,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="i398833cc0cbe482ca635f3baea15a579_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfNS00LTEtMS02NTQzMQ_0124e24d-24df-4a68-b1c3-e127d2ca99a5">41.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of RSUs vested during the three months ended March&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="ib19aa9edf1fe4cdebd33b4a75c81c3a7_D20230101-20230331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzNDc4OQ_24b4c0fb-e8b7-42ad-9ffa-49783003711b">2.6</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="ie0298f75c6f440a58c57320fb61d4a0a_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzNDMwMA_2837160c-2e07-46d2-9346-c6d6e1ec6536">29.8</ix:nonFraction> million of unrecognized RSU compensation expense that is expected to be amortized over a weighted average period of approximately <ix:nonNumeric contextRef="i2256dbf3cc9e4c8aab20a9ac4ed1d1c6_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzNDI5Mg_6dd74b57-f517-41c0-80b2-3d955427436d">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i10eede6b30cc414dbf22a74b29deb8c6_I20230331" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTI1MQ_1c645d3f-1d46-497b-aa30-58f8a919a802">916,138</ix:nonFraction> RSUs under the 2018 Plan that have vested or are expected to vest.</span></div></ix:continuation><div id="i884cf85f07be4320b5e4857b1da120ed_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMzIwNw_d4d07908-d749-4eb1-861b-8103c82bef85" continuedAt="i34ee6f8865b5424fad36662ffd2cb0e1" escape="true">Income Taxes </ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i34ee6f8865b5424fad36662ffd2cb0e1" continuedAt="icd7549c012984103bc79c2104fbc6035">For the three months ended March&#160;31, 2023, the Company recognized income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfOTk_4fc76848-c502-442b-a20c-b9b4357e127b">0.4</ix:nonFraction> million resulting in an effective tax rate of <ix:nonFraction unitRef="number" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMTQw_54362728-e79d-4634-bd43-0646d32a50ec">0.5</ix:nonFraction>%, as compared to income tax expense of $<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMTgx_b4395eb0-031f-47ae-a9a6-c62a2e23743f">4.5</ix:nonFraction> million resulting in an effective tax rate of (<ix:nonFraction unitRef="number" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMjIy_7d3056f4-8102-4c39-9c1d-d89d7e35629a">7.9</ix:nonFraction>)% in the same period for 2022. The primary reconciling items between the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMzIw_b15429cd-39fa-4b57-b89f-80f0651ae4cb">21.0</ix:nonFraction>% for the three months ended March&#160;31, 2023 and the Company&#8217;s overall effective tax rate of <ix:nonFraction unitRef="number" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfNDAx_fe13398b-2f2f-4a2f-8ca9-42bdd8eeb61a">0.5</ix:nonFraction>% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfNjg0_60cce8c5-23cc-4beb-9adf-73d19a19a0b6">21.0</ix:nonFraction>% for the three months ended March&#160;31, 2022 and the Company&#8217;s overall effective tax rate of (<ix:nonFraction unitRef="number" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfNzY1_e052a326-6803-419f-8bab-4d89725a3b20">7.9</ix:nonFraction>)% was the effect of equity compensation, deferred state income taxes and the valuation allowance recorded against the full amount of its net deferred tax assets.</ix:continuation></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icd7549c012984103bc79c2104fbc6035">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a full valuation allowance against the Company&#8217;s net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is based on the Company's historical cumulative losses which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RleHRyZWdpb246MjA3YTA4YmI4OTlmNDBhZDhiMjZkZDgyZWRmMmQ5MGVfNDA2_0eba5d99-9daf-44dc-8aac-fa1135191690" continuedAt="i2d5f6b8478da4770bf69ea2a3f7d9d62" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="i2d5f6b8478da4770bf69ea2a3f7d9d62"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RleHRyZWdpb246MjA3YTA4YmI4OTlmNDBhZDhiMjZkZDgyZWRmMmQ5MGVfNDA3_d49161c1-94d5-4a33-920e-a741ae94d571" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMi0xLTEtMS02NTQzMQ_d372fac0-4cf9-4894-896e-ffeb1c10f9c5">81.9</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMi0zLTEtMS02NTQzMQ_abdf8abb-c81b-4874-bc2e-dc07ff624a32">63.4</ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average number of common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;- basic and diluted</span></div></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMy0xLTEtMS02NTQzMQ_6fb8b296-b8b5-4f5a-9d44-4af7da8d0ddc"><ix:nonFraction unitRef="shares" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMy0xLTEtMS02NTQzMQ_f2adb9f5-7468-4a95-8e5a-a5d82f3bcf93">53.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMy0zLTEtMS02NTQzMQ_791efd23-494b-4019-b1d7-c7917128858d"><ix:nonFraction unitRef="shares" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMy0zLTEtMS02NTQzMQ_a9caa776-2cd3-4840-b305-939cba75f45f">53.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss per common share </span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">-  basic and diluted</span></div></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfNC0xLTEtMS02NTQzMQ_2863a3c7-7cd1-4c7a-8e69-0c385817a3c5"><ix:nonFraction unitRef="usdPerShare" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfNC0xLTEtMS02NTQzMQ_d8855081-a7a4-41f3-a6eb-c64e3e441efb">1.54</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfNC0zLTEtMS02NTQzMQ_64b6f744-3d35-4064-b855-1b6162e66767"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfNC0zLTEtMS02NTQzMQ_9d67e743-1041-4703-886c-88c319d0c3b3">1.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RleHRyZWdpb246MjA3YTA4YmI4OTlmNDBhZDhiMjZkZDgyZWRmMmQ5MGVfNDA4_6c63fc2e-298b-45a4-b879-5dbde9d160e5" escape="true"><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the three months ended March&#160;31, 2023 and 2022, and, therefore, excluded all stock options and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11a56379c5434b73ac2a8a2184bf2b26_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfMi0xLTEtMS02NTQzMQ_6a2a1f6f-074a-41ae-b36e-c5496af7786e"><ix:nonFraction unitRef="shares" contextRef="i11a56379c5434b73ac2a8a2184bf2b26_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfMi0xLTEtMS02NTQzMQ_c8eadaed-2414-4cb6-8ba4-c136a3e1d7ce">8.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ice51fdd252534ce4910cdfd6c31f0453_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfMi0zLTEtMS02NTQzMQ_90942dc7-cdad-4dec-b9ed-521a1454bc70"><ix:nonFraction unitRef="shares" contextRef="ice51fdd252534ce4910cdfd6c31f0453_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfMi0zLTEtMS02NTQzMQ_b03bbc20-f373-4102-95a4-d3fc3d9949bf">6.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79495c5a256b4d7db64470507e85fdaf_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNC0xLTEtMS02NTQzMQ_1a4157aa-b0ce-4e0f-914b-e701db68835b"><ix:nonFraction unitRef="shares" contextRef="i79495c5a256b4d7db64470507e85fdaf_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNC0xLTEtMS02NTQzMQ_c22ee5af-b759-4394-86c3-00173af4e1f0">1.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec101bcd50d841439204bb45185f462f_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNC0zLTEtMS02NTQzMQ_3e65deb9-4c4f-436b-a8a5-f54bc8ffd2ad"><ix:nonFraction unitRef="shares" contextRef="iec101bcd50d841439204bb45185f462f_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNC0zLTEtMS02NTQzMQ_6a063680-3b41-470e-be6d-742b03e36e8b">0.2</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNS0xLTEtMS02NTQzMQ_581faf11-4686-48d0-8e60-fc36a6edad02"><ix:nonFraction unitRef="shares" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNS0xLTEtMS02NTQzMQ_b5a24498-d1f9-4223-9a65-e0eef43a7030">9.3</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNS0zLTEtMS02NTQzMQ_7fbbcd23-2094-452d-b469-26a737e9aa8f"><ix:nonFraction unitRef="shares" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNS0zLTEtMS02NTQzMQ_e425b696-5883-4c33-adc8-f507e38d0f3e">6.6</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i884cf85f07be4320b5e4857b1da120ed_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA1MA_249b1651-b7a6-4759-a4b8-51a8160888f5" continuedAt="i76cfe583d5cd43e9ac26c409bbd384ce" escape="true">Equity Method Investments</ix:nonNumeric></span></div><ix:continuation id="i76cfe583d5cd43e9ac26c409bbd384ce" continuedAt="id65f92af2fa741549a354e69dd42e6ba"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP (&#8220;Bayer LP&#8221;) formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of <ix:nonFraction unitRef="number" contextRef="ia79bc328db4a4707a837e784c470a1b4_I20190731" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMzU2_6e2a5637-31d3-428f-a1aa-08775aec001a">50</ix:nonFraction>%. A <ix:nonFraction unitRef="number" contextRef="i97cfc9c7c575435c98bd43efeb5fb152_I20190731" decimals="2" name="arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYzMDU3OQ_6e83ceb9-a756-4c26-b576-c79601f71cf7">15</ix:nonFraction>% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled <ix:nonFraction unitRef="number" contextRef="i1a7e68f89e4c4b938c8c387fb7a06158_I20230331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYzMTM5MA_624d521d-4080-4c0b-a4c2-100751a6cbe1">46.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ib401d1efe8db4e449e1330c66a20922b_I20220331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYzMTM5NA_8a398fcc-ec73-4f87-b6e7-42208050c98b">47.7</ix:nonFraction>% as of March&#160;31, 2023 and 2022, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the preparation of the Company's consolidated financial statements for the yea</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">r ended December 31, 2022, the Company identified a prior period error related to the accounting of its investment in Oerth Bio in 2019. Previously, the Company disclosed that revenue of $<ix:nonFraction unitRef="usd" contextRef="ie9edfe32c55049d6b67f5d1ff33010d6_I20221231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYzMzg1Ng_20f0cc4a-00a9-471d-906e-cb169fef7efb">24.7</ix:nonFraction>&#160;million was deferred and would be recognized if and when Oerth Bio recognized revenue associated with the license. The Company has determined that the consideration received for the amounts associated with the deferred revenue should have been constrained, because at the time Bayer LP had contributed only a portion of its full cash commitment to Oerth Bio, and Bayer LP had the right to all the cash contributed, but not yet spent, upon liquidation of Oerth Bio. The constrained revenue should have been recognized upon both cash being contributed by Bayer LP and the related cash spent by Oerth Bio on research and development activities. As such, for each period presented, the revenue recognized is accompanied by corresponding equity method losses of the same amount. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company ev</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aluated the error</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd determined that the related impact did not materially misstate the previously issued unaudited condensed consoli</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dated financial statements for the three months ended March&#160;31, 2022. Although the Company concluded that the error was not material to its previously issued unaudited condensed consolidated financial statements, the Company has</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined it is appropriate to adjust its previously issued unaudited condensed consolidated financial statements for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to correct</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the error and improve comparability</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfNjA0NzMxMzk1OTA0OA_f8f695d0-b676-43ab-933f-7b495babb45e" continuedAt="i17a6a8070e2347c88135c6cabdf51970" escape="true">The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in stockholders&#8217; equity.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><ix:continuation id="id65f92af2fa741549a354e69dd42e6ba"><div style="margin-top:12pt"><ix:continuation id="i17a6a8070e2347c88135c6cabdf51970"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMi0xLTEtMS03MDYyNg_0adff91a-8085-494a-9545-cdb0510667ac">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMi0zLTEtMS03MDYyNg_a830a444-346d-48b6-8001-586af9261b95">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMi01LTEtMS03MDYyNg_e594f583-96e3-41f1-8a65-79ad3e008d5b">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMy0xLTEtMS03MDYyNg_d3e9bf3c-22fa-4fcf-95e6-96c62cfcd569">60.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMy0zLTEtMS03MDYyNg_a6eff5ab-5d59-4b5d-86ec-d1747b6d881e">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMy01LTEtMS03MDc0NA_9b3cb4be-65e8-43b5-8719-5c712ef49d16">57.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNC0xLTEtMS03MDYyNg_bc6bc3e6-1e59-45bd-b69a-5b527f3fbbc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNC0zLTEtMS03MDYyNg_fb674f9a-f663-4f18-b0fe-f88747d2b883">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNC01LTEtMS03MDYyNg_61e779ab-cff7-4f7a-88ab-e2a11514eb92">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNS0xLTEtMS03MDYyNg_7db36e1f-2cb3-4873-87f2-5bb487634d7d">63.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNS0zLTEtMS03MDYyNg_df72f6f5-3b9b-4bae-99bf-6d0d4b3d980a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNS01LTEtMS03MDYyNg_dc9cfaaf-c363-47d2-856b-2932c881da78">63.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi0xLTEtMS03MDYyNg_c211f1c6-49c7-4943-8c11-962369ac5179"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi0xLTEtMS03MDYyNg_e450988d-8201-4087-a07a-f4bfc01afa15">1.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi0zLTEtMS03MDYyNg_3576c47b-6fd5-45eb-8894-4753856f05b7"><ix:nonFraction unitRef="usdPerShare" contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi0zLTEtMS03MDYyNg_af9b65cc-e484-4676-9d2e-02cac40b910f">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi01LTEtMS03MDYyNg_d91bcedc-de5b-427e-8c6e-e3d723ab3c25"><ix:nonFraction unitRef="usdPerShare" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi01LTEtMS03MDYyNg_e8c864cd-21f9-4e6a-8c06-f1ed8a30af78">1.20</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNy0xLTEtMS03MDYyNg_ee00e2b2-c7e1-4455-aa7a-b4e54debd1df">77.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNy0zLTEtMS03MDYyNg_7d2bc362-d232-4b36-ba27-58acafeb9127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNy01LTEtMS03MDYyNg_24736a2a-e19c-4f0b-b91c-68924699c5f5">77.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss of Oerth Bio for the three months ended March&#160;31, 2023 and 2022 totaled $<ix:nonFraction unitRef="usd" contextRef="i1dcee608cf2542be9ac23c358b3e4eae_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfNzIz_a55bd68f-e214-4022-a41d-da2a3f5cac8e">2.4</ix:nonFraction> million</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i50b1538561114837a04b610d8fb7d5df_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfNzMw_eb0a798f-c558-41c7-af34-a1c52b4c061d">4.9</ix:nonFraction> million, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity method losses of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYyOTk0Mw_a3a8a387-8602-4ca5-927e-9d8b447e8255">1.1</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYyOTk1OA_d6d26d39-8057-486e-aa58-8f8d09708b9a">2.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2023 and 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying value of t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he investment was <ix:nonFraction unitRef="usd" contextRef="i7c7ac62b86294b8d8b81d6270bdf4b43_I20220331" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfOTEz_9b6b932d-cb0b-4afb-9aeb-5b2bd5c1943b"><ix:nonFraction unitRef="usd" contextRef="i5b3f861bb3b64d2eb62b4fffd96d22d2_I20230331" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfOTEz_f3ed14ca-79b0-4c60-994f-ba17331338a5">zero</ix:nonFraction></ix:nonFraction>.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three months ended March&#160;31, 2023 and 2022 were immaterial.</span></div></ix:continuation><div id="i884cf85f07be4320b5e4857b1da120ed_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84NS9mcmFnOmZmMWU0ZWMwYTM1ZDRjZjZhM2QxNTAzYjM4ZmI5NWE0L3RleHRyZWdpb246ZmYxZTRlYzBhMzVkNGNmNmEzZDE1MDNiMzhmYjk1YTRfNDAzOA_d855c0bc-cad3-4c22-b19a-14589acd55db" continuedAt="i4978e0894a2048eb8353975f09f86b26" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i4978e0894a2048eb8353975f09f86b26" continuedAt="i9169ec36ff1d434196548dd77ff38244"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;The Company's accrual for such matters totaled $<ix:nonFraction unitRef="usd" contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84NS9mcmFnOmZmMWU0ZWMwYTM1ZDRjZjZhM2QxNTAzYjM4ZmI5NWE0L3RleHRyZWdpb246ZmYxZTRlYzBhMzVkNGNmNmEzZDE1MDNiMzhmYjk1YTRfMTA5OTUxMTYzMjI5Ng_d6ef0106-b25f-4e05-8250-0b48d46adec9">7.0</ix:nonFraction>&#160;million as of March&#160;31, 2023, primarily related to a contract dispute that is in early stages. Due to the early stage of the dispute, the means of resolution are unknown and could involve contract modification and, or payment of consideration.&#160;An estimate of the possible range of loss associated with the dispute cannot be made at this time and the Company has accrued its best estimate as of March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical and Preclinical Development and Licensing Arrangements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">FMI Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Master In Vitro Diagnostics Agreement (the "FMI Agreement") with Foundation Medicine, Inc. ("Foundation Medicine") for the development and commercialization of one or more of Foundation Medicine&#8217;s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine may terminate the FMI Agreement with respect to an applicable program, if (a) a reasonably necessary third party license is not secured by Foundation Medicine or if the Company does not consent to payments for such license (b) Foundation Medicine </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><ix:continuation id="i9169ec36ff1d434196548dd77ff38244"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain license and other rights and certain obligations of Foundation Medicine survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine and may also be required to pay a termination fee, if applicable.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bavdegalutamide</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the development of FoundationOne&#174; Liquid CDx as a companion diagnostic for use with bavdegalutamide for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low to mid tens of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARV-766</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the development of FoundationOne&#174; Liquid CDx as a companion diagnostic for use with ARV-766 for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low <ix:nonFraction unitRef="usd" contextRef="i86e8d060431b44969048abce12f5e513_D20220604-20220604" decimals="-6" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt-sec:numwordsen" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84NS9mcmFnOmZmMWU0ZWMwYTM1ZDRjZjZhM2QxNTAzYjM4ZmI5NWE0L3RleHRyZWdpb246ZmYxZTRlYzBhMzVkNGNmNmEzZDE1MDNiMzhmYjk1YTRfMjYxOQ_48db7dc2-7823-46fe-a7c9-c116bb084c3e">ten</ix:nonFraction>s of millions of dollars in addition to certain validation fees per sample and related pass-through costs.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amount and certainty of cash flows from operations and from outside sources, so as to allow investors to better view our company from management&#8217;s perspective. You should read the following discussion and analysis of financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the consolidated financial statements and the related notes and discussion and analysis of financial condition and results of operations in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed on February&#160;23, 2023. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed on February&#160;23, 2023 and elsewhere in this Quarterly Report on Form 10-Q, our actual results may differ materially from those anticipated in or implied by these forward-looking statements. </span></div><div id="i884cf85f07be4320b5e4857b1da120ed_91"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. We use our PROTAC Discovery Engine, our proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body&#8217;s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We believe that our targeted protein degradation approach is a therapeutic modality that may provide distinct advantages over existing modalities, including traditional small molecule therapies and gene-based medicines. We have a robust preclinical pipeline of PROTAC protein degraders targeting a broad range of intracellular disease targets, including those representing proteins that currently cannot be addressed by existing small molecule therapies, commonly referred to as &#8220;undruggable&#8221; targets. We are using our PROTAC Discovery Engine to build an extensive pipeline of protein degradation product candidates to target diseases in areas of unmet need, including oncology (including immuno-oncology), neuroscience and other therapeutic areas. We have three investigational clinical stage programs:  Vepdegestrant (ARV-471), a novel PROTAC estrogen receptor, or ER, protein degrader for the treatment of patients with locally advanced or metastatic ER positive / human epidermal growth factor receptor 2, or HER2, negative, or ER+/HER2-, breast cancer and bavdegalutamide (ARV-110) and ARV-766, each an oral PROTAC protein degrader that targets the androgen receptor protein, or AR, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vepdegestrant (ARV-471)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. We are co-developing vepdegestrant with Pfizer, Inc., or Pfizer, pursuant to a collaboration agreement that we and Pfizer entered into in July 2021. We granted Pfizer worldwide co-exclusive rights to develop and commercialize vepdegestrant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, vepdegestrant demonstrated near-complete ER degradation in tumor cells, induced robust tumor shrinkage when dosed as a single agent in multiple ER-driven xenograft models, and showed superior anti-tumor activity when compared to a standard of care agent, fulvestrant, both as a single agent and in combination with a cyclin-dependent kinase, or CDK, 4/6 inhibitor. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the first quarter of 2023, we continued enrollment in VERITAC-2, a Phase 3-second-line clinical trial of vepdegestrant as a monotherapy for the treatment of patients with ER+/HER2- metastatic breast cancer. We expect to complete enrollment for VERITAC-2 in the second half of 2024. In the first quarter of 2023, we continued enrollment in TACTIVE-U, a Phase 1b clinical trial of vepdegestrant in combination with abemaciclib or ribociclib, TACTIVE-E, a clinical trial of vepdegestrant in combination with everolimus, and TACTIVE-N, a clinical trial of vepdegestrant as a monotherapy in the neoadjuvant setting. We expect to initiate additional arms </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of TACTIVE-U, a Phase 1b combination trial of vepdegestrant with other targeted therapies, during the second half of 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also, in the first quarter of 2023, we and Pfizer gained alignment with the U.S. Food and Drug Administration, or the FDA, on an approach for the planned first-line, metastatic ER+/HER2- breast cancer Phase 3 trial (VERITAC-3) of vepdegestrant in combination with IBRANCE&#174; (palbociclib). The safety lead-in is expected to initiate in the second half of 2023 and will start with a lead-in to evaluate the dose of palbociclib (100 mg or 75 mg) in combination with 200 mg vepdegestrant once daily. The objective is to select a dose of palbociclib (100 mg or 75 mg) that, when dosed with vepdegestrant 200 mg, results in a similar exposure and safety profile as palbociclib 125 mg in combination with aromatase inhibitors. This approach follows the recent analysis of data from the ongoing Phase 1b combination study of vepdegestrant with palbociclib, in which an increase in palbociclib exposure was observed relative to historical palbociclib pharmacokinetic data.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary results from the Part C dose escalation trial (the Phase 1b combination of vepdegestrant  palbociclib at 125 mg) demonstrate an observed clinical benefit rate (CBR; rate of confirmed complete response, confirmed partial response, or stable disease &#8805;24 weeks) of 60.7% (95% CI, 40.6 &#8211; 78.5) across all dose cohorts (17 of 28 CBR-evaluable patients; patients are CBR-evaluable if they received their first dose &gt;24 weeks prior to the cut-off). We expect, with Pfizer, to present data from the Phase 1b combination at a medical congress in the second half of 2023. In particular: </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">85.7% of the 28 CBR-evaluable patients had received CDK4/6 inhibitor therapy prior to study entry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase in palbociclib exposure was observed relative to historical palbociclib pharmacokinetic data; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A similar overall safety profile was observed compared with that reported in previous palbociclib and endocrine therapy combination studies, except for a higher incidence of grade 3/4 neutropenia, which was managed by monitoring and dose modification per the palbociclib label. Patients were started on palbociclib 125 mg irrespective of dose reduction during prior CDK4/6 inhibitor therapy.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we presented vepdegestrant preclinical data at American Association for Cancer Research (AACR) annual meeting demonstrating the potential utility of vepdegestrant as an endocrine therapy backbone for combination with other targeted agents in early and late-stage ER+/HER2- breast cancer and the potential mechanisms of acquired resistance to vepdegestrant that may be associated with alterations within Receptor Tyrosine Kinase/MAPK signaling pathways rather than ER signaling or E3 ligase machinery. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bavdegalutamide (ARV-110)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bavdegalutamide (ARV-110) is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the AR for the treatment of men with mCRPC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, bavdegalutamide demonstrated activity of AR mutation or overexpression, both common mechanisms of resistance to currently available AR-targeted therapies. In 2019, we initiated a Phase 1/2 clinical trial of bavdegalutamide designed to assess the safety, tolerability and pharmacokinetics of bavdegalutamide and which trial also included measures of anti-tumor activity as secondary endpoints, including reduction in prostate specific antigen, or PSA, a well-recognized biomarker of prostate cancer progression. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to initiate a global Phase 3 clinical trial of bavdegalutamide for the treatment of men with mCRPC with AR T878/H875 tumor mutations in the second half of 2023 and submit and present additional interim data, including radiographic progression free survival, from the ongoing Phase 1 and Phase 2 (ARDENT) clinical trials at a medical congress in the second half of 2023. Also in the second half of 2023, we expect to complete enrollment in the Phase 1b clinical trial of bavdegalutamide in combination with abiraterone for the treatment of men with mCRPC.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-766</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-766 is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide, as a potential treatment for men with mCRPC. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, ARV-766 degraded all tested resistance-driving point mutations of AR, including L702H, a mutation associated with treatment with abiraterone and other AR-pathway therapies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2023, we presented ARV-766 preclinical data at the AACR annual meeting. We expect to share data from the Phase 1 dose escalation trial of ARV-766 for the treatment of men with mCRPC in the second quarter of 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second half of 2023, we also anticipate initiating a Phase 1b or Phase 2 trial for either of bavdegalutamide or ARV-766 in patients with AR-dependent tumors who have not previously received novel hormonal agents, or NHA, such as enzalutamide or abiraterone, and who may benefit from bavdegalutamide or ARV-766 therapy. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are further diversifying our pipeline by developing new PROTAC targeted protein degraders against targets for which we believe protein degradation offers advantages to existing therapeutic modalities, including PROTAC degraders that are designed to reach targets in deep brain regions and are capable of being delivered through multiple routes of administration, including oral delivery. We have engineered PROTAC targeted protein degraders that, in preclinical studies, have successfully achieved blood-brain barrier penetration, a key step in developing drugs with the potential to treat neurodegenerative diseases. We believe there are many other indications for which our PROTAC technology may be advantageous. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In April 2023, we presented in-vivo and in-vitro data at AACR - Targeting RAS Special Conference demonstrating our G12D PROTAC degraders are potent, selective and led to tumor stasis in a mouse xenograft model with intermittent dosing and degradation of KRAS G12D provides an advantage vs. inhibition </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vitro </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">. We also presented new preclinical data at the CHDI Foundation&#8217;s Annual Huntington&#8217;s Disease Therapeutics Conference showing our PROTAC degraders potently and selectively degrade soluble mutant huntingtin (mHTT) in multiple cellular readouts, including rodent neurons, while sparing wild-type HTT.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By year-end 2023, we expect to submit an investigational new drug, or IND, application or clinical trial application, or CTA, for our PROTAC degrader designed to target each of the BCL6 protein, a protein mutated in patients with different forms of Non-Hodgkins Lymphoma, including Diffuse Large B-Cell Lymphoma, and the LRRK2 protein, a protein kinase that has been genetically linked to some forms of Parkinson's Disease. We also expect to progress at least two additional PROTAC protein degrader programs into IND-enabling or CTA-enabling studies by year-end 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in 2013. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trials and establishing arrangements with third parties for the manufacture of initial quantities of our product candidates. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity interests, proceeds from our collaborations, grant funding and debt financing. Since inception through March&#160;31, 2023, we raised approximately $1.3&#160;billion in gross proceeds from the sale of equity instruments and the exercise of stock options and had received an aggregate of $783.0&#160;million in payments primarily from collaboration partners.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage company. Vepdegestrant (ARV-471), bavdegalutamide (ARV-110) and ARV-766 are each in Phase 1/2 clinical trials, vepdegestrant is also in a Phase 3 clinical trial and our other drug discovery activities are at the research and preclinical development stages. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. Since inception, we have incurred significant operating losses and expect to incur increasing operating losses for at least the next several years due to costs associated with our ongoing and anticipated clinical activities for vepdegestrant, bavdegalutamide and ARV-766, development activities associated with our other product candidates, research activities in oncology, neurological and other disease areas to expand our pipeline, hiring additional personnel in research, clinical trials, quality and other functional areas, increased expenses incurred with contract manufacturing organizations to supply us with product for our preclinical and clinical studies and contract research organizations for the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">synthesis of compounds in our preclinical development activities, as well as other associated costs including the management of our intellectual property portfolio. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate revenue from sales of any product for many years, if ever. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research or product development programs or any future commercialization efforts, or to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_94"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. Our revenues to date have been generated through research collaboration and license agreements. Revenue is recognized ratably over our expected performance period under each agreement. We expect that any revenue for the next several years will be derived primarily from our current collaboration agreements and any additional collaborations that we may enter into in the future. To date, we have not received any sales-based milestone payments or royalties under any of the collaboration agreements. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into an Option and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, collectively referred to as Genentech, focused on PROTAC targeted protein degrader discovery and research for target proteins, or Targets, based on our proprietary platform technology, other than excluded Targets as described below. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Genentech Agreement, Genentech has the right to designate up to ten Targets for further discovery and research utilizing our PROTAC platform technology. Genentech may designate as a Target any protein to which a PROTAC targeted protein degrader, by design, binds to achieve its mechanism of action, subject to certain exclusions. Genentech also has the right to remove a Target from the collaboration and substitute a different Target that is not an excluded Target at any time prior to us commencing research on such Target or in certain circumstances following commencement of research by us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time we entered into the original agreement with Genentech, we received an upfront payment of $11.0 million, and at the time we entered into the Restated Genentech Agreement, we received an additional $34.5 million in upfront and expansion target payments. We are eligible to receive payments aggregating up to $44.0 million per Target upon the achievement of specified development milestones; payments aggregating up to $52.5 million per Target (assuming approval of two indications) subject to the achievement of specified regulatory milestones; and payments aggregating up to $60.0 million per PROTAC targeted protein degrader directed against the applicable Target, subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the licensed PROTAC targeted protein degrader at the time the milestone is achieved. We are also eligible to receive, on net sales of licensed PROTAC targeted protein degraders, mid-single digit royalties, which may be subject to reductions. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets, using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Research Collaboration Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Research Collaboration Agreement, Pfizer has designated a number of initial Targets. For each identified Target, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial Target candidates, subject to the stage of research for such Target. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, we received an upfront non-refundable payment and certain additional payments totaling $28.0 million in exchange for use of our technology license and to fund Pfizer-related research, as defined within the Pfizer Research Collaboration Agreement. We are eligible to receive up to an additional $37.5 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. We are also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as mid- to high-single digit tiered royalties, which may be subject to reductions, on net sales of PROTAC targeted protein degrader-related products. During the three months ended March&#160;31, 2023 and 2022, we received payments totaling $1.0 million and $3.5 million which were included in accounts receivable as of December 31, 2022 and 2021, respectively, for additional targets and services.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we entered into a Collaboration and License Agreement, or the Bayer Collaboration Agreement, with Bayer AG, or, together with its controlled affiliates, Bayer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets, using our proprietary platform technology, that are selected by Bayer, subject to certain exclusions and limitations. The Bayer Collaboration Agreement became effective in July 2019. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Bayer Collaboration Agreement, we and Bayer conduct a research program pursuant to separate research plans mutually agreed to by us and Bayer and tailored to each Target selected by Bayer. Bayer may make substitutions for any such initial Target candidates, subject to certain conditions and based on the stage of research for such Target. During the term of the Bayer Collaboration Agreement, we are not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any Target selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront non-refundable payment of $17.5 million. Bayer is committed to fund a total of $12.0 million in research funding payments through 2023, all of which was received as of March&#160;31, 2023, including $1.5 million and $3.0 million in the three months ended March 31, 2023 and 2022, respectively, subject to potential increases if our costs for research activities exceed the research funding payments allocated to a Target and certain conditions are met. We are also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, we are eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer ARV-471 Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a Collaboration Agreement with Pfizer, or the ARV-471 Collaboration Agreement, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound ARV-471, or the Licensed Products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ARV-471 Collaboration Agreement, we received an upfront, non-refundable payment of $650.0 million. In addition, we are eligible to receive up to an additional $1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer share equally (50/50) all development costs (including costs for conducting any clinical trials) for the Licensed Products, subject to certain exceptions. Except for certain regions described below, we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will also share equally (50/50) all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be the marketing authorization holder and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. We will determine with Pfizer which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of all profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the ARV-471 Collaboration Agreement will expire on a Licensed Product-by-Licensed Product and country-by-country basis when such Licensed Products are no longer commercialized or developed for commercialization in such country. Pfizer may terminate the ARV-471 Collaboration Agreement for convenience in its entirety or on a region-by-region basis subject to certain notice periods. Either party may terminate the ARV-471 Collaboration Agreement for the other party&#8217;s uncured material breach or insolvency. Subject to applicable terms of the ARV-471 Collaboration Agreement, including certain payments to Pfizer upon termination for our uncured material breach, effective upon termination of the ARV-471 Collaboration Agreement, we are entitled to retain specified licenses to be able to continue to exploit the Licensed Products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to specified exceptions, we and Pfizer have each agreed not to directly or indirectly research, develop, or commercialize any competing products outside of the ARV-471 Collaboration Agreement anywhere in the world during the term of the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">salaries, benefits and other related costs, including stock-based compensation expense, for personnel engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">expenses incurred under agreements with third parties, including CROs and other third parties that conduct research and preclinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs of laboratory supplies and developing preclinical studies and clinical trial materials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">third-party licensing fees. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee and infrastructure resources across our development programs, and as such, do not track all of our internal research and development expenses on a program-by-program basis. The following table summarizes our research and development expenses for our AR program, which includes </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bavdegalutamide and ARV-766, ER program, which includes vepdegestrant, and all other platform and exploratory research and development costs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">AR program development costs</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.6&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.1&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ER program development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33.1&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">95.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">64.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to conduct our ongoing clinical trials for vepdegestrant, bavdegalutamide and ARV-766, including our Phase 3 clinical trial for vepdegestrant, and continue to discover and develop additional product candidates. Research and development expenses related to vepdegestrant are shared equally with Pfizer from July 22, 2021, the effective date of the ARV-471 Collaboration Agreement. The ER program development costs in the table above reflect the cost sharing with Pfizer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot determine with certainty the duration and costs of future clinical trials of vepdegestrant, bavdegalutamide and ARV-766 or any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">successful completion of preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">receipt and related terms of marketing approvals from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">making arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">obtaining and maintaining third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">maintaining a continued acceptable safety profile of the products following approval; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">effectively competing with other therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we increase our personnel headcount to support increased research and development activities relating to our product candidates. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with the Nasdaq Stock Market and Securities and Exchange Commission requirements; director and officer insurance costs; and investor and public relations costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2013 through December&#160;31, 2022, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our federal or state earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. During the year ended December&#160;31, 2022, we fully utilized our previously held federal net operating loss and federal credit carryforwards due to taxable income resulting from revenue recognition for tax purposes from our ARV-471 Collaboration Agreement and the mandatory capitalization of qualified research and development expenses incurred on or after January 1, 2022 under the Tax Cuts and Jobs Act. For the three months ended March&#160;31, 2023 we recorded a tax benefit related to expected benefits from state net operating loss carryback claims. We expect to generate federal and state net operating losses and credit carryforwards in 2023 and future periods. The revenue recognition and capitalization of research expenses are timing differences for tax purposes and deferred tax assets were established. We have provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon our earnings history, it is more likely than not that the benefits will not be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, Arvinas, Inc. had four wholly-owned subsidiaries organized as C-corporations: Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_97"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our unaudited condensed consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting estimates from those described in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2022, filed with the Securities and Exchange Commission on February&#160;23, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_100"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March&#160;31, 2023 and 2022</span></div><div style="margin-top:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.4)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the three months ended March&#160;31, 2023 totaled $32.5&#160;million, compared to $26.5&#160;million for the three months ended March&#160;31, 2022. The increase of $6.0&#160;million was primarily due to an increase in revenue from the ARV-471 Collaboration Agreement with Pfizer totaling $15.9&#160;million, partially offset by a net decrease in revenue totaling $8.2&#160;million due to extensions of the period of revenue recognition under both the Pfizer Research Collaboration Agreement and Bayer Collaboration Agreement and a decrease of $1.2&#160;million of previously constrained deferred revenue related to our Oerth Bio joint venture.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended March&#160;31, 2023 totaled $95.3&#160;million, compared to $64.0&#160;million for the three months ended March&#160;31, 2022. The increase of $31.3&#160;million was primarily due to an increase in our continued investment in our platform and exploratory programs of $18.3&#160;million as well as increases in expenses related to our AR and ER programs of $3.5&#160;million and $9.5&#160;million, respectively. The increase in spending over all of our programs was primarily due to increased clinical trial costs and related drug manufacturing costs of $7.1&#160;million within our AR and ER programs. Direct expenses related to our platform and exploratory targets increased by $10.4&#160;million as we continued to expand the number of protein targets in the exploratory and lead optimization phases and continued to make investments into our platform discovery efforts.</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel related costs also increased by $11.1&#160;million, inclusive of $2.6&#160;million of stock compensation expense.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses totaled $24.9&#160;million for the three months ended March&#160;31, 2023, compared to $20.2&#160;million for the three months ended March&#160;31, 2022. The increase of $4.7&#160;million was primarily due to an increase of personnel related costs of $2.3&#160;million and professional fees of $1.4&#160;million.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income totaled $6.5&#160;million for the three months ended March&#160;31, 2023, compared to $1.1&#160;million for the three months ended March&#160;31, 2022. The increase of $5.4&#160;million was primarily due to higher interest income of $6.4&#160;million from higher interest rates, offset in part by higher realized losses on our marketable securities of $0.9&#160;million.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Income tax benefit totaled $0.4 million for the three months ended March&#160;31, 2023, compared to an income tax expense of $4.5 million for the three months ended March&#160;31, 2022.  Current year tax benefit was driven by expected benefits from state net operating loss carryback claims. Prior year tax expense was driven </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">by revenue recognition for tax purposes from our ARV-471 Collaboration Agreement and the capitalization of research and development expenses incurred on or after January 1, 2022.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss from Equity Method Investment </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from equity method investment totaled $1.1 million for the three months ended March&#160;31, 2023, compared to $2.3 million for the three months ended March&#160;31, 2022. The decrease of $1.2 million was due to lower net losses incurred by Oerth Bio for the three months ended March&#160;31, 2023.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_103"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through the sale of equity interests and through payments from collaboration partners, grant funding and loans from the State of Connecticut. Since inception through March&#160;31, 2023, we had received an aggregate of $783.0&#160;million in payments from collaboration partners, grant funding and forgivable and partially forgivable loans from the State of Connecticut, and raised approximately $1.3&#160;billion in gross proceeds from the sale of equity interests and the exercise of stock options, including: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">October 2018: completion of our initial public offering in which we issued and sold an aggregate of 7,700,482 shares of common stock, for aggregate gross proceeds of $123.2 million before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">July 2019: sale of 1,346,313 shares of common stock to Bayer AG for aggregate gross proceeds of $32.5 million; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">November 2019: completion of a follow-on offering in which we issued and sold 5,227,273 shares of common stock for aggregate gross proceeds of $115.0 million before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">September &#8211; December 2020: sale of 2,593,637 shares of common stock in an &#8220;at-the-market offering&#8221; for aggregate gross proceeds of $65.6 million before fees and expenses;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">December 2020: completion of a follow-on offering in which we issued and sold 6,571,428 shares of common stock for aggregate gross proceeds of $460.0 million before fees and expenses; and</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">September 2021: issuance of 3,457,815 shares of common stock to Pfizer for aggregate gross proceeds of $350.0 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we entered into a lease, which was amended in August 2022, for approximately 160,000 square feet of laboratory and office space, expected to be occupied in 2025. In connection with the signing of the lease and the related amendment, and at our election to increase the landlord&#8217;s contribution to the tenant improvement allowance, we initially issued a letter of credit totaling $4.5&#160;million, which was subsequently increased to $5.5 million, collateralized by a certificate of deposit in the same amount. Once occupied, the base rent will range from $7.7 million to $8.8 million annually over a ten-year lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an Equity Distribution Agreement with Piper Sandler &amp; Company and Cantor Fitzgerald &amp; Co., as agents, pursuant to which we may offer and sell from time to time, through the agents, up to $300.0 million of the common stock registered under our universal shelf registration statement pursuant to one or more &#8220;at-the-market" offering. As of March&#160;31, 2023, no shares have been issued under this agreement.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents, restricted cash and marketable securities totaled $1.1 billion as of March&#160;31, 2023 and $1.2 billion as of December&#160;31, 2022. We had an outstanding loan balance of $1.0 million as of March&#160;31, 2023 and December&#160;31, 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the period presented: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(91.2)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(57.1)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(34.1)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">138.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">130.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.0)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(46.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">94.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the three months ended March&#160;31, 2023 increased by $34.1 million, compared with the three months ended March&#160;31, 2022, primarily due to an increase in our net loss of $18.5 million, decreased cash inflows from accounts receivable of $14.0 million and increased reduction in deferred revenue of $8.7 million, partially offset by changes in account payable and accrued expenses of $6.8 million and prepaid expenses and other current assets of $4.6 million. Non-cash charges decreased by $2.6 million,  primarily due to net accretion of bond discounts/premiums of $6.7 million, partially offset by increased changes in stock compensation expense $3.3 million.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the three months ended March&#160;31, 2023 increased by $130.0 million, compared with the three months ended March&#160;31, 2022, due to an increase in net sales and maturities of marketable securities in excess of purchases of $129.0 million and a decrease in purchases of property and equipment of $1.0 million.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the three months ended March&#160;31, 2023 decreased by $1.0 million, compared with the three months ended March&#160;31, 2022, due to decreased proceeds from the exercise of stock options.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the preclinical and clinical development of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we anticipate that our expenses will increase substantially if, and as we:</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.02pt">continue clinical trials of our product candidate vepdegestrant (ARV-471), including progressing enrollment in the Phase 3 clinical trial of vepdegestrant in combination with palcociclib as a second-line treatment, initiating a Phase 1b combination trial of vepdegestrant in combination with other targeted therapies, and initiating a Phase 3 clinical trial of vepdegestrant in combination with palbociclib as a first line treatment, each to treat patients with locally advanced or metastatic ER+/HER2- breast cancer;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue clinical trials of our product candidate bavdegalutamide (ARV-110), including Phase 1/2 clinical trials, completing enrollment of the Phase 1b clinical trial of bavdegalutamide in combination with abiraterone, and initiating a global Phase 3 clinical trial of bavdegalutamide for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients with AR T878/H875 tumor mutations, in each case, for the treatment of men with mCRPC;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">continue a Phase 1/2 clinical trial of our product candidate ARV-766, and a Phase 2 expansion trial of ARV-766, in each case in men with mCRPC; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">submit IND and CTA applications for our BCL6 and our LRRK2 PROTAC protein degraders, respectively, with regulators;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">expand the capabilities of our PROTAC Discovery Engine; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we may obtain marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">expand, maintain and protect our intellectual property portfolio; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">hire additional development, including clinical and regulatory, and scientific personnel; and </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">add operational, financial and management information systems and personnel to support our research, product development and future commercialization efforts and support our operations as a public company.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents, restricted cash and marketable securities totaling approximately $1.1 billion as of March&#160;31, 2023. We believe that our cash, cash equivalents, restricted cash and marketable securities as of March&#160;31, 2023 will enable us to fund our planned operating expenses and capital expenditure requirements into 2026. We have based this estimate on assumptions that may prove to be wrong and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the progress, costs and results of our ongoing clinical trials for vepdegestrant (ARV-471), bavdegalutamide (ARV-110), and ARV-766 and any future clinical development of vepdegestrant, bavdegalutamide and ARV-766;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the scope, progress, costs and results of preclinical and clinical development for our other product candidates and development programs, including BCL6 and LRRK2; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurodegenerative research programs; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the success of our collaborations with Pfizer, Genentech, and Bayer;</span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:6pt;padding-left:63pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.8pt">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, for the development or commercialization of our product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these anticipated expenditures, we will need to obtain substantial additional financing in connection with our continuing operations. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations with Pfizer, Genentech and Bayer, we do not currently have any committed external source of funds. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we entered into an additional assistance agreement with the State of Connecticut, or the 2018 Assistance Agreement, to provide funding for the expansion and renovation of laboratory and office space.  We borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest only payments required for the first 60 months, and mature in September 2028. The 2018 assistance agreement requires that we be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. As of March&#160;31, 2023, $1.0 million remains outstanding under the 2018 Assistance Agreement.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents, restricted cash and marketable securities. Interest income earned on these assets totaled $7.6 million and $1.2&#160;million for the three months ended March&#160;31, 2023 and 2022, respectively. Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. As of March&#160;31, 2023, our cash equivalents consisted of bank deposits and money market funds, and our marketable securities included interest-earning securities. Our outstanding debt totaled $1.0 million as of March&#160;31, 2023 and December&#160;31, 2022 and carries a fixed interest rate of 3.25% per annum.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31, 2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended March&#160;31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business and regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. We are not currently a party to any material legal proceedings.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_118"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the those risks and uncertainties discussed in &#8220;Part I, Item 1A, Risk Factors,&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 filed with the SEC on </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;23, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> together with all of the other information contained in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. The risk factor disclosure in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 is qualified by the information that is described in this Quarterly Report on Form 10-Q. If any of the risks described in our Annual Report on Form 10-K for the year ended December&#160;31, 2022 actually occur, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment.</span></div><div id="i884cf85f07be4320b5e4857b1da120ed_121"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any securities that were not registered under the Securities Act during the three months ended March&#160;31, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.459%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.095%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm">Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex32.htm">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20230331x10qex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20230331x10qex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20230331x10qex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="arvn-20230331x10qex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Schema Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Definition Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Label Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inline </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104.00</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101). </span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><div id="i884cf85f07be4320b5e4857b1da120ed_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">Table o</a><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#i884cf85f07be4320b5e4857b1da120ed_7">f Contents</a></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Arvinas, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: May&#160;5, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ John Houston, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">John Houston, Ph.D.</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">President and Chief Executive Officer</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Principal Executive Officer)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: May&#160;5, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Sean Cassidy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Sean Cassidy</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer <br/>(principal financial officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date: May&#160;5, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David K. Loomis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">David K. Loomis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vice President and Chief Accounting Officer <br/>(Principal Accounting Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>arvn-20230331x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i6fa91cf3e0b142b2bef12cb7c143e297_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Houston, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.979%"><tr><td style="width:1.0%"></td><td style="width:48.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Houston, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>arvn-20230331x10qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iace73d11eb504be39ad1772642ae57c4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sean Cassidy, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Quarterly Report on Form 10-Q of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sean Cassidy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sean Cassidy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>arvn-20230331x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i507d3e9ce239433b8b52bdc921f5286c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.979%"><tr><td style="width:1.0%"></td><td style="width:48.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.486%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; John Houston, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">John Houston, Ph.D.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>arvn-20230331x10qex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i551bea8233c14e9299506e49e7dafa20_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:0.05pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; May&#160;5, 2023</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sean Cassidy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sean Cassidy</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>arvn-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f1eeee1-4d1b-4eb9-97f6-83d0702c4de4,g:c3df6ade-21e6-4d49-a1b5-7881af27fa72-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arvn="http://www.arvinas.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arvinas.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.arvinas.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsunauditedParenthetical" roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsunaudited" roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>0000007 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingPronouncementsandSignificantAccountingPolicies" roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Accounting Pronouncements and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreements" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements">
        <link:definition>0000009 - Disclosure - Research Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurements" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements">
        <link:definition>0000010 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovements" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements">
        <link:definition>0000011 - Disclosure - Property, Equipment and Leasehold Improvements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilities" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities">
        <link:definition>0000012 - Disclosure - Right-of-Use Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>0000013 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.arvinas.com/role/LongTermDebt">
        <link:definition>0000014 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.arvinas.com/role/Equity">
        <link:definition>0000015 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arvinas.com/role/IncomeTaxes">
        <link:definition>0000016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.arvinas.com/role/NetLossPerShare">
        <link:definition>0000017 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestments" roleURI="http://www.arvinas.com/role/EquityMethodInvestments">
        <link:definition>0000018 - Disclosure - Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arvinas.com/role/CommitmentsandContingencies">
        <link:definition>0000019 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingPronouncementsandSignificantAccountingPoliciesPolicies" roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Accounting Pronouncements and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingPronouncementsandSignificantAccountingPoliciesTables" roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesTables">
        <link:definition>0000021 - Disclosure - Accounting Pronouncements and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTables" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables">
        <link:definition>0000022 - Disclosure - Research Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsTables" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables">
        <link:definition>0000023 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsTables" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables">
        <link:definition>0000024 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesTables" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables">
        <link:definition>0000025 - Disclosure - Right-of-Use Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>0000026 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.arvinas.com/role/LongTermDebtTables">
        <link:definition>0000027 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.arvinas.com/role/EquityTables">
        <link:definition>0000028 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.arvinas.com/role/NetLossPerShareTables">
        <link:definition>0000029 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsTables" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsTables">
        <link:definition>0000030 - Disclosure - Equity Method Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>0000031 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails">
        <link:definition>0000032 - Disclosure - Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>0000033 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails">
        <link:definition>0000034 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails">
        <link:definition>0000035 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1">
        <link:definition>0000035 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails">
        <link:definition>0000036 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails">
        <link:definition>0000037 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails">
        <link:definition>0000038 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails">
        <link:definition>0000039 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails">
        <link:definition>0000040 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails">
        <link:definition>0000041 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000042 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>0000042 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>0000043 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofLongTermDebtDetails" roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails">
        <link:definition>0000044 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>0000045 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails">
        <link:definition>0000046 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails">
        <link:definition>0000047 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails">
        <link:definition>0000048 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofStockOptionActivityDetails" roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails">
        <link:definition>0000049 - Disclosure - Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryofRestrictedStockGrantActivityDetails" roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails">
        <link:definition>0000050 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesDetails">
        <link:definition>0000051 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareBasicandDilutedLossperCommonShareDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails">
        <link:definition>0000052 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails">
        <link:definition>0000053 - Disclosure - Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails">
        <link:definition>0000054 - Disclosure - Equity Method Investments- Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails">
        <link:definition>0000055 - Disclosure - Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000056 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arvn_PercentageOfIncrementalBorrowingForLeasePayments" abstract="false" name="PercentageOfIncrementalBorrowingForLeasePayments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" abstract="false" name="IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_MaximumAggregateOfferingPriceOfCommonStock" abstract="false" name="MaximumAggregateOfferingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DebtInstrumentInterestPaymentsTerm" abstract="false" name="DebtInstrumentInterestPaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RegulatoryAndSalesBasedMilestonesMember" abstract="true" name="RegulatoryAndSalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_TwoThousandAndEighteenAssistanceAgreementMember" abstract="true" name="TwoThousandAndEighteenAssistanceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SalesBasedMilestonePaymentsMember" abstract="true" name="SalesBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_TwoThousandEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OptionPaymentsToLicenseAgreementMember" abstract="true" name="OptionPaymentsToLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" abstract="true" name="GenentechIncorporationAndFHoffmanLaRocheLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_EquityDistributionAgreementMember" abstract="true" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_BaseLeaseRentPeriod" abstract="false" name="BaseLeaseRentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_SuccessBasedMilestonePaymentsMember" abstract="true" name="SuccessBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" abstract="true" name="SupplementalNonCashInformationRelatedToLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrentPayments" abstract="false" name="AccountsPayableContractBalancesCurrentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OerthBioLimitedLiabilityCorporationMember" abstract="true" name="OerthBioLimitedLiabilityCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LongTermDebtMaturityYearSix" abstract="false" name="LongTermDebtMaturityYearSix" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_BayerCropScienceLPMember" abstract="true" name="BayerCropScienceLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ProceedsFromMaturitiesOfMarketableSecurities" abstract="false" name="ProceedsFromMaturitiesOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" abstract="true" name="ResearchCollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" abstract="true" name="ChangeInCollaborationContractAssetAndOtherAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_RegulatoryMilestonePaymentsMember" abstract="true" name="RegulatoryMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchFundingPaymentsMember" abstract="true" name="ResearchFundingPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrentAdditions" abstract="false" name="AccountsPayableContractBalancesCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" abstract="true" name="GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PfizerIncorporationMember" abstract="true" name="PfizerIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AggregateIntrinsicValueAbstract" abstract="true" name="AggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_FoundationMedicineIncMember" abstract="true" name="FoundationMedicineIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" abstract="false" name="FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" abstract="true" name="ResearchCollaborationAndLicenseAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" abstract="false" name="DirectAndIncrementalCostsIncurredToObtainTheContract" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CapitalizedContractCostAmortizationDuringPeriod" abstract="false" name="CapitalizedContractCostAmortizationDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DevelopmentMilestonePaymentsMember" abstract="true" name="DevelopmentMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PercentageOfLiquidatedDamages" abstract="false" name="PercentageOfLiquidatedDamages" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arvn_CommercialMilestonesMember" abstract="true" name="CommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PiperSandlerAndCantorMember" abstract="true" name="PiperSandlerAndCantorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" abstract="true" name="IncomeStatementAndStatementOfComprehensiveIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ProceedsFromSaleOfMarketableSecurities" abstract="false" name="ProceedsFromSaleOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrent" abstract="false" name="AccountsPayableContractBalancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_EmployeesMember" abstract="true" name="EmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CollaborationContractAssetAndOtherAssets" abstract="false" name="CollaborationContractAssetAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_TwoThousandAndFourteenAssistanceAgreementMember" abstract="true" name="TwoThousandAndFourteenAssistanceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" abstract="true" name="CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" abstract="false" name="AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DebtInstrumentLoanForgiveness" abstract="false" name="DebtInstrumentLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsTable" abstract="true" name="ResearchCollaborationAndLicenseAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>arvn-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f1eeee1-4d1b-4eb9-97f6-83d0702c4de4,g:c3df6ade-21e6-4d49-a1b5-7881af27fa72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9c746795-e6e0-4509-a40b-ab97e9262c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_007c16e8-e5a2-4b5a-82f9-57603b9be81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c746795-e6e0-4509-a40b-ab97e9262c14" xlink:to="loc_us-gaap_LiabilitiesCurrent_007c16e8-e5a2-4b5a-82f9-57603b9be81a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_381eb892-a8f6-4c60-95c5-af2a5302cd68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c746795-e6e0-4509-a40b-ab97e9262c14" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_381eb892-a8f6-4c60-95c5-af2a5302cd68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_007bd933-1ab5-4091-a15b-323059e90950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c746795-e6e0-4509-a40b-ab97e9262c14" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_007bd933-1ab5-4091-a15b-323059e90950" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2f23296f-2524-4f7c-8693-c536c30b555b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9c746795-e6e0-4509-a40b-ab97e9262c14" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2f23296f-2524-4f7c-8693-c536c30b555b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e24517cc-e8a4-4b94-9113-05e4e15c5101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_708dad85-4bfd-45eb-b7ba-68bfe532cd19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e24517cc-e8a4-4b94-9113-05e4e15c5101" xlink:to="loc_us-gaap_Liabilities_708dad85-4bfd-45eb-b7ba-68bfe532cd19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b184748f-6d51-4273-8b04-382fa51fdbff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e24517cc-e8a4-4b94-9113-05e4e15c5101" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b184748f-6d51-4273-8b04-382fa51fdbff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ec0970b7-0ec1-433f-96aa-369d29715ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_e24517cc-e8a4-4b94-9113-05e4e15c5101" xlink:to="loc_us-gaap_StockholdersEquity_ec0970b7-0ec1-433f-96aa-369d29715ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0716a31f-c17f-4b50-95ed-cd2528604dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c3fedbe-b990-4948-a118-7cad9673b5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0716a31f-c17f-4b50-95ed-cd2528604dbf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c3fedbe-b990-4948-a118-7cad9673b5b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_1a563c0d-a314-47f4-9087-d900e35680d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0716a31f-c17f-4b50-95ed-cd2528604dbf" xlink:to="loc_us-gaap_RestrictedCashCurrent_1a563c0d-a314-47f4-9087-d900e35680d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_cdf053ae-2036-4941-a1a1-02a56c17da19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0716a31f-c17f-4b50-95ed-cd2528604dbf" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_cdf053ae-2036-4941-a1a1-02a56c17da19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_89e37935-a29f-47b2-a7e1-db9b82c45009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0716a31f-c17f-4b50-95ed-cd2528604dbf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_89e37935-a29f-47b2-a7e1-db9b82c45009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_4de43ea9-4b5f-42b2-bbe9-a5f03562530a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0716a31f-c17f-4b50-95ed-cd2528604dbf" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_4de43ea9-4b5f-42b2-bbe9-a5f03562530a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c55bb43f-4c3e-4c5e-866c-5f565a8d608f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0716a31f-c17f-4b50-95ed-cd2528604dbf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c55bb43f-4c3e-4c5e-866c-5f565a8d608f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7917e12e-60c1-4d1f-93a8-e72edafb04c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6df597f0-6d7f-4fa9-a398-32f04bf706e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7917e12e-60c1-4d1f-93a8-e72edafb04c9" xlink:to="loc_us-gaap_CommonStockValue_6df597f0-6d7f-4fa9-a398-32f04bf706e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74fe6679-612a-4bcb-be34-4420e9e0f627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7917e12e-60c1-4d1f-93a8-e72edafb04c9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74fe6679-612a-4bcb-be34-4420e9e0f627" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3818bd1b-51ae-448a-a8ab-3d8f7354062b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7917e12e-60c1-4d1f-93a8-e72edafb04c9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3818bd1b-51ae-448a-a8ab-3d8f7354062b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aed35961-3064-4b03-8fb1-6c5e47870257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7917e12e-60c1-4d1f-93a8-e72edafb04c9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aed35961-3064-4b03-8fb1-6c5e47870257" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8de010c4-31c6-4657-9030-c00bf6ef6bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3a7e27a0-b0d2-4baf-9847-34665d1aa0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8de010c4-31c6-4657-9030-c00bf6ef6bd3" xlink:to="loc_us-gaap_AssetsCurrent_3a7e27a0-b0d2-4baf-9847-34665d1aa0b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0cb250af-48cb-4d7a-9d5b-b44f94af4dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8de010c4-31c6-4657-9030-c00bf6ef6bd3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0cb250af-48cb-4d7a-9d5b-b44f94af4dd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e291101b-80cd-412b-9edc-7187496e04f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8de010c4-31c6-4657-9030-c00bf6ef6bd3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e291101b-80cd-412b-9edc-7187496e04f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_841ad518-1edb-4099-ab64-391634b616f4" xlink:href="arvn-20230331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8de010c4-31c6-4657-9030-c00bf6ef6bd3" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_841ad518-1edb-4099-ab64-391634b616f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9bc8a3cc-6a75-460d-95be-8057c7d805bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d772691a-e254-4b38-934c-0ed7aacc42fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9bc8a3cc-6a75-460d-95be-8057c7d805bf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d772691a-e254-4b38-934c-0ed7aacc42fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6902be81-962d-4ec0-8915-3c91f8eafd24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9bc8a3cc-6a75-460d-95be-8057c7d805bf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6902be81-962d-4ec0-8915-3c91f8eafd24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ffdf21ae-9d8b-4040-93ec-49a8fba83728" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9bc8a3cc-6a75-460d-95be-8057c7d805bf" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ffdf21ae-9d8b-4040-93ec-49a8fba83728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e4ddc000-05ac-4960-9b00-f568d856eb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9bc8a3cc-6a75-460d-95be-8057c7d805bf" xlink:to="loc_us-gaap_LongTermDebtCurrent_e4ddc000-05ac-4960-9b00-f568d856eb9a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d9ca512f-77c5-4a5b-a168-cc0394acdf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2be4b535-3c43-4e96-989c-1c8d55e7e0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d9ca512f-77c5-4a5b-a168-cc0394acdf40" xlink:to="loc_us-gaap_NetIncomeLoss_2be4b535-3c43-4e96-989c-1c8d55e7e0d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d05c70d5-91ec-482a-9ba5-d3302b342bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d9ca512f-77c5-4a5b-a168-cc0394acdf40" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d05c70d5-91ec-482a-9ba5-d3302b342bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8306616d-c742-4f9e-b565-f469458cf858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_656f3142-f6bd-4cee-910f-1d17cc4baf42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8306616d-c742-4f9e-b565-f469458cf858" xlink:to="loc_us-gaap_Revenues_656f3142-f6bd-4cee-910f-1d17cc4baf42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7becd209-3845-4262-9d45-4dd3be92b80d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8306616d-c742-4f9e-b565-f469458cf858" xlink:to="loc_us-gaap_OperatingExpenses_7becd209-3845-4262-9d45-4dd3be92b80d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0f899445-4562-42ed-9df1-271c0de26cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e4aab735-3b0f-4122-aa6f-24acab307004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0f899445-4562-42ed-9df1-271c0de26cdc" xlink:to="loc_us-gaap_OperatingIncomeLoss_e4aab735-3b0f-4122-aa6f-24acab307004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a8084818-d826-484e-8dc4-62ca7aa52fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_0f899445-4562-42ed-9df1-271c0de26cdc" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_a8084818-d826-484e-8dc4-62ca7aa52fa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3f3db609-bdc2-4acf-a46d-60ab9777068b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6f5dc29e-db41-47a0-a7c7-406b3e8db69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3f3db609-bdc2-4acf-a46d-60ab9777068b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6f5dc29e-db41-47a0-a7c7-406b3e8db69c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_83f07ae0-ba54-4736-a667-26ebcb96e0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3f3db609-bdc2-4acf-a46d-60ab9777068b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_83f07ae0-ba54-4736-a667-26ebcb96e0c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_44e5822e-d05a-4a5c-a176-ac9b858b6201" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1553cf39-978b-4a9f-aec8-5320eeb3efe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_44e5822e-d05a-4a5c-a176-ac9b858b6201" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1553cf39-978b-4a9f-aec8-5320eeb3efe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3b602fec-a463-4fc5-b9fb-0af23e2f7d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_44e5822e-d05a-4a5c-a176-ac9b858b6201" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3b602fec-a463-4fc5-b9fb-0af23e2f7d9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b4b7885-5c60-40da-b7c1-0a28d3f98de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ca554ee9-540b-4006-b993-93ae850a41bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1b4b7885-5c60-40da-b7c1-0a28d3f98de3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ca554ee9-540b-4006-b993-93ae850a41bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7f80d87a-ce58-44c9-8d08-6cf14e3db3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1b4b7885-5c60-40da-b7c1-0a28d3f98de3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7f80d87a-ce58-44c9-8d08-6cf14e3db3b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8730cab-eef2-498f-8fde-9922bec7c15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1b4b7885-5c60-40da-b7c1-0a28d3f98de3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8730cab-eef2-498f-8fde-9922bec7c15f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_313639f5-16ed-4e4d-b6ab-04da759f6ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1154bdc5-e432-4d2e-854c-5145e77648c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_313639f5-16ed-4e4d-b6ab-04da759f6ce1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1154bdc5-e432-4d2e-854c-5145e77648c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7e0a9caa-6d35-440c-98fd-c4c1766d7364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_313639f5-16ed-4e4d-b6ab-04da759f6ce1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7e0a9caa-6d35-440c-98fd-c4c1766d7364" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_393415ae-b1b6-4b21-a18e-4f7bb2c1aa1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_313639f5-16ed-4e4d-b6ab-04da759f6ce1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_393415ae-b1b6-4b21-a18e-4f7bb2c1aa1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_42966a87-b6ac-4b81-9425-1c6bb879d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_42966a87-b6ac-4b81-9425-1c6bb879d45b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_20acf5b6-9244-4601-8d8d-79f0e00dc905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_20acf5b6-9244-4601-8d8d-79f0e00dc905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6ade4e27-2597-4975-bd76-c2aab93270ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6ade4e27-2597-4975-bd76-c2aab93270ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_52cf381c-769d-4d0f-b6d3-470b9a408b95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_52cf381c-769d-4d0f-b6d3-470b9a408b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c49329c-e596-4489-a288-6beeb3119344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c49329c-e596-4489-a288-6beeb3119344" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_59f03b59-f884-4d1d-a295-fb82f368da7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_59f03b59-f884-4d1d-a295-fb82f368da7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d1d300de-868e-4fef-8e86-9bddec4bf8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_ShareBasedCompensation_d1d300de-868e-4fef-8e86-9bddec4bf8ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_2b024a8c-34c0-4386-a362-56a507a91b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_2b024a8c-34c0-4386-a362-56a507a91b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_f42a0922-3906-41d4-96f4-4ced3c4b754e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_f42a0922-3906-41d4-96f4-4ced3c4b754e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_575b7653-b578-44b8-95da-8400347dbf45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_DepreciationAndAmortization_575b7653-b578-44b8-95da-8400347dbf45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_663a74dd-29ab-48d3-89bb-eeb4c91d4d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_663a74dd-29ab-48d3-89bb-eeb4c91d4d5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_09006857-c387-4a42-861a-da152b096426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_NetIncomeLoss_09006857-c387-4a42-861a-da152b096426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_949451f6-c9cb-4be0-8ad4-2455995d497c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6cd882db-2123-4e6e-9944-aa063ef012fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_949451f6-c9cb-4be0-8ad4-2455995d497c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81daf0c1-7196-419a-af46-bd59fcd5bf02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_ba45a6cd-c1e1-4524-985d-7a2016f7b910" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_81daf0c1-7196-419a-af46-bd59fcd5bf02" xlink:to="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_ba45a6cd-c1e1-4524-985d-7a2016f7b910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d35b8a-5e04-4da6-b623-869e199ed2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_237ee91b-2e59-46db-ab09-0f0d939750f9" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d35b8a-5e04-4da6-b623-869e199ed2e9" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_237ee91b-2e59-46db-ab09-0f0d939750f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dd76e77b-ab04-494b-aa7d-18c50cf66cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d35b8a-5e04-4da6-b623-869e199ed2e9" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dd76e77b-ab04-494b-aa7d-18c50cf66cd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5a82c923-555f-435f-b43d-190c54b08c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d35b8a-5e04-4da6-b623-869e199ed2e9" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5a82c923-555f-435f-b43d-190c54b08c6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities_d8586f56-42ce-46be-b390-85e5d523d09f" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16d35b8a-5e04-4da6-b623-869e199ed2e9" xlink:to="loc_arvn_ProceedsFromSaleOfMarketableSecurities_d8586f56-42ce-46be-b390-85e5d523d09f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cc21871-f8db-404c-9feb-e34723a694c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_96df38ea-1b3f-49d8-80af-f13e737338f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cc21871-f8db-404c-9feb-e34723a694c5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_96df38ea-1b3f-49d8-80af-f13e737338f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_432e717e-b548-4f9d-8967-f272395650d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8cc21871-f8db-404c-9feb-e34723a694c5" xlink:to="loc_us-gaap_RestrictedCashCurrent_432e717e-b548-4f9d-8967-f272395650d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a6343b3-9f56-4cab-8e7b-238a43b6d244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1af76742-bc5c-492e-80de-d6c9844138df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a6343b3-9f56-4cab-8e7b-238a43b6d244" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1af76742-bc5c-492e-80de-d6c9844138df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_49c574f3-b887-4b69-81af-b7b922625386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a6343b3-9f56-4cab-8e7b-238a43b6d244" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_49c574f3-b887-4b69-81af-b7b922625386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a5ef910-8b66-4a54-9c66-4a58615d1f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6a6343b3-9f56-4cab-8e7b-238a43b6d244" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a5ef910-8b66-4a54-9c66-4a58615d1f30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6d8fb6c3-2ddf-460b-909b-225dd9d454fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9aaa29bf-5257-43e4-b8a3-a0e3073094b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6d8fb6c3-2ddf-460b-909b-225dd9d454fc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9aaa29bf-5257-43e4-b8a3-a0e3073094b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2ce30ff-f3d4-4d44-a144-430bcf88f01c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6d8fb6c3-2ddf-460b-909b-225dd9d454fc" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a2ce30ff-f3d4-4d44-a144-430bcf88f01c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a291dbc-ace7-45a4-afab-0d6f21287a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3c9047d6-beba-4ef8-b88b-8933815520a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a291dbc-ace7-45a4-afab-0d6f21287a85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3c9047d6-beba-4ef8-b88b-8933815520a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4ed475a3-353f-4e1c-a5dc-f83269834129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a291dbc-ace7-45a4-afab-0d6f21287a85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4ed475a3-353f-4e1c-a5dc-f83269834129" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5be04665-22e6-499a-a333-c304030b4059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a291dbc-ace7-45a4-afab-0d6f21287a85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5be04665-22e6-499a-a333-c304030b4059" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d5c736f0-cded-46c9-be8b-618455dee894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4a291dbc-ace7-45a4-afab-0d6f21287a85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_d5c736f0-cded-46c9-be8b-618455dee894" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1e4e6706-d938-4cdf-b2dc-0f041962ebe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1789dfb2-b581-42b8-9383-6cf1d883b6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1e4e6706-d938-4cdf-b2dc-0f041962ebe1" xlink:to="loc_us-gaap_OperatingLeaseLiability_1789dfb2-b581-42b8-9383-6cf1d883b6a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_46478fc7-509e-46d4-8a93-ce0b5106e7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1e4e6706-d938-4cdf-b2dc-0f041962ebe1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_46478fc7-509e-46d4-8a93-ce0b5106e7a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2d13343b-fd4c-42f0-9f1b-5adb4e6d08fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8af7dcd9-6e3a-400c-ad41-4556d85c6034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2d13343b-fd4c-42f0-9f1b-5adb4e6d08fc" xlink:to="loc_us-gaap_AccountsPayableCurrent_8af7dcd9-6e3a-400c-ad41-4556d85c6034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_f4285b0e-a8f5-43e5-860f-3368a8ccb1ad" xlink:href="arvn-20230331.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2d13343b-fd4c-42f0-9f1b-5adb4e6d08fc" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_f4285b0e-a8f5-43e5-860f-3368a8ccb1ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_dd722e6c-dc85-44a1-b477-1b98ed2f7d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2d13343b-fd4c-42f0-9f1b-5adb4e6d08fc" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_dd722e6c-dc85-44a1-b477-1b98ed2f7d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d4f1ee2e-040c-4473-913c-b033bd8edafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2d13343b-fd4c-42f0-9f1b-5adb4e6d08fc" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d4f1ee2e-040c-4473-913c-b033bd8edafe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e999ecaa-6748-4b23-b64e-4d429177f34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2d13343b-fd4c-42f0-9f1b-5adb4e6d08fc" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e999ecaa-6748-4b23-b64e-4d429177f34f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f90ef759-da85-4db0-ba7a-dfb0ccce5378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_264c01d8-da51-4ccd-aed4-c28733bffbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f90ef759-da85-4db0-ba7a-dfb0ccce5378" xlink:to="loc_us-gaap_LongTermDebtCurrent_264c01d8-da51-4ccd-aed4-c28733bffbb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_795cb56c-d3ef-4c24-a826-299fb19f1c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_f90ef759-da85-4db0-ba7a-dfb0ccce5378" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_795cb56c-d3ef-4c24-a826-299fb19f1c42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a7bb9014-33cc-402a-9d65-743e0b695abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3293badb-c08f-462b-944d-fa18b83bdb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a7bb9014-33cc-402a-9d65-743e0b695abf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3293badb-c08f-462b-944d-fa18b83bdb4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ce4fbba6-9e74-445d-8d19-8f93a157cb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a7bb9014-33cc-402a-9d65-743e0b695abf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_ce4fbba6-9e74-445d-8d19-8f93a157cb5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_506a6ed1-3ac3-40c9-a3fd-85cc4a8708f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a7bb9014-33cc-402a-9d65-743e0b695abf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_506a6ed1-3ac3-40c9-a3fd-85cc4a8708f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LongTermDebtMaturityYearSix_88b129de-e1d1-4843-aa48-0d3f62fea04a" xlink:href="arvn-20230331.xsd#arvn_LongTermDebtMaturityYearSix"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a7bb9014-33cc-402a-9d65-743e0b695abf" xlink:to="loc_arvn_LongTermDebtMaturityYearSix_88b129de-e1d1-4843-aa48-0d3f62fea04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3ccffaad-b7a4-4fd8-a097-03eb1cdd1fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a7bb9014-33cc-402a-9d65-743e0b695abf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3ccffaad-b7a4-4fd8-a097-03eb1cdd1fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8e43c1ae-c169-4421-b39b-96047f29fd27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a7bb9014-33cc-402a-9d65-743e0b695abf" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8e43c1ae-c169-4421-b39b-96047f29fd27" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>arvn-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f1eeee1-4d1b-4eb9-97f6-83d0702c4de4,g:c3df6ade-21e6-4d49-a1b5-7881af27fa72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="extended" id="i116d66fce8904d31823439ac001b2a6e_CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9a00949e-c950-4b75-abfe-02a1edc9ae50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9a00949e-c950-4b75-abfe-02a1edc9ae50" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c1b28a6a-8b3b-4d80-b182-43ee97d40a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c1b28a6a-8b3b-4d80-b182-43ee97d40a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_988a083a-69b3-4136-bb72-a40d42e73eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_StockholdersEquity_988a083a-69b3-4136-bb72-a40d42e73eff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8c6c058c-58ae-4197-9dee-0ceba1ba0413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8c6c058c-58ae-4197-9dee-0ceba1ba0413" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33f3da3d-14b1-4cef-95ca-884e59cc0d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_NetIncomeLoss_33f3da3d-14b1-4cef-95ca-884e59cc0d46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_92ce7ed3-1b45-4d37-9607-5ae25da660eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_92ce7ed3-1b45-4d37-9607-5ae25da660eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12f70e72-aae7-4ea9-b5a5-46e6ee54b3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12f70e72-aae7-4ea9-b5a5-46e6ee54b3b2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_820c7747-cbf2-4d95-b4d6-9c569c87d3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_820c7747-cbf2-4d95-b4d6-9c569c87d3a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_09a76f06-89fd-48f9-b466-5f54cf0e088f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5186984f-8a39-445f-bc91-bf0a6a7eed88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d5bfdb53-131e-4f23-8f29-6a052aa33eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9a00949e-c950-4b75-abfe-02a1edc9ae50" xlink:to="loc_us-gaap_StatementTable_d5bfdb53-131e-4f23-8f29-6a052aa33eb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9b119787-616f-43a6-a4ff-2eb84c3cac64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d5bfdb53-131e-4f23-8f29-6a052aa33eb9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9b119787-616f-43a6-a4ff-2eb84c3cac64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b119787-616f-43a6-a4ff-2eb84c3cac64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b119787-616f-43a6-a4ff-2eb84c3cac64" xlink:to="loc_us-gaap_EquityComponentDomain_9b119787-616f-43a6-a4ff-2eb84c3cac64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b119787-616f-43a6-a4ff-2eb84c3cac64" xlink:to="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5d77714a-344b-44ab-b223-a28318e6fe52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:to="loc_us-gaap_CommonStockMember_5d77714a-344b-44ab-b223-a28318e6fe52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8283772a-2762-47bb-83ab-7a165d34f52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:to="loc_us-gaap_RetainedEarningsMember_8283772a-2762-47bb-83ab-7a165d34f52b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41e21475-5816-4bf3-ab22-814f3e5ab31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41e21475-5816-4bf3-ab22-814f3e5ab31c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa6e4f79-290b-4b4b-b02f-1cc32e48d561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa6e4f79-290b-4b4b-b02f-1cc32e48d561" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended" id="id11e01a125214d70a3dfa56bacbbd467_ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_0d06670a-5280-4c34-96b4-90f84fcdf5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_0d06670a-5280-4c34-96b4-90f84fcdf5e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_30300455-e372-431b-8987-138d5b0eed32" xlink:href="arvn-20230331.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_30300455-e372-431b-8987-138d5b0eed32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_acbe85a1-cd2d-4de0-8cc0-b1c9daf46d8b" xlink:href="arvn-20230331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_acbe85a1-cd2d-4de0-8cc0-b1c9daf46d8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_a0788a58-39a6-44e2-ab87-c190dd343055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_us-gaap_ProceedsFromCollaborators_a0788a58-39a6-44e2-ab87-c190dd343055" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_fef8e215-2e2a-40f0-8023-7a4c9d0f2a26" xlink:href="arvn-20230331.xsd#arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_fef8e215-2e2a-40f0-8023-7a4c9d0f2a26" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_36fbea4f-67d6-4838-acc8-4fc455bc09fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_36fbea4f-67d6-4838-acc8-4fc455bc09fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cae21826-8f6e-4105-a835-fc252b1d20fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_srt_CounterpartyNameAxis_cae21826-8f6e-4105-a835-fc252b1d20fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cae21826-8f6e-4105-a835-fc252b1d20fa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_cae21826-8f6e-4105-a835-fc252b1d20fa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cae21826-8f6e-4105-a835-fc252b1d20fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_cae21826-8f6e-4105-a835-fc252b1d20fa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_128d8cfb-e54e-45a8-a672-7c6206fa7bf8" xlink:href="arvn-20230331.xsd#arvn_PfizerIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:to="loc_arvn_PfizerIncorporationMember_128d8cfb-e54e-45a8-a672-7c6206fa7bf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_07bc1b03-d7a9-44fe-8c6f-7b3e7c309ed0" xlink:href="arvn-20230331.xsd#arvn_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:to="loc_arvn_BayerAGMember_07bc1b03-d7a9-44fe-8c6f-7b3e7c309ed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_c7000a59-0b10-4c9a-92d1-6d6e58e00883" xlink:href="arvn-20230331.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_c7000a59-0b10-4c9a-92d1-6d6e58e00883" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6e3a4804-ff14-4e82-996f-8974f2cc85fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6e3a4804-ff14-4e82-996f-8974f2cc85fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e3a4804-ff14-4e82-996f-8974f2cc85fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e3a4804-ff14-4e82-996f-8974f2cc85fd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6e3a4804-ff14-4e82-996f-8974f2cc85fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e3a4804-ff14-4e82-996f-8974f2cc85fd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_b6a480a2-3554-490a-abfc-825aca301c56" xlink:href="arvn-20230331.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_b6a480a2-3554-490a-abfc-825aca301c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_e7e55455-085d-4a16-8bba-41a8557fc733" xlink:href="arvn-20230331.xsd#arvn_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_CollaborationAgreementMember_e7e55455-085d-4a16-8bba-41a8557fc733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_0a0f5079-54a1-4f57-a8cb-72e015a04386" xlink:href="arvn-20230331.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_0a0f5079-54a1-4f57-a8cb-72e015a04386" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember_8b9e3c6c-f861-4a2f-94ff-c6835b4e31f3" xlink:href="arvn-20230331.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_SalesBasedMilestonesMember_8b9e3c6c-f861-4a2f-94ff-c6835b4e31f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_e83f98ba-07e6-4091-ae1c-aa8862920442" xlink:href="arvn-20230331.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_ResearchFundingPaymentsMember_e83f98ba-07e6-4091-ae1c-aa8862920442" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_7866e102-de1a-4c8b-ba72-cee7c9ad17d7" xlink:href="arvn-20230331.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_7866e102-de1a-4c8b-ba72-cee7c9ad17d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_aba257e0-ded8-4866-963d-ca265ab0613e" xlink:href="arvn-20230331.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_aba257e0-ded8-4866-963d-ca265ab0613e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_4052be65-5a3b-4ff5-b62d-dd5f0801b2d9" xlink:href="arvn-20230331.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_4052be65-5a3b-4ff5-b62d-dd5f0801b2d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_a62451a5-222b-4097-afff-b4547c213add" xlink:href="arvn-20230331.xsd#arvn_CommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_CommercialMilestonesMember_a62451a5-222b-4097-afff-b4547c213add" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e271db0-a724-48cf-ac85-674744e0a7bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_srt_RangeAxis_3e271db0-a724-48cf-ac85-674744e0a7bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3e271db0-a724-48cf-ac85-674744e0a7bb_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3e271db0-a724-48cf-ac85-674744e0a7bb" xlink:to="loc_srt_RangeMember_3e271db0-a724-48cf-ac85-674744e0a7bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_daca2f12-0199-448c-96cc-a951cc9a9613" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3e271db0-a724-48cf-ac85-674744e0a7bb" xlink:to="loc_srt_RangeMember_daca2f12-0199-448c-96cc-a951cc9a9613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bbcc4615-03f2-451c-9874-54aeac87feb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_daca2f12-0199-448c-96cc-a951cc9a9613" xlink:to="loc_srt_MaximumMember_bbcc4615-03f2-451c-9874-54aeac87feb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3d515778-3d72-417a-a0b6-e4275d10650c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_srt_StatementScenarioAxis_3d515778-3d72-417a-a0b6-e4275d10650c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3d515778-3d72-417a-a0b6-e4275d10650c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3d515778-3d72-417a-a0b6-e4275d10650c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3d515778-3d72-417a-a0b6-e4275d10650c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2d9a6221-07cc-4af4-93b1-d1cd63eb09db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3d515778-3d72-417a-a0b6-e4275d10650c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2d9a6221-07cc-4af4-93b1-d1cd63eb09db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c72d5f84-03f4-4900-b604-f69bf991e75d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2d9a6221-07cc-4af4-93b1-d1cd63eb09db" xlink:to="loc_srt_ScenarioForecastMember_c72d5f84-03f4-4900-b604-f69bf991e75d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_396bbcb6-be43-43de-80f6-d331dd0324ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_396bbcb6-be43-43de-80f6-d331dd0324ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_396bbcb6-be43-43de-80f6-d331dd0324ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_396bbcb6-be43-43de-80f6-d331dd0324ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_396bbcb6-be43-43de-80f6-d331dd0324ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_31d49e18-ea9f-4f83-85aa-c85b52d0bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_396bbcb6-be43-43de-80f6-d331dd0324ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_31d49e18-ea9f-4f83-85aa-c85b52d0bcb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_15041a87-afb1-470c-8dd7-bba63e04ef4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_31d49e18-ea9f-4f83-85aa-c85b52d0bcb8" xlink:to="loc_us-gaap_SubsequentEventMember_15041a87-afb1-470c-8dd7-bba63e04ef4c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended" id="ie95031b8f92f4861b48fef1ec453e638_ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4ffba4c1-986e-439a-a2d1-9abbb2f1b408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4ffba4c1-986e-439a-a2d1-9abbb2f1b408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8eab7c3e-b3ae-454e-95bd-1b98655aa4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8eab7c3e-b3ae-454e-95bd-1b98655aa4b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_63ef9063-21b0-47a9-b8eb-6919d1c37f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_63ef9063-21b0-47a9-b8eb-6919d1c37f67" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="extended" id="i693076ea279b43fd84b2747aa835238e_ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4ffba4c1-986e-439a-a2d1-9abbb2f1b408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4ffba4c1-986e-439a-a2d1-9abbb2f1b408" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8eab7c3e-b3ae-454e-95bd-1b98655aa4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8eab7c3e-b3ae-454e-95bd-1b98655aa4b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended" id="ibaca923a52a14dafa1da65f367a6ff88_MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c74e8666-7b7e-4f06-9cc9-a38826bfe021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c74e8666-7b7e-4f06-9cc9-a38826bfe021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8eb46b5-a440-4ee4-9b83-01bcb2ca1603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8eb46b5-a440-4ee4-9b83-01bcb2ca1603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ab80cfed-8ab7-43aa-8a0b-836db6897bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ab80cfed-8ab7-43aa-8a0b-836db6897bbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f862ab36-99f6-436b-8d5c-a94d268d61ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f862ab36-99f6-436b-8d5c-a94d268d61ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae93df5-88c7-486d-9475-17aafa809b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae93df5-88c7-486d-9475-17aafa809b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aae93df5-88c7-486d-9475-17aafa809b2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae93df5-88c7-486d-9475-17aafa809b2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aae93df5-88c7-486d-9475-17aafa809b2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9624554e-ba66-428a-a7e6-11aaed2756ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae93df5-88c7-486d-9475-17aafa809b2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9624554e-ba66-428a-a7e6-11aaed2756ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_63cebb36-96b3-4998-a2f8-33ccfba83fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9624554e-ba66-428a-a7e6-11aaed2756ab" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_63cebb36-96b3-4998-a2f8-33ccfba83fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16399378-0d91-4719-8ed3-399caa551701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16399378-0d91-4719-8ed3-399caa551701" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16399378-0d91-4719-8ed3-399caa551701_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16399378-0d91-4719-8ed3-399caa551701" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16399378-0d91-4719-8ed3-399caa551701_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a41d5e4f-9ad6-4862-9bd8-82fd72fee1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16399378-0d91-4719-8ed3-399caa551701" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a41d5e4f-9ad6-4862-9bd8-82fd72fee1c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_36e4bcdd-00a7-40c3-996e-530e59138401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a41d5e4f-9ad6-4862-9bd8-82fd72fee1c2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_36e4bcdd-00a7-40c3-996e-530e59138401" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d4a8f329-6b06-4f2d-b1df-16d1d2142af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d4a8f329-6b06-4f2d-b1df-16d1d2142af1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4a8f329-6b06-4f2d-b1df-16d1d2142af1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4a8f329-6b06-4f2d-b1df-16d1d2142af1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d4a8f329-6b06-4f2d-b1df-16d1d2142af1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4a8f329-6b06-4f2d-b1df-16d1d2142af1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_348926a3-d53e-4028-8102-05f458b61c13" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_348926a3-d53e-4028-8102-05f458b61c13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember_e04351c0-33d3-4ab6-8101-8ea1cafe00cf" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember_e04351c0-33d3-4ab6-8101-8ea1cafe00cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_225f19b6-9974-4869-b275-343701c6eeea" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_225f19b6-9974-4869-b275-343701c6eeea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_4e87eead-e2ad-491c-a0e3-af6ec1e09875" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_4e87eead-e2ad-491c-a0e3-af6ec1e09875" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_4dc8a523-ea70-4c8e-8075-9dce0b4ca057" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_4dc8a523-ea70-4c8e-8075-9dce0b4ca057" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_8d66f66a-74a2-47ef-a59a-603420555f98" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_8d66f66a-74a2-47ef-a59a-603420555f98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_f9601873-5f30-4859-941c-3d8f717a1744" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_f9601873-5f30-4859-941c-3d8f717a1744" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember_383f872f-5f60-424f-9a0e-581cbed0c2b6" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember_383f872f-5f60-424f-9a0e-581cbed0c2b6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended" id="i3d5e021dd2c243668b651e99c1c466a4_PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b353ddf1-994a-4530-9656-9285b9b68489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b353ddf1-994a-4530-9656-9285b9b68489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_755a1c38-eabd-44b7-8f4b-5d3e6a520fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_755a1c38-eabd-44b7-8f4b-5d3e6a520fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_078df0f2-7cff-4636-aa33-059b00bf17e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_078df0f2-7cff-4636-aa33-059b00bf17e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aaa8d59-cb21-4ddf-a681-bfc5b6314877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aaa8d59-cb21-4ddf-a681-bfc5b6314877" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb36aa43-1149-4a57-b148-c3d552a99196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aaa8d59-cb21-4ddf-a681-bfc5b6314877" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb36aa43-1149-4a57-b148-c3d552a99196" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb36aa43-1149-4a57-b148-c3d552a99196_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb36aa43-1149-4a57-b148-c3d552a99196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb36aa43-1149-4a57-b148-c3d552a99196_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb36aa43-1149-4a57-b148-c3d552a99196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_ab125a33-020f-4a91-8120-095a57be1259" xlink:href="arvn-20230331.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:to="loc_arvn_LaboratoryEquipmentMember_ab125a33-020f-4a91-8120-095a57be1259" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_296cda4a-ac27-4ae1-a3c2-87f6bc515531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_296cda4a-ac27-4ae1-a3c2-87f6bc515531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_e0b4f4f7-3500-41a5-933d-335436b0a957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:to="loc_us-gaap_OfficeEquipmentMember_e0b4f4f7-3500-41a5-933d-335436b0a957" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended" id="i185315963b4d4f0f98872accdb51f3a8_RightofUseAssetsandLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_f02eac2c-1c10-4b6b-83ca-c8552d82e1a4" xlink:href="arvn-20230331.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_f02eac2c-1c10-4b6b-83ca-c8552d82e1a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_f09eae26-4ff5-4d9d-b06f-602a4d43b346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_f09eae26-4ff5-4d9d-b06f-602a4d43b346" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities_1eeecb94-88af-4a22-9cb8-1166da670016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_DebtSecurities_1eeecb94-88af-4a22-9cb8-1166da670016" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d0b8027d-d609-45f5-a21e-f1c7a2c94b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_LeaseCost_d0b8027d-d609-45f5-a21e-f1c7a2c94b38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod_0aebf782-f10d-4730-9d78-eaa371d2376b" xlink:href="arvn-20230331.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_arvn_BaseLeaseRentPeriod_0aebf782-f10d-4730-9d78-eaa371d2376b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ded5c48f-c9ca-477c-98c1-e50bdee7f731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ded5c48f-c9ca-477c-98c1-e50bdee7f731" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:to="loc_srt_RangeAxis_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1" xlink:to="loc_srt_RangeMember_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2ad2d13-0d77-4c65-88a9-7191ddb7a9bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1" xlink:to="loc_srt_RangeMember_a2ad2d13-0d77-4c65-88a9-7191ddb7a9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e91b68d1-c53f-45b1-b765-0e1da09d5f8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a2ad2d13-0d77-4c65-88a9-7191ddb7a9bc" xlink:to="loc_srt_MinimumMember_e91b68d1-c53f-45b1-b765-0e1da09d5f8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_69801250-c31e-474a-b854-e73031cf0ee2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a2ad2d13-0d77-4c65-88a9-7191ddb7a9bc" xlink:to="loc_srt_MaximumMember_69801250-c31e-474a-b854-e73031cf0ee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis_32241109-8ffc-4986-9c1c-f089f522a651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:to="loc_us-gaap_PledgingPurposeAxis_32241109-8ffc-4986-9c1c-f089f522a651" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_32241109-8ffc-4986-9c1c-f089f522a651_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PledgingPurposeAxis_32241109-8ffc-4986-9c1c-f089f522a651" xlink:to="loc_us-gaap_PledgingPurposeDomain_32241109-8ffc-4986-9c1c-f089f522a651_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_e4ffb68a-1135-4099-b504-4d1001f5ed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PledgingPurposeAxis_32241109-8ffc-4986-9c1c-f089f522a651" xlink:to="loc_us-gaap_PledgingPurposeDomain_e4ffb68a-1135-4099-b504-4d1001f5ed6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_483ccd73-90dd-4b71-9311-2da1c9fea9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PledgingPurposeDomain_e4ffb68a-1135-4099-b504-4d1001f5ed6b" xlink:to="loc_us-gaap_LetterOfCreditMember_483ccd73-90dd-4b71-9311-2da1c9fea9f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis_f8681733-69b4-436b-bbd7-fa5cddcc91a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:to="loc_us-gaap_PledgedStatusAxis_f8681733-69b4-436b-bbd7-fa5cddcc91a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_f8681733-69b4-436b-bbd7-fa5cddcc91a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PledgedStatusAxis_f8681733-69b4-436b-bbd7-fa5cddcc91a9" xlink:to="loc_us-gaap_PledgedStatusDomain_f8681733-69b4-436b-bbd7-fa5cddcc91a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_272ac289-f48a-479f-a861-6b7016954311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PledgedStatusAxis_f8681733-69b4-436b-bbd7-fa5cddcc91a9" xlink:to="loc_us-gaap_PledgedStatusDomain_272ac289-f48a-479f-a861-6b7016954311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember_3661dfdb-8f2b-476a-8f44-59e5f8465c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PledgedStatusDomain_272ac289-f48a-479f-a861-6b7016954311" xlink:to="loc_us-gaap_AssetPledgedAsCollateralMember_3661dfdb-8f2b-476a-8f44-59e5f8465c05" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended" id="i5ea30895bb4d4c1b8de30bced125c02d_LongTermDebtScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62a07273-7559-4b58-ba98-9c81ecc7215c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62a07273-7559-4b58-ba98-9c81ecc7215c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_eb98f293-468b-437f-9a05-35564cbdb8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_LongTermDebt_eb98f293-468b-437f-9a05-35564cbdb8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a678a977-aa17-40ce-8496-f1ea950b0ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_LongTermDebtCurrent_a678a977-aa17-40ce-8496-f1ea950b0ffa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_02a49e63-e9f3-4340-8788-a8c873fd18ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_02a49e63-e9f3-4340-8788-a8c873fd18ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11cfa791-a42d-42e8-b270-691caad19325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_DebtInstrumentTable_11cfa791-a42d-42e8-b270-691caad19325" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11cfa791-a42d-42e8-b270-691caad19325" xlink:to="loc_us-gaap_DebtInstrumentAxis_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_597529e1-bf0d-4e7b-b108-3e8566f55563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_597529e1-bf0d-4e7b-b108-3e8566f55563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_23609102-e566-49a4-83d4-4d058e67c2d6" xlink:href="arvn-20230331.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_597529e1-bf0d-4e7b-b108-3e8566f55563" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_23609102-e566-49a4-83d4-4d058e67c2d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended" id="i910e77e47dba4a1abdda9ea62e5fe285_LongTermDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_69cceda2-8b9c-4757-bebe-e8e39c98a3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_69cceda2-8b9c-4757-bebe-e8e39c98a3ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_e88d1b6d-ab99-4a73-b413-87008a5e2348" xlink:href="arvn-20230331.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_e88d1b6d-ab99-4a73-b413-87008a5e2348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_66bce0b6-851d-4b5f-8c7e-b36c350554cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_66bce0b6-851d-4b5f-8c7e-b36c350554cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_bd51b62b-f8ad-4a1a-a00a-e8a8b506b5e5" xlink:href="arvn-20230331.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_bd51b62b-f8ad-4a1a-a00a-e8a8b506b5e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_1e803875-500a-47fb-8416-58f05091b791" xlink:href="arvn-20230331.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_1e803875-500a-47fb-8416-58f05091b791" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5e3fe9b5-5c11-48c0-a652-a45939574962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_us-gaap_InterestExpense_5e3fe9b5-5c11-48c0-a652-a45939574962" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a521a20-4bbd-4c8d-96e7-e28738011130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a521a20-4bbd-4c8d-96e7-e28738011130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1a521a20-4bbd-4c8d-96e7-e28738011130_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a521a20-4bbd-4c8d-96e7-e28738011130" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1a521a20-4bbd-4c8d-96e7-e28738011130_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72b82bdf-d8f4-4d45-8c6a-96a3dbb16871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a521a20-4bbd-4c8d-96e7-e28738011130" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72b82bdf-d8f4-4d45-8c6a-96a3dbb16871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_9affffd4-bd65-42fe-bf1d-a22d7d71de2e" xlink:href="arvn-20230331.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72b82bdf-d8f4-4d45-8c6a-96a3dbb16871" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_9affffd4-bd65-42fe-bf1d-a22d7d71de2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_b2872bee-7157-4e11-a5ab-d583d0b75a1f" xlink:href="arvn-20230331.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72b82bdf-d8f4-4d45-8c6a-96a3dbb16871" xlink:to="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_b2872bee-7157-4e11-a5ab-d583d0b75a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bbbf7c22-78f5-45ce-8063-926f32ed601f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:to="loc_srt_StatementGeographicalAxis_bbbf7c22-78f5-45ce-8063-926f32ed601f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bbbf7c22-78f5-45ce-8063-926f32ed601f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bbbf7c22-78f5-45ce-8063-926f32ed601f" xlink:to="loc_srt_SegmentGeographicalDomain_bbbf7c22-78f5-45ce-8063-926f32ed601f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_37d5114e-d41c-4465-bcaf-8df4f90a0b57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bbbf7c22-78f5-45ce-8063-926f32ed601f" xlink:to="loc_srt_SegmentGeographicalDomain_37d5114e-d41c-4465-bcaf-8df4f90a0b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_86d0fecd-a7cc-437e-b59a-bb64fcd46f38" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_37d5114e-d41c-4465-bcaf-8df4f90a0b57" xlink:to="loc_stpr_CT_86d0fecd-a7cc-437e-b59a-bb64fcd46f38" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended" id="icb32b41e98254db1901ce55f573a7725_EquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_e3d46269-12e4-47f5-9c7f-70622f30b8d7" xlink:href="arvn-20230331.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_e3d46269-12e4-47f5-9c7f-70622f30b8d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_955901ea-d29a-446d-90a8-7d6c857be02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_955901ea-d29a-446d-90a8-7d6c857be02d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5ef7b79f-1fb9-412a-9dbf-4c567ca7e5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5ef7b79f-1fb9-412a-9dbf-4c567ca7e5e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_eaae9726-fe3f-44dc-967c-0c5d06c2eec2" xlink:href="arvn-20230331.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_eaae9726-fe3f-44dc-967c-0c5d06c2eec2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_27ef71cc-1a13-43ab-be18-4c6a903ee732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_27ef71cc-1a13-43ab-be18-4c6a903ee732" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5ede27f8-aeb0-420f-8c31-ca21291060ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5ede27f8-aeb0-420f-8c31-ca21291060ef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6621a602-5531-41d9-8db5-53bdafee415c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6621a602-5531-41d9-8db5-53bdafee415c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_58fbcdc6-9756-487f-9c21-df395699da1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_58fbcdc6-9756-487f-9c21-df395699da1a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_20c060dc-9bef-4dae-9192-08c25c2c6b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_20c060dc-9bef-4dae-9192-08c25c2c6b2e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0775f3fd-6e2f-4bb9-8f5e-1100ab57d2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0775f3fd-6e2f-4bb9-8f5e-1100ab57d2f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6fadef2c-cd03-425f-a268-16ac64b52bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6fadef2c-cd03-425f-a268-16ac64b52bef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2ca76183-372b-4dd1-bd5c-d969ea1c17d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2ca76183-372b-4dd1-bd5c-d969ea1c17d2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4b7d448-8ff7-49e6-b6b2-e039d508b373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4b7d448-8ff7-49e6-b6b2-e039d508b373" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6515e49b-1285-4d68-b970-63fdd469b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6515e49b-1285-4d68-b970-63fdd469b5f9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8cc8d9e3-fa6e-44bc-9206-253d29e72638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8cc8d9e3-fa6e-44bc-9206-253d29e72638" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_07b07a68-ff66-4636-83c3-95c4b971fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_07b07a68-ff66-4636-83c3-95c4b971fdf8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_58d981eb-102b-4375-bf7e-4ddc72f4db8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_58d981eb-102b-4375-bf7e-4ddc72f4db8e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_ebe10f28-436c-4830-9f48-926ed74901aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_ebe10f28-436c-4830-9f48-926ed74901aa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_11e231dc-f67f-4ebd-b8a7-3cc92dfda754" xlink:href="arvn-20230331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_11e231dc-f67f-4ebd-b8a7-3cc92dfda754" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33420dc1-ac16-42ad-b199-cddd381fc56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33420dc1-ac16-42ad-b199-cddd381fc56d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_33420dc1-ac16-42ad-b199-cddd381fc56d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33420dc1-ac16-42ad-b199-cddd381fc56d" xlink:to="loc_us-gaap_EquityComponentDomain_33420dc1-ac16-42ad-b199-cddd381fc56d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76b3685f-c969-4b55-9d4f-832badfaaa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33420dc1-ac16-42ad-b199-cddd381fc56d" xlink:to="loc_us-gaap_EquityComponentDomain_76b3685f-c969-4b55-9d4f-832badfaaa4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9e7f5ece-5db0-4fb6-aa0f-075c94804493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76b3685f-c969-4b55-9d4f-832badfaaa4c" xlink:to="loc_us-gaap_CommonStockMember_9e7f5ece-5db0-4fb6-aa0f-075c94804493" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cdbd6a1d-e9d4-4743-bbc3-abf379f43624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cdbd6a1d-e9d4-4743-bbc3-abf379f43624" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdbd6a1d-e9d4-4743-bbc3-abf379f43624_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdbd6a1d-e9d4-4743-bbc3-abf379f43624" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cdbd6a1d-e9d4-4743-bbc3-abf379f43624_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2479862-f18f-439d-8055-09f304a896d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdbd6a1d-e9d4-4743-bbc3-abf379f43624" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2479862-f18f-439d-8055-09f304a896d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_70afe426-ecd5-4d7e-b4d0-46feff275659" xlink:href="arvn-20230331.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2479862-f18f-439d-8055-09f304a896d5" xlink:to="loc_arvn_EquityDistributionAgreementMember_70afe426-ecd5-4d7e-b4d0-46feff275659" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7eb5306e-f140-4358-b754-7664b05fbe94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7eb5306e-f140-4358-b754-7664b05fbe94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7eb5306e-f140-4358-b754-7664b05fbe94_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7eb5306e-f140-4358-b754-7664b05fbe94" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7eb5306e-f140-4358-b754-7664b05fbe94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4113143f-f6ad-4fbe-a590-6dbfc53426a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7eb5306e-f140-4358-b754-7664b05fbe94" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4113143f-f6ad-4fbe-a590-6dbfc53426a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_d8df0c2f-e88c-41f0-a019-823742ba8766" xlink:href="arvn-20230331.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4113143f-f6ad-4fbe-a590-6dbfc53426a7" xlink:to="loc_arvn_AtTheMarketOfferingMember_d8df0c2f-e88c-41f0-a019-823742ba8766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bef75ad3-767e-4eb9-93de-138ae8eb6cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4113143f-f6ad-4fbe-a590-6dbfc53426a7" xlink:to="loc_us-gaap_EmployeeStockMember_bef75ad3-767e-4eb9-93de-138ae8eb6cdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13ce127e-8730-46e6-87ed-ed059caa875e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_srt_CounterpartyNameAxis_13ce127e-8730-46e6-87ed-ed059caa875e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ce127e-8730-46e6-87ed-ed059caa875e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_13ce127e-8730-46e6-87ed-ed059caa875e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13ce127e-8730-46e6-87ed-ed059caa875e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0b11abf-9ae7-4816-a1fc-fecd47ba2642" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_13ce127e-8730-46e6-87ed-ed059caa875e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0b11abf-9ae7-4816-a1fc-fecd47ba2642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember_3b6af03f-1c32-43a1-a554-47705a71c2ed" xlink:href="arvn-20230331.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0b11abf-9ae7-4816-a1fc-fecd47ba2642" xlink:to="loc_arvn_PiperSandlerAndCantorMember_3b6af03f-1c32-43a1-a554-47705a71c2ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da3a3eb2-b61b-4f22-8448-7ec964d0228e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_srt_RangeAxis_da3a3eb2-b61b-4f22-8448-7ec964d0228e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da3a3eb2-b61b-4f22-8448-7ec964d0228e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_da3a3eb2-b61b-4f22-8448-7ec964d0228e" xlink:to="loc_srt_RangeMember_da3a3eb2-b61b-4f22-8448-7ec964d0228e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2656fe7b-083d-4cd0-baeb-ee0388bba37a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_da3a3eb2-b61b-4f22-8448-7ec964d0228e" xlink:to="loc_srt_RangeMember_2656fe7b-083d-4cd0-baeb-ee0388bba37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7282b215-c709-4199-9db8-97f35c524e7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2656fe7b-083d-4cd0-baeb-ee0388bba37a" xlink:to="loc_srt_MinimumMember_7282b215-c709-4199-9db8-97f35c524e7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1b67af8-0426-4ea9-8c59-4347a447b300" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2656fe7b-083d-4cd0-baeb-ee0388bba37a" xlink:to="loc_srt_MaximumMember_a1b67af8-0426-4ea9-8c59-4347a447b300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b0fa755-394f-430e-a96f-020070713d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_PlanNameAxis_9b0fa755-394f-430e-a96f-020070713d02" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9b0fa755-394f-430e-a96f-020070713d02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9b0fa755-394f-430e-a96f-020070713d02" xlink:to="loc_us-gaap_PlanNameDomain_9b0fa755-394f-430e-a96f-020070713d02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ef92d0c4-cdd5-408d-8132-d54ccaeaceb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9b0fa755-394f-430e-a96f-020070713d02" xlink:to="loc_us-gaap_PlanNameDomain_ef92d0c4-cdd5-408d-8132-d54ccaeaceb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_ce5e3628-9a92-42e0-aa2b-24994e76bce0" xlink:href="arvn-20230331.xsd#arvn_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ef92d0c4-cdd5-408d-8132-d54ccaeaceb1" xlink:to="loc_arvn_StockIncentivePlanMember_ce5e3628-9a92-42e0-aa2b-24994e76bce0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_50b33436-eb36-4b5f-b0e2-308793eaee14" xlink:href="arvn-20230331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ef92d0c4-cdd5-408d-8132-d54ccaeaceb1" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_50b33436-eb36-4b5f-b0e2-308793eaee14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_a482bbfc-0ef2-4670-86a4-bc34be7b2edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_GranteeStatusAxis_a482bbfc-0ef2-4670-86a4-bc34be7b2edb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_a482bbfc-0ef2-4670-86a4-bc34be7b2edb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_a482bbfc-0ef2-4670-86a4-bc34be7b2edb" xlink:to="loc_us-gaap_GranteeStatusDomain_a482bbfc-0ef2-4670-86a4-bc34be7b2edb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_b919d837-ece8-40b0-b9d0-665f6f8d86d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_a482bbfc-0ef2-4670-86a4-bc34be7b2edb" xlink:to="loc_us-gaap_GranteeStatusDomain_b919d837-ece8-40b0-b9d0-665f6f8d86d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_fa9fe566-041b-487a-bcca-79b6859610c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_b919d837-ece8-40b0-b9d0-665f6f8d86d4" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_fa9fe566-041b-487a-bcca-79b6859610c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_96471319-0b6e-4154-9417-1f1386455927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_AwardTypeAxis_96471319-0b6e-4154-9417-1f1386455927" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96471319-0b6e-4154-9417-1f1386455927_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_96471319-0b6e-4154-9417-1f1386455927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_96471319-0b6e-4154-9417-1f1386455927_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a423767f-32a4-460f-b958-bcbcf7754eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_96471319-0b6e-4154-9417-1f1386455927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a423767f-32a4-460f-b958-bcbcf7754eb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_66438157-970c-499b-a177-bb8d8549fb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a423767f-32a4-460f-b958-bcbcf7754eb1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_66438157-970c-499b-a177-bb8d8549fb1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e883af76-f10a-49aa-9c16-3daf75a13423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a423767f-32a4-460f-b958-bcbcf7754eb1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e883af76-f10a-49aa-9c16-3daf75a13423" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended" id="i652426ced0d7436388c7165bd314f288_EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d0a69aa4-9322-4c92-8dc1-e6a99faceead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d0a69aa4-9322-4c92-8dc1-e6a99faceead" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9171641f-0103-44df-99a1-7059a2e3ac06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9171641f-0103-44df-99a1-7059a2e3ac06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4e8d246d-69c2-420c-8c28-96179e1de56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4e8d246d-69c2-420c-8c28-96179e1de56b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b37e66bf-6e87-462c-9840-fa238d2d5e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b37e66bf-6e87-462c-9840-fa238d2d5e29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_943fd4b7-c4f4-46a6-9e2e-1245cdb1b06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_943fd4b7-c4f4-46a6-9e2e-1245cdb1b06e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_310888a2-74f4-4e79-b8c1-d9734084352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_310888a2-74f4-4e79-b8c1-d9734084352e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6e5f4bf1-37e0-471f-828d-355195475fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6e5f4bf1-37e0-471f-828d-355195475fd5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1e66b2f4-6050-4c07-837d-d5aed67ebb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:to="loc_us-gaap_AwardTypeAxis_1e66b2f4-6050-4c07-837d-d5aed67ebb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e66b2f4-6050-4c07-837d-d5aed67ebb35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1e66b2f4-6050-4c07-837d-d5aed67ebb35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1e66b2f4-6050-4c07-837d-d5aed67ebb35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c321774-13b2-43ca-a772-8c118f81ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1e66b2f4-6050-4c07-837d-d5aed67ebb35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c321774-13b2-43ca-a772-8c118f81ca61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4123c2b3-73fc-4b92-bd52-07f31e9dd622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c321774-13b2-43ca-a772-8c118f81ca61" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4123c2b3-73fc-4b92-bd52-07f31e9dd622" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:to="loc_srt_RangeAxis_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f" xlink:to="loc_srt_RangeMember_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0489d0cc-1c66-4c41-944f-e083573a94d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f" xlink:to="loc_srt_RangeMember_0489d0cc-1c66-4c41-944f-e083573a94d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fa8bb4b9-2327-4712-998f-ae8a879bf509" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0489d0cc-1c66-4c41-944f-e083573a94d4" xlink:to="loc_srt_MinimumMember_fa8bb4b9-2327-4712-998f-ae8a879bf509" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7eab5e0f-a2a6-4744-8ea8-f7fda66d3284" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0489d0cc-1c66-4c41-944f-e083573a94d4" xlink:to="loc_srt_MaximumMember_7eab5e0f-a2a6-4744-8ea8-f7fda66d3284" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquitySummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="extended" id="i25fa5f6fba8f4068ac7bcac75cf831d7_EquitySummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1cb1d5d-9627-4275-82b3-1d01aea3753f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1cb1d5d-9627-4275-82b3-1d01aea3753f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_92ee7513-9739-4203-a203-bedbf056864b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_92ee7513-9739-4203-a203-bedbf056864b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_204f9eeb-e551-4178-b4eb-0a099d19feee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_204f9eeb-e551-4178-b4eb-0a099d19feee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9bb4a06f-502d-48a0-85ce-5766d18ee222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9bb4a06f-502d-48a0-85ce-5766d18ee222" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3c2edc0-14bc-474e-a463-41db2e2631b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_91295e20-92c7-4144-9778-d49e9c143fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_91295e20-92c7-4144-9778-d49e9c143fde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d60d209-3421-428a-b1c2-aab0c6215013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d60d209-3421-428a-b1c2-aab0c6215013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4d3e2afa-a34c-4290-8919-166a3222a98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4d3e2afa-a34c-4290-8919-166a3222a98e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_53addbe2-d8e6-4f6f-84f7-a948927b4ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_53addbe2-d8e6-4f6f-84f7-a948927b4ebf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3feb5ef1-b04b-43c6-8a63-128afb2f8692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3feb5ef1-b04b-43c6-8a63-128afb2f8692" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3902bc03-cd8f-4549-bcaf-27895749bc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_69bd56c0-25ed-48c5-a7a4-e36c92816730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_69bd56c0-25ed-48c5-a7a4-e36c92816730" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aa0fdb1a-12ac-420f-9625-ec6e43fa1e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aa0fdb1a-12ac-420f-9625-ec6e43fa1e79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e496dfb-be52-4a0d-839c-a3688287e01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aa0fdb1a-12ac-420f-9625-ec6e43fa1e79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e496dfb-be52-4a0d-839c-a3688287e01e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e1fbc61b-6c3e-4939-bad2-b2902a9f63d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aa0fdb1a-12ac-420f-9625-ec6e43fa1e79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e1fbc61b-6c3e-4939-bad2-b2902a9f63d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract_dad3932a-9608-4174-ac8c-bd7553549210" xlink:href="arvn-20230331.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_arvn_AggregateIntrinsicValueAbstract_dad3932a-9608-4174-ac8c-bd7553549210" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_47d5c9f2-f5bb-47b6-a05f-ea7fabc0f400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_dad3932a-9608-4174-ac8c-bd7553549210" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_47d5c9f2-f5bb-47b6-a05f-ea7fabc0f400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7c21b75a-6fdc-47ff-88ad-88b36a5fdc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_dad3932a-9608-4174-ac8c-bd7553549210" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7c21b75a-6fdc-47ff-88ad-88b36a5fdc70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7b29c171-13f3-43b0-889b-e80a08ee6aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:to="loc_us-gaap_PlanNameAxis_7b29c171-13f3-43b0-889b-e80a08ee6aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7b29c171-13f3-43b0-889b-e80a08ee6aae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7b29c171-13f3-43b0-889b-e80a08ee6aae" xlink:to="loc_us-gaap_PlanNameDomain_7b29c171-13f3-43b0-889b-e80a08ee6aae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_98056025-90c8-419f-8e96-96603c54ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7b29c171-13f3-43b0-889b-e80a08ee6aae" xlink:to="loc_us-gaap_PlanNameDomain_98056025-90c8-419f-8e96-96603c54ff08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_a1e85bbc-b5c3-42fa-a27f-2bb9c17aa3b1" xlink:href="arvn-20230331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_98056025-90c8-419f-8e96-96603c54ff08" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_a1e85bbc-b5c3-42fa-a27f-2bb9c17aa3b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_da2285ef-0785-4063-a6e2-f700e069feea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:to="loc_srt_TitleOfIndividualAxis_da2285ef-0785-4063-a6e2-f700e069feea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_da2285ef-0785-4063-a6e2-f700e069feea_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_da2285ef-0785-4063-a6e2-f700e069feea" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_da2285ef-0785-4063-a6e2-f700e069feea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28415308-019d-43b7-9719-aea38887cdc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_da2285ef-0785-4063-a6e2-f700e069feea" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28415308-019d-43b7-9719-aea38887cdc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesAndDirectorsMember_3afd0285-cc34-42ef-b3c8-53a97f7e6b9c" xlink:href="arvn-20230331.xsd#arvn_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28415308-019d-43b7-9719-aea38887cdc9" xlink:to="loc_arvn_EmployeesAndDirectorsMember_3afd0285-cc34-42ef-b3c8-53a97f7e6b9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquitySummaryofRestrictedStockGrantActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="extended" id="ia0149005278846a2ace18be6793fb140_EquitySummaryofRestrictedStockGrantActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_257ca517-55ab-4395-b2c2-3276808089f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_257ca517-55ab-4395-b2c2-3276808089f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fb69386-8b8e-4f4b-acb3-dc7aaa5190a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fb69386-8b8e-4f4b-acb3-dc7aaa5190a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e057253f-8d2d-463d-a217-7d888b6c04b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e057253f-8d2d-463d-a217-7d888b6c04b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_736e07dd-4ac2-4f65-a76f-2923d1cfb555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_736e07dd-4ac2-4f65-a76f-2923d1cfb555" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d24237cc-a091-47e0-9789-074c9a87061d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d24237cc-a091-47e0-9789-074c9a87061d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e06d8917-a54b-4964-bd6d-377be21cbdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_257ca517-55ab-4395-b2c2-3276808089f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f3ea5ab2-c0c5-45aa-a8bb-ed15ac7cc0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f3ea5ab2-c0c5-45aa-a8bb-ed15ac7cc0cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfd6444c-aad5-4fbd-9bfd-c1ca9af3d5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfd6444c-aad5-4fbd-9bfd-c1ca9af3d5e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0376f82e-b106-413f-93bd-7c2b5ef26339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0376f82e-b106-413f-93bd-7c2b5ef26339" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5edaebfd-cd08-43b8-b5fd-f1f8bc3fb962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5edaebfd-cd08-43b8-b5fd-f1f8bc3fb962" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19c3c642-1a94-42d3-9326-efcf39a35381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_257ca517-55ab-4395-b2c2-3276808089f6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5da69dc2-51d8-493e-872a-1d4aa5a00ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:to="loc_us-gaap_PlanNameAxis_5da69dc2-51d8-493e-872a-1d4aa5a00ef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5da69dc2-51d8-493e-872a-1d4aa5a00ef4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5da69dc2-51d8-493e-872a-1d4aa5a00ef4" xlink:to="loc_us-gaap_PlanNameDomain_5da69dc2-51d8-493e-872a-1d4aa5a00ef4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9bdab79d-72be-4674-b76a-8b8933bdde32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5da69dc2-51d8-493e-872a-1d4aa5a00ef4" xlink:to="loc_us-gaap_PlanNameDomain_9bdab79d-72be-4674-b76a-8b8933bdde32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_43745322-dc8c-4acc-a3cd-2104c8175d60" xlink:href="arvn-20230331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_9bdab79d-72be-4674-b76a-8b8933bdde32" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_43745322-dc8c-4acc-a3cd-2104c8175d60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:to="loc_us-gaap_AwardTypeAxis_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9009c00-1761-4c25-87f5-2c5b429e4315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9009c00-1761-4c25-87f5-2c5b429e4315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2f3dd7b-c098-428f-a655-6eb282c7964b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9009c00-1761-4c25-87f5-2c5b429e4315" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2f3dd7b-c098-428f-a655-6eb282c7964b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9bbd0234-cd80-43e6-9465-5038937f59b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:to="loc_srt_TitleOfIndividualAxis_9bbd0234-cd80-43e6-9465-5038937f59b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9bbd0234-cd80-43e6-9465-5038937f59b7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_9bbd0234-cd80-43e6-9465-5038937f59b7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9bbd0234-cd80-43e6-9465-5038937f59b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8a129bee-75e2-436c-bb5b-b6b071a9863f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_9bbd0234-cd80-43e6-9465-5038937f59b7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8a129bee-75e2-436c-bb5b-b6b071a9863f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_ae46ef25-45ff-4287-815b-a7256e7769b0" xlink:href="arvn-20230331.xsd#arvn_EmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8a129bee-75e2-436c-bb5b-b6b071a9863f" xlink:to="loc_arvn_EmployeesMember_ae46ef25-45ff-4287-815b-a7256e7769b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="extended" id="i1436ddae37c04eab92e710c7f992c42b_NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_685abd1c-2d34-46c7-a819-9fa6e37f4b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92816f90-ffd2-4141-aaff-0b6f3d3ad9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_685abd1c-2d34-46c7-a819-9fa6e37f4b8a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92816f90-ffd2-4141-aaff-0b6f3d3ad9ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3a0e13de-64f8-45c3-9c81-477010523ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_685abd1c-2d34-46c7-a819-9fa6e37f4b8a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3a0e13de-64f8-45c3-9c81-477010523ea1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3a0e13de-64f8-45c3-9c81-477010523ea1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c20da64-ea05-4681-8d29-b5e76b0981c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c20da64-ea05-4681-8d29-b5e76b0981c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0f9fc50c-a1e0-4fb8-a018-22697a40515c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c20da64-ea05-4681-8d29-b5e76b0981c4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0f9fc50c-a1e0-4fb8-a018-22697a40515c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c868a0d4-5474-4f62-98e8-b9a617b77346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c20da64-ea05-4681-8d29-b5e76b0981c4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c868a0d4-5474-4f62-98e8-b9a617b77346" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityMethodInvestmentsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails" xlink:type="extended" id="i89cf499cbe104373b1e0c0c85a4675b6_EquityMethodInvestmentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8714a786-5ced-44d5-a5e6-352b9e4e6b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8714a786-5ced-44d5-a5e6-352b9e4e6b58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_fb1689bd-0a6a-4be6-b59e-1ec7ee77d99d" xlink:href="arvn-20230331.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_fb1689bd-0a6a-4be6-b59e-1ec7ee77d99d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_52ff507d-071c-4f6c-ac53-cb1d102a5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_ContractWithCustomerLiability_52ff507d-071c-4f6c-ac53-cb1d102a5b6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a5dc85d1-8e7c-4fa7-aeb2-00555557bde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_ProfitLoss_a5dc85d1-8e7c-4fa7-aeb2-00555557bde8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_64281bb9-9065-48cf-b901-ce378de5c364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_64281bb9-9065-48cf-b901-ce378de5c364" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b039eec8-51c3-49b2-b097-4be65e3e73ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_EquityMethodInvestments_b039eec8-51c3-49b2-b097-4be65e3e73ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d46fdcc9-a61a-49f2-96a6-c041787e00ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:to="loc_srt_CounterpartyNameAxis_d46fdcc9-a61a-49f2-96a6-c041787e00ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d46fdcc9-a61a-49f2-96a6-c041787e00ec_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d46fdcc9-a61a-49f2-96a6-c041787e00ec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d46fdcc9-a61a-49f2-96a6-c041787e00ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37c5d58f-6ec2-4372-b533-1bb696d12b5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d46fdcc9-a61a-49f2-96a6-c041787e00ec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37c5d58f-6ec2-4372-b533-1bb696d12b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_30658bc5-a515-4a99-9980-70caba2df7b4" xlink:href="arvn-20230331.xsd#arvn_BayerCropScienceLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37c5d58f-6ec2-4372-b533-1bb696d12b5c" xlink:to="loc_arvn_BayerCropScienceLPMember_30658bc5-a515-4a99-9980-70caba2df7b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b12f86d-af5c-4abb-a2f1-208275cbc6ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b12f86d-af5c-4abb-a2f1-208275cbc6ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8b12f86d-af5c-4abb-a2f1-208275cbc6ae_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b12f86d-af5c-4abb-a2f1-208275cbc6ae" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8b12f86d-af5c-4abb-a2f1-208275cbc6ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d2fe77db-62f8-4741-8340-c8bb1ec4b1a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b12f86d-af5c-4abb-a2f1-208275cbc6ae" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d2fe77db-62f8-4741-8340-c8bb1ec4b1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_d5b9cd01-c1e8-478d-8b5f-aa080166d059" xlink:href="arvn-20230331.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d2fe77db-62f8-4741-8340-c8bb1ec4b1a3" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_d5b9cd01-c1e8-478d-8b5f-aa080166d059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1baff7a5-a39a-40be-966e-93e777d87dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1baff7a5-a39a-40be-966e-93e777d87dae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1baff7a5-a39a-40be-966e-93e777d87dae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1baff7a5-a39a-40be-966e-93e777d87dae" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_1baff7a5-a39a-40be-966e-93e777d87dae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_582cf0c3-4600-4e3e-ba11-96fb915c6cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1baff7a5-a39a-40be-966e-93e777d87dae" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_582cf0c3-4600-4e3e-ba11-96fb915c6cbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_5cd2e447-1245-4025-985e-3ae5e750a0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_582cf0c3-4600-4e3e-ba11-96fb915c6cbb" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_5cd2e447-1245-4025-985e-3ae5e750a0c4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" xlink:type="extended" id="i50eaf653dbf54540b572758697c9989c_EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6768da8e-2a9c-47f1-859b-015cfd8116b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_Revenues_6768da8e-2a9c-47f1-859b-015cfd8116b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e8bc9037-68dc-45b1-a1bf-e076ff304050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_OperatingIncomeLoss_e8bc9037-68dc-45b1-a1bf-e076ff304050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1b43f5f0-e20d-47d2-8d66-3ddad94956d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1b43f5f0-e20d-47d2-8d66-3ddad94956d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7bcc01df-424c-4167-ac55-93e6aae4e08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_NetIncomeLoss_7bcc01df-424c-4167-ac55-93e6aae4e08a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9c9d998e-4856-4095-95b2-94dcc9b5f373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_EarningsPerShareBasic_9c9d998e-4856-4095-95b2-94dcc9b5f373" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_483c790e-ced6-42ff-aa5a-958212515265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_483c790e-ced6-42ff-aa5a-958212515265" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c710f58-54c8-4369-81ae-039a1ebadc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c710f58-54c8-4369-81ae-039a1ebadc8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_e1e5092c-d033-46ec-8f75-17f7f3ded1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_e1e5092c-d033-46ec-8f75-17f7f3ded1bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_e1e5092c-d033-46ec-8f75-17f7f3ded1bc" xlink:to="loc_srt_RestatementAxis_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca" xlink:to="loc_srt_RestatementDomain_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_2d1896a4-8b26-4a4b-aabd-0321d546db10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca" xlink:to="loc_srt_RestatementDomain_2d1896a4-8b26-4a4b-aabd-0321d546db10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1b2c3107-4bbf-43c2-a53d-0ca67ab0140c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2d1896a4-8b26-4a4b-aabd-0321d546db10" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1b2c3107-4bbf-43c2-a53d-0ca67ab0140c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7b68df19-1eea-4277-84a6-c543d4376a56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2d1896a4-8b26-4a4b-aabd-0321d546db10" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7b68df19-1eea-4277-84a6-c543d4376a56" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i143e276b90fe4a39b8f30de18d095bd2_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems_fcb8b272-e4d8-4e25-8c93-00f0afff051f" xlink:href="arvn-20230331.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b5c168b9-5116-4622-a366-825e3c5e8cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_fcb8b272-e4d8-4e25-8c93-00f0afff051f" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b5c168b9-5116-4622-a366-825e3c5e8cdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_31313edf-f2bc-41d9-b19b-b85bdec9f653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_fcb8b272-e4d8-4e25-8c93-00f0afff051f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_31313edf-f2bc-41d9-b19b-b85bdec9f653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:href="arvn-20230331.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_fcb8b272-e4d8-4e25-8c93-00f0afff051f" xlink:to="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a72df2d0-ff18-4bf2-b5da-0e103747e658" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:to="loc_srt_CounterpartyNameAxis_a72df2d0-ff18-4bf2-b5da-0e103747e658" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a72df2d0-ff18-4bf2-b5da-0e103747e658_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a72df2d0-ff18-4bf2-b5da-0e103747e658" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a72df2d0-ff18-4bf2-b5da-0e103747e658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ccf81f5-3136-43cd-8b88-4fa4d25d2977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a72df2d0-ff18-4bf2-b5da-0e103747e658" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ccf81f5-3136-43cd-8b88-4fa4d25d2977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FoundationMedicineIncMember_36598e34-b645-404f-a439-bcb86b7aa5d1" xlink:href="arvn-20230331.xsd#arvn_FoundationMedicineIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ccf81f5-3136-43cd-8b88-4fa4d25d2977" xlink:to="loc_arvn_FoundationMedicineIncMember_36598e34-b645-404f-a439-bcb86b7aa5d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d39bd54-6bc7-45c3-9d2c-7a199934a929" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:to="loc_srt_RangeAxis_7d39bd54-6bc7-45c3-9d2c-7a199934a929" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d39bd54-6bc7-45c3-9d2c-7a199934a929_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7d39bd54-6bc7-45c3-9d2c-7a199934a929" xlink:to="loc_srt_RangeMember_7d39bd54-6bc7-45c3-9d2c-7a199934a929_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9865fb6c-b8dd-47c9-8f4f-cdab45fc4813" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7d39bd54-6bc7-45c3-9d2c-7a199934a929" xlink:to="loc_srt_RangeMember_9865fb6c-b8dd-47c9-8f4f-cdab45fc4813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c96fd3cc-5d99-4696-8b2f-af339c7b0a74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9865fb6c-b8dd-47c9-8f4f-cdab45fc4813" xlink:to="loc_srt_MaximumMember_c96fd3cc-5d99-4696-8b2f-af339c7b0a74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2cc1ad6d-f9ea-4007-a68e-5103379c001a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2cc1ad6d-f9ea-4007-a68e-5103379c001a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cc1ad6d-f9ea-4007-a68e-5103379c001a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2cc1ad6d-f9ea-4007-a68e-5103379c001a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2cc1ad6d-f9ea-4007-a68e-5103379c001a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85c91002-92d3-4acd-80c8-ac5ced29c826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2cc1ad6d-f9ea-4007-a68e-5103379c001a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85c91002-92d3-4acd-80c8-ac5ced29c826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember_823e6ab1-3a55-475a-a0e0-3a4b2cc5c7d8" xlink:href="arvn-20230331.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85c91002-92d3-4acd-80c8-ac5ced29c826" xlink:to="loc_arvn_SuccessBasedMilestonePaymentsMember_823e6ab1-3a55-475a-a0e0-3a4b2cc5c7d8" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>arvn-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f1eeee1-4d1b-4eb9-97f6-83d0702c4de4,g:c3df6ade-21e6-4d49-a1b5-7881af27fa72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_srt_RestatementAxis_d9a54fbe-82fb-47ae-b2d5-3629791772cc_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7699453c-5807-4d0c-85d7-dd479bea7f92_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_cfeb1dba-e3e0-40a9-8b64-9765f248d073_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_15db036f-97a0-44e5-bd33-e540ea73ebec_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_356a44aa-c2ec-4702-a986-9ff6160406e2_terseLabel_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arvn-20230331.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_9faf6ffc-3f29-4079-8085-74234af69d77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8e390362-1002-4e7c-b320-cbecf063425e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_0d9c5927-36a1-40b1-bad4-2bbb369f1f91_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2023-2024</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e395cc2e-dc1d-43e6-825d-d0e1499e92b4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1dee9c88-446b-4655-9ee0-1a66e7aa6e56_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5ce2aa8e-94e7-4e99-8b24-d2bb6082e878_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_975aea4c-68bd-4d0e-82bf-5f35c2922c69_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6271d555-3e15-4edb-bea9-379be3041f65_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_efbb2523-6592-4116-a610-0ed492ffc6f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_71eb9e30-0991-4fd4-a1e4-fcc9cde65531_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_documentation_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:href="arvn-20230331.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:to="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_bff6a5a7-59e9-47cf-a95e-3863d2b25158_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetPledgedAsCollateralMember_49ce49bb-c1de-4e93-b7c4-a181945ec0db_terseLabel_en-US" xlink:label="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Pledged as Collateral</link:label>
    <link:label id="lab_us-gaap_AssetPledgedAsCollateralMember_label_en-US" xlink:label="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Pledged as Collateral [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetPledgedAsCollateralMember" xlink:to="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_da574554-3d8e-4e39-9cc7-25a91694a937_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2d3b4bf8-8a93-4c60-81b6-dcaf9bbebfca_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise/ vesting of stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e21bff0f-4a72-4b5b-b1cd-52fa567f0e77_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ce3711ca-3d62-4182-a0d1-ae4eec7f6d6c_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_88df6693-d7cb-438b-9396-f8d6f0e5f5e0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument bearing interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2ea916ec-c39a-492e-9127-e32edb8763e5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_57713b9a-3d1e-4eca-bce3-d98619b7cc65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_29f70a2b-1fda-4170-8fdc-0d9334aeeb20_terseLabel_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable" xlink:href="arvn-20230331.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommitmentsAndContingenciesTable" xlink:to="lab_arvn_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_cb375e57-77b2-4801-b5a2-444069802f24_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1f600b7c-dc41-42c0-a58b-3b0c67eaff55_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4de15d44-75f0-47d2-859e-a2cd47e41bfd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a50a62c3-a96d-4e42-9f83-714fcdbd0ddc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_219b4992-762c-4d98-b3aa-e55f1ce61373_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d9272bf2-f947-4341-8a98-f2f65162983d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c2a2657b-7dce-48e8-b3a2-ac3bb975b1ac_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_792da4fb-732f-43ca-af5c-419cae3a2c7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Minimum Future Payments on Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_4b0f5855-698f-4642-a6bc-7f947d4b2ac6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_f1886889-165f-42bd-af0f-d6d9e669e0a2_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2024</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_489dd9b6-fac4-4bb7-827d-8b073d347347_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7a020dfe-541b-43d0-9138-98a8ce8d41b5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_7782c2db-abaf-45cb-82c8-edf278828ffc_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_b07e4a3e-0d1d-46f6-b585-0d0b7a3fc11f_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone Payments</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:href="arvn-20230331.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:to="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_0fe6057a-a7b9-4b9a-975d-8ae19ea9f0d1_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_dbb611a7-7e13-4919-8b65-8d0ae6841174_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_2b00da09-0060-4eb2-bf05-6f9f83d3787b_terseLabel_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future grant of incentive units to service providers percentage</link:label>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_label_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Grant Of Incentive Units To Service Providers Percentage</link:label>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_documentation_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future grant of incentive units to service providers, percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:href="arvn-20230331.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:to="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_4924bb21-a22a-4f05-bb8b-cc4cbc09cce6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_fa7f275e-5d7f-416c-b24c-12b2cab60918_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_759c6839-22cb-4e5d-8008-8f4cc2195d1c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue receivable if milestones achieved</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_e9520ca6-71f9-4dda-afd5-65e20c22cf1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_14fe852d-a5c8-4e72-aad4-c3e08c5f3d1a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecurities_4401f8e6-a76f-4872-98be-4a3c0c9e4511_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit for collateralized by certificate of deposit</link:label>
    <link:label id="lab_us-gaap_DebtSecurities_label_en-US" xlink:label="lab_us-gaap_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecurities" xlink:to="lab_us-gaap_DebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember_87e0c2c2-39ff-4055-ad11-a4817ca33632_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2023</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three One [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b11818e2-5939-464f-beaf-dbd90da3e39f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_5ad2d3fa-f0a7-49bb-992e-50c6065f2e40_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and issuance of ESPP shares</link:label>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_label_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</link:label>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_documentation_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:to="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_989a7862-93a1-4c31-8200-e521562ade5d_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Grant Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_48c1e747-9ece-4f11-b2d8-d43bc68ed531_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dd197f55-52ac-42a1-9560-93b553cd04bd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_349f7859-4ce4-4770-b8e7-abd8e8a5760d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67b93020-54da-42e8-9c98-5e6f49cf3369_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_f4bb4da7-87f6-481e-ae1a-d5c6ecea1eb2_terseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Additions</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:href="arvn-20230331.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_eb8de341-3bc3-4015-b92f-bfb8a7f77218_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_44b8a647-8815-48c9-9dc4-7d0ec40bb60f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgedStatusAxis_332a98ea-05f6-4130-83b7-20ca2eb0db54_terseLabel_en-US" xlink:label="lab_us-gaap_PledgedStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Status [Axis]</link:label>
    <link:label id="lab_us-gaap_PledgedStatusAxis_label_en-US" xlink:label="lab_us-gaap_PledgedStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgedStatusAxis" xlink:to="lab_us-gaap_PledgedStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_afd92b89-c208-4d05-98de-25d0bc25afab_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d8649210-960c-4bdb-aad3-49f32d7ae3f8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_2ff01a62-a170-45ec-9445-5aad44602972_periodStartLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_5f4ba55f-99c0-452c-80ed-3b97d428452d_periodEndLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent" xlink:href="arvn-20230331.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrent" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b59c8bcb-ba38-4c8b-9d6c-4fa73054915c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce483c95-f903-4f68-8461-af96441d3602_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_21a729ff-2cf5-4294-aeb5-6153ce132cd5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_ae3a476a-686c-4c4d-b704-a5db24370714_terseLabel_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_label_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth Bio Limited Liability Corporation [Member]</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_documentation_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oerth Bio LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:href="arvn-20230331.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:to="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_04809aa2-f8dc-4825-a3d1-c2e60f4b114e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Available-for-Sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_5122188d-176d-419e-ab2a-8d3bfbaa8e18_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2023</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_66c8d953-5cbd-406a-84d6-69fa7f8fba4c_terseLabel_en-US" xlink:label="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional upfront non-refundable amount received under previous agreement</link:label>
    <link:label id="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_label_en-US" xlink:label="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Upfront Non Refundable Amount Received Under Previous Agreement</link:label>
    <link:label id="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_documentation_en-US" xlink:label="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional upfront non-refundable amount received under previous agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:href="arvn-20230331.xsd#arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:to="lab_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d4a66d90-45b1-418a-8a7d-d73fc3fab21a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_ff06c79b-bf1a-45df-9deb-48b6d06d9351_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b0643c6e-87fc-4b23-b9d7-f37e762102ad_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_1257e471-817d-443f-8bcc-07a536f53a84_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest payments term (in months)</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_label_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Interest Payments Term</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument interest payments term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:href="arvn-20230331.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:to="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_77eaab11-c23e-43d0-badb-04c22b7c733a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_46d5f721-679f-4e58-804f-507baa27e089_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_623922d6-290e-45c0-b56b-5688f7f242f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_7f1da0c4-a1a4-4385-89b8-7898cd580131_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e5c7600-1a29-4183-96db-9d18b75a313e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_df9b8ac2-b512-47cc-8cf0-a0c349eb95db_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_669c916d-3e35-402a-afca-bef9cdcc8f94_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_c8d28100-6ef0-4dc8-97b3-7f0540a4f9d0_terseLabel_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:href="arvn-20230331.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:to="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_aca3a6a3-a03d-4169-8beb-03c4d3bb6484_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options, vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_b579680e-749b-4a1c-bd0e-fcc1b60e8ee5_terseLabel_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_label_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity distribution agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember" xlink:href="arvn-20230331.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EquityDistributionAgreementMember" xlink:to="lab_arvn_EquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_119ca8ad-d1d4-4485-8ed6-fd3588cb8ef2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_dc537d21-883b-4d40-a0c8-d846fdf96343_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_eca7bd71-0aab-4bee-8c46-77cd8069e224_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_d12bcc11-bc34-4da0-b613-59b94f89cb04_terseLabel_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities: Deferred revenue</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="arvn-20230331.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5cb81f8d-f08d-4095-b319-18c44d805b93_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_6cbe2ae3-91de-4d21-9d16-2510722df8ed_negatedLabel_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_label_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization During Period</link:label>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_documentation_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:href="arvn-20230331.xsd#arvn_CapitalizedContractCostAmortizationDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:to="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_6d0100d6-afe1-4a8c-bd16-ee54976c68ec_terseLabel_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent lease term (in years)</link:label>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_label_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Lease Rent Period</link:label>
    <link:label id="lab_arvn_BaseLeaseRentPeriod_documentation_en-US" xlink:label="lab_arvn_BaseLeaseRentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base lease rent period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod" xlink:href="arvn-20230331.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BaseLeaseRentPeriod" xlink:to="lab_arvn_BaseLeaseRentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_c323ff40-1f6d-44c2-9313-0f09e1197303_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease for laboratory and office space</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5fe42879-599f-4492-bd5f-4adcab39e127_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc68721e-5915-4549-a53c-1129988c19c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d309bd63-90d6-43e0-995c-c2b57c4a1856_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c4c6517c-3728-4e26-b476-a3e945671825_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_84b0119a-cdfd-4be3-a6b6-b1afef33b561_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2024-2025</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Five [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_036cc3d9-d045-43c0-8928-ad0471907121_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LongTermDebtMaturityYearSix_1f6afe1d-6bc2-49b1-bf0d-f9d796c2a92b_terseLabel_en-US" xlink:label="lab_arvn_LongTermDebtMaturityYearSix" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_arvn_LongTermDebtMaturityYearSix_label_en-US" xlink:label="lab_arvn_LongTermDebtMaturityYearSix" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Six</link:label>
    <link:label id="lab_arvn_LongTermDebtMaturityYearSix_documentation_en-US" xlink:label="lab_arvn_LongTermDebtMaturityYearSix" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LongTermDebtMaturityYearSix" xlink:href="arvn-20230331.xsd#arvn_LongTermDebtMaturityYearSix"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LongTermDebtMaturityYearSix" xlink:to="lab_arvn_LongTermDebtMaturityYearSix" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_544fef5b-0ba6-44c4-9315-f9b694b79334_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6ad57d90-778e-4143-b951-8af2c0bed2bc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_5b686276-e4ed-4893-b774-32fb28e9496a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_787a7b40-1b98-4b98-859b-1d043d4fe193_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_12b29c5d-59a4-4801-b4d2-97f5bdaaebbc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contract Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ad20e9b0-6796-44e6-80c7-5eee3d767959_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_03e65e94-cfd5-445c-bae4-4897415c7875_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2023</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_be3d1d37-120a-4413-90fe-0cd1f59990d0_terseLabel_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper Sandler and Cantor</link:label>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_label_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper Sandler And Cantor [Member]</link:label>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_documentation_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Piper sandler and cantor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember" xlink:href="arvn-20230331.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PiperSandlerAndCantorMember" xlink:to="lab_arvn_PiperSandlerAndCantorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_1fcefaea-dafb-4e03-b568-cb4f96793531_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_12a83fd5-4dbf-4bf6-a646-6a4bd6950688_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_36557625-5450-45d7-8fc1-e7225584c214_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember_be7814b8-d5b2-4106-b4d8-d18511e45ea4_terseLabel_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing 2024-2026</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember_label_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Six [Member]</link:label>
    <link:label id="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember_documentation_en-US" xlink:label="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Six</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember" xlink:to="lab_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7093c55a-92fb-43cd-ab10-c946d9add372_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_6afd3629-ad79-4e6d-b85b-623b59c8049a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_04b9cab2-97ef-4fd5-8119-e347a4af12d8_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current installments</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5ec8c4db-a510-4be7-b40b-df1614811b84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec2b8997-0065-4e00-8617-7c2b00e1f2d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_bf4440f7-207b-491b-9630-813763d4b003_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f4fc4277-d31e-4b61-b761-4fe46852a660_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_43ce38f6-4b06-4696-a0e9-2e5b264a16f2_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_30f8921e-3ab0-400f-a4fb-94fba198605c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_a1b5bb65-f5f0-430c-a4b0-ede751be49fd_terseLabel_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing 2023-2024</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_label_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]</link:label>
    <link:label id="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_documentation_en-US" xlink:label="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:to="lab_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_03151f7b-1837-4e3d-a063-60f1f67b20ab_terseLabel_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement direct and incremental costs incurred</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_label_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct And Incremental Costs Incurred To Obtain The Contract</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_documentation_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Direct and incremental costs incurred to obtain the contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:href="arvn-20230331.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:to="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_8f1eaa62-4c25-49fe-94f9-f3b96677eec9_terseLabel_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract" xlink:href="arvn-20230331.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract" xlink:to="lab_arvn_AggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_07e63a5a-d97c-4438-989d-eb977e0b96ab_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_27db05c6-8848-4880-8d3e-b21df69d4c17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b78913ef-b3b9-4826-a6be-2d6c260e9596_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_4bffc564-859f-414d-a5ce-45033f957692_terseLabel_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, restricted cash and marketable securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_label_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:href="arvn-20230331.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:to="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4362634-85d6-4990-8d74-a53e4bcf8e15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_48c5f3d5-ac9b-4f53-917c-a498e8790d0e_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a299d12d-c1ef-45e3-92e4-96912898574c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense not yet recognized, period of recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c3255c26-4feb-4451-8022-ce8406fe8758_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_40d31a0f-31ef-4208-a601-5474c6302155_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a06e473b-8a1b-4fe6-9ef2-60bf7f139981_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued and sold (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ac1cb126-f567-4f4d-8720-426995e87d39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_8239ebcd-b588-4db4-970d-ca5ab872df05_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgingPurposeAxis_d0d1e195-6c5e-44f1-996b-d845e0066162_terseLabel_en-US" xlink:label="lab_us-gaap_PledgingPurposeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledging Purpose [Axis]</link:label>
    <link:label id="lab_us-gaap_PledgingPurposeAxis_label_en-US" xlink:label="lab_us-gaap_PledgingPurposeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledging Purpose [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgingPurposeAxis" xlink:to="lab_us-gaap_PledgingPurposeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_677dd139-fabd-4194-8aec-f8165d5998f6_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_06382209-17a5-4950-8a40-c3714f0dd94d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_9c44c363-6109-44c8-b456-b60b05d24743_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_7714b50b-6bdf-4d8b-bd58-f81d095c4eb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Correction of the Immaterial Error for the Period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_cb209485-f416-43f5-80ae-48ab8f8b780e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments (up to low)</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_8bbb6291-e4f6-4414-80d0-eac181ad07ca_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c306c08d-c57f-4ba0-b017-b7ee06a7d6f2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2f0f86f3-cfcd-4b0f-af79-101d41cc4c82_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_FoundationMedicineIncMember_872e9dbe-a03d-4a27-b73c-1c460ad67021_terseLabel_en-US" xlink:label="lab_arvn_FoundationMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc.</link:label>
    <link:label id="lab_arvn_FoundationMedicineIncMember_label_en-US" xlink:label="lab_arvn_FoundationMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc. [Member]</link:label>
    <link:label id="lab_arvn_FoundationMedicineIncMember_documentation_en-US" xlink:label="lab_arvn_FoundationMedicineIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foundation Medicine, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FoundationMedicineIncMember" xlink:href="arvn-20230331.xsd#arvn_FoundationMedicineIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_FoundationMedicineIncMember" xlink:to="lab_arvn_FoundationMedicineIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_714676fc-a2a7-4089-b521-0352782c30f9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd470a23-52c0-4bd7-b729-bc58c238c429_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_cf9ce3ca-9861-43ca-8d8b-a7a5c4df4ea6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_313a66e4-a5e9-4a35-b45d-5e0a2e3413d5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6b1027c7-cf5a-4d2b-a766-b6dad4657439_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_0da5a43b-7a07-4871-8ce8-697c49d186e6_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Assistance Agreement</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_label_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Eighteen Assistance Agreement [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and eighteen assistance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:href="arvn-20230331.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:to="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_e8b15c13-5198-4745-99dc-d1c46b68cda1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_db15535b-b4f2-4d6b-8c20-b5d36e5320f1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4f3d413e-2fcb-4eb1-9b91-cc9c6d5415a0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_34ef2bbb-3837-4ad7-b5b0-37b63f8a0cd3_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_39b2f41c-9a48-4578-bc57-f7d1d343b587_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3feaf38a-43d7-4bcc-9a99-12f350fd5483_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1fb55d04-a86f-49bf-b228-e8b1708fd122_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_168d70c7-37ef-402e-be18-dec8ca6a76b6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_efd1f1a5-a907-4893-911e-fd88072eec8b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expenses)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_138f99a0-a6a0-45d2-9cd8-196e3e184ea3_terseLabel_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">adjustments</link:label>
    <link:label id="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_label_en-US" xlink:label="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period, Error Correction, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ff7bdd1e-0e63-42f7-b8ae-a265a54fd52c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommercialMilestonesMember_fb48b985-2b54-4995-a82e-5fe1894f98fb_terseLabel_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_label_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_documentation_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember" xlink:href="arvn-20230331.xsd#arvn_CommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommercialMilestonesMember" xlink:to="lab_arvn_CommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_ae2fe230-6d66-44db-8e5a-8d0079a3a598_terseLabel_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration contract asset and other assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_label_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Contract Asset And Other Assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_documentation_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration contract asset and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:href="arvn-20230331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:to="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_72258a4e-b444-4272-ac19-4871c203dc3c_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_494f3eac-6ac0-4cbb-800b-5e9c101a62d0_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable related to collaborations</link:label>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Payable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20230331.xsd#arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_67c04a67-1fcf-4361-bc12-a62f8f77d1a7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_9d88d4b7-ab5c-4bc4-aa1d-e215ecf3a92f_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_048f8008-9ba2-4a15-859b-a781a7590027_terseLabel_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-Based Milestone Payments</link:label>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Success-Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember" xlink:href="arvn-20230331.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SuccessBasedMilestonePaymentsMember" xlink:to="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_24305f85-d05d-453c-b557-a1be40f30478_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_b7c7fd4b-0f38-4b00-be68-5eb8245f14d5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8c77b999-da55-4be2-9efc-273f6efb155e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7f4fb780-7c8d-467d-968b-efae30de85dd_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_dfe0e5b2-d5c6-46e3-9382-fc39aaef4860_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_b41fdb85-3416-4ea1-85ed-5efb26ceed13_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_9efb6512-b3e7-4d9e-b9ea-c8ac96322c91_verboseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:href="arvn-20230331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:to="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e41ab778-dfcd-4ffa-9db2-1337fd2fb68a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_121fb4e7-de30-4205-aaa7-14e4f09fecfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_77dc3838-1cd5-4fdf-923f-8ecd8fe45e20_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to collaboration agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20230331.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_c63a5868-8bde-4865-b237-079661e8b6db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_dec51138-2226-49c5-a57c-eba235873ae3_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_791eec2e-e41b-45f2-9fa0-254fbad4e977_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0b29c8cb-6d44-4de0-b9a6-9eea9f90592a_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_762937e0-d785-4195-a27f-2a1756307135_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_58cc161a-aab9-478f-badf-c3d7ad45d0cf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Price Allocated to Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_50b35d31-5ba2-4f5a-833f-3e2a6518482c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5657b0fd-abe0-4e6a-8870-1927a900a970_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_fc235aeb-60e4-4d3c-8b33-702367a33c2e_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of collaboration contract asset</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fb42f86a-2014-4d43-8183-defa5ad9fdd9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b968093a-3deb-4827-9a44-ab6386a3300d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_4ac0f85d-0797-4a3e-a582-e19d626bc06c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9d593314-6b45-4725-a982-5ae585b48b44_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_035e0212-5556-4c55-9571-15715a73f7a7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense on options not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_d9d50c28-298f-40c0-811a-e9c573064c04_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ff2997c6-69fb-49be-8d68-03bd20e6856f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_2c7b27fb-ddd2-4c92-9487-c0259dd92a35_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ff6c6639-aba9-4f4a-8563-e3e95edb6d49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares remained available for purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_58a2e1ec-6163-4bb6-b23c-635524832c1c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_91f65d65-1ece-41ca-9564-9794e5be02cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_51e341b9-154b-4cce-bfe0-084ee5db56ae_terseLabel_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash information:</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_label_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Non Cash Information Related To Leases [Abstract]</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_documentation_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:href="arvn-20230331.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:to="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6d9b3b3c-5a3e-4d14-928b-eb4aaa6e032d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_d13e7082-4b4e-4aeb-90a7-9a941ccd1ce0_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ebff337e-9660-4e64-91d3-fb6d99210325_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d3a5e1e3-0f2d-418f-9929-2823a733e055_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_381fb97d-0dba-427e-9d2a-dee139bf0347_terseLabel_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Funding Payments</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_label_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Funding Payments [Member]</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_documentation_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research funding payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember" xlink:href="arvn-20230331.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchFundingPaymentsMember" xlink:to="lab_arvn_ResearchFundingPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_53ff38cc-d6f8-4e55-9952-7a8a32eb3938_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_9d895bce-50ce-4b70-b29e-533ae9004f1b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_8dd64318-d651-4876-8987-86379e44f908_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_00b7aab0-a87c-4bd9-a696-75d5e12031c5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3605682f-494c-4a33-a53e-dda01f812d84_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2746e8d8-a054-4787-98bb-e322bf1197d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a48c6618-1016-4337-a82f-47570b468b41_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_a2a17ea7-b216-4457-bd77-9e6657ef9af3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_04c1891f-1520-4976-bb5e-bfa7d44b6eb2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_59396c61-89a8-440f-9d66-af618f7454a2_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_c655e04e-7c00-4797-8439-b8b779904af6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_44e75974-fc58-480e-8489-20816bdbc7b1_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_label_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturities Of Marketable Securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:to="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2098cb81-377b-449d-b09a-dd425e460b8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CT_6b96f804-bae5-4119-a228-31439842fccc_terseLabel_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of Connecticut</link:label>
    <link:label id="lab_stpr_CT_label_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONNECTICUT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CT" xlink:to="lab_stpr_CT" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_11463018-8f8e-4249-aa74-cd1a7928433a_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockIncentivePlanMember_ea849158-f9f8-4c4a-81ea-f0b44b21b72d_terseLabel_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Plan</link:label>
    <link:label id="lab_arvn_StockIncentivePlanMember_label_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_arvn_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_arvn_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember" xlink:href="arvn-20230331.xsd#arvn_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockIncentivePlanMember" xlink:to="lab_arvn_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_31594e7d-fdce-4574-acf5-439a3529cab6_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested and expected to vest (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Vested And Expected To Vest Exercisable Number</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:href="arvn-20230331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a5b70519-20b7-42e4-8f60-159b550e7b25_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_876af10a-a69c-440e-b75e-356308401402_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_00f8f811-5912-4dbf-b61f-f53338761932_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ecb26651-2838-40a7-bc78-9ae8438ad884_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ced16ed4-0886-44f8-9fd3-4720a4835471_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_04002c85-c9dd-49c0-ab28-abf0ebd61893_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_dce59e43-936c-4228-8605-fd23845fde89_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8771d43f-d185-4fec-8110-303b2c15245f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f780e44f-b40e-43f6-a6f4-ef026b74c057_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_ab3ae46d-c34a-49f7-9a83-dedd6f31bf6f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fcf6d6b3-e832-463e-8c67-a22eea482ef4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_ddc994fb-4f13-4a20-9a96-34fab5ce4816_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_ed32849e-28ff-42e1-bc6f-baa42b4fad4d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_e2c8fd55-00a1-4765-8e1e-d6eaacc7c02b_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_label_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument Loan Forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument loan forgiveness.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness" xlink:href="arvn-20230331.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentLoanForgiveness" xlink:to="lab_arvn_DebtInstrumentLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_3fdfd4aa-26a6-4690-95bb-4fa3ef9f6cf7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_fa6bf6fb-3a72-4807-a16a-f0ed54474896_terseLabel_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Inc. and F. Hoffman-La Roche Ltd.</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_label_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech Incorporation And F Hoffman La Roche Limited [Member]</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_documentation_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech, Incorporation. and F. Hoffman-La Roche Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:href="arvn-20230331.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:to="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_ed0d1e1e-feb1-4c5c-9a53-3e3637dbc95a_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f97c6c78-0f7c-4b81-9c14-1544635ec7be_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_fb786b0e-fb08-411a-ad54-f88fc8fc5706_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_292a54f6-dd93-42b0-9a5a-44cb90d130f0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_d76277f1-c3ce-417b-a56d-cf85501d6e8c_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of liquidated damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_label_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Liquidated Damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_documentation_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of liquidated damages.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages" xlink:href="arvn-20230331.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfLiquidatedDamages" xlink:to="lab_arvn_PercentageOfLiquidatedDamages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e9b6c986-f84b-4bfa-9240-91f0fe87fc54_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_43c9715f-b79d-41c4-a5b3-6f5ea252360a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_90d3e00a-6f0f-4e35-9ad1-d3a0b190beb2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f69986a7-390f-4d2c-a2e4-e0cb719a11a5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_48001acc-c9b6-4476-aa6a-3788947668a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a25a2100-54b5-4b4b-ac4c-62e314222e2a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2e3b984a-2bde-4226-abfa-525d7fea175c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0ddfab48-aa42-4eff-b6c9-eb47045f4211_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8edaead3-453c-4aed-a7b3-871844b8a26e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9352fb0a-2bbf-4e1c-976a-cb986b972915_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_69a89be9-f767-4d10-b832-3a723cd85206_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a98d5873-5ae9-4ccb-a394-ece1a8a1830b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_144972e7-916d-4257-a181-02b0218f529a_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2864a728-42c6-444c-a897-d66b3979e1b2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_e93ef003-e61f-4507-9dff-c518930e6106_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49729d09-0a92-4f53-a76f-8b770c3e0add_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bbc56b42-a865-4408-b3c8-31b21a10f0a7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_521e448e-ab20-40e8-8f7a-35220f8737a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1ae571bf-ea84-410a-b55c-6475d9ac8183_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_06065024-57d6-46e7-9c60-d59686d622f8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationAgreementMember_fd79f9f2-c88a-45fa-a382-373f4aa08d6b_terseLabel_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_label_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember" xlink:href="arvn-20230331.xsd#arvn_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationAgreementMember" xlink:to="lab_arvn_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_045c14ff-136e-4c8c-bf97-c9b9676965a0_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d28202c-7fe5-4851-97b9-3edc04c93dd9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4402a421-6227-4be3-a579-9d318547d775_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_e24a88fe-80d6-4829-9f0a-a86a7abb8207_terseLabel_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems" xlink:href="arvn-20230331.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems" xlink:to="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_a89be500-3960-4356-8a05-05b26dfaceed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in reserved shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2a09eb4a-ed01-4fb8-919f-8d864e563903_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 53.4 and 53.2 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_104356bf-39f2-40a7-8ab7-05cf6bbccc21_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_40724899-8caf-4826-ac40-d57f346cc8dd_negatedTerseLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current Payments</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:href="arvn-20230331.xsd#arvn_AccountsPayableContractBalancesCurrentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_e44bd17d-7050-45b5-add9-f22d16b24126_terseLabel_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_label_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Common Stock</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_documentation_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:href="arvn-20230331.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:to="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638aa96b-0726-415b-bdd8-75e921e43b53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_54898bb5-de1b-452b-a18a-ac43eeeb3998_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Excluded From Computation of Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cbe4365b-9b46-4381-b5f0-090b079c2850_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e78ef14-cd1b-489f-bb40-f7580bf924c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8442a96c-11a0-4554-8551-3b48f4767f3c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8516dd10-8af5-4800-8981-304d5f6ce20c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6aeb70d5-800a-459c-b41c-88befaa492c7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_85b3415b-5052-4244-bfb7-bc4be92ff389_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4f3bf7c6-6d75-44c6-b0f8-205d481fa4a2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_7afe6213-2a5f-46dd-a06f-4f3fe2959660_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_26bb8fe4-2bb2-485d-b42b-048f3bf13bab_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgedStatusDomain_e4220c5a-dc38-4642-a51d-8d4175b9bc5c_terseLabel_en-US" xlink:label="lab_us-gaap_PledgedStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Status [Domain]</link:label>
    <link:label id="lab_us-gaap_PledgedStatusDomain_label_en-US" xlink:label="lab_us-gaap_PledgedStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledged Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgedStatusDomain" xlink:to="lab_us-gaap_PledgedStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_4ce5d588-f164-457a-a40e-9592f3856707_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_dbcd9456-3a2b-47e2-b86d-ed1ce6e969f9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and leasehold improvements unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d5766765-082d-4278-b229-43dd8131430e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e942bd97-3f45-40fc-98cc-70cc689d2710_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c14d51b-25f1-4fc5-965c-145e95836c7b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_faef975e-23a0-4a17-8ebc-e156acfdc7ca_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_2575d204-5514-4d02-a8a6-fb58b6133e1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_fe034faf-ebeb-4dfd-a7d5-baef173920af_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_label_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Marketable Securities</link:label>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:to="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b47d6dd7-1461-4c53-870d-206a4c93d081_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_eb01c2bd-9adf-466b-bd5e-65e900b167ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_354d961b-29b5-43e0-b8d2-02d0468c5215_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_db0711ba-96e1-45c8-8557-1b5ac806e52b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0077f35f-e70e-4fd2-9228-af5d892b5a72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_46867446-fffb-4e5c-a8b3-22a25841e975_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_2008c222-ae00-4c43-b3d9-488db4d20e65_negatedTerseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:href="arvn-20230331.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_b4c07bde-a98f-479d-99cc-c48bf61eb4d7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory rate, percentage</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a5aec747-b5b9-4fb1-ace0-3a6836359011_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_81618403-873b-4d64-8f76-b6388e6ce10f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bf284fb2-cab7-44d6-8a33-f0d61927d8c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3c03801-e4e5-4ee8-a168-bd8c8d73aa8e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_2621bf95-26e7-4486-9c05-82b4cd4a8abe_terseLabel_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets: Collaboration contract asset</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_label_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:href="arvn-20230331.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:to="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_aa08a266-887b-49c8-a034-cd071db45396_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c0dee75e-98ef-4809-b724-46d697d5e6d3_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8c97a527-6542-45d7-9403-182c59390ea5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_af357ea0-241b-4f88-bba8-46630d01f961_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_217d6c18-964a-490b-9d38-2d463462ee13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_0a9a66a3-ce33-49da-9991-bd6be4fcaf95_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_a1f9913d-c1f0-4e38-b70d-1daf78886163_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_59be48fb-46e1-4773-ab0d-8745d506fa4f_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0e33f53c-0d9b-4ced-9818-d25e57aca325_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise/ vesting of stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_51e7791c-4815-474e-818a-143aa22f072b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_0d91c66d-b22e-42f1-99ab-895180bd463c_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_08dca8d2-988d-4d72-a375-0516d381b058_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_bdcd1c19-ba05-43f3-b860-ba3df3fb5433_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_b1f634cb-0b20-484d-be03-e603adf7713b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_db6b1dc0-bf83-4ac1-bf77-f82b8e9957db_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9be20e5d-0955-4c4f-a579-811988e0b704_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_46191801-f442-4107-a4cd-f17a53924ce7_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerCropScienceLPMember_e9f352b2-a8b4-4145-ad7c-dec297a61a5c_terseLabel_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer LP</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_label_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Crop Science L P [Member]</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_documentation_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer CropScience LP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember" xlink:href="arvn-20230331.xsd#arvn_BayerCropScienceLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerCropScienceLPMember" xlink:to="lab_arvn_BayerCropScienceLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_673b9800-1baf-4df6-a3e4-c7ad056672c9_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_1438d437-b279-4ef9-ac4d-cbb44fce4d59_terseLabel_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="arvn-20230331.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_f10367db-3c4c-4c0b-b872-0393307c10be_terseLabel_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payments To License Agreement</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_label_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Payments To License Agreement [Member]</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_documentation_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option payments to license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:href="arvn-20230331.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:to="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_2b213158-3e61-4bd3-ab28-6ecd9eab6c86_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable related to collaborations</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20230331.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_32708930-c2d9-4639-9a5a-3b925bc520cc_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and Sales-Based Milestones</link:label>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_label_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory And Sales Based Milestones [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory and sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:href="arvn-20230331.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:to="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1c7f754c-e10a-43da-9d1a-7653486d2fe5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_54c049db-bc25-41b2-81ad-96a452b6f4b2_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_e0b9e148-0dec-42a1-9b7f-99ffef02371f_terseLabel_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_label_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block]</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_documentation_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:href="arvn-20230331.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:to="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7feb9fdc-f5f3-4d4d-afca-39f11aa9a4d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d7f8bb68-273a-4bdd-a20b-776400e7dc7d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_0ca7d12f-ff45-431b-b109-469c41b4b875_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_79762d78-8ae2-4c50-ba30-0cb906bcfd40_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from balances held at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerAGMember_c302dab7-7c51-48d2-8f57-2f2e665dfd41_terseLabel_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer Collaboration Agreement</link:label>
    <link:label id="lab_arvn_BayerAGMember_label_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer A G [Member]</link:label>
    <link:label id="lab_arvn_BayerAGMember_documentation_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer AG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember" xlink:href="arvn-20230331.xsd#arvn_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerAGMember" xlink:to="lab_arvn_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_01098073-5354-4975-afcf-8642fa7bddc5_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EmployeesMember_b538be2f-3085-4be9-9912-2ef3dd3f6ed8_terseLabel_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_arvn_EmployeesMember_label_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees [Member]</link:label>
    <link:label id="lab_arvn_EmployeesMember_documentation_en-US" xlink:label="lab_arvn_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember" xlink:href="arvn-20230331.xsd#arvn_EmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EmployeesMember" xlink:to="lab_arvn_EmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_430ecaf9-1f5d-4824-990e-0418175d2387_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c2b10cb6-3812-42e9-824c-8c12448c69df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_10d80eb1-2c23-4774-87f2-df6182e9a4ee_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_97846082-47fc-47c3-96ac-a533feb104e2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Pronouncements and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b2293bd1-b92e-4b4e-9ac9-120c2e9948d3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_19957327-606d-425f-bb2d-cd23f729aab8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6d404567-20b9-4837-b7f5-fea4e5227745_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bbad3bc5-d53e-4d9b-93f6-8dc95c515f93_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_baf920c9-5335-4e81-b097-72a319253a67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7c0a893e-c4f3-44da-b90a-701f6783a785_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0d1f7fe0-4563-48b3-b17e-d87f07bfe657_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_3bde04b5-4fe1-4fa6-b47a-34cf1c244251_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_937d6f89-125a-4307-889f-0d878af540ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_cc4b10a9-3ae7-43aa-8548-2dd456638f63_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4e32b726-43a9-4bbf-a7ad-37c83576a7f0_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net accretion of bond discounts/premiums</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_300aae27-ce13-47af-a3b4-98035010e57c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_1a324b01-b246-4f58-8752-9d546e7de76a_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">as previously reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_195c69be-c881-4247-970c-8b5b77f4a922_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_694c4925-9c9d-4bb4-b31d-c0ce2f30888e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b12bbdf8-798b-4833-bca2-cff88c854c4f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c4620a0d-ab9a-4056-bd7f-ac4103e2271f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_1590d128-73fb-4d76-b0fb-277e3741c16c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_21222531-ad84-4515-9755-10a7de77374b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_83ed7f9c-a485-4130-af66-2b814940b333_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Based Milestones</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Based Milestones [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember" xlink:href="arvn-20230331.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonesMember" xlink:to="lab_arvn_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_a35b9cbb-eb57-4a7f-b858-b94e86cb8f54_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_d85f49a8-dcfc-4c05-bf05-c4bafc2e22d7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ed501f4b-d6ee-4f26-9ceb-d679441385c2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_3bd01208-ba62-4f15-af64-48204fdf3896_terseLabel_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance represented as percentage on outstanding common stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_label_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_documentation_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:href="arvn-20230331.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:to="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_af8ea260-6b2c-480d-ac7c-0c7dd73701dd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cad856bb-b60d-4a18-8dc3-f8c282178215_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_d60b8822-cdbb-468a-9fb4-7fdf2c6e4492_terseLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current Additions</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Contract Balances, Current Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:href="arvn-20230331.xsd#arvn_AccountsPayableContractBalancesCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_50a49fc5-ba9f-4dd8-9400-fee5974ca79e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_00246d8a-5c1a-4bec-81e0-45260530b367_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest in joint venture (percentage)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a745a480-f9bd-4629-9792-2307f1caa35c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_93fa9c47-ce17-4342-a5f3-74e694e29667_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4c8d9113-f432-46ce-b767-e57a1dd97888_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fc9474a7-d91a-46c0-b83a-40bbcb6ffcdf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c2b2caa-8690-4995-b1a7-55f23f6e45d0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_00f61a9b-30b0-46e1-841e-bfd6ee511b9c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_dcc23893-b4da-4a3f-b32c-e5089bbff2c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_7627f20b-f40a-43b5-915a-116cbb7cb8db_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b50cd301-bc3d-483d-9de4-934a456a87ce_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_0a2a5900-7d78-43ff-9051-829a62733494_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_401da331-a299-4b30-b012-6e084cb6a059_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes and loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_915cae65-d942-4d28-bb90-bab39bfbb1a5_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_56094b27-2759-446e-b257-741bb77a3057_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0e210315-2ce4-4f7a-b424-65b00a29532c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in reserved shares as percentage of outstanding common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ec4e6738-2be5-4c63-8424-a11514e8eb4a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_8ef8f4aa-4836-444e-bd77-e95c45bce6f1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue adjustments arising from contract modifications</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PfizerIncorporationMember_dece354b-8794-4f03-a3f6-9ea8224aee85_terseLabel_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Inc.</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_label_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer Incorporation [Member]</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_documentation_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember" xlink:href="arvn-20230331.xsd#arvn_PfizerIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PfizerIncorporationMember" xlink:to="lab_arvn_PfizerIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgingPurposeDomain_7aa8ed1a-0699-473c-a49d-9415701c0f1f_terseLabel_en-US" xlink:label="lab_us-gaap_PledgingPurposeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledging Purpose [Domain]</link:label>
    <link:label id="lab_us-gaap_PledgingPurposeDomain_label_en-US" xlink:label="lab_us-gaap_PledgingPurposeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pledging Purpose [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgingPurposeDomain" xlink:to="lab_us-gaap_PledgingPurposeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_601e2f9b-90d1-48b5-8e03-49a5f7e41de2_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_3213414c-5990-4f0e-9964-13a0f63b84ba_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f443de59-e781-4102-ba3b-15a26f5247b9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_c40895a8-3906-4a0e-99fa-841d40892559_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bac8bbf8-25e0-494f-89db-3ad75ae98915_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_5a2a6270-3799-4a52-ae11-77efdfe5a763_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9123cff3-3abd-4ad3-b97f-0e63912975f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7dfdbc81-e6f5-4ec6-9921-4c19e628767f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f53606a1-49a2-4742-b930-0fc47051cb99_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_48edd94d-c7e2-4ef3-8efd-fcbc5e6b4fcf_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_6b79f679-cfff-484e-b7db-9c432c855734_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e8528c6a-3b30-43ef-9fb4-4f6073b7b748_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5d7bfb22-d34a-4b9a-8342-d5289631d220_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4d0921c0-9cc0-4610-b591-e6fb129223e9_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_521bdf78-6e0d-4562-89fa-774a23a3116b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based award, vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_79058540-34b7-442a-be19-14b5ea5d1a1a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1b2b7a8c-73ef-4f24-be00-116c48ef23a6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e1a245c0-c6da-4027-8dcb-06524a50b813_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3abf9d55-3c51-404e-99e5-36ff7fd23d13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_fa8ce589-0d85-4429-aec1-ce61d7b49efc_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4c01e95c-df07-48a7-b9ca-78f74fa7942a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_4c549bfc-589e-4460-814b-172ecd301bd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_f8149a5e-c994-4593-8aa6-2c90f70df0bb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_330e8a9f-86d5-4feb-bf75-6dfcd098cd1f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_81741281-4631-4e8f-b264-2fe731815c5d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_cd58f6e7-48f0-4bf3-b5d6-cb8a9113f001_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_ee7a5686-9c0e-45e3-b666-9b1ed3eed4fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_fd3e14aa-3eb8-41d8-8335-909c78338a63_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b6e58aed-1450-454b-91ab-b01adff70cc6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_b2eb0d44-4bdd-4fe2-aa22-8132d3d73e42_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Related to Marketing Approvals</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:href="arvn-20230331.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:to="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_780bb880-a2d5-4e8e-bb3e-cd38e2cbfd90_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2a9c9d3c-2b67-4cf9-b2cd-476b8785b338_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4526ad81-d133-46f3-8fa4-f5e083b87a68_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cffafe18-539d-4a26-a08d-fcd9a778ec7e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_b89dc8ab-d5e0-40fc-a719-714bd0180589_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_efa08d70-e1a4-4eb2-9274-59fe5aa1c63a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b9b758fd-af51-46da-8ad2-9fcd5a620146_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive units authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_e7980ea1-0cc6-47fb-a5ab-565ceab04d9b_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of incremental borrowing for lease payments</link:label>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_label_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Incremental Borrowing For Lease Payments</link:label>
    <link:label id="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments_documentation_en-US" xlink:label="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of incremental borrowing for lease payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:href="arvn-20230331.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:to="lab_arvn_PercentageOfIncrementalBorrowingForLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2f205f78-69f5-4a9f-b542-dc4526aa455f_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_4b1cd720-8c3b-47ba-a918-c4debe1a1bff_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20230331.xsd#arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EmployeesAndDirectorsMember_261a7ea6-4e75-4ba4-8fa8-4fdec55042ea_terseLabel_en-US" xlink:label="lab_arvn_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_arvn_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_arvn_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees And Directors [Member]</link:label>
    <link:label id="lab_arvn_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_arvn_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees And Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesAndDirectorsMember" xlink:href="arvn-20230331.xsd#arvn_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EmployeesAndDirectorsMember" xlink:to="lab_arvn_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1d266176-c29c-4fad-b386-dd81fb492047_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_c5ca1a0f-2bb1-4c5e-b006-b85153c1870f_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Assistance Agreement</link:label>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_label_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Assistance Agreement [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen assistance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:href="arvn-20230331.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:to="lab_arvn_TwoThousandAndFourteenAssistanceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_14ef069f-d255-418a-822b-addf4238e350_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_41254682-46c7-45c4-a148-17bca5699c2c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6c660f2e-9242-4d06-966c-c930aafffaf1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_67505786-ef51-4b7c-9694-352a8b6d53ff_terseLabel_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember" xlink:href="arvn-20230331.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LaboratoryEquipmentMember" xlink:to="lab_arvn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_7017f07a-f4b2-440b-8908-227d239c6c66_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_70c19d4d-099f-4630-b6f1-df09decb0942_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_f2ab9cc6-089b-4d59-abfd-2d3e69b73cef_terseLabel_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-Market Offering</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember" xlink:href="arvn-20230331.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AtTheMarketOfferingMember" xlink:to="lab_arvn_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eac64702-0772-4e84-a9b9-3e2567d2d4b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d0d4250c-7f4e-477c-8beb-ffda8cac1736_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a4c47a4f-463b-4e37-9564-20290dba543d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_766c1c7c-86f7-4a3e-b0fe-2f65e748cc2e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_f9b5cc31-f1f9-4482-831a-88903298fc2c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and other</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_0debbfb0-95f7-4896-9008-4d8f6253a554_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_031c2660-7d39-4595-9b73-413b67570f6e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7bae12e5-e7fc-471a-9138-6fa4c1f603ec_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_05011008-55e2-494f-a68a-4a342a81146c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9abde4a7-3a71-44f7-90eb-df4afb344f67_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ae7bd129-442b-49bf-b36c-7fa3d0c65005_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_92df5777-869b-48cb-9746-9b8f774b0f31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_330f34c7-f487-47dd-904c-9a51cfa18a00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_35d530fc-e93d-4edd-8247-e8a93a122fa3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_0c0b372f-5e16-4e20-804b-1b5ddf78dfe2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_048689a7-9ea9-4a7d-b362-0980657acd9e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e086e874-8a7f-437f-8f4a-6ecaab6388e8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_e2f8c6e8-01ed-490b-88e3-71c33b4b14b8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8df2c706-b175-4101-8740-e3635d4ea025_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_7438db19-8029-4951-bac6-7800370518c8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_eb6d0c76-678d-4390-a1d6-c187711d0b1d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>arvn-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:1f1eeee1-4d1b-4eb9-97f6-83d0702c4de4,g:c3df6ade-21e6-4d49-a1b5-7881af27fa72-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/CoverPage" xlink:type="simple" xlink:href="arvn-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_41f39308-010b-45f1-848c-0c3239b632cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_DocumentType_41f39308-010b-45f1-848c-0c3239b632cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d5f06c4e-1c89-4242-9a2e-82f419a35f3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_DocumentQuarterlyReport_d5f06c4e-1c89-4242-9a2e-82f419a35f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c78dbb15-3045-4571-9fd8-b2576dd74121" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_DocumentPeriodEndDate_c78dbb15-3045-4571-9fd8-b2576dd74121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_550d2497-6734-4a2b-87d3-22864dcfe942" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_DocumentTransitionReport_550d2497-6734-4a2b-87d3-22864dcfe942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d79ae799-d86a-469e-ac62-e81a8b821852" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityFileNumber_d79ae799-d86a-469e-ac62-e81a8b821852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b1c5076a-6fa1-4cd1-9916-489b9458a1fd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityRegistrantName_b1c5076a-6fa1-4cd1-9916-489b9458a1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_fa9a7434-8f7d-4b60-9261-b880faea2656" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityIncorporationStateCountryCode_fa9a7434-8f7d-4b60-9261-b880faea2656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_69e48a77-d18a-4d8f-99e0-7961afb6695d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityTaxIdentificationNumber_69e48a77-d18a-4d8f-99e0-7961afb6695d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_3f788970-b56e-48c6-917f-1374ad91315b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityAddressAddressLine1_3f788970-b56e-48c6-917f-1374ad91315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_97b5e5de-987a-4f8a-9fe0-601756138e79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityAddressAddressLine2_97b5e5de-987a-4f8a-9fe0-601756138e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f45570dc-f154-4e94-8579-d0b73f79887b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityAddressCityOrTown_f45570dc-f154-4e94-8579-d0b73f79887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a7c4854c-2bd0-4ec6-8e02-35d042f2ef96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityAddressStateOrProvince_a7c4854c-2bd0-4ec6-8e02-35d042f2ef96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_585a9c8c-eb3e-4bb2-9ae4-f91bb30e6fc4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityAddressPostalZipCode_585a9c8c-eb3e-4bb2-9ae4-f91bb30e6fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2709b885-ad70-4c7d-824f-360cc0b327e1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_CityAreaCode_2709b885-ad70-4c7d-824f-360cc0b327e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_352a8e96-e229-47b6-a1c5-049c47aca778" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_LocalPhoneNumber_352a8e96-e229-47b6-a1c5-049c47aca778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3d43e987-dc1f-4a73-8bfb-3f07b075a2d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_Security12bTitle_3d43e987-dc1f-4a73-8bfb-3f07b075a2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_d551e27d-245b-4e4f-ac31-481edecbdc48" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_TradingSymbol_d551e27d-245b-4e4f-ac31-481edecbdc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e791f809-3b19-463a-b0e9-f550fb99b1fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_SecurityExchangeName_e791f809-3b19-463a-b0e9-f550fb99b1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_28df870c-167d-4b4a-b61f-b03e2fd55e19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityCurrentReportingStatus_28df870c-167d-4b4a-b61f-b03e2fd55e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_962eac11-7a74-4b86-99cd-1817647f0aa4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityInteractiveDataCurrent_962eac11-7a74-4b86-99cd-1817647f0aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e43d7f8d-d1f3-4277-959e-01fc008ec2d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityFilerCategory_e43d7f8d-d1f3-4277-959e-01fc008ec2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_1fbdb4d8-2b87-4490-bdbe-64059e6a8983" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntitySmallBusiness_1fbdb4d8-2b87-4490-bdbe-64059e6a8983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0995a0dc-b1f1-4d8e-9d97-2895b6b7b0b9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityEmergingGrowthCompany_0995a0dc-b1f1-4d8e-9d97-2895b6b7b0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_7334f38f-baf1-4937-9d6d-4f7b66019c13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityShellCompany_7334f38f-baf1-4937-9d6d-4f7b66019c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_fa98de4b-5aff-4b02-bbbc-e13d2641162d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_fa98de4b-5aff-4b02-bbbc-e13d2641162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_76f010da-1ee0-40a0-8698-587e2dd1b0bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_AmendmentFlag_76f010da-1ee0-40a0-8698-587e2dd1b0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_6b013904-541b-41c5-a54e-cfc3bda1ab6c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_DocumentFiscalYearFocus_6b013904-541b-41c5-a54e-cfc3bda1ab6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_908f3b27-0c9a-4362-ba6c-ee53d315b230" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_DocumentFiscalPeriodFocus_908f3b27-0c9a-4362-ba6c-ee53d315b230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_51b91ac4-009a-4e19-8bec-f92b8d8adfdd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_EntityCentralIndexKey_51b91ac4-009a-4e19-8bec-f92b8d8adfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_469fa72e-fdb0-494d-8555-28aa55c9d2b4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ce4fa14f-1f53-4359-a781-86e11062d917" xlink:to="loc_dei_CurrentFiscalYearEndDate_469fa72e-fdb0-494d-8555-28aa55c9d2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedBalanceSheetsunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_25f39879-7c69-42ff-976a-5dd39fb7a26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c0f2f258-49f5-4b42-82dc-bc246fe8e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25f39879-7c69-42ff-976a-5dd39fb7a26e" xlink:to="loc_us-gaap_AssetsAbstract_c0f2f258-49f5-4b42-82dc-bc246fe8e4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c0f2f258-49f5-4b42-82dc-bc246fe8e4fa" xlink:to="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b581f29f-839d-4bc7-84e5-d59504b08e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b581f29f-839d-4bc7-84e5-d59504b08e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_f6acbcf9-020b-434a-8971-7953a2085479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:to="loc_us-gaap_RestrictedCashCurrent_f6acbcf9-020b-434a-8971-7953a2085479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_84161087-f642-4b83-a48e-6b15ecb02fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_84161087-f642-4b83-a48e-6b15ecb02fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_00c6fd96-8bc3-4e4a-a697-cb31903bb71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_00c6fd96-8bc3-4e4a-a697-cb31903bb71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_d74ad405-e028-4e3e-9389-25ec71385237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_d74ad405-e028-4e3e-9389-25ec71385237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_10961644-1009-4af2-bf41-530b94630ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_10961644-1009-4af2-bf41-530b94630ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f764818a-c055-44bf-815f-3a5a0f2444da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_cd8784f8-280c-42ad-95b6-9fd067996202" xlink:to="loc_us-gaap_AssetsCurrent_f764818a-c055-44bf-815f-3a5a0f2444da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f7a7614b-f3bb-4ada-a1cd-e9990a4523fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c0f2f258-49f5-4b42-82dc-bc246fe8e4fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f7a7614b-f3bb-4ada-a1cd-e9990a4523fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f7bcdaa3-8a74-4109-937d-dc77ded06ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c0f2f258-49f5-4b42-82dc-bc246fe8e4fa" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f7bcdaa3-8a74-4109-937d-dc77ded06ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_0b019262-68f1-4e5d-a530-e621fcc317fa" xlink:href="arvn-20230331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c0f2f258-49f5-4b42-82dc-bc246fe8e4fa" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_0b019262-68f1-4e5d-a530-e621fcc317fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_71ce3077-677e-4754-8c50-bf94db9796e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c0f2f258-49f5-4b42-82dc-bc246fe8e4fa" xlink:to="loc_us-gaap_Assets_71ce3077-677e-4754-8c50-bf94db9796e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_25f39879-7c69-42ff-976a-5dd39fb7a26e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_83ea8d03-4582-4ed5-93b2-c6b6aa21f49d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_83ea8d03-4582-4ed5-93b2-c6b6aa21f49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_40a188ea-7582-4ccf-a918-cbaf6289d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83ea8d03-4582-4ed5-93b2-c6b6aa21f49d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_40a188ea-7582-4ccf-a918-cbaf6289d9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_131e6ffe-2945-4f91-8df9-94b288ba0645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83ea8d03-4582-4ed5-93b2-c6b6aa21f49d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_131e6ffe-2945-4f91-8df9-94b288ba0645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_38e5dcdb-7d79-48f4-9e1a-f511633f6441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83ea8d03-4582-4ed5-93b2-c6b6aa21f49d" xlink:to="loc_us-gaap_LongTermDebtCurrent_38e5dcdb-7d79-48f4-9e1a-f511633f6441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_05666126-744f-4e51-b74c-5a180e139bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83ea8d03-4582-4ed5-93b2-c6b6aa21f49d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_05666126-744f-4e51-b74c-5a180e139bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5a6127e0-d3fc-453f-a399-472d8faf03bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_83ea8d03-4582-4ed5-93b2-c6b6aa21f49d" xlink:to="loc_us-gaap_LiabilitiesCurrent_5a6127e0-d3fc-453f-a399-472d8faf03bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a5ba3010-14d2-41e5-9e75-26770112bc61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a5ba3010-14d2-41e5-9e75-26770112bc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c930079a-4d0f-4e00-a7f2-bbdb98ef69f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c930079a-4d0f-4e00-a7f2-bbdb98ef69f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4554375d-a77b-41c6-8d59-3809bc81e8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4554375d-a77b-41c6-8d59-3809bc81e8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3a3b68ba-597b-438e-b0fd-a81f1f3a3d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:to="loc_us-gaap_Liabilities_3a3b68ba-597b-438e-b0fd-a81f1f3a3d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2a26dee2-0883-4813-86d2-9e4e4c3305cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2a26dee2-0883-4813-86d2-9e4e4c3305cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4461bbfe-d853-406d-800d-96204794d46e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4461bbfe-d853-406d-800d-96204794d46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_93c50e44-6613-4a6a-8a82-4e45ad683807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4461bbfe-d853-406d-800d-96204794d46e" xlink:to="loc_us-gaap_CommonStockValue_93c50e44-6613-4a6a-8a82-4e45ad683807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32a26010-121a-43ad-ae37-039278a38d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4461bbfe-d853-406d-800d-96204794d46e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32a26010-121a-43ad-ae37-039278a38d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_713e15e8-8a68-4967-8c72-8186aa9033cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4461bbfe-d853-406d-800d-96204794d46e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_713e15e8-8a68-4967-8c72-8186aa9033cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_916fb5e9-5ecc-4cdd-8877-58b889cc583f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4461bbfe-d853-406d-800d-96204794d46e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_916fb5e9-5ecc-4cdd-8877-58b889cc583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c23f2da9-06ec-4b6c-8025-a2bef11e7bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4461bbfe-d853-406d-800d-96204794d46e" xlink:to="loc_us-gaap_StockholdersEquity_c23f2da9-06ec-4b6c-8025-a2bef11e7bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6dde251e-b0a0-4d8c-8f5e-a854197e935e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9ebad5a0-4f6c-4242-968b-b1ce12637502" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6dde251e-b0a0-4d8c-8f5e-a854197e935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedBalanceSheetsunauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_36ae0325-48a1-4b0d-9542-0768a4901783" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f1236706-ec8e-435e-8447-5d32bde11cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36ae0325-48a1-4b0d-9542-0768a4901783" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f1236706-ec8e-435e-8447-5d32bde11cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4950973a-7635-4f13-b2fb-31ff70e59f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36ae0325-48a1-4b0d-9542-0768a4901783" xlink:to="loc_us-gaap_CommonStockSharesIssued_4950973a-7635-4f13-b2fb-31ff70e59f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3e444135-4929-4741-95c4-5221b282d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_36ae0325-48a1-4b0d-9542-0768a4901783" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3e444135-4929-4741-95c4-5221b282d3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_dc8e3659-4c75-4684-b4e2-13364c322cf8" xlink:href="arvn-20230331.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_dc8e3659-4c75-4684-b4e2-13364c322cf8" xlink:to="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ae8d7096-feb9-455c-bc6e-ba8509ebefc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_Revenues_ae8d7096-feb9-455c-bc6e-ba8509ebefc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_16722a0f-7a5b-4435-9f91-95079b5d0a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_OperatingExpensesAbstract_16722a0f-7a5b-4435-9f91-95079b5d0a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b4057d18-31ca-4124-94df-578627acd237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_16722a0f-7a5b-4435-9f91-95079b5d0a2c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b4057d18-31ca-4124-94df-578627acd237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1f95a6f8-977c-4ee0-b276-b5d282b0be39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_16722a0f-7a5b-4435-9f91-95079b5d0a2c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1f95a6f8-977c-4ee0-b276-b5d282b0be39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fda8a9d4-5ee9-49d1-816f-8fd452d80ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_16722a0f-7a5b-4435-9f91-95079b5d0a2c" xlink:to="loc_us-gaap_OperatingExpenses_fda8a9d4-5ee9-49d1-816f-8fd452d80ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1b96518a-98f3-4521-9cd2-26e2f2fc7108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_OperatingIncomeLoss_1b96518a-98f3-4521-9cd2-26e2f2fc7108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4eb1e6a2-2c3d-4e0b-a934-0ef0beaabb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4eb1e6a2-2c3d-4e0b-a934-0ef0beaabb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_352a3afd-09b2-4a47-b7c3-0f6ef709ac82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4eb1e6a2-2c3d-4e0b-a934-0ef0beaabb28" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_352a3afd-09b2-4a47-b7c3-0f6ef709ac82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6770dc07-8e79-4fa6-a0e6-3a771adf44aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4eb1e6a2-2c3d-4e0b-a934-0ef0beaabb28" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6770dc07-8e79-4fa6-a0e6-3a771adf44aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b580e049-ab4a-4824-a27b-8005c4ff72e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_4eb1e6a2-2c3d-4e0b-a934-0ef0beaabb28" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_b580e049-ab4a-4824-a27b-8005c4ff72e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_09894d80-249b-4938-846f-a8fe6c880fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_09894d80-249b-4938-846f-a8fe6c880fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_66ef2b7c-5ac5-4f47-b828-5dcc7dee19de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_66ef2b7c-5ac5-4f47-b828-5dcc7dee19de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_599cc60f-7774-4c41-a133-3dd8f7e65bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_599cc60f-7774-4c41-a133-3dd8f7e65bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cb0afc47-652f-45e8-bbc3-19503ad7e6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_NetIncomeLoss_cb0afc47-652f-45e8-bbc3-19503ad7e6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_1932d37f-bef0-448c-99cb-deaf7069d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_EarningsPerShareBasic_1932d37f-bef0-448c-99cb-deaf7069d0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_dc0b7376-eda8-4f9b-9554-fa9eee007c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_dc0b7376-eda8-4f9b-9554-fa9eee007c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8e7fc3f-9420-46a6-8a1a-18d89c195684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8e7fc3f-9420-46a6-8a1a-18d89c195684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44e79cd7-6432-4cba-90c6-80487eb5caf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3c7c7f23-14c0-48fc-ade7-59c195b302bb" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_44e79cd7-6432-4cba-90c6-80487eb5caf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a835a76-94d7-4484-8405-68f8513e2b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_dc8e3659-4c75-4684-b4e2-13364c322cf8" xlink:to="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a835a76-94d7-4484-8405-68f8513e2b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_837b5fa5-1914-47af-be0a-7e03889dc932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a835a76-94d7-4484-8405-68f8513e2b6a" xlink:to="loc_us-gaap_NetIncomeLoss_837b5fa5-1914-47af-be0a-7e03889dc932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_be6912e3-5072-4434-9941-95af8db720c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a835a76-94d7-4484-8405-68f8513e2b6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_be6912e3-5072-4434-9941-95af8db720c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5fc5c0ca-d83e-4270-9e6c-677e49bef51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_be6912e3-5072-4434-9941-95af8db720c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5fc5c0ca-d83e-4270-9e6c-677e49bef51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7ca9baa9-13a4-4856-9381-a1851a1e78a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9a835a76-94d7-4484-8405-68f8513e2b6a" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_7ca9baa9-13a4-4856-9381-a1851a1e78a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_baf3b3c4-232a-4fa1-9f49-abbb6ea29643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d5bfdb53-131e-4f23-8f29-6a052aa33eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_baf3b3c4-232a-4fa1-9f49-abbb6ea29643" xlink:to="loc_us-gaap_StatementTable_d5bfdb53-131e-4f23-8f29-6a052aa33eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9b119787-616f-43a6-a4ff-2eb84c3cac64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d5bfdb53-131e-4f23-8f29-6a052aa33eb9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9b119787-616f-43a6-a4ff-2eb84c3cac64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9b119787-616f-43a6-a4ff-2eb84c3cac64" xlink:to="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5d77714a-344b-44ab-b223-a28318e6fe52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:to="loc_us-gaap_CommonStockMember_5d77714a-344b-44ab-b223-a28318e6fe52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8283772a-2762-47bb-83ab-7a165d34f52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:to="loc_us-gaap_RetainedEarningsMember_8283772a-2762-47bb-83ab-7a165d34f52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_41e21475-5816-4bf3-ab22-814f3e5ab31c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_41e21475-5816-4bf3-ab22-814f3e5ab31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa6e4f79-290b-4b4b-b02f-1cc32e48d561" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f793b6d9-41f7-4db4-9724-059d82ee004c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_fa6e4f79-290b-4b4b-b02f-1cc32e48d561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9a00949e-c950-4b75-abfe-02a1edc9ae50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d5bfdb53-131e-4f23-8f29-6a052aa33eb9" xlink:to="loc_us-gaap_StatementLineItems_9a00949e-c950-4b75-abfe-02a1edc9ae50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9a00949e-c950-4b75-abfe-02a1edc9ae50" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c1b28a6a-8b3b-4d80-b182-43ee97d40a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c1b28a6a-8b3b-4d80-b182-43ee97d40a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_988a083a-69b3-4136-bb72-a40d42e73eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_StockholdersEquity_988a083a-69b3-4136-bb72-a40d42e73eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8c6c058c-58ae-4197-9dee-0ceba1ba0413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8c6c058c-58ae-4197-9dee-0ceba1ba0413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33f3da3d-14b1-4cef-95ca-884e59cc0d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_NetIncomeLoss_33f3da3d-14b1-4cef-95ca-884e59cc0d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_92ce7ed3-1b45-4d37-9607-5ae25da660eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_92ce7ed3-1b45-4d37-9607-5ae25da660eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12f70e72-aae7-4ea9-b5a5-46e6ee54b3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12f70e72-aae7-4ea9-b5a5-46e6ee54b3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_820c7747-cbf2-4d95-b4d6-9c569c87d3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_820c7747-cbf2-4d95-b4d6-9c569c87d3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_09a76f06-89fd-48f9-b466-5f54cf0e088f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_09a76f06-89fd-48f9-b466-5f54cf0e088f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5186984f-8a39-445f-bc91-bf0a6a7eed88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_813e29c3-dccb-4590-907d-38f91a7f59af" xlink:to="loc_us-gaap_StockholdersEquity_5186984f-8a39-445f-bc91-bf0a6a7eed88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="simple" xlink:href="arvn-20230331.xsd#CondensedConsolidatedStatementsofCashFlowsunaudited"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9cbdf050-9c9e-4968-97ec-f1c0aff3049d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bbdfb26a-ff28-4620-8f02-664b9709ccbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9cbdf050-9c9e-4968-97ec-f1c0aff3049d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bbdfb26a-ff28-4620-8f02-664b9709ccbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a704504-0d5e-4304-a725-bfb5dc150ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bbdfb26a-ff28-4620-8f02-664b9709ccbb" xlink:to="loc_us-gaap_NetIncomeLoss_8a704504-0d5e-4304-a725-bfb5dc150ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bbdfb26a-ff28-4620-8f02-664b9709ccbb" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b9b02b6c-d164-41d0-a376-55423b21d63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:to="loc_us-gaap_DepreciationAndAmortization_b9b02b6c-d164-41d0-a376-55423b21d63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_05326bb2-73f2-4e56-9a36-11276a706025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_05326bb2-73f2-4e56-9a36-11276a706025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_2e6b689c-57ce-41c7-873b-761e2ed5345e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleGainLoss_2e6b689c-57ce-41c7-873b-761e2ed5345e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d67a9aea-be5a-40e3-ab6e-ed54086aed7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d67a9aea-be5a-40e3-ab6e-ed54086aed7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_29a72e29-bfde-467c-b12b-5de060e99c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_29a72e29-bfde-467c-b12b-5de060e99c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d23662f0-ab7f-442b-8459-95994f3d0f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:to="loc_us-gaap_ShareBasedCompensation_d23662f0-ab7f-442b-8459-95994f3d0f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7eb5f77b-ebff-4220-b88f-8b47cc6bb63a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53db3764-e45b-466b-8072-c8a95e010f09" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7eb5f77b-ebff-4220-b88f-8b47cc6bb63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d3ad3ced-7850-42bd-9648-e6445c645163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7eb5f77b-ebff-4220-b88f-8b47cc6bb63a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d3ad3ced-7850-42bd-9648-e6445c645163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_94c38d38-df47-4268-a796-913f10f048f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7eb5f77b-ebff-4220-b88f-8b47cc6bb63a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_94c38d38-df47-4268-a796-913f10f048f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_826452e9-6b45-4ca7-90a3-3d7196f629e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7eb5f77b-ebff-4220-b88f-8b47cc6bb63a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_826452e9-6b45-4ca7-90a3-3d7196f629e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8399a4c9-ff01-45d0-bfaf-d2e2cd0c5c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7eb5f77b-ebff-4220-b88f-8b47cc6bb63a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8399a4c9-ff01-45d0-bfaf-d2e2cd0c5c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_da72c7dc-00f3-41c0-bddf-84403c177930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7eb5f77b-ebff-4220-b88f-8b47cc6bb63a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_da72c7dc-00f3-41c0-bddf-84403c177930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_194e1a06-30f3-42cd-8e11-49602dab9bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7eb5f77b-ebff-4220-b88f-8b47cc6bb63a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_194e1a06-30f3-42cd-8e11-49602dab9bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d16aec0c-ae39-4336-b371-9502113110ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bbdfb26a-ff28-4620-8f02-664b9709ccbb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d16aec0c-ae39-4336-b371-9502113110ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a755091-93cc-45a7-a0a6-4e399047f888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9cbdf050-9c9e-4968-97ec-f1c0aff3049d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a755091-93cc-45a7-a0a6-4e399047f888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee8ff470-2279-4e86-a11d-a194fefe2dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a755091-93cc-45a7-a0a6-4e399047f888" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ee8ff470-2279-4e86-a11d-a194fefe2dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_bfaa810c-0b90-4592-ba56-fd00a72fd016" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a755091-93cc-45a7-a0a6-4e399047f888" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_bfaa810c-0b90-4592-ba56-fd00a72fd016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities_07cc3bda-bdee-449d-b42a-6c83289d1373" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a755091-93cc-45a7-a0a6-4e399047f888" xlink:to="loc_arvn_ProceedsFromSaleOfMarketableSecurities_07cc3bda-bdee-449d-b42a-6c83289d1373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bbffb4c1-7302-479d-bf70-cc0bda8811c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a755091-93cc-45a7-a0a6-4e399047f888" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bbffb4c1-7302-479d-bf70-cc0bda8811c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_82da8977-26cd-4f6e-85bd-aba94c90426b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a755091-93cc-45a7-a0a6-4e399047f888" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_82da8977-26cd-4f6e-85bd-aba94c90426b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48cf59cf-e7af-4974-a4f6-0d3abf3ffe87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9cbdf050-9c9e-4968-97ec-f1c0aff3049d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48cf59cf-e7af-4974-a4f6-0d3abf3ffe87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_8b88239b-b27e-4809-b654-2245391a32ac" xlink:href="arvn-20230331.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48cf59cf-e7af-4974-a4f6-0d3abf3ffe87" xlink:to="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_8b88239b-b27e-4809-b654-2245391a32ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e0f8834-6b44-4217-8267-9ab02ff3ab0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48cf59cf-e7af-4974-a4f6-0d3abf3ffe87" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0e0f8834-6b44-4217-8267-9ab02ff3ab0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64346d29-4a56-47d4-8e62-4a88f49cb712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9cbdf050-9c9e-4968-97ec-f1c0aff3049d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64346d29-4a56-47d4-8e62-4a88f49cb712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e008ed58-f5b1-40a9-b377-c710bf2a89e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9cbdf050-9c9e-4968-97ec-f1c0aff3049d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e008ed58-f5b1-40a9-b377-c710bf2a89e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d6a325d-eb13-4b63-a957-4d61873f4589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9cbdf050-9c9e-4968-97ec-f1c0aff3049d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7d6a325d-eb13-4b63-a957-4d61873f4589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f24340e-2a4d-4c2b-a8e1-c32b10102976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9cbdf050-9c9e-4968-97ec-f1c0aff3049d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f24340e-2a4d-4c2b-a8e1-c32b10102976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b71cdbd6-2285-4018-a2a9-e080a0513bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f24340e-2a4d-4c2b-a8e1-c32b10102976" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b71cdbd6-2285-4018-a2a9-e080a0513bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="arvn-20230331.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8f56eadd-27ca-4c73-b2e8-c995a379921e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_94ffeec4-e2e2-449a-82e8-cf5ccf7b5138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8f56eadd-27ca-4c73-b2e8-c995a379921e" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_94ffeec4-e2e2-449a-82e8-cf5ccf7b5138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountingPronouncementsandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_39aceef7-7175-4247-beac-479a65db06ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7ba4888c-cac3-4642-a998-42503452c10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_39aceef7-7175-4247-beac-479a65db06ac" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_7ba4888c-cac3-4642-a998-42503452c10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_91a6748b-616b-44ed-9f85-047a8f78aed6" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_581c75ee-6fbb-481f-8fd8-79eeed544103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_91a6748b-616b-44ed-9f85-047a8f78aed6" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_581c75ee-6fbb-481f-8fd8-79eeed544103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="arvn-20230331.xsd#MarketableSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_25d83a4f-b468-47c1-9483-ef561b254d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4e596b98-8b70-4291-99b3-3172d5f75de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25d83a4f-b468-47c1-9483-ef561b254d35" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4e596b98-8b70-4291-99b3-3172d5f75de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="simple" xlink:href="arvn-20230331.xsd#PropertyEquipmentandLeaseholdImprovements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a4179686-db91-4aa5-9338-2719e9d0218a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a57c2218-681d-448e-bce6-fde7a49a0228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a4179686-db91-4aa5-9338-2719e9d0218a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a57c2218-681d-448e-bce6-fde7a49a0228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_adb0a4de-ceee-4d81-bc86-0bad254c75b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_9cd2b1bd-50d1-4d80-8224-fe899c304250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_adb0a4de-ceee-4d81-bc86-0bad254c75b4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_9cd2b1bd-50d1-4d80-8224-fe899c304250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_96f8f3b5-4c5d-408e-a507-8d176f6b2083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_b322c93b-be75-4e97-b7ca-96dde7c37040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_96f8f3b5-4c5d-408e-a507-8d176f6b2083" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_b322c93b-be75-4e97-b7ca-96dde7c37040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebt" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e3dd0d31-0ec9-49f0-bd69-d71dbc6e63cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_6114d1e3-8d49-493a-82a3-6b582f220abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e3dd0d31-0ec9-49f0-bd69-d71dbc6e63cf" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_6114d1e3-8d49-493a-82a3-6b582f220abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/Equity" xlink:type="simple" xlink:href="arvn-20230331.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_328e983c-1896-4340-bfe0-230ef4baa04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1f815536-58a8-4120-8c07-8a6129eac98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_328e983c-1896-4340-bfe0-230ef4baa04e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1f815536-58a8-4120-8c07-8a6129eac98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arvn-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0654414d-756a-4d7d-a3ae-f1ec2651f213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_72b3b5d0-0010-4f9d-aaae-71175bb207d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0654414d-756a-4d7d-a3ae-f1ec2651f213" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_72b3b5d0-0010-4f9d-aaae-71175bb207d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arvn-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7e569cc1-833f-47ef-b3ae-78d169998b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a06d6593-0e13-46d6-93ea-4757497ec04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7e569cc1-833f-47ef-b3ae-78d169998b98" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a06d6593-0e13-46d6-93ea-4757497ec04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityMethodInvestments"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_99f49f57-eb24-4a5a-9c30-2a7dcf924ece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_11d65b2f-f4a9-4bea-8a55-954b9a2aa958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_99f49f57-eb24-4a5a-9c30-2a7dcf924ece" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_11d65b2f-f4a9-4bea-8a55-954b9a2aa958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arvn-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dc5a486f-c90e-4bf8-a216-3c320aeea02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d96295b4-4f39-4960-8514-4a48003d0f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dc5a486f-c90e-4bf8-a216-3c320aeea02d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d96295b4-4f39-4960-8514-4a48003d0f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountingPronouncementsandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_02d588f4-1854-4f22-af9d-25c6956efbc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2e066c80-d8e8-419f-aa49-4e56c67ab5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02d588f4-1854-4f22-af9d-25c6956efbc3" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2e066c80-d8e8-419f-aa49-4e56c67ab5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d07e6568-e729-491d-9124-5746dcc48bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02d588f4-1854-4f22-af9d-25c6956efbc3" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d07e6568-e729-491d-9124-5746dcc48bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_79916aeb-fd97-4c13-a32f-f998314b802e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02d588f4-1854-4f22-af9d-25c6956efbc3" xlink:to="loc_us-gaap_UseOfEstimates_79916aeb-fd97-4c13-a32f-f998314b802e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_92c03133-95a4-4983-b9ca-1d822a2795cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02d588f4-1854-4f22-af9d-25c6956efbc3" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_92c03133-95a4-4983-b9ca-1d822a2795cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a7f1ebed-889a-4f55-ad52-8df62f0bd05c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02d588f4-1854-4f22-af9d-25c6956efbc3" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a7f1ebed-889a-4f55-ad52-8df62f0bd05c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3102ec1c-f78e-44d9-90ba-bdf29e31920c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_02d588f4-1854-4f22-af9d-25c6956efbc3" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3102ec1c-f78e-44d9-90ba-bdf29e31920c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountingPronouncementsandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a8305a0b-f0c8-41d9-8a0e-e2a6c3239adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_03502d34-a760-427e-97a9-78163346ba30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8305a0b-f0c8-41d9-8a0e-e2a6c3239adf" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_03502d34-a760-427e-97a9-78163346ba30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_6ec01fbf-41c9-4073-a41a-9fcf92f9d7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a8305a0b-f0c8-41d9-8a0e-e2a6c3239adf" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_6ec01fbf-41c9-4073-a41a-9fcf92f9d7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_60dc48c5-cf04-47d3-b6e5-6d01ec2ec036" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f8720091-e360-4562-a989-0ceeb2752066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_60dc48c5-cf04-47d3-b6e5-6d01ec2ec036" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f8720091-e360-4562-a989-0ceeb2752066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_ed8acbfb-209d-4bca-a8e8-21d2bab422ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_60dc48c5-cf04-47d3-b6e5-6d01ec2ec036" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_ed8acbfb-209d-4bca-a8e8-21d2bab422ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#MarketableSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5276fb75-2d2a-482c-900b-442e86fe305b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_4e484d36-5ab2-4f98-afda-7d6eb74f8d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5276fb75-2d2a-482c-900b-442e86fe305b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_4e484d36-5ab2-4f98-afda-7d6eb74f8d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#PropertyEquipmentandLeaseholdImprovementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1b24a376-df3c-429a-8e0d-d206ceeb57a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f87a790f-dbcd-4321-b7a8-79c7f7e9e1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1b24a376-df3c-429a-8e0d-d206ceeb57a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f87a790f-dbcd-4321-b7a8-79c7f7e9e1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3a6b55df-4249-4e6e-8ff8-5d5df235e58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_0f5f3152-d246-48fe-b5d5-7928ccfa2472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a6b55df-4249-4e6e-8ff8-5d5df235e58e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_0f5f3152-d246-48fe-b5d5-7928ccfa2472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_9af177c6-c6de-4f6f-ad89-dc0488c0950f" xlink:href="arvn-20230331.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a6b55df-4249-4e6e-8ff8-5d5df235e58e" xlink:to="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock_9af177c6-c6de-4f6f-ad89-dc0488c0950f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_317a723a-65f9-4a16-b428-ea0afdc6357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3a6b55df-4249-4e6e-8ff8-5d5df235e58e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_317a723a-65f9-4a16-b428-ea0afdc6357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d4c70caf-b150-4580-8dda-1bee31148ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2b738eaa-3fb4-4503-b6e5-03a56c8e24da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d4c70caf-b150-4580-8dda-1bee31148ab1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2b738eaa-3fb4-4503-b6e5-03a56c8e24da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d902b2af-9d2b-4d5c-bdca-7194d3b7ad26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_295887b4-b6f1-47ad-9b1d-573fc24bb71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d902b2af-9d2b-4d5c-bdca-7194d3b7ad26" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_295887b4-b6f1-47ad-9b1d-573fc24bb71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2992de5b-f47c-4c1e-99f8-27a5291e8d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d902b2af-9d2b-4d5c-bdca-7194d3b7ad26" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2992de5b-f47c-4c1e-99f8-27a5291e8d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_475bf382-e24e-4077-bc45-5d770b782276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3788126b-f007-4a0a-b67d-fc4577fb1d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_475bf382-e24e-4077-bc45-5d770b782276" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3788126b-f007-4a0a-b67d-fc4577fb1d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_055beb60-53dc-49a9-83c7-cf45256af9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_475bf382-e24e-4077-bc45-5d770b782276" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_055beb60-53dc-49a9-83c7-cf45256af9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_90ffb10e-da0f-4a97-a080-44091f51cf42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_475bf382-e24e-4077-bc45-5d770b782276" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_90ffb10e-da0f-4a97-a080-44091f51cf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2c55b5ae-1a5d-4375-9eb6-af98055b3ef8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4a03a9c9-837a-4e28-8c4c-f0f6a256e8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2c55b5ae-1a5d-4375-9eb6-af98055b3ef8" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_4a03a9c9-837a-4e28-8c4c-f0f6a256e8b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6b282fde-3dd3-412b-b889-1324e4f54ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2c55b5ae-1a5d-4375-9eb6-af98055b3ef8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6b282fde-3dd3-412b-b889-1324e4f54ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsTables" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityMethodInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4e9e26a0-b67b-4a58-85de-542b2421dba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_14fd121b-a2c6-4ef9-91fd-56ffabe06cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4e9e26a0-b67b-4a58-85de-542b2421dba4" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_14fd121b-a2c6-4ef9-91fd-56ffabe06cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bf22a87-fb44-4f01-8247-12ecba3c0c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_70facee8-c8da-4eb5-adac-8f94e0e326b1" xlink:href="arvn-20230331.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3bf22a87-fb44-4f01-8247-12ecba3c0c86" xlink:to="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_70facee8-c8da-4eb5-adac-8f94e0e326b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e25f348-9fd8-4063-9edf-15a0e8331cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5a6a296-5504-47ea-abae-c5f929881216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e25f348-9fd8-4063-9edf-15a0e8331cc4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5a6a296-5504-47ea-abae-c5f929881216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_0249ebdf-fe12-4172-a67a-cd21827ebe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e25f348-9fd8-4063-9edf-15a0e8331cc4" xlink:to="loc_us-gaap_RestrictedCashCurrent_0249ebdf-fe12-4172-a67a-cd21827ebe8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a12a52f9-8dd2-42d3-b122-88e4412adfc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e25f348-9fd8-4063-9edf-15a0e8331cc4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a12a52f9-8dd2-42d3-b122-88e4412adfc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_41c8c48b-6537-4e23-8251-823250055c25" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_41c8c48b-6537-4e23-8251-823250055c25" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_cae21826-8f6e-4105-a835-fc252b1d20fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_srt_CounterpartyNameAxis_cae21826-8f6e-4105-a835-fc252b1d20fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_cae21826-8f6e-4105-a835-fc252b1d20fa" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_128d8cfb-e54e-45a8-a672-7c6206fa7bf8" xlink:href="arvn-20230331.xsd#arvn_PfizerIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:to="loc_arvn_PfizerIncorporationMember_128d8cfb-e54e-45a8-a672-7c6206fa7bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_07bc1b03-d7a9-44fe-8c6f-7b3e7c309ed0" xlink:href="arvn-20230331.xsd#arvn_BayerAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:to="loc_arvn_BayerAGMember_07bc1b03-d7a9-44fe-8c6f-7b3e7c309ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_c7000a59-0b10-4c9a-92d1-6d6e58e00883" xlink:href="arvn-20230331.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ed97de83-fd4e-4ea5-bad2-de8eda5505e5" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_c7000a59-0b10-4c9a-92d1-6d6e58e00883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6e3a4804-ff14-4e82-996f-8974f2cc85fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6e3a4804-ff14-4e82-996f-8974f2cc85fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6e3a4804-ff14-4e82-996f-8974f2cc85fd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_b6a480a2-3554-490a-abfc-825aca301c56" xlink:href="arvn-20230331.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_b6a480a2-3554-490a-abfc-825aca301c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_e7e55455-085d-4a16-8bba-41a8557fc733" xlink:href="arvn-20230331.xsd#arvn_CollaborationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_CollaborationAgreementMember_e7e55455-085d-4a16-8bba-41a8557fc733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_0a0f5079-54a1-4f57-a8cb-72e015a04386" xlink:href="arvn-20230331.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_0a0f5079-54a1-4f57-a8cb-72e015a04386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember_8b9e3c6c-f861-4a2f-94ff-c6835b4e31f3" xlink:href="arvn-20230331.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_SalesBasedMilestonesMember_8b9e3c6c-f861-4a2f-94ff-c6835b4e31f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_e83f98ba-07e6-4091-ae1c-aa8862920442" xlink:href="arvn-20230331.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_ResearchFundingPaymentsMember_e83f98ba-07e6-4091-ae1c-aa8862920442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_7866e102-de1a-4c8b-ba72-cee7c9ad17d7" xlink:href="arvn-20230331.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_7866e102-de1a-4c8b-ba72-cee7c9ad17d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_aba257e0-ded8-4866-963d-ca265ab0613e" xlink:href="arvn-20230331.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_aba257e0-ded8-4866-963d-ca265ab0613e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_4052be65-5a3b-4ff5-b62d-dd5f0801b2d9" xlink:href="arvn-20230331.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_4052be65-5a3b-4ff5-b62d-dd5f0801b2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_a62451a5-222b-4097-afff-b4547c213add" xlink:href="arvn-20230331.xsd#arvn_CommercialMilestonesMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99469b85-b662-48b2-8abe-929ed882be36" xlink:to="loc_arvn_CommercialMilestonesMember_a62451a5-222b-4097-afff-b4547c213add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3e271db0-a724-48cf-ac85-674744e0a7bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_srt_RangeAxis_3e271db0-a724-48cf-ac85-674744e0a7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_daca2f12-0199-448c-96cc-a951cc9a9613" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3e271db0-a724-48cf-ac85-674744e0a7bb" xlink:to="loc_srt_RangeMember_daca2f12-0199-448c-96cc-a951cc9a9613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bbcc4615-03f2-451c-9874-54aeac87feb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_daca2f12-0199-448c-96cc-a951cc9a9613" xlink:to="loc_srt_MaximumMember_bbcc4615-03f2-451c-9874-54aeac87feb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3d515778-3d72-417a-a0b6-e4275d10650c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_srt_StatementScenarioAxis_3d515778-3d72-417a-a0b6-e4275d10650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2d9a6221-07cc-4af4-93b1-d1cd63eb09db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3d515778-3d72-417a-a0b6-e4275d10650c" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2d9a6221-07cc-4af4-93b1-d1cd63eb09db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_c72d5f84-03f4-4900-b604-f69bf991e75d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2d9a6221-07cc-4af4-93b1-d1cd63eb09db" xlink:to="loc_srt_ScenarioForecastMember_c72d5f84-03f4-4900-b604-f69bf991e75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_396bbcb6-be43-43de-80f6-d331dd0324ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_396bbcb6-be43-43de-80f6-d331dd0324ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_31d49e18-ea9f-4f83-85aa-c85b52d0bcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_396bbcb6-be43-43de-80f6-d331dd0324ab" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_31d49e18-ea9f-4f83-85aa-c85b52d0bcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_15041a87-afb1-470c-8dd7-bba63e04ef4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_31d49e18-ea9f-4f83-85aa-c85b52d0bcb8" xlink:to="loc_us-gaap_SubsequentEventMember_15041a87-afb1-470c-8dd7-bba63e04ef4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_bbd7dc13-3e6e-463f-8ac5-56ddea9d4876" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_0d06670a-5280-4c34-96b4-90f84fcdf5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_0d06670a-5280-4c34-96b4-90f84fcdf5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_30300455-e372-431b-8987-138d5b0eed32" xlink:href="arvn-20230331.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_30300455-e372-431b-8987-138d5b0eed32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_acbe85a1-cd2d-4de0-8cc0-b1c9daf46d8b" xlink:href="arvn-20230331.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_acbe85a1-cd2d-4de0-8cc0-b1c9daf46d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_a0788a58-39a6-44e2-ab87-c190dd343055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_us-gaap_ProceedsFromCollaborators_a0788a58-39a6-44e2-ab87-c190dd343055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_fef8e215-2e2a-40f0-8023-7a4c9d0f2a26" xlink:href="arvn-20230331.xsd#arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement_fef8e215-2e2a-40f0-8023-7a4c9d0f2a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_36fbea4f-67d6-4838-acc8-4fc455bc09fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_f69f8c47-623e-416b-85dd-8cd4480709c6" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract_36fbea4f-67d6-4838-acc8-4fc455bc09fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_c6b39289-548b-48e9-ad3b-f585b55ee4fc" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_79fdd7b7-16ad-48ef-ad46-11a75f2e537a" xlink:href="arvn-20230331.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_c6b39289-548b-48e9-ad3b-f585b55ee4fc" xlink:to="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_79fdd7b7-16ad-48ef-ad46-11a75f2e537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2617e7ae-ab5a-4bf4-b259-bf69789ef084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_79fdd7b7-16ad-48ef-ad46-11a75f2e537a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2617e7ae-ab5a-4bf4-b259-bf69789ef084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_f6082f94-5cd0-4f61-afa0-11f8080292e2" xlink:href="arvn-20230331.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_79fdd7b7-16ad-48ef-ad46-11a75f2e537a" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_f6082f94-5cd0-4f61-afa0-11f8080292e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_3f6181ef-6299-4bb4-9511-850ae704a707" xlink:href="arvn-20230331.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_79fdd7b7-16ad-48ef-ad46-11a75f2e537a" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_3f6181ef-6299-4bb4-9511-850ae704a707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_decb8892-f2d0-4b69-bb65-20cd524bcb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_79fdd7b7-16ad-48ef-ad46-11a75f2e537a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_decb8892-f2d0-4b69-bb65-20cd524bcb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_58394b12-9b3b-4c11-8781-cd0b8de355a8" xlink:href="arvn-20230331.xsd#arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_c6b39289-548b-48e9-ad3b-f585b55ee4fc" xlink:to="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_58394b12-9b3b-4c11-8781-cd0b8de355a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent_6a1a4255-91c4-4c9e-9c30-e0e76fe44f7c" xlink:href="arvn-20230331.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_58394b12-9b3b-4c11-8781-cd0b8de355a8" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrent_6a1a4255-91c4-4c9e-9c30-e0e76fe44f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentAdditions_d22cee6a-c41f-4138-b78e-fe6b63c31bb7" xlink:href="arvn-20230331.xsd#arvn_AccountsPayableContractBalancesCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_58394b12-9b3b-4c11-8781-cd0b8de355a8" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrentAdditions_d22cee6a-c41f-4138-b78e-fe6b63c31bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentPayments_879f8982-cefc-4af5-bde3-3b97abdd57ec" xlink:href="arvn-20230331.xsd#arvn_AccountsPayableContractBalancesCurrentPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_58394b12-9b3b-4c11-8781-cd0b8de355a8" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrentPayments_879f8982-cefc-4af5-bde3-3b97abdd57ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent_c3270c75-80e9-452d-8199-a5b28ef33082" xlink:href="arvn-20230331.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_58394b12-9b3b-4c11-8781-cd0b8de355a8" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrent_c3270c75-80e9-452d-8199-a5b28ef33082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_58755145-a3a5-4efe-8387-97fccd886286" xlink:href="arvn-20230331.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_c6b39289-548b-48e9-ad3b-f585b55ee4fc" xlink:to="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_58755145-a3a5-4efe-8387-97fccd886286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_d7e49e20-1a7b-4d1f-9e1f-e9cd11227828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_58755145-a3a5-4efe-8387-97fccd886286" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_d7e49e20-1a7b-4d1f-9e1f-e9cd11227828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_9f40b80f-a8c9-43ad-b7fc-98c0a552b47c" xlink:href="arvn-20230331.xsd#arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_58755145-a3a5-4efe-8387-97fccd886286" xlink:to="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_9f40b80f-a8c9-43ad-b7fc-98c0a552b47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod_bb931447-33e8-4b8e-80da-8cdef5f20b64" xlink:href="arvn-20230331.xsd#arvn_CapitalizedContractCostAmortizationDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_58755145-a3a5-4efe-8387-97fccd886286" xlink:to="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod_bb931447-33e8-4b8e-80da-8cdef5f20b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_318fd527-bdd5-4b4c-aee1-0366009ac71b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_58755145-a3a5-4efe-8387-97fccd886286" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_318fd527-bdd5-4b4c-aee1-0366009ac71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_4e5a6d5f-66f9-4f62-824b-e2183005640e" xlink:href="arvn-20230331.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_c6b39289-548b-48e9-ad3b-f585b55ee4fc" xlink:to="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_4e5a6d5f-66f9-4f62-824b-e2183005640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_01301eb2-aa0b-4f8b-afde-21210b58dc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_4e5a6d5f-66f9-4f62-824b-e2183005640e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_01301eb2-aa0b-4f8b-afde-21210b58dc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5e417516-1cc1-4b6d-865e-0304dbc21a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_4e5a6d5f-66f9-4f62-824b-e2183005640e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5e417516-1cc1-4b6d-865e-0304dbc21a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_05a7cae7-993f-41d5-b3f9-1f53243378a2" xlink:href="arvn-20230331.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_4e5a6d5f-66f9-4f62-824b-e2183005640e" xlink:to="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_05a7cae7-993f-41d5-b3f9-1f53243378a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_975c27ea-957f-40d7-9e74-fda7d80c9126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_4e5a6d5f-66f9-4f62-824b-e2183005640e" xlink:to="loc_us-gaap_ContractWithCustomerLiability_975c27ea-957f-40d7-9e74-fda7d80c9126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_9f4d89ee-2bf0-4dc1-acc1-f0472a6214fb" xlink:href="arvn-20230331.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_9f4d89ee-2bf0-4dc1-acc1-f0472a6214fb" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_63ef9063-21b0-47a9-b8eb-6919d1c37f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_63ef9063-21b0-47a9-b8eb-6919d1c37f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4c551605-70c7-4449-a18f-46fa13745d28" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_4ffba4c1-986e-439a-a2d1-9abbb2f1b408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_4ffba4c1-986e-439a-a2d1-9abbb2f1b408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8eab7c3e-b3ae-454e-95bd-1b98655aa4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_dcde5e07-2949-408e-9295-9a7703ebc838" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_8eab7c3e-b3ae-454e-95bd-1b98655aa4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="arvn-20230331.xsd#ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_37f67d47-e5c2-40d1-845c-2ef1fbd71eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_37f67d47-e5c2-40d1-845c-2ef1fbd71eab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae93df5-88c7-486d-9475-17aafa809b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae93df5-88c7-486d-9475-17aafa809b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9624554e-ba66-428a-a7e6-11aaed2756ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_aae93df5-88c7-486d-9475-17aafa809b2f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9624554e-ba66-428a-a7e6-11aaed2756ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_63cebb36-96b3-4998-a2f8-33ccfba83fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9624554e-ba66-428a-a7e6-11aaed2756ab" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_63cebb36-96b3-4998-a2f8-33ccfba83fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16399378-0d91-4719-8ed3-399caa551701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16399378-0d91-4719-8ed3-399caa551701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a41d5e4f-9ad6-4862-9bd8-82fd72fee1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_16399378-0d91-4719-8ed3-399caa551701" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a41d5e4f-9ad6-4862-9bd8-82fd72fee1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_36e4bcdd-00a7-40c3-996e-530e59138401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_a41d5e4f-9ad6-4862-9bd8-82fd72fee1c2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_36e4bcdd-00a7-40c3-996e-530e59138401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d4a8f329-6b06-4f2d-b1df-16d1d2142af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d4a8f329-6b06-4f2d-b1df-16d1d2142af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d4a8f329-6b06-4f2d-b1df-16d1d2142af1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_348926a3-d53e-4028-8102-05f458b61c13" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_348926a3-d53e-4028-8102-05f458b61c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember_e04351c0-33d3-4ab6-8101-8ea1cafe00cf" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember_e04351c0-33d3-4ab6-8101-8ea1cafe00cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_225f19b6-9974-4869-b275-343701c6eeea" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember_225f19b6-9974-4869-b275-343701c6eeea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_4e87eead-e2ad-491c-a0e3-af6ec1e09875" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember_4e87eead-e2ad-491c-a0e3-af6ec1e09875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_4dc8a523-ea70-4c8e-8075-9dce0b4ca057" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember_4dc8a523-ea70-4c8e-8075-9dce0b4ca057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_8d66f66a-74a2-47ef-a59a-603420555f98" xlink:href="arvn-20230331.xsd#arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember_8d66f66a-74a2-47ef-a59a-603420555f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_f9601873-5f30-4859-941c-3d8f717a1744" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember_f9601873-5f30-4859-941c-3d8f717a1744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember_383f872f-5f60-424f-9a0e-581cbed0c2b6" xlink:href="arvn-20230331.xsd#arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4d1fb7ac-0167-47f3-8af0-d3612b52025c" xlink:to="loc_arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember_383f872f-5f60-424f-9a0e-581cbed0c2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c5f67282-e0c4-4f4c-9d42-189716ea1ac5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c74e8666-7b7e-4f06-9cc9-a38826bfe021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c74e8666-7b7e-4f06-9cc9-a38826bfe021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8eb46b5-a440-4ee4-9b83-01bcb2ca1603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e8eb46b5-a440-4ee4-9b83-01bcb2ca1603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ab80cfed-8ab7-43aa-8a0b-836db6897bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ab80cfed-8ab7-43aa-8a0b-836db6897bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f862ab36-99f6-436b-8d5c-a94d268d61ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_564ffd80-83ce-4d11-9b64-b177d3f45abc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f862ab36-99f6-436b-8d5c-a94d268d61ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2d5184bc-f58b-437c-a5b0-8d3a31e2b879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aaa8d59-cb21-4ddf-a681-bfc5b6314877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2d5184bc-f58b-437c-a5b0-8d3a31e2b879" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aaa8d59-cb21-4ddf-a681-bfc5b6314877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb36aa43-1149-4a57-b148-c3d552a99196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aaa8d59-cb21-4ddf-a681-bfc5b6314877" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb36aa43-1149-4a57-b148-c3d552a99196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_eb36aa43-1149-4a57-b148-c3d552a99196" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_ab125a33-020f-4a91-8120-095a57be1259" xlink:href="arvn-20230331.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:to="loc_arvn_LaboratoryEquipmentMember_ab125a33-020f-4a91-8120-095a57be1259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_296cda4a-ac27-4ae1-a3c2-87f6bc515531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_296cda4a-ac27-4ae1-a3c2-87f6bc515531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_e0b4f4f7-3500-41a5-933d-335436b0a957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_98fddeef-e72a-4a08-ab21-92c95f1fdd1b" xlink:to="loc_us-gaap_OfficeEquipmentMember_e0b4f4f7-3500-41a5-933d-335436b0a957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7aaa8d59-cb21-4ddf-a681-bfc5b6314877" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b353ddf1-994a-4530-9656-9285b9b68489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b353ddf1-994a-4530-9656-9285b9b68489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_755a1c38-eabd-44b7-8f4b-5d3e6a520fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_755a1c38-eabd-44b7-8f4b-5d3e6a520fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_078df0f2-7cff-4636-aa33-059b00bf17e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c0842802-d715-40c2-886b-372b9ae1ed48" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_078df0f2-7cff-4636-aa33-059b00bf17e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_504c9bd1-f83f-4e63-a78d-2184c376a6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_69edc89a-645b-4252-956e-3711dcefa2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_504c9bd1-f83f-4e63-a78d-2184c376a6dc" xlink:to="loc_us-gaap_DepreciationAndAmortization_69edc89a-645b-4252-956e-3711dcefa2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0cd5026e-47d6-420a-9905-7c3b6be3b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0cd5026e-47d6-420a-9905-7c3b6be3b40c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:to="loc_srt_RangeAxis_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2ad2d13-0d77-4c65-88a9-7191ddb7a9bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c8d9d32d-4d42-43ca-a0ff-78154f01b7d1" xlink:to="loc_srt_RangeMember_a2ad2d13-0d77-4c65-88a9-7191ddb7a9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e91b68d1-c53f-45b1-b765-0e1da09d5f8e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a2ad2d13-0d77-4c65-88a9-7191ddb7a9bc" xlink:to="loc_srt_MinimumMember_e91b68d1-c53f-45b1-b765-0e1da09d5f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_69801250-c31e-474a-b854-e73031cf0ee2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a2ad2d13-0d77-4c65-88a9-7191ddb7a9bc" xlink:to="loc_srt_MaximumMember_69801250-c31e-474a-b854-e73031cf0ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis_32241109-8ffc-4986-9c1c-f089f522a651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:to="loc_us-gaap_PledgingPurposeAxis_32241109-8ffc-4986-9c1c-f089f522a651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_e4ffb68a-1135-4099-b504-4d1001f5ed6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgingPurposeAxis_32241109-8ffc-4986-9c1c-f089f522a651" xlink:to="loc_us-gaap_PledgingPurposeDomain_e4ffb68a-1135-4099-b504-4d1001f5ed6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_483ccd73-90dd-4b71-9311-2da1c9fea9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgingPurposeDomain_e4ffb68a-1135-4099-b504-4d1001f5ed6b" xlink:to="loc_us-gaap_LetterOfCreditMember_483ccd73-90dd-4b71-9311-2da1c9fea9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis_f8681733-69b4-436b-bbd7-fa5cddcc91a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:to="loc_us-gaap_PledgedStatusAxis_f8681733-69b4-436b-bbd7-fa5cddcc91a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_272ac289-f48a-479f-a861-6b7016954311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PledgedStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgedStatusAxis_f8681733-69b4-436b-bbd7-fa5cddcc91a9" xlink:to="loc_us-gaap_PledgedStatusDomain_272ac289-f48a-479f-a861-6b7016954311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember_3661dfdb-8f2b-476a-8f44-59e5f8465c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgedStatusDomain_272ac289-f48a-479f-a861-6b7016954311" xlink:to="loc_us-gaap_AssetPledgedAsCollateralMember_3661dfdb-8f2b-476a-8f44-59e5f8465c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_8352cc27-6453-48cd-a13f-d15f0a0a2119" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_f02eac2c-1c10-4b6b-83ca-c8552d82e1a4" xlink:href="arvn-20230331.xsd#arvn_PercentageOfIncrementalBorrowingForLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_arvn_PercentageOfIncrementalBorrowingForLeasePayments_f02eac2c-1c10-4b6b-83ca-c8552d82e1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_f09eae26-4ff5-4d9d-b06f-602a4d43b346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_f09eae26-4ff5-4d9d-b06f-602a4d43b346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities_1eeecb94-88af-4a22-9cb8-1166da670016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_DebtSecurities_1eeecb94-88af-4a22-9cb8-1166da670016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d0b8027d-d609-45f5-a21e-f1c7a2c94b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_LeaseCost_d0b8027d-d609-45f5-a21e-f1c7a2c94b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BaseLeaseRentPeriod_0aebf782-f10d-4730-9d78-eaa371d2376b" xlink:href="arvn-20230331.xsd#arvn_BaseLeaseRentPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_arvn_BaseLeaseRentPeriod_0aebf782-f10d-4730-9d78-eaa371d2376b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ded5c48f-c9ca-477c-98c1-e50bdee7f731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_4624357e-3942-4271-9815-c07a4670be38" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ded5c48f-c9ca-477c-98c1-e50bdee7f731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4442021c-a2ee-413a-a591-ebcb4c2eec5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d05f06a2-ed53-4fb1-987d-637a7f5b56ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4442021c-a2ee-413a-a591-ebcb4c2eec5d" xlink:to="loc_us-gaap_OperatingLeaseCost_d05f06a2-ed53-4fb1-987d-637a7f5b56ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b3d33daa-f5cb-4e6e-b428-bbb3d90e774e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_14307924-6398-4e2c-a732-6cc34b5207e4" xlink:href="arvn-20230331.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3d33daa-f5cb-4e6e-b428-bbb3d90e774e" xlink:to="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_14307924-6398-4e2c-a732-6cc34b5207e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_bab34a87-8240-44b9-8b3a-30da997d10e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_14307924-6398-4e2c-a732-6cc34b5207e4" xlink:to="loc_us-gaap_OperatingLeasePayments_bab34a87-8240-44b9-8b3a-30da997d10e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_b7d942ef-b74c-426f-ac72-d81e4c210422" xlink:href="arvn-20230331.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b3d33daa-f5cb-4e6e-b428-bbb3d90e774e" xlink:to="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_b7d942ef-b74c-426f-ac72-d81e4c210422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_038a4ed6-4cad-41c9-babf-0502c239d28a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_b7d942ef-b74c-426f-ac72-d81e4c210422" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_038a4ed6-4cad-41c9-babf-0502c239d28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e1f1af21-144f-4daa-94eb-c246119ce532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f0b271ae-3f0e-4577-b2c4-404465ab505d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1f1af21-144f-4daa-94eb-c246119ce532" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f0b271ae-3f0e-4577-b2c4-404465ab505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_23de96e1-a52c-4ba0-bb2d-38de54cd63c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1f1af21-144f-4daa-94eb-c246119ce532" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_23de96e1-a52c-4ba0-bb2d-38de54cd63c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c2409b3b-4734-437f-8d7f-c4ea0938a645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1f1af21-144f-4daa-94eb-c246119ce532" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c2409b3b-4734-437f-8d7f-c4ea0938a645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ea4907ea-69fd-4c00-81ef-d98ccdf0659c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1f1af21-144f-4daa-94eb-c246119ce532" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ea4907ea-69fd-4c00-81ef-d98ccdf0659c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ed47598-85c4-4bea-b21f-ac0ec622fc34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1f1af21-144f-4daa-94eb-c246119ce532" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3ed47598-85c4-4bea-b21f-ac0ec622fc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_654db903-113a-451f-bf19-6a5d331605b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1f1af21-144f-4daa-94eb-c246119ce532" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_654db903-113a-451f-bf19-6a5d331605b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c993b508-240f-42eb-a6a1-fb1167bdc7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e1f1af21-144f-4daa-94eb-c246119ce532" xlink:to="loc_us-gaap_OperatingLeaseLiability_c993b508-240f-42eb-a6a1-fb1167bdc7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="arvn-20230331.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_072f5ba8-4f73-4cc1-ba8b-2d340c694096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_aca984b2-122b-4a08-b8fc-c6dbcf6c1ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_072f5ba8-4f73-4cc1-ba8b-2d340c694096" xlink:to="loc_us-gaap_AccountsPayableCurrent_aca984b2-122b-4a08-b8fc-c6dbcf6c1ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_fbf1f513-557d-49e6-8e33-ce572392323d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_072f5ba8-4f73-4cc1-ba8b-2d340c694096" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_fbf1f513-557d-49e6-8e33-ce572392323d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_c1730aa6-b5b0-469e-8170-54f067f414f3" xlink:href="arvn-20230331.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_fbf1f513-557d-49e6-8e33-ce572392323d" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_c1730aa6-b5b0-469e-8170-54f067f414f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_3d536499-6458-44ff-b0d6-341f21be3e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_fbf1f513-557d-49e6-8e33-ce572392323d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_3d536499-6458-44ff-b0d6-341f21be3e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9aace2a0-8ae5-4755-8129-fa17fcafdb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_fbf1f513-557d-49e6-8e33-ce572392323d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9aace2a0-8ae5-4755-8129-fa17fcafdb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_15fa126c-4273-430a-a41b-0ad8b733fd30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_fbf1f513-557d-49e6-8e33-ce572392323d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_15fa126c-4273-430a-a41b-0ad8b733fd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_583f2078-fe00-4c57-99f1-9fc1bbb4c90c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_072f5ba8-4f73-4cc1-ba8b-2d340c694096" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_583f2078-fe00-4c57-99f1-9fc1bbb4c90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_47a47e25-d59b-456b-be25-5e43832b05ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11cfa791-a42d-42e8-b270-691caad19325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_47a47e25-d59b-456b-be25-5e43832b05ae" xlink:to="loc_us-gaap_DebtInstrumentTable_11cfa791-a42d-42e8-b270-691caad19325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11cfa791-a42d-42e8-b270-691caad19325" xlink:to="loc_us-gaap_DebtInstrumentAxis_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_597529e1-bf0d-4e7b-b108-3e8566f55563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bc4bebdc-f6f8-40e6-8ca9-94de53f7916e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_597529e1-bf0d-4e7b-b108-3e8566f55563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_23609102-e566-49a4-83d4-4d058e67c2d6" xlink:href="arvn-20230331.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_597529e1-bf0d-4e7b-b108-3e8566f55563" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_23609102-e566-49a4-83d4-4d058e67c2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11cfa791-a42d-42e8-b270-691caad19325" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62a07273-7559-4b58-ba98-9c81ecc7215c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_62a07273-7559-4b58-ba98-9c81ecc7215c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_eb98f293-468b-437f-9a05-35564cbdb8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_LongTermDebt_eb98f293-468b-437f-9a05-35564cbdb8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_a678a977-aa17-40ce-8496-f1ea950b0ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_LongTermDebtCurrent_a678a977-aa17-40ce-8496-f1ea950b0ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_02a49e63-e9f3-4340-8788-a8c873fd18ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e698c98c-8918-4630-a06a-a5b9b2c9b7f2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_02a49e63-e9f3-4340-8788-a8c873fd18ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_74b41185-6178-4f40-80c4-0d3ffc8986e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_74b41185-6178-4f40-80c4-0d3ffc8986e2" xlink:to="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_1a521a20-4bbd-4c8d-96e7-e28738011130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:to="loc_us-gaap_DebtInstrumentAxis_1a521a20-4bbd-4c8d-96e7-e28738011130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_72b82bdf-d8f4-4d45-8c6a-96a3dbb16871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1a521a20-4bbd-4c8d-96e7-e28738011130" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_72b82bdf-d8f4-4d45-8c6a-96a3dbb16871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_9affffd4-bd65-42fe-bf1d-a22d7d71de2e" xlink:href="arvn-20230331.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72b82bdf-d8f4-4d45-8c6a-96a3dbb16871" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_9affffd4-bd65-42fe-bf1d-a22d7d71de2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_b2872bee-7157-4e11-a5ab-d583d0b75a1f" xlink:href="arvn-20230331.xsd#arvn_TwoThousandAndFourteenAssistanceAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_72b82bdf-d8f4-4d45-8c6a-96a3dbb16871" xlink:to="loc_arvn_TwoThousandAndFourteenAssistanceAgreementMember_b2872bee-7157-4e11-a5ab-d583d0b75a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bbbf7c22-78f5-45ce-8063-926f32ed601f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:to="loc_srt_StatementGeographicalAxis_bbbf7c22-78f5-45ce-8063-926f32ed601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_37d5114e-d41c-4465-bcaf-8df4f90a0b57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bbbf7c22-78f5-45ce-8063-926f32ed601f" xlink:to="loc_srt_SegmentGeographicalDomain_37d5114e-d41c-4465-bcaf-8df4f90a0b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_86d0fecd-a7cc-437e-b59a-bb64fcd46f38" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CT"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_37d5114e-d41c-4465-bcaf-8df4f90a0b57" xlink:to="loc_stpr_CT_86d0fecd-a7cc-437e-b59a-bb64fcd46f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_870de9f4-639b-4207-b2b9-6c2d8bc15b21" xlink:to="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_69cceda2-8b9c-4757-bebe-e8e39c98a3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_69cceda2-8b9c-4757-bebe-e8e39c98a3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_e88d1b6d-ab99-4a73-b413-87008a5e2348" xlink:href="arvn-20230331.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_e88d1b6d-ab99-4a73-b413-87008a5e2348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_66bce0b6-851d-4b5f-8c7e-b36c350554cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_66bce0b6-851d-4b5f-8c7e-b36c350554cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_bd51b62b-f8ad-4a1a-a00a-e8a8b506b5e5" xlink:href="arvn-20230331.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_bd51b62b-f8ad-4a1a-a00a-e8a8b506b5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_1e803875-500a-47fb-8416-58f05091b791" xlink:href="arvn-20230331.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_1e803875-500a-47fb-8416-58f05091b791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5e3fe9b5-5c11-48c0-a652-a45939574962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_85d75f89-38d6-410a-a411-aead8603508d" xlink:to="loc_us-gaap_InterestExpense_5e3fe9b5-5c11-48c0-a652-a45939574962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c1b3ee2a-1360-4732-95f4-745cbde28854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ee3cc2c5-7e16-4129-9881-8258bf82dcba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1b3ee2a-1360-4732-95f4-745cbde28854" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ee3cc2c5-7e16-4129-9881-8258bf82dcba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66484cab-4024-4289-b6c4-b62db16be529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1b3ee2a-1360-4732-95f4-745cbde28854" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_66484cab-4024-4289-b6c4-b62db16be529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ce1ddcb6-a091-4d0f-b2a6-be328f70d2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1b3ee2a-1360-4732-95f4-745cbde28854" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ce1ddcb6-a091-4d0f-b2a6-be328f70d2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1362193b-4ab5-464c-bf6c-e7566707da8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1b3ee2a-1360-4732-95f4-745cbde28854" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1362193b-4ab5-464c-bf6c-e7566707da8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3366c3bb-df73-4621-9dc3-7ea7e174ef00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1b3ee2a-1360-4732-95f4-745cbde28854" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_3366c3bb-df73-4621-9dc3-7ea7e174ef00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LongTermDebtMaturityYearSix_f9efac0e-5a92-49b1-bae1-34359310be78" xlink:href="arvn-20230331.xsd#arvn_LongTermDebtMaturityYearSix"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1b3ee2a-1360-4732-95f4-745cbde28854" xlink:to="loc_arvn_LongTermDebtMaturityYearSix_f9efac0e-5a92-49b1-bae1-34359310be78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e023c956-78da-4ace-90aa-1b5e795c8e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1b3ee2a-1360-4732-95f4-745cbde28854" xlink:to="loc_us-gaap_LongTermDebt_e023c956-78da-4ace-90aa-1b5e795c8e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98db1969-a543-47c7-85c6-5cf731e99d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_98db1969-a543-47c7-85c6-5cf731e99d58" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_33420dc1-ac16-42ad-b199-cddd381fc56d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_33420dc1-ac16-42ad-b199-cddd381fc56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76b3685f-c969-4b55-9d4f-832badfaaa4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_33420dc1-ac16-42ad-b199-cddd381fc56d" xlink:to="loc_us-gaap_EquityComponentDomain_76b3685f-c969-4b55-9d4f-832badfaaa4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9e7f5ece-5db0-4fb6-aa0f-075c94804493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76b3685f-c969-4b55-9d4f-832badfaaa4c" xlink:to="loc_us-gaap_CommonStockMember_9e7f5ece-5db0-4fb6-aa0f-075c94804493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_cdbd6a1d-e9d4-4743-bbc3-abf379f43624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_cdbd6a1d-e9d4-4743-bbc3-abf379f43624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2479862-f18f-439d-8055-09f304a896d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_cdbd6a1d-e9d4-4743-bbc3-abf379f43624" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2479862-f18f-439d-8055-09f304a896d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_70afe426-ecd5-4d7e-b4d0-46feff275659" xlink:href="arvn-20230331.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2479862-f18f-439d-8055-09f304a896d5" xlink:to="loc_arvn_EquityDistributionAgreementMember_70afe426-ecd5-4d7e-b4d0-46feff275659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7eb5306e-f140-4358-b754-7664b05fbe94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7eb5306e-f140-4358-b754-7664b05fbe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4113143f-f6ad-4fbe-a590-6dbfc53426a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7eb5306e-f140-4358-b754-7664b05fbe94" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4113143f-f6ad-4fbe-a590-6dbfc53426a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_d8df0c2f-e88c-41f0-a019-823742ba8766" xlink:href="arvn-20230331.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4113143f-f6ad-4fbe-a590-6dbfc53426a7" xlink:to="loc_arvn_AtTheMarketOfferingMember_d8df0c2f-e88c-41f0-a019-823742ba8766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_bef75ad3-767e-4eb9-93de-138ae8eb6cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4113143f-f6ad-4fbe-a590-6dbfc53426a7" xlink:to="loc_us-gaap_EmployeeStockMember_bef75ad3-767e-4eb9-93de-138ae8eb6cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13ce127e-8730-46e6-87ed-ed059caa875e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_srt_CounterpartyNameAxis_13ce127e-8730-46e6-87ed-ed059caa875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0b11abf-9ae7-4816-a1fc-fecd47ba2642" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_13ce127e-8730-46e6-87ed-ed059caa875e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0b11abf-9ae7-4816-a1fc-fecd47ba2642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember_3b6af03f-1c32-43a1-a554-47705a71c2ed" xlink:href="arvn-20230331.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a0b11abf-9ae7-4816-a1fc-fecd47ba2642" xlink:to="loc_arvn_PiperSandlerAndCantorMember_3b6af03f-1c32-43a1-a554-47705a71c2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_da3a3eb2-b61b-4f22-8448-7ec964d0228e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_srt_RangeAxis_da3a3eb2-b61b-4f22-8448-7ec964d0228e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2656fe7b-083d-4cd0-baeb-ee0388bba37a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_da3a3eb2-b61b-4f22-8448-7ec964d0228e" xlink:to="loc_srt_RangeMember_2656fe7b-083d-4cd0-baeb-ee0388bba37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7282b215-c709-4199-9db8-97f35c524e7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2656fe7b-083d-4cd0-baeb-ee0388bba37a" xlink:to="loc_srt_MinimumMember_7282b215-c709-4199-9db8-97f35c524e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a1b67af8-0426-4ea9-8c59-4347a447b300" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2656fe7b-083d-4cd0-baeb-ee0388bba37a" xlink:to="loc_srt_MaximumMember_a1b67af8-0426-4ea9-8c59-4347a447b300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9b0fa755-394f-430e-a96f-020070713d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_PlanNameAxis_9b0fa755-394f-430e-a96f-020070713d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ef92d0c4-cdd5-408d-8132-d54ccaeaceb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9b0fa755-394f-430e-a96f-020070713d02" xlink:to="loc_us-gaap_PlanNameDomain_ef92d0c4-cdd5-408d-8132-d54ccaeaceb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIncentivePlanMember_ce5e3628-9a92-42e0-aa2b-24994e76bce0" xlink:href="arvn-20230331.xsd#arvn_StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ef92d0c4-cdd5-408d-8132-d54ccaeaceb1" xlink:to="loc_arvn_StockIncentivePlanMember_ce5e3628-9a92-42e0-aa2b-24994e76bce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_50b33436-eb36-4b5f-b0e2-308793eaee14" xlink:href="arvn-20230331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ef92d0c4-cdd5-408d-8132-d54ccaeaceb1" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_50b33436-eb36-4b5f-b0e2-308793eaee14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_a482bbfc-0ef2-4670-86a4-bc34be7b2edb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_GranteeStatusAxis_a482bbfc-0ef2-4670-86a4-bc34be7b2edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_b919d837-ece8-40b0-b9d0-665f6f8d86d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_a482bbfc-0ef2-4670-86a4-bc34be7b2edb" xlink:to="loc_us-gaap_GranteeStatusDomain_b919d837-ece8-40b0-b9d0-665f6f8d86d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_fa9fe566-041b-487a-bcca-79b6859610c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_b919d837-ece8-40b0-b9d0-665f6f8d86d4" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_fa9fe566-041b-487a-bcca-79b6859610c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_96471319-0b6e-4154-9417-1f1386455927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_AwardTypeAxis_96471319-0b6e-4154-9417-1f1386455927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a423767f-32a4-460f-b958-bcbcf7754eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_96471319-0b6e-4154-9417-1f1386455927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a423767f-32a4-460f-b958-bcbcf7754eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_66438157-970c-499b-a177-bb8d8549fb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a423767f-32a4-460f-b958-bcbcf7754eb1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_66438157-970c-499b-a177-bb8d8549fb1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e883af76-f10a-49aa-9c16-3daf75a13423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a423767f-32a4-460f-b958-bcbcf7754eb1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e883af76-f10a-49aa-9c16-3daf75a13423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0fd94bcb-f958-4ce2-aeda-c572dd87157c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_e3d46269-12e4-47f5-9c7f-70622f30b8d7" xlink:href="arvn-20230331.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_e3d46269-12e4-47f5-9c7f-70622f30b8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_955901ea-d29a-446d-90a8-7d6c857be02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_955901ea-d29a-446d-90a8-7d6c857be02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5ef7b79f-1fb9-412a-9dbf-4c567ca7e5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_5ef7b79f-1fb9-412a-9dbf-4c567ca7e5e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_eaae9726-fe3f-44dc-967c-0c5d06c2eec2" xlink:href="arvn-20230331.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_eaae9726-fe3f-44dc-967c-0c5d06c2eec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_27ef71cc-1a13-43ab-be18-4c6a903ee732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_27ef71cc-1a13-43ab-be18-4c6a903ee732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5ede27f8-aeb0-420f-8c31-ca21291060ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5ede27f8-aeb0-420f-8c31-ca21291060ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6621a602-5531-41d9-8db5-53bdafee415c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6621a602-5531-41d9-8db5-53bdafee415c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_58fbcdc6-9756-487f-9c21-df395699da1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_58fbcdc6-9756-487f-9c21-df395699da1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_20c060dc-9bef-4dae-9192-08c25c2c6b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_20c060dc-9bef-4dae-9192-08c25c2c6b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0775f3fd-6e2f-4bb9-8f5e-1100ab57d2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0775f3fd-6e2f-4bb9-8f5e-1100ab57d2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6fadef2c-cd03-425f-a268-16ac64b52bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6fadef2c-cd03-425f-a268-16ac64b52bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2ca76183-372b-4dd1-bd5c-d969ea1c17d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2ca76183-372b-4dd1-bd5c-d969ea1c17d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4b7d448-8ff7-49e6-b6b2-e039d508b373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a4b7d448-8ff7-49e6-b6b2-e039d508b373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6515e49b-1285-4d68-b970-63fdd469b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6515e49b-1285-4d68-b970-63fdd469b5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8cc8d9e3-fa6e-44bc-9206-253d29e72638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8cc8d9e3-fa6e-44bc-9206-253d29e72638" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_07b07a68-ff66-4636-83c3-95c4b971fdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_07b07a68-ff66-4636-83c3-95c4b971fdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_58d981eb-102b-4375-bf7e-4ddc72f4db8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_58d981eb-102b-4375-bf7e-4ddc72f4db8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_ebe10f28-436c-4830-9f48-926ed74901aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_ebe10f28-436c-4830-9f48-926ed74901aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_11e231dc-f67f-4ebd-b8a7-3cc92dfda754" xlink:href="arvn-20230331.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d2a2172e-d249-46b7-8f9a-e4da62f8ac18" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber_11e231dc-f67f-4ebd-b8a7-3cc92dfda754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c23a8cd1-9704-441e-856e-bcacfd8a425f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c23a8cd1-9704-441e-856e-bcacfd8a425f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1e66b2f4-6050-4c07-837d-d5aed67ebb35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:to="loc_us-gaap_AwardTypeAxis_1e66b2f4-6050-4c07-837d-d5aed67ebb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c321774-13b2-43ca-a772-8c118f81ca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1e66b2f4-6050-4c07-837d-d5aed67ebb35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c321774-13b2-43ca-a772-8c118f81ca61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4123c2b3-73fc-4b92-bd52-07f31e9dd622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7c321774-13b2-43ca-a772-8c118f81ca61" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4123c2b3-73fc-4b92-bd52-07f31e9dd622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:to="loc_srt_RangeAxis_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0489d0cc-1c66-4c41-944f-e083573a94d4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d4f2c9ad-47e9-43b9-9f0a-2470a398cf5f" xlink:to="loc_srt_RangeMember_0489d0cc-1c66-4c41-944f-e083573a94d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fa8bb4b9-2327-4712-998f-ae8a879bf509" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0489d0cc-1c66-4c41-944f-e083573a94d4" xlink:to="loc_srt_MinimumMember_fa8bb4b9-2327-4712-998f-ae8a879bf509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7eab5e0f-a2a6-4744-8ea8-f7fda66d3284" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0489d0cc-1c66-4c41-944f-e083573a94d4" xlink:to="loc_srt_MaximumMember_7eab5e0f-a2a6-4744-8ea8-f7fda66d3284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19b6ea54-60db-4e98-80a2-e620305628ff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d0a69aa4-9322-4c92-8dc1-e6a99faceead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_d0a69aa4-9322-4c92-8dc1-e6a99faceead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9171641f-0103-44df-99a1-7059a2e3ac06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9171641f-0103-44df-99a1-7059a2e3ac06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4e8d246d-69c2-420c-8c28-96179e1de56b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4e8d246d-69c2-420c-8c28-96179e1de56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b37e66bf-6e87-462c-9840-fa238d2d5e29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b37e66bf-6e87-462c-9840-fa238d2d5e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_943fd4b7-c4f4-46a6-9e2e-1245cdb1b06e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_943fd4b7-c4f4-46a6-9e2e-1245cdb1b06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_310888a2-74f4-4e79-b8c1-d9734084352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_310888a2-74f4-4e79-b8c1-d9734084352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6e5f4bf1-37e0-471f-828d-355195475fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec5c3b9d-0754-4fa3-93b7-9ee5ada94a43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_6e5f4bf1-37e0-471f-828d-355195475fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquitySummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_667c22b2-711f-4e44-abf3-7d3dde201a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_667c22b2-711f-4e44-abf3-7d3dde201a4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7b29c171-13f3-43b0-889b-e80a08ee6aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:to="loc_us-gaap_PlanNameAxis_7b29c171-13f3-43b0-889b-e80a08ee6aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_98056025-90c8-419f-8e96-96603c54ff08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7b29c171-13f3-43b0-889b-e80a08ee6aae" xlink:to="loc_us-gaap_PlanNameDomain_98056025-90c8-419f-8e96-96603c54ff08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_a1e85bbc-b5c3-42fa-a27f-2bb9c17aa3b1" xlink:href="arvn-20230331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_98056025-90c8-419f-8e96-96603c54ff08" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_a1e85bbc-b5c3-42fa-a27f-2bb9c17aa3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_da2285ef-0785-4063-a6e2-f700e069feea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:to="loc_srt_TitleOfIndividualAxis_da2285ef-0785-4063-a6e2-f700e069feea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28415308-019d-43b7-9719-aea38887cdc9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_da2285ef-0785-4063-a6e2-f700e069feea" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28415308-019d-43b7-9719-aea38887cdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesAndDirectorsMember_3afd0285-cc34-42ef-b3c8-53a97f7e6b9c" xlink:href="arvn-20230331.xsd#arvn_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28415308-019d-43b7-9719-aea38887cdc9" xlink:to="loc_arvn_EmployeesAndDirectorsMember_3afd0285-cc34-42ef-b3c8-53a97f7e6b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_db7f2537-727f-4fad-969e-22eb0732d96e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1cb1d5d-9627-4275-82b3-1d01aea3753f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d1cb1d5d-9627-4275-82b3-1d01aea3753f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_92ee7513-9739-4203-a203-bedbf056864b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_92ee7513-9739-4203-a203-bedbf056864b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_204f9eeb-e551-4178-b4eb-0a099d19feee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_204f9eeb-e551-4178-b4eb-0a099d19feee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9bb4a06f-502d-48a0-85ce-5766d18ee222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9bb4a06f-502d-48a0-85ce-5766d18ee222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3c2edc0-14bc-474e-a463-41db2e2631b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0b2e0887-8c96-463f-8bb4-01266fad0e88" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d3c2edc0-14bc-474e-a463-41db2e2631b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_91295e20-92c7-4144-9778-d49e9c143fde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_91295e20-92c7-4144-9778-d49e9c143fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d60d209-3421-428a-b1c2-aab0c6215013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6d60d209-3421-428a-b1c2-aab0c6215013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4d3e2afa-a34c-4290-8919-166a3222a98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4d3e2afa-a34c-4290-8919-166a3222a98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_53addbe2-d8e6-4f6f-84f7-a948927b4ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_53addbe2-d8e6-4f6f-84f7-a948927b4ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3feb5ef1-b04b-43c6-8a63-128afb2f8692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3feb5ef1-b04b-43c6-8a63-128afb2f8692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3902bc03-cd8f-4549-bcaf-27895749bc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_2d053be0-0018-4e6b-819d-af5676ab2b59" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3902bc03-cd8f-4549-bcaf-27895749bc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_69bd56c0-25ed-48c5-a7a4-e36c92816730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_69bd56c0-25ed-48c5-a7a4-e36c92816730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aa0fdb1a-12ac-420f-9625-ec6e43fa1e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aa0fdb1a-12ac-420f-9625-ec6e43fa1e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e496dfb-be52-4a0d-839c-a3688287e01e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aa0fdb1a-12ac-420f-9625-ec6e43fa1e79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e496dfb-be52-4a0d-839c-a3688287e01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e1fbc61b-6c3e-4939-bad2-b2902a9f63d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_aa0fdb1a-12ac-420f-9625-ec6e43fa1e79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e1fbc61b-6c3e-4939-bad2-b2902a9f63d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract_dad3932a-9608-4174-ac8c-bd7553549210" xlink:href="arvn-20230331.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd10e7fe-143e-4a4c-a3aa-b54500395e79" xlink:to="loc_arvn_AggregateIntrinsicValueAbstract_dad3932a-9608-4174-ac8c-bd7553549210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_47d5c9f2-f5bb-47b6-a05f-ea7fabc0f400" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_dad3932a-9608-4174-ac8c-bd7553549210" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_47d5c9f2-f5bb-47b6-a05f-ea7fabc0f400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7c21b75a-6fdc-47ff-88ad-88b36a5fdc70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_dad3932a-9608-4174-ac8c-bd7553549210" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7c21b75a-6fdc-47ff-88ad-88b36a5fdc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquitySummaryofRestrictedStockGrantActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1de15ad-8429-4594-8a1d-872940fa8321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c1de15ad-8429-4594-8a1d-872940fa8321" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5da69dc2-51d8-493e-872a-1d4aa5a00ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:to="loc_us-gaap_PlanNameAxis_5da69dc2-51d8-493e-872a-1d4aa5a00ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9bdab79d-72be-4674-b76a-8b8933bdde32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5da69dc2-51d8-493e-872a-1d4aa5a00ef4" xlink:to="loc_us-gaap_PlanNameDomain_9bdab79d-72be-4674-b76a-8b8933bdde32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_43745322-dc8c-4acc-a3cd-2104c8175d60" xlink:href="arvn-20230331.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_9bdab79d-72be-4674-b76a-8b8933bdde32" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_43745322-dc8c-4acc-a3cd-2104c8175d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:to="loc_us-gaap_AwardTypeAxis_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9009c00-1761-4c25-87f5-2c5b429e4315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0839cb19-e2e9-40d6-9a6c-f6c90d756b6b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9009c00-1761-4c25-87f5-2c5b429e4315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c2f3dd7b-c098-428f-a655-6eb282c7964b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f9009c00-1761-4c25-87f5-2c5b429e4315" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c2f3dd7b-c098-428f-a655-6eb282c7964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9bbd0234-cd80-43e6-9465-5038937f59b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:to="loc_srt_TitleOfIndividualAxis_9bbd0234-cd80-43e6-9465-5038937f59b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8a129bee-75e2-436c-bb5b-b6b071a9863f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_9bbd0234-cd80-43e6-9465-5038937f59b7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8a129bee-75e2-436c-bb5b-b6b071a9863f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EmployeesMember_ae46ef25-45ff-4287-815b-a7256e7769b0" xlink:href="arvn-20230331.xsd#arvn_EmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8a129bee-75e2-436c-bb5b-b6b071a9863f" xlink:to="loc_arvn_EmployeesMember_ae46ef25-45ff-4287-815b-a7256e7769b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_257ca517-55ab-4395-b2c2-3276808089f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b503fab8-1c30-4f31-a27c-89c0ce31857d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_257ca517-55ab-4395-b2c2-3276808089f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_257ca517-55ab-4395-b2c2-3276808089f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fb69386-8b8e-4f4b-acb3-dc7aaa5190a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7fb69386-8b8e-4f4b-acb3-dc7aaa5190a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e057253f-8d2d-463d-a217-7d888b6c04b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e057253f-8d2d-463d-a217-7d888b6c04b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_736e07dd-4ac2-4f65-a76f-2923d1cfb555" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_736e07dd-4ac2-4f65-a76f-2923d1cfb555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d24237cc-a091-47e0-9789-074c9a87061d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d24237cc-a091-47e0-9789-074c9a87061d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e06d8917-a54b-4964-bd6d-377be21cbdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3a9add07-e111-4798-aa03-e73130880b5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e06d8917-a54b-4964-bd6d-377be21cbdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_257ca517-55ab-4395-b2c2-3276808089f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f3ea5ab2-c0c5-45aa-a8bb-ed15ac7cc0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f3ea5ab2-c0c5-45aa-a8bb-ed15ac7cc0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfd6444c-aad5-4fbd-9bfd-c1ca9af3d5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bfd6444c-aad5-4fbd-9bfd-c1ca9af3d5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0376f82e-b106-413f-93bd-7c2b5ef26339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0376f82e-b106-413f-93bd-7c2b5ef26339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5edaebfd-cd08-43b8-b5fd-f1f8bc3fb962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5edaebfd-cd08-43b8-b5fd-f1f8bc3fb962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19c3c642-1a94-42d3-9326-efcf39a35381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ff44f926-ce46-4231-b673-7be7e4d82d9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_19c3c642-1a94-42d3-9326-efcf39a35381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ce1236fd-e495-43a7-8a31-9a72ae65817f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_611a1096-9475-47a4-be48-75bfdd25f83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce1236fd-e495-43a7-8a31-9a72ae65817f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_611a1096-9475-47a4-be48-75bfdd25f83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8445b61d-fe82-4ffb-8ea7-1bf1f0e1692f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce1236fd-e495-43a7-8a31-9a72ae65817f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8445b61d-fe82-4ffb-8ea7-1bf1f0e1692f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11a8030c-464e-4eb7-964a-ba6bc8403f89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce1236fd-e495-43a7-8a31-9a72ae65817f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11a8030c-464e-4eb7-964a-ba6bc8403f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#NetLossPerShareBasicandDilutedLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f993f293-ca1a-4606-a035-c669e80600dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9e45ea9b-3834-44fb-b35c-049f22b0641e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f993f293-ca1a-4606-a035-c669e80600dc" xlink:to="loc_us-gaap_NetIncomeLoss_9e45ea9b-3834-44fb-b35c-049f22b0641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9ee83bad-d98e-40a0-82d5-bb093d848f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f993f293-ca1a-4606-a035-c669e80600dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9ee83bad-d98e-40a0-82d5-bb093d848f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1c9a4245-1163-4591-b920-d4bd8fa3812d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f993f293-ca1a-4606-a035-c669e80600dc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1c9a4245-1163-4591-b920-d4bd8fa3812d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_29d259d4-dc50-411c-9030-8c07ef155594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f993f293-ca1a-4606-a035-c669e80600dc" xlink:to="loc_us-gaap_EarningsPerShareBasic_29d259d4-dc50-411c-9030-8c07ef155594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_51d223a5-693f-4656-b45d-034ce3ce5136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f993f293-ca1a-4606-a035-c669e80600dc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_51d223a5-693f-4656-b45d-034ce3ce5136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c920acff-f89c-4796-a07e-e446e15cf3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3a0e13de-64f8-45c3-9c81-477010523ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c920acff-f89c-4796-a07e-e446e15cf3e4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3a0e13de-64f8-45c3-9c81-477010523ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3a0e13de-64f8-45c3-9c81-477010523ea1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c20da64-ea05-4681-8d29-b5e76b0981c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7ab9640e-83d4-4bf1-bd91-6f5f87d0cf78" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c20da64-ea05-4681-8d29-b5e76b0981c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0f9fc50c-a1e0-4fb8-a018-22697a40515c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c20da64-ea05-4681-8d29-b5e76b0981c4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0f9fc50c-a1e0-4fb8-a018-22697a40515c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c868a0d4-5474-4f62-98e8-b9a617b77346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3c20da64-ea05-4681-8d29-b5e76b0981c4" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c868a0d4-5474-4f62-98e8-b9a617b77346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_685abd1c-2d34-46c7-a819-9fa6e37f4b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3a0e13de-64f8-45c3-9c81-477010523ea1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_685abd1c-2d34-46c7-a819-9fa6e37f4b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92816f90-ffd2-4141-aaff-0b6f3d3ad9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_685abd1c-2d34-46c7-a819-9fa6e37f4b8a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_92816f90-ffd2-4141-aaff-0b6f3d3ad9ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityMethodInvestmentsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_219aa260-5b3e-4818-90e8-135eff027766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_219aa260-5b3e-4818-90e8-135eff027766" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d46fdcc9-a61a-49f2-96a6-c041787e00ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:to="loc_srt_CounterpartyNameAxis_d46fdcc9-a61a-49f2-96a6-c041787e00ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37c5d58f-6ec2-4372-b533-1bb696d12b5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d46fdcc9-a61a-49f2-96a6-c041787e00ec" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37c5d58f-6ec2-4372-b533-1bb696d12b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_30658bc5-a515-4a99-9980-70caba2df7b4" xlink:href="arvn-20230331.xsd#arvn_BayerCropScienceLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_37c5d58f-6ec2-4372-b533-1bb696d12b5c" xlink:to="loc_arvn_BayerCropScienceLPMember_30658bc5-a515-4a99-9980-70caba2df7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b12f86d-af5c-4abb-a2f1-208275cbc6ae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b12f86d-af5c-4abb-a2f1-208275cbc6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d2fe77db-62f8-4741-8340-c8bb1ec4b1a3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b12f86d-af5c-4abb-a2f1-208275cbc6ae" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d2fe77db-62f8-4741-8340-c8bb1ec4b1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_d5b9cd01-c1e8-478d-8b5f-aa080166d059" xlink:href="arvn-20230331.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d2fe77db-62f8-4741-8340-c8bb1ec4b1a3" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_d5b9cd01-c1e8-478d-8b5f-aa080166d059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1baff7a5-a39a-40be-966e-93e777d87dae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1baff7a5-a39a-40be-966e-93e777d87dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_582cf0c3-4600-4e3e-ba11-96fb915c6cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_1baff7a5-a39a-40be-966e-93e777d87dae" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_582cf0c3-4600-4e3e-ba11-96fb915c6cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_5cd2e447-1245-4025-985e-3ae5e750a0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_582cf0c3-4600-4e3e-ba11-96fb915c6cbb" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember_5cd2e447-1245-4025-985e-3ae5e750a0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_51ece55e-3da0-479c-ba07-3b0bea540535" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8714a786-5ced-44d5-a5e6-352b9e4e6b58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8714a786-5ced-44d5-a5e6-352b9e4e6b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_fb1689bd-0a6a-4be6-b59e-1ec7ee77d99d" xlink:href="arvn-20230331.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_fb1689bd-0a6a-4be6-b59e-1ec7ee77d99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_52ff507d-071c-4f6c-ac53-cb1d102a5b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_ContractWithCustomerLiability_52ff507d-071c-4f6c-ac53-cb1d102a5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a5dc85d1-8e7c-4fa7-aeb2-00555557bde8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_ProfitLoss_a5dc85d1-8e7c-4fa7-aeb2-00555557bde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_64281bb9-9065-48cf-b901-ce378de5c364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_64281bb9-9065-48cf-b901-ce378de5c364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_b039eec8-51c3-49b2-b097-4be65e3e73ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_51e5289c-a252-4cc7-b350-ce2ffabeb397" xlink:to="loc_us-gaap_EquityMethodInvestments_b039eec8-51c3-49b2-b097-4be65e3e73ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_efc3220b-9036-4504-942e-092ad776ea49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_e1e5092c-d033-46ec-8f75-17f7f3ded1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_efc3220b-9036-4504-942e-092ad776ea49" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_e1e5092c-d033-46ec-8f75-17f7f3ded1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_e1e5092c-d033-46ec-8f75-17f7f3ded1bc" xlink:to="loc_srt_RestatementAxis_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_2d1896a4-8b26-4a4b-aabd-0321d546db10" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_6dabbcfb-20e3-4df9-bccc-a16dd55b78ca" xlink:to="loc_srt_RestatementDomain_2d1896a4-8b26-4a4b-aabd-0321d546db10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_1b2c3107-4bbf-43c2-a53d-0ca67ab0140c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2d1896a4-8b26-4a4b-aabd-0321d546db10" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_1b2c3107-4bbf-43c2-a53d-0ca67ab0140c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7b68df19-1eea-4277-84a6-c543d4376a56" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2d1896a4-8b26-4a4b-aabd-0321d546db10" xlink:to="loc_srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_7b68df19-1eea-4277-84a6-c543d4376a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_e1e5092c-d033-46ec-8f75-17f7f3ded1bc" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6768da8e-2a9c-47f1-859b-015cfd8116b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_Revenues_6768da8e-2a9c-47f1-859b-015cfd8116b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e8bc9037-68dc-45b1-a1bf-e076ff304050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_OperatingIncomeLoss_e8bc9037-68dc-45b1-a1bf-e076ff304050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1b43f5f0-e20d-47d2-8d66-3ddad94956d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1b43f5f0-e20d-47d2-8d66-3ddad94956d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7bcc01df-424c-4167-ac55-93e6aae4e08a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_NetIncomeLoss_7bcc01df-424c-4167-ac55-93e6aae4e08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9c9d998e-4856-4095-95b2-94dcc9b5f373" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_EarningsPerShareBasic_9c9d998e-4856-4095-95b2-94dcc9b5f373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_483c790e-ced6-42ff-aa5a-958212515265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_483c790e-ced6-42ff-aa5a-958212515265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c710f58-54c8-4369-81ae-039a1ebadc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_3dec7626-85f2-47a8-8dfc-780316e34bbc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c710f58-54c8-4369-81ae-039a1ebadc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arvn-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e90b114a-1ac0-40b0-b132-d098be093932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:href="arvn-20230331.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e90b114a-1ac0-40b0-b132-d098be093932" xlink:to="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a72df2d0-ff18-4bf2-b5da-0e103747e658" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:to="loc_srt_CounterpartyNameAxis_a72df2d0-ff18-4bf2-b5da-0e103747e658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ccf81f5-3136-43cd-8b88-4fa4d25d2977" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a72df2d0-ff18-4bf2-b5da-0e103747e658" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ccf81f5-3136-43cd-8b88-4fa4d25d2977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FoundationMedicineIncMember_36598e34-b645-404f-a439-bcb86b7aa5d1" xlink:href="arvn-20230331.xsd#arvn_FoundationMedicineIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9ccf81f5-3136-43cd-8b88-4fa4d25d2977" xlink:to="loc_arvn_FoundationMedicineIncMember_36598e34-b645-404f-a439-bcb86b7aa5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d39bd54-6bc7-45c3-9d2c-7a199934a929" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:to="loc_srt_RangeAxis_7d39bd54-6bc7-45c3-9d2c-7a199934a929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9865fb6c-b8dd-47c9-8f4f-cdab45fc4813" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7d39bd54-6bc7-45c3-9d2c-7a199934a929" xlink:to="loc_srt_RangeMember_9865fb6c-b8dd-47c9-8f4f-cdab45fc4813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c96fd3cc-5d99-4696-8b2f-af339c7b0a74" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9865fb6c-b8dd-47c9-8f4f-cdab45fc4813" xlink:to="loc_srt_MaximumMember_c96fd3cc-5d99-4696-8b2f-af339c7b0a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2cc1ad6d-f9ea-4007-a68e-5103379c001a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2cc1ad6d-f9ea-4007-a68e-5103379c001a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85c91002-92d3-4acd-80c8-ac5ced29c826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2cc1ad6d-f9ea-4007-a68e-5103379c001a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85c91002-92d3-4acd-80c8-ac5ced29c826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember_823e6ab1-3a55-475a-a0e0-3a4b2cc5c7d8" xlink:href="arvn-20230331.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_85c91002-92d3-4acd-80c8-ac5ced29c826" xlink:to="loc_arvn_SuccessBasedMilestonePaymentsMember_823e6ab1-3a55-475a-a0e0-3a4b2cc5c7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems_fcb8b272-e4d8-4e25-8c93-00f0afff051f" xlink:href="arvn-20230331.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_a0aa9717-0739-4ee7-9ffc-608267d569fc" xlink:to="loc_arvn_CommitmentsAndContingenciesLineItems_fcb8b272-e4d8-4e25-8c93-00f0afff051f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b5c168b9-5116-4622-a366-825e3c5e8cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_fcb8b272-e4d8-4e25-8c93-00f0afff051f" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_b5c168b9-5116-4622-a366-825e3c5e8cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_31313edf-f2bc-41d9-b19b-b85bdec9f653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_fcb8b272-e4d8-4e25-8c93-00f0afff051f" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_31313edf-f2bc-41d9-b19b-b85bdec9f653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429653792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARVINAS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2566120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Science Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">395 Winchester Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-1456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,398,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001655759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430531824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 130.2<span></span>
</td>
<td class="nump">$ 81.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">993.3<span></span>
</td>
<td class="nump">1,124.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,148.2<span></span>
</td>
<td class="nump">1,240.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,175.8<span></span>
</td>
<td class="nump">1,268.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">66.0<span></span>
</td>
<td class="nump">74.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">214.9<span></span>
</td>
<td class="nump">218.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long term debt</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">282.9<span></span>
</td>
<td class="nump">295.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">378.9<span></span>
</td>
<td class="nump">405.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">664.8<span></span>
</td>
<td class="nump">703.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 53.4 and 53.2 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,047.3)<span></span>
</td>
<td class="num">(965.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,570.8<span></span>
</td>
<td class="nump">1,549.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(12.6)<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">511.0<span></span>
</td>
<td class="nump">564.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,175.8<span></span>
</td>
<td class="nump">$ 1,268.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration contract asset and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434861824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">53.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">53.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430564880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">95.3<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">120.2<span></span>
</td>
<td class="nump">84.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(87.7)<span></span>
</td>
<td class="num">(57.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income taxes and loss from equity method investment</a></td>
<td class="num">(81.2)<span></span>
</td>
<td class="num">(56.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81.9)<span></span>
</td>
<td class="num">$ (63.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">53.3<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">53.3<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81.9)<span></span>
</td>
<td class="num">$ (63.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">6.6<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (75.3)<span></span>
</td>
<td class="num">$ (77.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795425996592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 781.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (682.9)<span></span>
</td>
<td class="nump">$ 1,469.2<span></span>
</td>
<td class="num">$ (4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(63.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(63.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise/ vesting of stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise/ vesting of stock-based compensation</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 723.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(746.3)<span></span>
</td>
<td class="nump">1,488.3<span></span>
</td>
<td class="num">(18.7)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">53.2<span></span>
</td>
<td class="nump">53.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 564.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(965.4)<span></span>
</td>
<td class="nump">1,549.4<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(81.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise/ vesting of stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise/ vesting of stock-based compensation</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">53.4<span></span>
</td>
<td class="nump">53.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 511.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (1,047.3)<span></span>
</td>
<td class="nump">$ 1,570.8<span></span>
</td>
<td class="num">$ (12.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430446864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81.9)<span></span>
</td>
<td class="num">$ (63.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of bond discounts/premiums</a></td>
<td class="num">(3.4)<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss', window );">Loss on sale of marketable securities</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of collaboration contract asset</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">19.9<span></span>
</td>
<td class="nump">16.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(8.8)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(29.9)<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(91.2)<span></span>
</td>
<td class="num">(57.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(175.7)<span></span>
</td>
<td class="num">(263.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">280.3<span></span>
</td>
<td class="nump">273.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromSaleOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">35.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and leasehold improvements</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">138.6<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares', window );">Proceeds from exercise of stock options and issuance of ESPP shares</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">48.9<span></span>
</td>
<td class="num">(46.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">86.8<span></span>
</td>
<td class="nump">112.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">135.7<span></span>
</td>
<td class="nump">66.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, equipment and leasehold improvements unpaid at period end</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromMaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795516692304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its subsidiaries (&#8220;Arvinas&#8221; or the "Company&#8221;) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (&#8220;SEC&#8221;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2022, forming part of Arvinas&#8217; 2022 Annual Report on Form 10-K filed with the SEC on February&#160;23, 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following reclassification has been made to prior period financial information in order to conform with current period presentation: Accounts payable and Accrued expenses have been condensed into Accounts payable and accrued liabilities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed in the Company's 2022 Annual Report on Form 10-K, the Company revised the accounting for its investment in Oerth Bio LLC ("Oerth Bio"). Accordingly, Arvinas recorded an adjustment to the unaudited condensed consolidated financial statements for the three months ended March 31, 2022 that were previously included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. See Note 12,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity Method Investments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further details.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities of approximately $1.1 billion as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434327328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Pronouncements and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Accounting Pronouncements and Significant Accounting Policies</a></td>
<td class="text">Accounting Pronouncements and Significant Accounting Policies<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new accounting standards as issued. As of March&#160;31, 2023, the Company has not identified any new standards that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to the Company&#8217;s significant accounting policies during the three months ended March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the condensed consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434309440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreements</a></td>
<td class="text">Research Collaboration and License Agreements  <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARV-471 Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#8220;Pfizer&#8221;) (the &#8220;ARV-471 Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound ARV-471 (the &#8220;Licensed Products&#8221;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0 million. In addition, the Company is eligible to receive up to an additional $1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9 million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $12.9 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#8220;Bayer Collaboration Agreement&#8221;) setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras ("PROTAC&#174; targeted protein degraders") that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#8217;s technology license. Bayer AG is committed to fund an additional $12.0 million through 2023, all of which was received as of March&#160;31, 2023, including $1.5&#160;million and $3.0&#160;million in the three months ended March&#160;31, 2023 and 2022, respectively. These payments are being recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible to receive up to $197.5&#160;million in development milestone payments and up to $490.0&#160;million in sales-based milestone payments for all designated targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no development or sales-based milestone payments or royalties received through March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#8220;Pfizer Research Collaboration Agreement&#8221;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional $37.5&#160;million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $225.0&#160;million in development milestone payments and up to $550.0&#160;million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the three months ended March&#160;31, 2023 and 2022, the Company received payments totaling $1.0 million and $3.5 million which were included in accounts receivable as of December 31, 2022 and 2021, respectively, for additional targets and services which are being recognized as revenue over the total period of performance. There were no sales-based milestone payments or royalties received through March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genentech Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#8220;Restated Genentech Agreement&#8221;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $44.0&#160;million per target in development milestone payments, $52.5&#160;million in regulatory milestone payments and $60.0&#160;million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances for the three months ended March&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable related to collaborations</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">623.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(31.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">593.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">719.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, the Company recorded cumulative catch-up adjustments from contract modifications totaling $(8.2) million relating to performance obligations which were satisfied in prior periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of March&#160;31, 2023 was $593.8 million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">163.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">200.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">593.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration And License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434195072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text">Marketable Securities and Fair Value Measurements The Company&#8217;s marketable securities consist of corporate bonds and government securities which are adjusted to fair value as of each balance sheet date based on quoted prices, which are considered Level 2 inputs. <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">688.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.4)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">682.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">200.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,005.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">993.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">802.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9.3)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">793.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">205.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,143.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,124.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of accounts receivable and accounts payable and accrued liabilities approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434304656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Leasehold Improvements</a></td>
<td class="text">Property, Equipment and Leasehold Improvements <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation and amortization expense totaled $1.2 million and $1.5 million for the three months ended March&#160;31, 2023 and 2022, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434245168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right-of-Use Assets and Liabilities</a></td>
<td class="text">Right-of-Use Assets and LiabilitiesThe Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the condensed consolidated balance sheets.<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments, which ranges from 3.0% - 4.1%. Lease expense is recognized on a straight-line basis over the lease term. The Company considers options to extend or terminate leases in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Company entered into a lease arrangement, which was amended in August 2022, for approximately 160,000 square feet of laboratory and office space, expected to be occupied in 2025. In connection with the signing of the lease and the related amendment, and at the Company&#8217;s election to increase the landlord&#8217;s contribution to the tenant improvement allowance, the Company initially issued a letter of credit totaling $4.5&#160;million, which was subsequently increased to $5.5 million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash in the consolidated balance sheets. Once occupied, the base rent will range from $7.7 million to $8.8 million annually over a ten-year lease term.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than January 2026. The leases have a weighted average remaining term of 2.1 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2023, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430416688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts Payable and Accrued Liabilities <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430389504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an additional assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an assistance agreement with the State of Connecticut entered into in 2014 under which all the borrowings by the Company were forgiven, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $2.5 million plus liquidated damages of 7.5%. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, interest expense was immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430401600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $300.0 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the common stock registered under the Company's universal shelf registration statement pursuant to one or more &#8220;at-the-market" offerings. During the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March&#160;31, 2023, no shares were issued under this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#8220;2018 ESPP&#8221;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company&#8217;s common stock. The number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of March&#160;31, 2023, 2,495,756 shares remained available for purchase. During the three months ended March&#160;31, 2023 and 2022, the Company issued 23,206 and 5,749 shares of common stock, respectively, of common stock under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Incentive Share Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Fourth Amendment to the Company&#8217;s Incentive Share Plan (the &#8220;Incentive Plan&#8221;) adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the terms of the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTczMw_e1a2df49-e8a5-4fa7-9eb4-8efbc048bb75">one</span> to four years. The Incentive Plan was terminated in September 2018. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#8217;s common stock, 4% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of March&#160;31, 2023, 2,115,004 shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered, or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, the Company recognized compensation expense of $19.9 million and $16.6 million, respectively, related to the issuance of incentive awards, including $0.3 million and $0.1 million, respectively, related to the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there was $97.7 million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately 1.9 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the three months ended March&#160;31, 2023 and 2022 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.6 - 74.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.2 - 76.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6 - 7.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.4% - 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5% - 2.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$30.40 - $36.27</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$64.19 - $78.91</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the Company&#8217;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include stock options granted to employees and directors.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,814,634&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.06&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,470,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(46,982)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,196,239&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exercisable as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,114,735&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value per share of options granted during the three months ended March&#160;31, 2023 was $23.38. The total intrinsic value of options exercised during the three months ended March&#160;31, 2023 was $0.5 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there was $67.9 million of unrecognized stock option compensation expense that is expected to be amortized over a weighted average period of approximately 1.7 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there were 7,743,483 stock options under the 2018 Plan that have vested or are expected to vest.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (RSUs)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include RSUs granted to employees. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">489,216&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.37&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">702,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(81,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,107,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of RSUs vested during the three months ended March&#160;31, 2023 was $2.6 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there was $29.8 million of unrecognized RSU compensation expense that is expected to be amortized over a weighted average period of approximately 2.2 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, there were 916,138 RSUs under the 2018 Plan that have vested or are expected to vest.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434199664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes For the three months ended March&#160;31, 2023, the Company recognized income tax benefit of $0.4 million resulting in an effective tax rate of 0.5%, as compared to income tax expense of $4.5 million resulting in an effective tax rate of (7.9)% in the same period for 2022. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended March&#160;31, 2023 and the Company&#8217;s overall effective tax rate of 0.5% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended March&#160;31, 2022 and the Company&#8217;s overall effective tax rate of (7.9)% was the effect of equity compensation, deferred state income taxes and the valuation allowance recorded against the full amount of its net deferred tax assets.A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a full valuation allowance against the Company&#8217;s net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is based on the Company's historical cumulative losses which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434385008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(81.9)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(63.4)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average number of common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;- basic and diluted</span></div></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.3&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.0&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss per common share </span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">-  basic and diluted</span></div></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.54)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.20)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the three months ended March&#160;31, 2023 and 2022, and, therefore, excluded all stock options and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434191488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments</a></td>
<td class="text">Equity Method Investments<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP (&#8220;Bayer LP&#8221;) formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of 50%. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 46.0% and 47.7% as of March&#160;31, 2023 and 2022, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the preparation of the Company's consolidated financial statements for the yea</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">r ended December 31, 2022, the Company identified a prior period error related to the accounting of its investment in Oerth Bio in 2019. Previously, the Company disclosed that revenue of $24.7&#160;million was deferred and would be recognized if and when Oerth Bio recognized revenue associated with the license. The Company has determined that the consideration received for the amounts associated with the deferred revenue should have been constrained, because at the time Bayer LP had contributed only a portion of its full cash commitment to Oerth Bio, and Bayer LP had the right to all the cash contributed, but not yet spent, upon liquidation of Oerth Bio. The constrained revenue should have been recognized upon both cash being contributed by Bayer LP and the related cash spent by Oerth Bio on research and development activities. As such, for each period presented, the revenue recognized is accompanied by corresponding equity method losses of the same amount. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company ev</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aluated the error</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd determined that the related impact did not materially misstate the previously issued unaudited condensed consoli</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dated financial statements for the three months ended March&#160;31, 2022. Although the Company concluded that the error was not material to its previously issued unaudited condensed consolidated financial statements, the Company has</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined it is appropriate to adjust its previously issued unaudited condensed consolidated financial statements for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to correct</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the error and improve comparability</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in stockholders&#8217; equity.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss of Oerth Bio for the three months ended March&#160;31, 2023 and 2022 totaled $2.4 million</span><span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $4.9 million, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized equity method losses of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March&#160;31, 2023 and 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carrying value of t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he investment was zero.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three months ended March&#160;31, 2023 and 2022 were immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430401600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;The Company's accrual for such matters totaled $7.0&#160;million as of March&#160;31, 2023, primarily related to a contract dispute that is in early stages. Due to the early stage of the dispute, the means of resolution are unknown and could involve contract modification and, or payment of consideration.&#160;An estimate of the possible range of loss associated with the dispute cannot be made at this time and the Company has accrued its best estimate as of March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical and Preclinical Development and Licensing Arrangements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">FMI Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a Master In Vitro Diagnostics Agreement (the "FMI Agreement") with Foundation Medicine, Inc. ("Foundation Medicine") for the development and commercialization of one or more of Foundation Medicine&#8217;s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine may terminate the FMI Agreement with respect to an applicable program, if (a) a reasonably necessary third party license is not secured by Foundation Medicine or if the Company does not consent to payments for such license (b) Foundation Medicine </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain license and other rights and certain obligations of Foundation Medicine survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine and may also be required to pay a termination fee, if applicable.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bavdegalutamide</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the development of FoundationOne&#174; Liquid CDx as a companion diagnostic for use with bavdegalutamide for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low to mid tens of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARV-766</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the development of FoundationOne&#174; Liquid CDx as a companion diagnostic for use with ARV-766 for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low tens of millions of dollars in addition to certain validation fees per sample and related pass-through costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795425432448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Pronouncements and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (&#8220;SEC&#8221;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2022, forming part of Arvinas&#8217; 2022 Annual Report on Form 10-K filed with the SEC on February&#160;23, 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">The following reclassification has been made to prior period financial information in order to conform with current period presentation: Accounts payable and Accrued expenses have been condensed into Accounts payable and accrued liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">The preparation of the Company&#8217;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text">Risks and UncertaintiesThe Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reviews</span><span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new accounting standards as issued. As of March&#160;31, 2023, the Company has not identified any new standards that it believes will have a material impact on the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted CashRestricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434211952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Pronouncements and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the condensed consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the condensed consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434152688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Contract Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances for the three months ended March&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable related to collaborations</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">15.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(15.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">623.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">740.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(31.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(24.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">593.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">719.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Transaction Price Allocated to Performance Obligations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of March&#160;31, 2023 was $593.8 million, which is expected to be recognized in the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">163.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">200.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">90.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">55.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">593.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Collaboration And License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430543824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Summary of Available-for-Sale Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available-for-sale marketable securities measured at fair value on a recurring basis. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">688.8&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.4)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">682.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">206.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">200.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">56.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,005.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(12.8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">993.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Valuation</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Hierarchy</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">802.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9.3)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">793.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">205.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(9.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">196.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">61.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,143.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(19.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,124.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434245168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Equipment and Leasehold Improvements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(17.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(16.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429536144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of March&#160;31, 2023, were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430397808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.3&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">35.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">66.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">74.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434207328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Minimum Future Payments on Long-Term Debt</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.052%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795434878000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during the three months ended March&#160;31, 2023 and 2022 was determined using the Black-Scholes option pricing model with the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.022%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">March 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.6 - 74.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">73.2 - 76.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6 - 7.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.6 - 7.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.4% - 4.2%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5% - 2.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$30.40 - $36.27</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$64.19 - $78.91</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include stock options granted to employees and directors.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, <br/>except weighted average exercise price)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Options </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining Contractual</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Term (Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6,814,634&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.06&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.5&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,470,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(46,982)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(41,416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">63.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Outstanding as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8,196,239&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Exercisable as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4,114,735&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">40.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of Restricted Stock Grant Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include RSUs granted to employees. </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted Average</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Grant Date</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Per</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">489,216&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">51.37&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">702,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(81,223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">43.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cancelled</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(2,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">58.13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unvested RSUs as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1,107,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">41.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795431203120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Loss per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(81.9)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(63.4)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted average number of common shares outstanding</span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;- basic and diluted</span></div></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.3&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">53.0&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss per common share </span><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">-  basic and diluted</span></div></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.54)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.20)</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Securities Excluded From Computation of Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the three months ended March&#160;31, 2023 and 2022, and, therefore, excluded all stock options and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">For the Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795433352144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Correction of the Immaterial Error for the Period</a></td>
<td class="text">The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in stockholders&#8217; equity.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as previously reported</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as adjusted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430416688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details)<br> $ in Billions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities', window );">Cash, cash equivalents, restricted cash and marketable securities</a></td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash and Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430497792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 130.2<span></span>
</td>
<td class="nump">$ 81.3<span></span>
</td>
<td class="nump">$ 62.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 135.7<span></span>
</td>
<td class="nump">$ 86.8<span></span>
</td>
<td class="nump">$ 66.8<span></span>
</td>
<td class="nump">$ 112.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795424181360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="nump">$ 12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Revenue adjustments arising from contract modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">$ 28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory and Sales-Based Milestones | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract', window );">Collaboration agreement direct and incremental costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales-Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales Based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Option Payments To License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Research Funding Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Research Funding Payments | Scenario Forecast | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Development Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Sales Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer Collaboration Agreement | Sales Based Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="nump">$ 34,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement', window );">Additional upfront non-refundable amount received under previous agreement</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Regulatory Milestone Related to Marketing Approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Development Milestone Payments | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech, Inc. and F. Hoffman-La Roche Ltd. | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional upfront non-refundable amount received under previous agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration contract asset and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct and incremental costs incurred to obtain the contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DirectAndIncrementalCostsIncurredToObtainTheContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429737632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Summary of Contract Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts receivable related to collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions', window );">Additions</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived', window );">Payments received</a></td>
<td class="num">(2.5)<span></span>
</td>
<td class="num">(15.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts payable related to collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrent', window );">Beginning balance</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrentAdditions', window );">Additions</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrentPayments', window );">Payments made</a></td>
<td class="num">(5.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrent', window );">Ending balance</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward', window );"><strong>Contract assets: Collaboration contract asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Beginning balance</a></td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CapitalizedContractCostAmortizationDuringPeriod', window );">Amortization</a></td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Ending balance</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities: Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">623.7<span></span>
</td>
<td class="nump">740.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from balances held at the beginning of the period</a></td>
<td class="num">(31.4)<span></span>
</td>
<td class="num">(24.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions to collaboration agreements</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 593.8<span></span>
</td>
<td class="nump">$ 719.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CapitalizedContractCostAmortizationDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CapitalizedContractCostAmortizationDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Payable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Receivable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795424034320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 593.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2023-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 163.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2024-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 200.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2025-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 90.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 55.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2027-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 34.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2028-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 10.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2029-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2029-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 38.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2029-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2029-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429130592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details) - Level 2 - Fair Value, Measurements, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,005.9<span></span>
</td>
<td class="nump">$ 1,143.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(12.8)<span></span>
</td>
<td class="num">(19.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">993.3<span></span>
</td>
<td class="nump">1,124.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate Bonds Maturing 2023-2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">688.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">682.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate Bonds Maturing 2024-2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">206.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">200.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government Securities Maturing 2023-2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">56.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">56.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government Securities Maturing 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">54.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 54.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate Bonds Maturing 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">802.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">793.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate Bonds Maturing 2024-2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government Securities Maturing 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government Securities Maturing 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429762640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">$ 31.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(17.6)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">13.4<span></span>
</td>
<td class="nump">13.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">17.4<span></span>
</td>
<td class="nump">17.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">10.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and leasehold improvements, gross</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430618336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430540240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Additional Information (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Lease for laboratory and office space | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_BaseLeaseRentPeriod', window );">Base rent lease term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Asset Pledged as Collateral</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecurities', window );">Letter of credit for collateralized by certificate of deposit</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments', window );">Percentage of incremental borrowing for lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Base rent</a></td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments', window );">Percentage of incremental borrowing for lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Base rent</a></td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_BaseLeaseRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base lease rent period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_BaseLeaseRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfIncrementalBorrowingForLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of incremental borrowing for lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfIncrementalBorrowingForLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430359856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430585488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract', window );"><strong>Supplemental non-cash information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new lease obligations</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SupplementalNonCashInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795431246512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795426017216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">34.9<span></span>
</td>
<td class="nump">35.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee expenses</a></td>
<td class="nump">7.2<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and other</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="nump">$ 74.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795430540064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current installments</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429260112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument bearing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentLoanForgiveness', window );">Loan forgiveness</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument bearing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentInterestPaymentsTerm', window );">Debt instrument interest payments term (in months)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember', window );">2014 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentInterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payments term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentInterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument loan forgiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfLiquidatedDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of liquidated damages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfLiquidatedDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndFourteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795424057008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_LongTermDebtMaturityYearSix', window );">2028</a></td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_LongTermDebtMaturityYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, Year Six</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_LongTermDebtMaturityYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795423866112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Intrinsic value of options, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Incentive units authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,199,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember', window );">Incentive Plan | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,007<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,115,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase in reserved shares as percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation expense on options not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,743,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber', window );">Restricted stock units vested and expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Annual increase in reserved shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,989,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based award, vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2018 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock', window );">Common stock reserved for issuance represented as percentage on outstanding common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,495,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,206<span></span>
</td>
<td class="nump">5,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">2018 ESPP | Incentive Plan | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common | Equity Distribution Agreement | At-the-Market Offering | Piper Sandler and Cantor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_MaximumAggregateOfferingPriceOfCommonStock', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued and sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_MaximumAggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate offering price of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_MaximumAggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429799648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">72.60%<span></span>
</td>
<td class="nump">73.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">74.20%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 30.40<span></span>
</td>
<td class="nump">$ 64.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 36.27<span></span>
</td>
<td class="nump">$ 78.91<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795426597520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Stock Option Activity (Details) - 2018 Plan - Employees and Directors - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">6,814,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,470,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(46,982)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(41,416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">8,196,239<span></span>
</td>
<td class="nump">6,814,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, ending balance (in shares)</a></td>
<td class="nump">4,114,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 49.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">34.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">17.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">63.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">46.51<span></span>
</td>
<td class="nump">$ 49.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 40.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 19.1<span></span>
</td>
<td class="nump">$ 34.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 18.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429798160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Restricted Stock Grant Activity (Details) - 2018 Plan - Restricted stock units - Employees<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">489,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">702,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(81,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(2,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">1,107,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 51.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">34.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">43.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">58.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 41.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=arvn_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=arvn_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795426387216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">$ (0.4)<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate, percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="num">(7.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429661824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Loss per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81.9)<span></span>
</td>
<td class="num">$ (63.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding, basic (in shares)</a></td>
<td class="nump">53.3<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding, diluted (in shares)</a></td>
<td class="nump">53.3<span></span>
</td>
<td class="nump">53.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795424166848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">9.3<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795424153296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments- Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="nump">$ 593,800,000<span></span>
</td>
<td class="nump">$ 719,400,000<span></span>
</td>
<td class="nump">$ 623,700,000<span></span>
</td>
<td class="nump">$ 740,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember', window );">Equity Method Investment, Nonconsolidated Investee or Group of Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage', window );">Future grant of incentive units to service providers percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember', window );">Bayer LP | Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest in joint venture (percentage)</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">47.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future grant of incentive units to service providers, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795429102912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(87.7)<span></span>
</td>
<td class="num">(57.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (81.9)<span></span>
</td>
<td class="num">$ (63.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.54)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="nump">$ 75.3<span></span>
</td>
<td class="nump">$ 77.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">as previously reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (63.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember', window );">adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139795424134848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 04, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_FoundationMedicineIncMember', window );">Foundation Medicine, Inc. | Maximum | Success-Based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Milestone payments (up to low)</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126928961&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_FoundationMedicineIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_FoundationMedicineIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SuccessBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SuccessBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>arvn-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arvn="http://www.arvinas.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arvn-20230331.xsd" xlink:type="simple"/>
    <context id="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1a2e98f70424438bb4719063e8b7d933_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="i09295186e9a140a3bc02f7ddae9c7af0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia9c824c6990342a0943fa8aa395e6afd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i59fa16591da24cb9adc1d260cd702bec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief60b65dbbed473d990406fe18f4b016_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i423be60354244b2b97bcb6297024fc30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i563f01175e814770b8ddb607671d6584_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ica93aa257210457588a3dab513ca1281_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i70b2b0d2b07c477095aa99f00b3e6c9e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i41eb626a0ca84eb981b494af99468c57_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i91476a3a87b74bfb9daea385c949ed11_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iac513c7ce70543009a9875454577f845_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if47c42e24d824e89abf05132bc64e379_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7ae605f935c04bc2af190e140938586b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i903857c45a8b454f9d0bd288463f9c45_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id6273a26513740c895cd8fe246ea1135_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i228a677a2c5646269e41ad33bcbd8f12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i705af897c9a04f31ab086c30d2b350b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia6df2f2c7c5f476fba8a03b362862a96_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90d558a1de93477b87122ce5cd92cc9f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i472c99b27af24b9b91e801b0d2386fd1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iebe10aedc0da40bca216552454ea7f4a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="icfd52ecfa49241f8aa987e6cc3468342_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iafbcae8733b64e3c9cf754f838374162_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6353ac0a26204afa914428ef8c857213_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id20e86e77f8c48b79f279e320e800292_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iaa1890c1439a43ad896af5dfd768c60b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if4c84844e17f4bfd94a9daafad1c7718_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i42ba466978ac4cc992589866c331756a_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i16fd9a5fa79d4e9eaa80190af360005c_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryAndSalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ief3a7076223347cfbc4892d71334d77b_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i3786932f15544cce9cf0079227cdc57b_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="ibcccbc739c0445b2b27349bd42442433_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic2695362632e4befb50d084f5a874ac1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3ba7e9e46b0c438a8a2acede1d5ac4a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ic50dd3e602a14d7c9a8c73c1b9f0f130_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5482ad9db1e14d4db0c6cbc2489c89aa_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iaf97ed42f0f34c4a8af32817ae8aca05_I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="i64eaa7a6fadd4ef88cc9a1286c396bbc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3f1c7c35f0f643bbb3ac71053516932f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic25e5433c3b74da39b3c37e3b0ee0ce2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie5fab18a22d24d848daaf8e985758c58_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if970016974254601910f92dc80515772_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id250d3ecdba042e2af065ac3f57d8f6b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4b3dfdf46ccd4f02aeacc06bab7ab70d_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i934d8ddc1394497d98263e0baef3dfd8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia0fa77171342487db29bfb9fd0cd234c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i06109f1daf3f44819497e002b80fa05c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie2e16ac4423a4e249adbc8e38cfdd227_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i825cb221649b48da99a61c73b128281b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ibdfdecb591af4d2d9d467b467c44e0d9_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i2e2b79e3ac2541ffa660c65a665640e6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i15ccbabc704747d3912f2887cdca2f5e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3ca6fcbbbc8d453cb429124dadde0a44_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i378f9a67bc7a479fad0da9c643e33fd7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6a57f027039d402e89fbc95c1127d3cb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7e5587709ab9441eb95639b688acbf26_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i333fef30c76849dabbf515e19bb3c4dd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i64e73ce4a2fb4d8ea4d59c53e7967503_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5ba9fc908d7b41deaf9a3fd3e31184cb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6a68588de37d4285a34afb43c82aef31_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic6a4b3cb93314f7080a27916d29a1b7c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2029-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifd2c16269e704252a73fa8151a039fbe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie9a393896693451891e7d053aeeb18be_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2e55fd027b044723af517c59364224f0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i57e3228d892b4e7db62595d4014c6676_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic4888c9b0c614731bbdccc05e61bd058_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1de7a0ae0b92460dad81ea74516f18bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i43b0f02819274e57b2bf846e659c640e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arvn:GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75559e9dfb844d268302204b2976b7f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b2563537aad4601938c78056cfd46bb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i870416186c7946d69aba9f21340eedf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c0acd6e5355425eb14e8f4f51b13bc2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i43c92c58dac14ec68b6636151c731626_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i32031c903a404074b539bf9f44fb8502_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i79f9dcb9a8e74e788892552ed47ce8d1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57728ffde72e4b07b7b3bc9db63630f8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i90241bd38fea438fb4cc4148142c1b17_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if3420f377cc5416b93dcea5b7709551a_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ic584b3416c774aeca2c48f904781e806_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i2a4cff069a1143b88d3a8e8910d7959f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6a4ae741e33e4f4fa646fc2cce479c2d_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i0c9b7a41f6414722ac66b829dfd54b50_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="if6dcdbc12c344074b65cede1612dc7bc_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i2e5965f2e88e4a6da0dccbe7de98fca3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4017a9b524ac448cb97651cbacb79c29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i33ef3273b7a642339a52f317c1217bf0_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i9efa444c10024282a78558891448955e_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="i3aed769f8e3c49e5b63cbed7fce3cc16_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i50005b9bf68d4708a6d599e4e722b8e3_I20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="i4511588e1c85470592130c5c36ee5bfb_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndFourteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i7bf0fb8e4f384b26bc23d6ceb6be7d53_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i6b0bcf64028344e6af483706f401290e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib28dd8ea2b9a41c2971d1c69a31155e1_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="i4a71274815094838ab3c597fb2f26a9a_D20200101-20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="ib9aec8988f694ff0bdcb13df74a26b2b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id759bd76e92c4ede87b28afc4a41b568_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i92f1e3b8a73c406baaa7a7de9b0f3308_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9dc4b7a143d749d3b66e3a8d62fc9739_I20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="i40cf39bc022f4665873ab50b0f55d26f_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i4bbe490912764883b0d0a04c6f91955c_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="id11bdfbfc5664070828281a7fc7b86c7_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="ibd1b3df3c405457383f5264958d864d2_I20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="id5f5df6145fa4e158ed350838e5a7e21_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib1a047b63716450a86e6886de00be9f1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i10eede6b30cc414dbf22a74b29deb8c6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5ca05a3c3aa44683a1997583823075d6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie10a2301e42b4cbb841833dc0c008446_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iabfae107724143078681007be335943e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ibbf44409a8a841bf993b6c95041b34d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ied3d963eb80c4cf0821da8185cb0c1b4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1dc82bdb7f3249e3a8fa6593ba2f1e2f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i349c99c38fd24411a3098e192d5bb289_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i12c09bc9792f4d4d82779a6ecdfd5cd4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia907332b480c40519a54ef9abc49ebf1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id992f35185d74bae9954007b9459fa21_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i34c0d5650542472988dfa8a33538b992_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1f3f89b30e484ddb9d12fd481d56197e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i15fe088644044a698fa4be67f06f4289_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b701e816ca846fca1f71db5b8b65b28_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id05b975a531b4a769c53cd848058ea5a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8313eb035f2049c096523de984254655_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4397b2ab6c394deebbeeccdb3d6ef0f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i398833cc0cbe482ca635f3baea15a579_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">arvn:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib19aa9edf1fe4cdebd33b4a75c81c3a7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie0298f75c6f440a58c57320fb61d4a0a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2256dbf3cc9e4c8aab20a9ac4ed1d1c6_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i11a56379c5434b73ac2a8a2184bf2b26_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ice51fdd252534ce4910cdfd6c31f0453_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i79495c5a256b4d7db64470507e85fdaf_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iec101bcd50d841439204bb45185f462f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia79bc328db4a4707a837e784c470a1b4_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i97cfc9c7c575435c98bd43efeb5fb152_I20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="i1a7e68f89e4c4b938c8c387fb7a06158_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib401d1efe8db4e449e1330c66a20922b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie9edfe32c55049d6b67f5d1ff33010d6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodErrorCorrectionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1dcee608cf2542be9ac23c358b3e4eae_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i50b1538561114837a04b610d8fb7d5df_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7c7ac62b86294b8d8b81d6270bdf4b43_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5b3f861bb3b64d2eb62b4fffd96d22d2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i86e8d060431b44969048abce12f5e513_D20220604-20220604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:FoundationMedicineIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-04</startDate>
            <endDate>2022-06-04</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl8yLTEtMS0xLTY1NDMx_60e4998f-e462-4c41-ac85-f89fd94ef68a">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl8zLTEtMS0xLTY1NDMx_c7a1690b-f606-4131-a00a-a2d563c76681">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl80LTEtMS0xLTY1NDMx_8bb1d878-9b79-40f9-b5d5-a08f9abf0dee">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl81LTEtMS0xLTY1NDMx_ed9240ac-1f8b-4645-aca0-11c8b0b5a7e5">0001655759</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80L2ZyYWc6ZDcyODRhY2Q3NDBlNGQ5NjgyMThiNWY1YjQ1YmM0MjYvdGFibGU6MjkyYmZmMjU1ZDhhNDhkYzk0MmM3NTRmNDJkZWFjMGIvdGFibGVyYW5nZToyOTJiZmYyNTVkOGE0OGRjOTQyYzc1NGY0MmRlYWMwYl82LTEtMS0xLTY1NDMx_f4313031-1aba-4bf5-8a1c-3cb01834f515">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i6a57f027039d402e89fbc95c1127d3cb_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfMS0xLTEtMS02NTQzMQ_c8ba6401-3d4d-4221-bc59-fa120b3f7830">P9M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i7e5587709ab9441eb95639b688acbf26_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfMi0xLTEtMS02NTQzMQ_177be2ae-3cb5-4253-bf61-8b7b4e61e305">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i333fef30c76849dabbf515e19bb3c4dd_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfMy0xLTEtMS02NTQzMQ_2135248f-5fd0-4f2b-a8f4-94e1bde31a5d">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i64e73ce4a2fb4d8ea4d59c53e7967503_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfNC0xLTEtMS02NTQzMQ_d2635b3d-11f0-4a9d-bc8a-e30fe4d6f99f">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i5ba9fc908d7b41deaf9a3fd3e31184cb_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfNS0xLTEtMS02NTQzMQ_04cf2725-d0b0-433f-92e7-4e9a065eaa90">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i6a68588de37d4285a34afb43c82aef31_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfNi0xLTEtMS02NTQzMQ_d1a881c5-7b37-4689-af3c-3e0a861fadb9">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ic6a4b3cb93314f7080a27916d29a1b7c_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80Ni9mcmFnOjM5NTA1NDgyZDEzYjQ1MjhhYjI4NDBiOTg2NWI0NTljL3RhYmxlOmQ2MGQ5ZDZiZGYxZDQ4MWViMzc1OGFmZTk3NzBjMzAxL3RhYmxlcmFuZ2U6ZDYwZDlkNmJkZjFkNDgxZWIzNzU4YWZlOTc3MGMzMDFfNy0xLTEtMS02NTQzMQ_57d237f5-1a2e-43ee-90cd-206505a7ef5d"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i40cf39bc022f4665873ab50b0f55d26f_D20180301-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTczMw_e1a2df49-e8a5-4fa7-9eb4-8efbc048bb75">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQx_779506a3-fdb7-483f-8526-b1b42ba0dee4">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6NzA2OTRkN2ZlMjhkNGU2M2I5OGQ3NTdkMzc1NzkyNDkvdGFibGVyYW5nZTo3MDY5NGQ3ZmUyOGQ0ZTYzYjk4ZDc1N2QzNzU3OTI0OV8wLTAtMS0xLTY1NDMx_969ad9dd-a4c3-457d-b9b3-43f8dbed849c">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMjE_5bc0536c-06fc-4387-be78-c1525d02e89e">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6YmVkZjg0NWUxYjIyNDQ5OWIwNTEzOTI5MzkyY2Y5MTQvdGFibGVyYW5nZTpiZWRmODQ1ZTFiMjI0NDk5YjA1MTM5MjkzOTJjZjkxNF8wLTAtMS0xLTY1NDMx_b1f20ce7-cc3e-4798-a904-45e8169957d0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQ2_6d3a1054-681c-4a5d-9aa1-3bf54b9e114d">001-38672</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQ3_1c45f7ad-61ff-413f-ba34-9b2b4ff85a5c">ARVINAS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8wLTAtMS0xLTY1NDMx_97ec3c7f-9a78-47a5-836d-3ac997123a09">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8wLTEtMS0xLTY1NDMx_1656beb5-ebab-41cf-9f5a-c4ae1fed8b46">47-2566120</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTAtMS0xLTY1NDMxL3RleHRyZWdpb246ODRkOGY4M2YyNTNkNDU5MGFmMDY4ZGM2M2E1YmJkMzhfNQ_1c30830a-0f88-4ce1-994c-cc16c612137c">5 Science Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTAtMS0xLTY1NDMxL3RleHRyZWdpb246ODRkOGY4M2YyNTNkNDU5MGFmMDY4ZGM2M2E1YmJkMzhfOQ_f9fea624-9d1c-4d62-97d6-3b6aa87395f9">395 Winchester Ave</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTAtMS0xLTY1NDMxL3RleHRyZWdpb246ODRkOGY4M2YyNTNkNDU5MGFmMDY4ZGM2M2E1YmJkMzhfMTQ_fff16694-f2b9-4a57-9aea-75250e162c71">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTAtMS0xLTY1NDMxL3RleHRyZWdpb246ODRkOGY4M2YyNTNkNDU5MGFmMDY4ZGM2M2E1YmJkMzhfMTg_3a6ac6fe-dfd0-40d5-9174-ba0f6929d143">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6ZGI2MTVlOTI1NzY2NDlmYzg0MDQwOGY1YmQzOGE1MmUvdGFibGVyYW5nZTpkYjYxNWU5MjU3NjY0OWZjODQwNDA4ZjViZDM4YTUyZV8yLTEtMS0xLTY1NDMx_fccfb1d1-4377-4d09-9a25-026551df5111">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQy_b5c5957c-68c5-4c5d-b534-bdab841fcc3a">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQz_28581221-345d-4e09-9811-d0a976165354">535-1456</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6YTg0ZWQwMTU3ZWQ3NGYzNWI1NmQ2YzI4ZWIwMjJhZTcvdGFibGVyYW5nZTphODRlZDAxNTdlZDc0ZjM1YjU2ZDZjMjhlYjAyMmFlN18xLTAtMS0xLTY1NDMx_f2294647-741c-4f2a-b806-cb9a1a77e003">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6YTg0ZWQwMTU3ZWQ3NGYzNWI1NmQ2YzI4ZWIwMjJhZTcvdGFibGVyYW5nZTphODRlZDAxNTdlZDc0ZjM1YjU2ZDZjMjhlYjAyMmFlN18xLTItMS0xLTY1NDMx_83a3dd50-588c-40f7-bdb2-b8470f743fb2">ARVN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6YTg0ZWQwMTU3ZWQ3NGYzNWI1NmQ2YzI4ZWIwMjJhZTcvdGFibGVyYW5nZTphODRlZDAxNTdlZDc0ZjM1YjU2ZDZjMjhlYjAyMmFlN18xLTQtMS0xLTY1NDMx_08cf07b5-567d-4f23-96f9-29368174409c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTM4_b84ed4de-c45d-45d5-a688-404d1f7cc84b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQ0_8a1e6d0f-f803-4af4-9ee1-f419b9a69fd4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6MzhkMWIyMDRhNzQ5NDg3N2I4OTc4ZDIxNGE1MjU4ZGQvdGFibGVyYW5nZTozOGQxYjIwNGE3NDk0ODc3Yjg5NzhkMjE0YTUyNThkZF8wLTAtMS0xLTY1NDMx_95279753-21ca-4593-ae50-e62dd0f9619f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6MzhkMWIyMDRhNzQ5NDg3N2I4OTc4ZDIxNGE1MjU4ZGQvdGFibGVyYW5nZTozOGQxYjIwNGE3NDk0ODc3Yjg5NzhkMjE0YTUyNThkZF8xLTMtMS0xLTY1NDMx_8c8a2320-d51c-40c2-889b-ef56222ece4e">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGFibGU6MzhkMWIyMDRhNzQ5NDg3N2I4OTc4ZDIxNGE1MjU4ZGQvdGFibGVyYW5nZTozOGQxYjIwNGE3NDk0ODc3Yjg5NzhkMjE0YTUyNThkZF8yLTMtMS0xLTY1NDMx_15abbb80-18ee-408b-90c7-a4aa3b4d309c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMTQw_a0ad9bc6-8280-417f-a15d-ba447ea36740">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1a2e98f70424438bb4719063e8b7d933_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xL2ZyYWc6ZjIzNjUzYTY5YjM0NDYxZWExMjY1ODE5M2I2NmEzNDIvdGV4dHJlZ2lvbjpmMjM2NTNhNjliMzQ0NjFlYTEyNjU4MTkzYjY2YTM0Ml8yMDcw_673775b5-06e0-4fa6-b247-30a48bec24e3"
      unitRef="shares">53398353</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMy0xLTEtMS02NTQzMQ_877283eb-4f51-4e24-833e-f83ec0a1012e"
      unitRef="usd">130200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMy0zLTEtMS02NTQzMQ_8dab89d4-b2b4-4aa3-aeda-6ef18855231b"
      unitRef="usd">81300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNC0xLTEtMS02NTQzMQ_d8656e32-08e1-4af9-b8b0-e78d9dc77d77"
      unitRef="usd">5500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNC0zLTEtMS02NTQzMQ_ef35e20e-936b-4152-a2db-0ab8c6d6b4ad"
      unitRef="usd">5500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNS0xLTEtMS02NTQzMQ_17820d3a-b2c0-4896-b7c7-fcae9d527e83"
      unitRef="usd">993300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNS0zLTEtMS02NTQzMQ_c0f3e895-052a-440b-8f75-28eccfe8c17a"
      unitRef="usd">1124000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNi0xLTEtMS02NTQzMQ_f474be29-d16c-4359-a532-49a31bfcf0fb"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNi0zLTEtMS02NTQzMQ_f4a10be1-2d8e-4954-af4a-2274361f93ef"
      unitRef="usd">1000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNy0xLTEtMS02NTQzMQ_eadb57ef-f710-4075-920d-275e0f56ad4e"
      unitRef="usd">4700000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfNy0zLTEtMS02NTQzMQ_dcc45b3a-ede8-46e8-9227-9a8d836a9c80"
      unitRef="usd">7000000.0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfOC0xLTEtMS02NTQzMQ_05209609-8015-4bda-bd6a-c6a35e637022"
      unitRef="usd">14500000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfOC0zLTEtMS02NTQzMQ_cd5aebf2-d057-480a-bc95-a5b67662d6c5"
      unitRef="usd">21400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfOS0xLTEtMS02NTQzMQ_cf40d57b-ffd3-4475-b891-d219da1cc00b"
      unitRef="usd">1148200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfOS0zLTEtMS02NTQzMQ_2bc41e2b-c927-4303-a55e-0293600e4177"
      unitRef="usd">1240200000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTAtMS0xLTEtNjU0MzE_48da5f7c-8986-470c-b791-50fe8754b2dc"
      unitRef="usd">13400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTAtMy0xLTEtNjU0MzE_6fdc6476-f20d-46b2-a0b7-5756b3cb1738"
      unitRef="usd">13400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTEtMS0xLTEtNjU0MzE_af6a33c8-0b18-44f0-b986-ab4a34358447"
      unitRef="usd">3900000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTEtMy0xLTEtNjU0MzE_cd8a51fb-0711-4b51-88e9-29c421e765ea"
      unitRef="usd">4400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTItMS0xLTEtNjU0MzE_68165a87-39d7-4424-93e6-2b9cc59369e9"
      unitRef="usd">10300000</arvn:CollaborationContractAssetAndOtherAssets>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTItMy0xLTEtNjU0MzE_112757f3-65db-4a3d-91d8-904364c5db87"
      unitRef="usd">10800000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:Assets
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTMtMS0xLTEtNjU0MzE_d4047896-9ef6-4f3a-8b39-055fe8cc4c6f"
      unitRef="usd">1175800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTMtMy0xLTEtNjU0MzE_8cf2b183-c458-4667-8e9f-e68424bf6673"
      unitRef="usd">1268800000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTYtMS0xLTEtNjU0MzE_00e095bc-04fc-4dc7-ad03-e170388f503e"
      unitRef="usd">66000000.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTYtMy0xLTEtNjU0MzE_01db2b8e-5fa3-4a1b-8695-5753522a0d79"
      unitRef="usd">74700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTctMS0xLTEtNjU0MzE_47788eb8-b735-41af-b87f-7f379cf2b5cc"
      unitRef="usd">214900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTctMy0xLTEtNjU0MzE_03097886-85fb-41fc-9574-580bf3b8f1b6"
      unitRef="usd">218600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTgtMS0xLTEtNjk0ODI_4c0dba88-babf-4a0b-8cbc-8bcc6413aeee"
      unitRef="usd">100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTgtMy0xLTEtNjk0ODI_80261507-78e4-4e9e-84a6-97555550c819"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTgtMS0xLTEtNjU0MzE_d9ec2cc3-9c5a-4d78-87d4-ae1e4999c741"
      unitRef="usd">1900000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTgtMy0xLTEtNjU0MzE_410f4b1f-cadd-49dd-810f-739baee9a2a1"
      unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTktMS0xLTEtNjU0MzE_e27c6496-0297-4525-b5ae-f3f575f0baa7"
      unitRef="usd">282900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMTktMy0xLTEtNjU0MzE_3c85b895-6103-4ee8-8045-19a0eb362f8a"
      unitRef="usd">295100000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjAtMS0xLTEtNjU0MzE_c8d19186-fb37-42fe-a6d6-3b53e94d6adf"
      unitRef="usd">378900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjAtMy0xLTEtNjU0MzE_9e00ae31-1f5f-4a61-8ff8-75be0b42383b"
      unitRef="usd">405100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjEtMS0xLTEtNjU0MzE_121cab09-d15e-40d2-a7dc-58cc0639a282"
      unitRef="usd">900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjEtMy0xLTEtNjU0MzE_a9cfcabf-e3c4-4cf5-a610-5ebd14dac48c"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjItMS0xLTEtNjU0MzE_ccbfbfd2-8f5d-4788-9716-7f2f6b8bc5cd"
      unitRef="usd">2100000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjItMy0xLTEtNjU0MzE_95a7cea1-65bb-4ccf-82bf-3172da7f73a1"
      unitRef="usd">2700000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjMtMS0xLTEtNjU0MzE_773e8984-dc90-480e-bd07-4234bfbbdefe"
      unitRef="usd">664800000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjMtMy0xLTEtNjU0MzE_b8f16428-f2e1-4c54-8bf1-970470b210ae"
      unitRef="usd">703900000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjQtMS0xLTEtNjU0MzE_924f6b2a-eb71-4c8b-a573-729b047d154c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjQtMy0xLTEtNjU0MzE_4fc8a865-9060-4d5c-a36d-812a3a4ceab9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl8xOQ_2150cc16-7cc4-4670-bf69-247e8bb4442b"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl8xOQ_5dcdf6ac-d478-4be6-b0b5-61369083e5e4"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl8zMw_541d17f8-7698-4081-9fc6-3cb05b4d9f1e"
      unitRef="shares">53400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl8zMw_7edfd7fd-0410-4d6b-9391-14bf3178b3f4"
      unitRef="shares">53400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl80MA_38921954-8f07-47f8-afcb-3cef7b245e46"
      unitRef="shares">53200000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMC0xLTEtNjU0MzEvdGV4dHJlZ2lvbjowOWFmNDlmYTIxODM0NjEwYmVjNDg5YzhlZGQxZjA4Zl80MA_bf240e75-5a9d-443e-a456-65f1dcbd77c8"
      unitRef="shares">53200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMS0xLTEtNjU0MzE_68a23f39-65a7-459c-bdd3-99efadc50781"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjYtMy0xLTEtNjU0MzE_1a56f271-89e7-47a1-9d6e-448912b06749"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjctMS0xLTEtNjU0MzE_dce59a62-3e30-45e3-8a32-f7eb3a854c36"
      unitRef="usd">-1047300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjctMy0xLTEtNjU0MzE_245dc333-e55f-4390-9190-adcd4cd84029"
      unitRef="usd">-965400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjgtMS0xLTEtNjU0MzE_6a5b13e7-668d-408d-acf1-0be332f7080c"
      unitRef="usd">1570800000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjgtMy0xLTEtNjU0MzE_14197110-d083-4cfe-a549-eda46975b67c"
      unitRef="usd">1549400000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjktMS0xLTEtNjU0MzE_a83bf1c4-8866-4d44-83f2-6ecbf8224c24"
      unitRef="usd">-12600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMjktMy0xLTEtNjU0MzE_84355694-0d1b-4f04-b521-7f117caef06c"
      unitRef="usd">-19200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMzAtMS0xLTEtNjU0MzE_d1ea0594-5f8a-46e1-b0b1-45102bc73bb4"
      unitRef="usd">511000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMzAtMy0xLTEtNjU0MzE_2ee14d63-c92d-44a7-81c0-531538bfb024"
      unitRef="usd">564900000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMzEtMS0xLTEtNjU0MzE_89423683-0c84-4d7f-9939-6511f53fe82a"
      unitRef="usd">1175800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8xOS9mcmFnOjIzNjlkYThjNGJjYjQ5NmVhOTFjMTc5YTM5MzliMzgwL3RhYmxlOjA3MmQyOGFhOWUzNDQ0OGQ4MjAzY2NjYmI1OWQ5Nzg2L3RhYmxlcmFuZ2U6MDcyZDI4YWE5ZTM0NDQ4ZDgyMDNjY2NiYjU5ZDk3ODZfMzEtMy0xLTEtNjU0MzE_a1774470-29b1-4afe-913f-88f790b42ed4"
      unitRef="usd">1268800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMi0xLTEtMS02NTQzMQ_c2ccbc8b-d328-4b33-8376-5a34efbbd298"
      unitRef="usd">32500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMi0zLTEtMS02NTQzMQ_d6a570ef-d7ea-429f-8657-c53ced19dc23"
      unitRef="usd">26500000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNC0xLTEtMS02NTQzMQ_b53697e3-1b81-45bd-9fcd-5b69d08c58f7"
      unitRef="usd">95300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNC0zLTEtMS02NTQzMQ_d3d25cdd-cfff-4cc1-81b5-ba36a7b58d69"
      unitRef="usd">64000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNS0xLTEtMS02NTQzMQ_49f112d7-716e-4b97-8459-7d614cd97410"
      unitRef="usd">24900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNS0zLTEtMS02NTQzMQ_f5916834-497c-435d-9022-f9aaa57aa008"
      unitRef="usd">20200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNi0xLTEtMS02NTQzMQ_8f42c13c-d27a-4944-ab92-4d6bc25c1515"
      unitRef="usd">120200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNi0zLTEtMS02NTQzMQ_af4d6bb3-3bea-40e2-9da0-b55d9dc7deeb"
      unitRef="usd">84200000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNy0xLTEtMS02NTQzMQ_420f9620-6357-4cb6-bc96-12d6593f7927"
      unitRef="usd">-87700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfNy0zLTEtMS02NTQzMQ_b41d2684-fa41-4a55-b5fe-ab2ca9a1a22d"
      unitRef="usd">-57700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfOS0xLTEtMS02NTQzMQ_26cc7420-32b6-434f-8fe1-261f0911de7c"
      unitRef="usd">-1100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfOS0zLTEtMS02NTQzMQ_55ebde09-278d-4805-a8ef-4a141c3a95f6"
      unitRef="usd">-100000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTAtMS0xLTEtNjU0MzE_2270be7e-c314-4dd2-87b7-15242649d74c"
      unitRef="usd">7600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTAtMy0xLTEtNjU0MzE_f0126acc-aae3-44d0-8f36-41d979a12e97"
      unitRef="usd">1200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTItMS0xLTEtNjU0MzE_e7d0f4ef-eb77-4c50-814c-56ef02c848ea"
      unitRef="usd">6500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTItMy0xLTEtNjU0MzE_8c6a1bc3-8e18-4111-93c4-71fcca0a480e"
      unitRef="usd">1100000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTMtMS0xLTEtNjU0MzE_8617980f-1485-4b1a-b2d3-02bb4d29ba81"
      unitRef="usd">-81200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTMtMy0xLTEtNjU0MzE_0f51e303-6a8d-4394-bb06-d899cd8472dc"
      unitRef="usd">-56600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTQtMS0xLTEtNjU0MzE_4fc76848-c502-442b-a20c-b9b4357e127b"
      unitRef="usd">-400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTQtMy0xLTEtNjU0MzE_b4395eb0-031f-47ae-a9a6-c62a2e23743f"
      unitRef="usd">4500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTUtMS0xLTEtNjYxMzc_444fb160-547b-4265-823f-1e0040171278"
      unitRef="usd">-1100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTUtMy0xLTEtNjYxMzc_c2fd0c7a-392c-4188-a282-c107bb985c72"
      unitRef="usd">-2300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTUtMS0xLTEtNjU0MzE_c9c51be3-939a-4e73-8c70-738e3e29539c"
      unitRef="usd">-81900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTUtMy0xLTEtNjU0MzE_3f09a15a-74eb-493f-b4c5-c323e372d68d"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTYtMS0xLTEtNjU0MzE_37bf92ca-1e2f-4b65-91ba-4c3cac97ccdc"
      unitRef="usdPerShare">-1.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTYtMS0xLTEtNjU0MzE_7a60d933-0f8f-4e49-8901-c3bdf2e56e98"
      unitRef="usdPerShare">-1.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTYtMy0xLTEtNjU0MzE_844d245b-1dd7-4c8a-9f9c-6a1752819502"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTYtMy0xLTEtNjU0MzE_8e59b7f1-82a9-422b-b3c6-4993a1a5234d"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTctMS0xLTEtNjU0MzE_38641114-e869-4b1e-9ffa-951c10e9cc24"
      unitRef="shares">53300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTctMS0xLTEtNjU0MzE_52671e94-1e89-4265-8ec2-9a40e34d0713"
      unitRef="shares">53300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTctMy0xLTEtNjU0MzE_7de70be2-79fa-44c5-b984-c599bb83138a"
      unitRef="shares">53000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yMi9mcmFnOjY1ZmI5NTU5NDRhNzQwZGI5YzhiYzAxMzBlYjJkZDM5L3RhYmxlOjZjN2U1MjNlMTJjMzRmODk4OTk3NzE2NWMzMzA0MGYwL3RhYmxlcmFuZ2U6NmM3ZTUyM2UxMmMzNGY4OTg5OTc3MTY1YzMzMDQwZjBfMTctMy0xLTEtNjU0MzE_f2a1906a-f1fb-4e54-96a1-6b9666c4c824"
      unitRef="shares">53000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfMi0xLTEtMS02NTQzMQ_f2e5a155-0690-469d-85f7-21f9bd79fbe0"
      unitRef="usd">-81900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfMi0zLTEtMS02NTQzMQ_943dbb66-c9fe-4203-810a-a180c5042cbf"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfNC0xLTEtMS02NTQzMQ_530d128d-322a-48b2-8030-a2ec5b02a98b"
      unitRef="usd">6600000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfNC0zLTEtMS02NTQzMQ_4bd8e5c4-24d2-4307-9c08-eabd1e0293d9"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfNS0xLTEtMS02NTQzMQ_9144776b-f527-4301-aa64-93c68f53f6c3"
      unitRef="usd">-75300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yNS9mcmFnOmUyYjI0NDE3NDc2NzQ2Zjk5MmZjZDVhMDZlMGE2YzNiL3RhYmxlOjk4ZTMwZDFmZWRiNTQ5Mzg5NmFjNWMwZTMzZTI0N2UyL3RhYmxlcmFuZ2U6OThlMzBkMWZlZGI1NDkzODk2YWM1YzBlMzNlMjQ3ZTJfNS0zLTEtMS02NTQzMQ_59bb7722-3c42-414b-9378-3572387c56b6"
      unitRef="usd">-77500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i59fa16591da24cb9adc1d260cd702bec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi0xLTEtMS02NTQzMQ_2b6a5f12-7de5-41c2-81c4-cb5ab562b865"
      unitRef="shares">53200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i59fa16591da24cb9adc1d260cd702bec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi0zLTEtMS02NTQzMQ_aa079b89-321c-4ccd-ac7a-3da4b40a2f1d"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ief60b65dbbed473d990406fe18f4b016_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi01LTEtMS02NTQzMQ_915bb015-d59b-4faa-b002-0b0d7f1209f8"
      unitRef="usd">-965400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i423be60354244b2b97bcb6297024fc30_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi03LTEtMS02NTQzMQ_8b8934c9-62d6-4e0b-b1ae-c2b750068e36"
      unitRef="usd">1549400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i563f01175e814770b8ddb607671d6584_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi05LTEtMS02NTQzMQ_d382deba-f6d2-4258-bb1e-909ab4a5f203"
      unitRef="usd">-19200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMi0xMS0xLTEtNjU0MzE_2ce01421-9368-4d0b-a5dd-8e2bfc342cf2"
      unitRef="usd">564900000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica93aa257210457588a3dab513ca1281_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMy03LTEtMS02NTQzMQ_3dfb7241-bde6-4bda-99c0-47d755ae58ee"
      unitRef="usd">19900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMy0xMS0xLTEtNjU0MzE_b677487d-b7c6-4af5-82bf-818c5478ad60"
      unitRef="usd">19900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i70b2b0d2b07c477095aa99f00b3e6c9e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNC01LTEtMS02NTQzMQ_efb0dba2-6649-49e2-b402-b4e523f07428"
      unitRef="usd">-81900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNC0xMS0xLTEtNjU0MzE_1eb0e25f-796e-411e-acae-f0cf64bddd79"
      unitRef="usd">-81900000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i41eb626a0ca84eb981b494af99468c57_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNi0xLTEtMS02NTQzMQ_3cb2914f-4677-4984-a54d-feb9c7c12d63"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ica93aa257210457588a3dab513ca1281_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNi03LTEtMS02NTQzMQ_cd17687d-7288-4fd2-9882-4f0f104aaadb"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNi0xMS0xLTEtNjU0MzE_1de04f09-6efa-4ecb-aad4-1a56228c47d3"
      unitRef="usd">1500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i91476a3a87b74bfb9daea385c949ed11_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNy05LTEtMS02NTQzMQ_16524b23-da67-4980-a689-5e3ed3767c44"
      unitRef="usd">6600000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfNy0xMS0xLTEtNjU0MzE_fd831456-1b34-4065-8443-6c380642e8bf"
      unitRef="usd">6600000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iac513c7ce70543009a9875454577f845_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC0xLTEtMS02NTQzMQ_a562015c-0d5d-4521-98d2-42b189fed156"
      unitRef="shares">53400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iac513c7ce70543009a9875454577f845_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC0zLTEtMS02NTQzMQ_643746d7-a209-411f-852b-3908911419ee"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if47c42e24d824e89abf05132bc64e379_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC01LTEtMS02NTQzMQ_2ce0a70b-9960-427d-8a1a-382d794e8ec1"
      unitRef="usd">-1047300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7ae605f935c04bc2af190e140938586b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC03LTEtMS02NTQzMQ_40ef82a0-2a6d-4308-87b7-6fde92b57684"
      unitRef="usd">1570800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i903857c45a8b454f9d0bd288463f9c45_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC05LTEtMS02NTQzMQ_05c5ce48-0409-43e9-a5fd-8bbde71a94aa"
      unitRef="usd">-12600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOC0xMS0xLTEtNjU0MzE_190892ae-7848-4c42-9521-e4cddc061266"
      unitRef="usd">511000000.0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id6273a26513740c895cd8fe246ea1135_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS0xLTEtMS02NTQzMQ_54174ecb-035a-44d5-bda9-6a4c5090ed34"
      unitRef="shares">53000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id6273a26513740c895cd8fe246ea1135_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS0zLTEtMS02NTQzMQ_13499e9d-cb01-4554-ae55-9a285e6c0abd"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i228a677a2c5646269e41ad33bcbd8f12_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS01LTEtMS02NTQzMQ_8dfbbb24-bd76-4f2a-9ba0-900b4361352e"
      unitRef="usd">-682900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i705af897c9a04f31ab086c30d2b350b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS03LTEtMS02NTQzMQ_f46f9d39-9edc-44c3-b4ab-6a46fa115cb3"
      unitRef="usd">1469200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia6df2f2c7c5f476fba8a03b362862a96_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS05LTEtMS02NTQzMQ_059c2a8e-3c5d-44a5-ba12-453f9e59d296"
      unitRef="usd">-4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfOS0xMS0xLTEtNjU0MzE_b6242e5d-3466-4083-88d3-8cbdad02be56"
      unitRef="usd">781700000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i90d558a1de93477b87122ce5cd92cc9f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTAtNy0xLTEtNjU0MzE_6ae79f61-d36a-4e5f-814e-a986ed1189c6"
      unitRef="usd">16600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTAtMTEtMS0xLTY1NDMx_3ad0f883-3509-4246-bd11-2abc7979239e"
      unitRef="usd">16600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i472c99b27af24b9b91e801b0d2386fd1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTEtNS0xLTEtNjU0MzE_0b16d11d-87a6-44eb-8553-bf1b101ef90a"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTEtMTEtMS0xLTY1NDMx_ecac1593-0697-411a-8b5a-25385809bcf2"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iebe10aedc0da40bca216552454ea7f4a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTMtMS0xLTEtNjU0MzE_3894c5f1-577e-4649-aa6d-db071e30bb66"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i90d558a1de93477b87122ce5cd92cc9f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTMtNy0xLTEtNjU0MzE_7bc63ee2-7b4b-490a-8f1e-c0931f9bdbf6"
      unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTMtMTEtMS0xLTY1NDMx_f2d272bc-77af-49e9-a800-c013d3dcd0d1"
      unitRef="usd">2500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="icfd52ecfa49241f8aa987e6cc3468342_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTUtOS0xLTEtNjU0MzE_f0744439-d223-466a-85a4-020400dc44a9"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTUtMTEtMS0xLTY1NDMx_2025d5aa-aa95-4471-b3e9-1ae5cd707b16"
      unitRef="usd">-14100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iafbcae8733b64e3c9cf754f838374162_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtMS0xLTEtNjU0MzE_3809ffc6-8b87-49dd-8a73-f5f4dcab08d5"
      unitRef="shares">53100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iafbcae8733b64e3c9cf754f838374162_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtMy0xLTEtNjU0MzE_04b1d89d-2d4a-4a1d-a2e6-28ea29a8c830"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6353ac0a26204afa914428ef8c857213_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtNS0xLTEtNjU0MzE_0e55cc72-be78-422b-9329-9b3c687f596b"
      unitRef="usd">-746300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id20e86e77f8c48b79f279e320e800292_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtNy0xLTEtNjU0MzE_37faf0b4-9f64-4873-925a-cbfb43feb0b7"
      unitRef="usd">1488300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa1890c1439a43ad896af5dfd768c60b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtOS0xLTEtNjU0MzE_e4c6af69-c2a1-4042-81c9-6bb47e1a765c"
      unitRef="usd">-18700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8yOC9mcmFnOmU2NzFmMTFkZWNiZjQ3OWU5NzAwMDI3NzE3ZjBkZWI0L3RhYmxlOjUxNjBiNDZjZDA3ZTQzY2I4ZDc1MGRiZTdmMDUxNzJlL3RhYmxlcmFuZ2U6NTE2MGI0NmNkMDdlNDNjYjhkNzUwZGJlN2YwNTE3MmVfMTYtMTEtMS0xLTY1NDMx_ab730d97-d5c4-4458-a42d-ab91f23ad327"
      unitRef="usd">723300000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMy0xLTEtMS02NTQzMQ_68244e1a-b535-4b19-99c6-8baa65e009ec"
      unitRef="usd">-81900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMy0zLTEtMS02NTQzMQ_4e77d7e2-2fed-432e-b8ef-d90e665ab87d"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfNS0xLTEtMS02NTQzMQ_72b51db3-849d-4a94-9475-94caaf233443"
      unitRef="usd">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfNS0zLTEtMS02NTQzMQ_1495026d-34ab-446c-94ec-4fdbff5365ef"
      unitRef="usd">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfNi0xLTEtMS02NTQzMQ_ef904022-bf41-4ca9-95bd-f3454298cbef"
      unitRef="usd">3400000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfNi0zLTEtMS02NTQzMQ_5cdc3884-4549-41a7-a3af-4659804d826c"
      unitRef="usd">-3300000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfOC0xLTEtMS02NTQzMQ_3c7b5aaa-5a7e-4845-a132-4d2f19db0af1"
      unitRef="usd">-900000</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleGainLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfOC0zLTEtMS02NTQzMQ_78c6f6df-8c25-4903-b559-42d8c996e3cc"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleGainLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfOS0xLTEtMS02NTQzMQ_eb47902a-7963-4055-9f1e-6d77e6f5779d"
      unitRef="usd">500000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfOS0zLTEtMS02NTQzMQ_731c490b-4311-4214-be0a-6cabe2ddcedc"
      unitRef="usd">600000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTAtMS0xLTEtNjU0MzE_d760f376-8562-4a7d-9cd7-1df3306167e1"
      unitRef="usd">600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTAtMy0xLTEtNjU0MzE_1187a8f4-e359-4e4e-8c97-9adcdd50c1f3"
      unitRef="usd">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTItMS0xLTEtNjU0MzE_c05d3233-449a-40d5-b541-df72016ec49a"
      unitRef="usd">19900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTItMy0xLTEtNjU0MzE_b8a4e7d2-8d33-490f-931b-6817bdf4d39d"
      unitRef="usd">16600000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTQtMS0xLTEtNjU0MzE_56a8e7eb-4b80-45e6-8be1-8a52d065bd9a"
      unitRef="usd">-1000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTQtMy0xLTEtNjU0MzE_fd55c424-8a4c-4b36-9611-005c3c56f755"
      unitRef="usd">-15000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTUtMS0xLTEtNjU0MzE_0e3aa7c2-ac7a-4046-8f39-4cedf5cab172"
      unitRef="usd">-2300000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTUtMy0xLTEtNjU0MzE_0374cd1b-2249-4793-91a5-459b24a4fefd"
      unitRef="usd">-4100000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTYtMS0xLTEtNjU0MzE_48f28beb-0110-4752-a257-84e4c630fbf4"
      unitRef="usd">-6900000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTYtMy0xLTEtNjU0MzE_37903b19-2250-41f4-8563-87d43e5cbeca"
      unitRef="usd">-2300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTgtMS0xLTEtNjU0MzE_87595073-56d1-49ff-aa8a-73dd37de7f79"
      unitRef="usd">-8800000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTgtMy0xLTEtNjU0MzE_0b7256c4-6cf6-4fa9-b051-f0f6d4b1b788"
      unitRef="usd">-15600000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTktMS0xLTEtNjU0MzE_465462da-aba6-4fda-b58d-292cbb8ef93c"
      unitRef="usd">-500000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMTktMy0xLTEtNjU0MzE_47871e22-0124-4667-9de8-a43b06d5ce87"
      unitRef="usd">-600000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjAtMS0xLTEtNjU0MzE_5752b750-93f2-4a0f-9285-997d73df54ae"
      unitRef="usd">-29900000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjAtMy0xLTEtNjU0MzE_5ff50af6-52c6-47b3-9fe7-b2c9b9252bfe"
      unitRef="usd">-21200000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjEtMS0xLTEtNjU0MzE_35b106ec-bb2f-48b0-8253-0ac84c248bed"
      unitRef="usd">-91200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjEtMy0xLTEtNjU0MzE_04000ca1-89a3-46d6-969c-4a898fd4682c"
      unitRef="usd">-57100000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjMtMS0xLTEtNjU0MzE_b8f50e66-d562-4071-ba4f-360df8c85b2b"
      unitRef="usd">175700000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjMtMy0xLTEtNjU0MzE_b86d1f99-e563-4865-aeaa-ee72d61ba77b"
      unitRef="usd">263200000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjQtMS0xLTEtNjU0MzE_bd4e9e4d-5bff-4fc0-833f-b88bd71ad182"
      unitRef="usd">280300000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjQtMy0xLTEtNjU0MzE_73c13831-6001-4e77-bdd0-3cbbcd446137"
      unitRef="usd">273900000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjUtMS0xLTEtNjU0MzE_57a7b457-bc0c-4c60-a591-a2906bc4f321"
      unitRef="usd">35100000</arvn:ProceedsFromSaleOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjUtMy0xLTEtNjU0MzE_87a2d4b2-474d-4a45-bb4e-42da7d4b0514"
      unitRef="usd">0</arvn:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjYtMS0xLTEtNjU0MzE_cec92d52-5c16-41fe-b081-50ea7a024913"
      unitRef="usd">1100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjYtMy0xLTEtNjU0MzE_fd1ebf0c-0f58-4f10-9c0e-b23aa8302d14"
      unitRef="usd">2100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjgtMS0xLTEtNjU0MzE_c4f7676c-4c6f-41bf-a5bb-1e1181aca18c"
      unitRef="usd">138600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMjgtMy0xLTEtNjU0MzE_56cd0015-660b-4a38-a204-737d0ee1afd1"
      unitRef="usd">8600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzItMS0xLTEtNjU0MzE_7a682df4-d686-4f87-ba0c-7751291fd225"
      unitRef="usd">1500000</arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares>
    <arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzItMy0xLTEtNjU0MzE_2d3262ac-fbe0-4f42-8a89-5cab04ad187a"
      unitRef="usd">2500000</arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzMtMS0xLTEtNjU0MzE_3aa6e0f9-4686-43e1-8808-d104f225cc62"
      unitRef="usd">1500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzMtMy0xLTEtNjU0MzE_6c40fb5a-9ec1-4d40-a08e-89d111e1251e"
      unitRef="usd">2500000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzQtMS0xLTEtNjU0MzE_bf97d84a-7c79-40bc-afdb-e13365b48ced"
      unitRef="usd">48900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzQtMy0xLTEtNjU0MzE_446dad33-af0b-447b-8067-b5949a26bb31"
      unitRef="usd">-46000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzUtMS0xLTEtNjU0MzE_4fa2c5dd-61b1-4506-a26c-fe0287ae997c"
      unitRef="usd">86800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzUtMy0xLTEtNjU0MzE_77b40cf3-5030-43fa-866b-d7375709d322"
      unitRef="usd">112800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzYtMS0xLTEtNjU0MzE_d2f75d79-b11f-4848-9f1a-3627adfe5c01"
      unitRef="usd">135700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzYtMy0xLTEtNjU0MzE_6c93af09-5adb-4b26-ac30-448fed11d731"
      unitRef="usd">66800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzgtMS0xLTEtNjU0MzE_bad871c7-702a-4993-8a7d-8f945c9b95bb"
      unitRef="usd">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zMS9mcmFnOjk2NjBmOTFmNGQxNDQ5YzFiNzM4YjI2MWNiMzY0N2E2L3RhYmxlOmFiNDZiZWRkNDk1NzRiNWQ4ZWM4MWE2NTdmMjdkMjBjL3RhYmxlcmFuZ2U6YWI0NmJlZGQ0OTU3NGI1ZDhlYzgxYTY1N2YyN2QyMGNfMzgtMy0xLTEtNjU0MzE_5ff72fcf-5c4e-4605-920a-d480dade211f"
      unitRef="usd">100000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzMg_407cfcf3-8e94-4da9-bd1b-f2db771d234a">Nature of Business and Basis of Presentation&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. and its subsidiaries (&#x201c;Arvinas&#x201d; or the "Company&#x201d;) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#x201c;Exchange Act&#x201d;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (&#x201c;SEC&#x201d;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2022, forming part of Arvinas&#x2019; 2022 Annual Report on Form 10-K filed with the SEC on February&#160;23, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following reclassification has been made to prior period financial information in order to conform with current period presentation: Accounts payable and Accrued expenses have been condensed into Accounts payable and accrued liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed in the Company's 2022 Annual Report on Form 10-K, the Company revised the accounting for its investment in Oerth Bio LLC ("Oerth Bio"). Accordingly, Arvinas recorded an adjustment to the unaudited condensed consolidated financial statements for the three months ended March 31, 2022 that were previously included in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. See Note 12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity Method Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of equity interests, proceeds from collaborations, grant funding and debt financing. The Company had cash, cash equivalents, restricted cash and marketable securities of approximately $1.1 billion as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzMw_d0a8ea24-700c-4808-b092-d5de99d5d9b5">The accompanying unaudited condensed consolidated financial statements include the accounts of Arvinas, Inc. and its subsidiaries. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended (&#x201c;Exchange Act&#x201d;). Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to Securities and Exchange Commission (&#x201c;SEC&#x201d;) rules. In the opinion of management, all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation have been included. The condensed consolidated balance sheet as of December&#160;31, 2022 has been derived from the Company's audited consolidated financial statements as of that date. The financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December&#160;31, 2022, forming part of Arvinas&#x2019; 2022 Annual Report on Form 10-K filed with the SEC on February&#160;23, 2023.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzNA_f28f6187-a5e8-41c0-80b8-3175a9e17266">The following reclassification has been made to prior period financial information in order to conform with current period presentation: Accounts payable and Accrued expenses have been condensed into Accounts payable and accrued liabilities</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzNQ_28f83fff-f19c-473c-a4b6-3d945f075463">The preparation of the Company&#x2019;s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfNDMzNg_19c033e3-e221-47d5-80c3-f8c8178c9383">Risks and UncertaintiesThe Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability.</us-gaap:ConcentrationRiskCreditRisk>
    <arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF8zNy9mcmFnOmFmY2YxNTY2MGVhMTQ2YWI4OGQ2ZWFiYmQ1YmM4ZTcyL3RleHRyZWdpb246YWZjZjE1NjYwZWExNDZhYjg4ZDZlYWJiZDViYzhlNzJfMzU1OA_75aff7f2-c953-4d2c-ac75-56484b0c2ac7"
      unitRef="usd">1100000000</arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMzY5_833e4547-b359-4652-a977-8f60b5be6f0a">Accounting Pronouncements and Significant Accounting Policies&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reviews&lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;new accounting standards as issued. As of March&#160;31, 2023, the Company has not identified any new standards that it believes will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no changes to the Company&#x2019;s significant accounting policies during the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the condensed consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMjc0ODc3OTA3NjA4Ng_2b42784d-22f3-4aa7-a6fc-23aa86411e49">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reviews&lt;/span&gt;&lt;span style="color:#252525;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;new accounting standards as issued. As of March&#160;31, 2023, the Company has not identified any new standards that it believes will have a material impact on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMjc0ODc3OTA3NjA4NQ_8325360e-6eaa-444f-bf66-60ab62049786">Cash, Cash Equivalents and Restricted CashRestricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount as required under the terms of the Company's laboratory and office space lease entered into in May 2021 and amended in August 2022.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMjc0ODc3OTA3NjA4Nw_55681459-8d1c-482f-a302-fd73a1167d42">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the condensed consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RleHRyZWdpb246ZjY1MzE2NjM3YmUxNGIwODllZmIzNzAwN2E3MWFkMjJfMjc0ODc3OTA3NjA4Nw_f396f305-e182-4aa7-9173-ea2c921f84be">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported withing the condensed consolidated balance sheets to the total amounts shown in the consolidated statements of cash flows for the three months ended March&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMi0xLTEtMS02Nzc0Mw_877283eb-4f51-4e24-833e-f83ec0a1012e"
      unitRef="usd">130200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMi0zLTEtMS02Nzc0Mw_f361feb2-c8e0-43f5-b4f1-ec0b7aaa6b80"
      unitRef="usd">62300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMy0xLTEtMS02Nzc0Mw_d8656e32-08e1-4af9-b8b0-e78d9dc77d77"
      unitRef="usd">5500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMy0zLTEtMS02Nzc0Mw_4a3e39d3-657e-48b9-aacb-d50a819f6365"
      unitRef="usd">4500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMy0xLTEtMS02Nzg1Ng_ccb95cf5-d326-4655-aaf3-30fe9b3a7354"
      unitRef="usd">135700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80MC9mcmFnOmY2NTMxNjYzN2JlMTRiMDg5ZWZiMzcwMDdhNzFhZDIyL3RhYmxlOjMzYTFlYzNhY2RlMzQwZDViMDhkZTc0MTFhZGY0MjdjL3RhYmxlcmFuZ2U6MzNhMWVjM2FjZGUzNDBkNWIwOGRlNzQxMWFkZjQyN2NfMy0zLTEtMS02Nzg1Ng_d89ac005-615d-44c2-bfd3-68109e43a18c"
      unitRef="usd">66800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNjI2OA_87ae2d39-673e-41da-9cff-eaee442801a6">Research Collaboration and License Agreements  &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ARV-471 Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2021, the Company entered into a Collaboration Agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;) (the &#x201c;ARV-471 Collaboration Agreement&#x201d;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#x2019;s proprietary compound ARV-471 (the &#x201c;Licensed Products&#x201d;). Under the ARV-471 Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0 million. In addition, the Company is eligible to receive up to an additional $1.4 billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will be the marketing authorization holder in the United States and, subject to marketing approval, book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a direct result of the Company&#x2019;s entry into the ARV-471 Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9 million. In accordance with ASC 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized an asset of $12.9 million in collaboration contract asset and other assets in the condensed consolidated balance sheet at inception of the agreement, which is being amortized as general and administrative expense over the total estimated period of performance under the ARV-471 Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bayer Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the &#x201c;Bayer Collaboration Agreement&#x201d;) setting forth the Company&#x2019;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras ("PROTAC&#xae; targeted protein degraders") that mediate the degradation of target proteins. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#x2019;s technology license. Bayer AG is committed to fund an additional $12.0 million through 2023, all of which was received as of March&#160;31, 2023, including $1.5&#160;million and $3.0&#160;million in the three months ended March&#160;31, 2023 and 2022, respectively. These payments are being recognized over the total estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also eligible to receive up to $197.5&#160;million in development milestone payments and up to $490.0&#160;million in sales-based milestone payments for all designated targets. In addition, the Company is eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which may be subject to reductions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no development or sales-based milestone payments or royalties received through March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pfizer Research Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the &#x201c;Pfizer Research Collaboration Agreement&#x201d;). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#x2019;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized as revenue over the total estimated period of performance. The Company is eligible to receive up to an additional $37.5&#160;million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. The Company is also entitled to receive up to $225.0&#160;million in development milestone payments and up to $550.0&#160;million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. During the three months ended March&#160;31, 2023 and 2022, the Company received payments totaling $1.0 million and $3.5 million which were included in accounts receivable as of December 31, 2022 and 2021, respectively, for additional targets and services which are being recognized as revenue over the total period of performance. There were no sales-based milestone payments or royalties received through March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Genentech Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the &#x201c;Restated Genentech Agreement&#x201d;) with Genentech, Inc. and F. Hoffman-La Roche Ltd. (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Restated Genentech Agreement, the Company received additional upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the performance period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is eligible to receive up to $44.0&#160;million per target in development milestone payments, $52.5&#160;million in regulatory milestone payments and $60.0&#160;million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's contract balances for the three months ended March&#160;31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts payable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;623.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(31.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;593.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;719.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, the Company recorded cumulative catch-up adjustments from contract modifications totaling $(8.2) million relating to performance obligations which were satisfied in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of March&#160;31, 2023 was $593.8 million, which is expected to be recognized in the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;200.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;593.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i42ba466978ac4cc992589866c331756a_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTEw_bbdc86f1-e3ab-4213-9816-59372ad92196"
      unitRef="usd">650000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i16fd9a5fa79d4e9eaa80190af360005c_I20210731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTgy_a5e30585-cbc2-4e08-8217-732320da767b"
      unitRef="usd">1400000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ief3a7076223347cfbc4892d71334d77b_I20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNzI1_e2adbc62-1922-415b-a9fa-eeadd1a3b07e"
      unitRef="usd">400000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i3786932f15544cce9cf0079227cdc57b_I20210731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNzky_49219609-ab78-4eac-80ac-dab7d047b9fd"
      unitRef="usd">1000000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ibcccbc739c0445b2b27349bd42442433_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTQ5NzU1ODIyMzM2_49084bf9-e986-4daf-ad99-c8e3d05986af"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ic2695362632e4befb50d084f5a874ac1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTQ5NzU1ODIyMzM2_da2b1399-11dd-4c1b-9b40-de05dfdf10e3"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <arvn:DirectAndIncrementalCostsIncurredToObtainTheContract
      contextRef="i3ba7e9e46b0c438a8a2acede1d5ac4a7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTg4NQ_79bdb4ad-96b2-4449-9450-a4835a9e58ea"
      unitRef="usd">12900000</arvn:DirectAndIncrementalCostsIncurredToObtainTheContract>
    <arvn:CollaborationContractAssetAndOtherAssets
      contextRef="ic50dd3e602a14d7c9a8c73c1b9f0f130_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTk4NQ_62c41c05-08b4-42bc-b7e4-414638b0231a"
      unitRef="usd">12900000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5482ad9db1e14d4db0c6cbc2489c89aa_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMjczNQ_80558201-65a6-43fb-9b9c-08f84b78c7b5"
      unitRef="usd">17500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="iaf97ed42f0f34c4a8af32817ae8aca05_I20231231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMjg0MA_9d0bdd22-56d6-4b30-9ba8-83a55bbb6262"
      unitRef="usd">12000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i64eaa7a6fadd4ef88cc9a1286c396bbc_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTA5OTUxMTYzNDQzOA_fe4d36b2-185a-4523-9968-ebfc7934dade"
      unitRef="usd">1500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i3f1c7c35f0f643bbb3ac71053516932f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTA5OTUxMTYzNDQ1Mg_254d3aed-de9e-47ae-b886-6260ae999820"
      unitRef="usd">3000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ic25e5433c3b74da39b3c37e3b0ee0ce2_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzA0MA_d0d8c36b-4e45-4b9e-90a8-69641daa4dcf"
      unitRef="usd">197500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie5fab18a22d24d848daaf8e985758c58_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzA4Nw_82dd4013-0913-401a-9c56-f665ad7a7e1f"
      unitRef="usd">490000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="if970016974254601910f92dc80515772_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzM3MA_2ca53062-1495-41f3-a8f3-487fb2c25196"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="id250d3ecdba042e2af065ac3f57d8f6b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzM3MA_abdc24b9-d8bb-4cf1-aaf5-cf695159c1f8"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i4b3dfdf46ccd4f02aeacc06bab7ab70d_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMzgwMw_a376c93d-1984-4418-b35d-e9d319734ef9"
      unitRef="usd">28000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i934d8ddc1394497d98263e0baef3dfd8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDExOQ_83c99100-725c-47a9-ac45-4deaccb4777b"
      unitRef="usd">37500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ia0fa77171342487db29bfb9fd0cd234c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDMwMQ_0447095f-ec1b-485c-8bd7-9d0072241b4a"
      unitRef="usd">225000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i06109f1daf3f44819497e002b80fa05c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDM0OA_a9ca0b2f-6898-4e87-bba9-de7ee5dc2045"
      unitRef="usd">550000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ie2e16ac4423a4e249adbc8e38cfdd227_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDU3Nw_4e0811f4-10f9-4951-b065-9546e43d9ac4"
      unitRef="usd">1000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i825cb221649b48da99a61c73b128281b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTA5OTUxMTYzNDU4Mg_331e8b7f-8e19-44d2-8c65-a3bd68357592"
      unitRef="usd">3500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ic2695362632e4befb50d084f5a874ac1_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNDc4NA_c628cad1-2479-43af-9747-4140ccae9919"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ibdfdecb591af4d2d9d467b467c44e0d9_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTIyMg_40bc0719-eea8-4daf-bd29-be2333bfbd1d"
      unitRef="usd">34500000</us-gaap:ProceedsFromCollaborators>
    <arvn:AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement
      contextRef="ibdfdecb591af4d2d9d467b467c44e0d9_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTI0MQ_c6127e2c-afba-4eba-89ab-f6b424b61e06"
      unitRef="usd">11000000</arvn:AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i2e2b79e3ac2541ffa660c65a665640e6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTcwMQ_ff4d32ab-f04e-442b-b802-93d0a4126487"
      unitRef="usd">44000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i15ccbabc704747d3912f2887cdca2f5e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTc1MA_91be116d-e979-4019-b574-8bfd1aaf2b2b"
      unitRef="usd">52500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i3ca6fcbbbc8d453cb429124dadde0a44_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTc5MA_b4113909-bdb8-4d01-88c5-f2e8852eabb1"
      unitRef="usd">60000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i378f9a67bc7a479fad0da9c643e33fd7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNTg5Ng_a1155e26-308b-4a01-9d34-2dbf36a4bd65"
      unitRef="usd">0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNjI2Ng_dead96cf-fe63-4f40-9921-f0c952762044">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's contract balances for the three months ended March&#160;31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(15.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts payable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;623.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;740.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(31.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;593.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;719.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMi0xLTEtMS02NTQzMQ_d7b8632c-3f01-43f1-8aee-1aed74d3a209"
      unitRef="usd">1000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMi0zLTEtMS02NTQzMQ_723d7635-c976-46ed-9bb5-2927775fa0f4"
      unitRef="usd">15000000.0</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMy0xLTEtMS02NTQzMQ_0a8143d9-ed68-4495-af3c-807874530a1d"
      unitRef="usd">1500000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMy0zLTEtMS02NTQzMQ_0dfb1d19-c0ce-4682-b6e8-0619d9c3fb03"
      unitRef="usd">0</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNC0xLTEtMS02NTQzMQ_0f3d228a-ea4d-4d6e-8b3f-9b0701d50ddb"
      unitRef="usd">2500000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNC0zLTEtMS02NTQzMQ_77b62c77-4755-4c42-8227-e80842ee72f4"
      unitRef="usd">15000000.0</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNS0xLTEtMS02NTQzMQ_cd49eac2-baec-4cea-a686-e8609ce102be"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNS0zLTEtMS02NTQzMQ_6d3ef6d5-86f5-40bd-8cf2-195b36538ff3"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsPayableContractBalancesCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNy0xLTEtMS03MDI4NA_5cb340da-2b81-482e-87d0-17b7e1f7833e"
      unitRef="usd">5000000.0</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrent
      contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNy0zLTEtMS03MDI4NA_c85e8999-680f-4b08-8ef1-b3382811b6c2"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrentAdditions
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOC0xLTEtMS03MDI4NA_855d104b-66a1-4214-98e0-c9f0543b949a"
      unitRef="usd">1700000</arvn:AccountsPayableContractBalancesCurrentAdditions>
    <arvn:AccountsPayableContractBalancesCurrentAdditions
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOC0zLTEtMS03MDI4NA_f37b3188-6ea2-4e44-87e1-f68300823733"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrentAdditions>
    <arvn:AccountsPayableContractBalancesCurrentPayments
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOS0xLTEtMS03MDI4NA_849f9c96-bcac-4c1e-b556-9415758c1100"
      unitRef="usd">5000000.0</arvn:AccountsPayableContractBalancesCurrentPayments>
    <arvn:AccountsPayableContractBalancesCurrentPayments
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOS0zLTEtMS03MDI4NA_90a8bc9b-96f6-4940-8328-f9e7dee4fb7f"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrentPayments>
    <arvn:AccountsPayableContractBalancesCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTAtMS0xLTEtNzAyODQ_f45d9b40-556b-4769-86fc-8db8bc065486"
      unitRef="usd">1700000</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrent
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTAtMy0xLTEtNzAyODQ_80b62da9-4292-4f60-b7d1-f473dded9653"
      unitRef="usd">0</arvn:AccountsPayableContractBalancesCurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNy0xLTEtMS02NTQzMQ_07220e10-24f2-4bae-8366-904c6687813b"
      unitRef="usd">10700000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfNy0zLTEtMS02NTQzMQ_fb6fd04c-dcfb-4d84-8df4-cdd81e16bdb4"
      unitRef="usd">12500000</us-gaap:ContractWithCustomerAssetNet>
    <arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOC0xLTEtMS02NTQzMQ_5b08d817-7ad3-4d4f-b40e-dd1e5f9bdad0"
      unitRef="usd">0</arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOC0zLTEtMS02NTQzMQ_569e517f-bb3f-4b05-8574-c319045a2df8"
      unitRef="usd">0</arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:CapitalizedContractCostAmortizationDuringPeriod
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOS0xLTEtMS02NTQzMQ_232c1c17-ff3f-4d8e-8cd0-5fb0413eac51"
      unitRef="usd">600000</arvn:CapitalizedContractCostAmortizationDuringPeriod>
    <arvn:CapitalizedContractCostAmortizationDuringPeriod
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfOS0zLTEtMS02NTQzMQ_96c625a0-952e-45bf-972d-68d1517cc2a4"
      unitRef="usd">400000</arvn:CapitalizedContractCostAmortizationDuringPeriod>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTAtMS0xLTEtNjU0MzE_95ddd0f5-1d28-4f03-b461-fdcd52913456"
      unitRef="usd">10100000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTAtMy0xLTEtNjU0MzE_c1383052-d9b6-472f-af9c-a698126adb02"
      unitRef="usd">12100000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTItMS0xLTEtNjU0MzE_45ca9049-d3d1-4ced-a759-44888906a052"
      unitRef="usd">623700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTItMy0xLTEtNjU0MzE_16c8c816-90f4-4bd6-ac12-8cdf38e1bba0"
      unitRef="usd">740600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTMtMS0xLTEtNjU0MzE_f29655bc-5726-40be-9817-0020a9da2ed3"
      unitRef="usd">-31400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTMtMy0xLTEtNjU0MzE_83f3b6aa-6d26-45dd-aaf3-b3d323e79c44"
      unitRef="usd">-24200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTQtMS0xLTEtNjU0MzE_2b0020e6-a5bf-4056-ac38-236b6129977f"
      unitRef="usd">1500000</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTQtMy0xLTEtNjU0MzE_9694cc39-1215-40f5-8a52-40dc272ff8f9"
      unitRef="usd">3000000.0</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTUtMS0xLTEtNjU0MzE_1dca20be-aa06-4bc4-817f-e5ebde74d788"
      unitRef="usd">593800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="if4c84844e17f4bfd94a9daafad1c7718_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOmZjYWQzOWZiYzE4NzQzYzA4ZGMwNmFiODUwZTBmODk4L3RhYmxlcmFuZ2U6ZmNhZDM5ZmJjMTg3NDNjMDhkYzA2YWI4NTBlMGY4OThfMTUtMy0xLTEtNjU0MzE_729b6b31-52e0-4589-b092-efa1558e3a12"
      unitRef="usd">719400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfMTA5OTUxMTYzNTM3Nw_3a4e7536-42ee-4bad-bdf4-6aafe0b1127b"
      unitRef="usd">-8200000</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNjI2Nw_5a773027-7d8e-4cb7-b61a-fe5c91c2ebf0">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of March&#160;31, 2023 was $593.8 million, which is expected to be recognized in the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;163.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;200.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;90.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;593.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RleHRyZWdpb246YzBjMjI2YTFmYzQzNDJjNmFiM2U0NTk3Y2I0MGNmMzlfNjIwMQ_6aa1f5bd-f1f6-4ce7-8916-f1c3a9609a3c"
      unitRef="usd">593800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6a57f027039d402e89fbc95c1127d3cb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfMS0xLTEtMS02NTQzMQ_c35a4625-2ae6-4ac6-8485-1eb9f7932be3"
      unitRef="usd">163400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i7e5587709ab9441eb95639b688acbf26_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfMi0xLTEtMS02NTQzMQ_cc63bfa2-8df5-4155-9810-6770631c8bee"
      unitRef="usd">200900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i333fef30c76849dabbf515e19bb3c4dd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfMy0xLTEtMS02NTQzMQ_970b438d-8b64-430f-946d-749542e628ec"
      unitRef="usd">90200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i64e73ce4a2fb4d8ea4d59c53e7967503_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfNC0xLTEtMS02NTQzMQ_adaa2bbf-9a81-4871-b132-6b3a20439fd7"
      unitRef="usd">55300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5ba9fc908d7b41deaf9a3fd3e31184cb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfNS0xLTEtMS02NTQzMQ_5ae15918-c651-4507-a99d-652100b1e5b6"
      unitRef="usd">34700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i6a68588de37d4285a34afb43c82aef31_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfNi0xLTEtMS02NTQzMQ_81c1d0bf-8d84-4a76-9bb1-eb5b29e81c76"
      unitRef="usd">10800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic6a4b3cb93314f7080a27916d29a1b7c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfNy0xLTEtMS02NTQzMQ_76b41d56-9d70-42c6-95c5-fcaa869519db"
      unitRef="usd">38500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80My9mcmFnOmMwYzIyNmExZmM0MzQyYzZhYjNlNDU5N2NiNDBjZjM5L3RhYmxlOjk3YjUyNGMzMTQ0MjRjYzVhNTM2NjNkZjUyMzYyNzY3L3RhYmxlcmFuZ2U6OTdiNTI0YzMxNDQyNGNjNWE1MzY2M2RmNTIzNjI3NjdfOC0xLTEtMS02NTQzMQ_e76b9c7a-85ec-4039-9797-6013f0249a62"
      unitRef="usd">593800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RleHRyZWdpb246MDc0ZDZkYzYyMmY2NDRlZTgxZGUyMzc2M2IxMzVhMDRfNTgz_30172cb2-c04d-485c-8a22-6de0d7b65d69">Marketable Securities and Fair Value Measurements The Company&#x2019;s marketable securities consist of corporate bonds and government securities which are adjusted to fair value as of each balance sheet date based on quoted prices, which are considered Level 2 inputs. &lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities measured at fair value on a recurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;688.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;682.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;206.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,005.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;993.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;793.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(19.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,124.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of accounts receivable and accounts payable and accrued liabilities approximate their &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RleHRyZWdpb246MDc0ZDZkYzYyMmY2NDRlZTgxZGUyMzc2M2IxMzVhMDRfNTg0_00de8ff7-4209-4d53-b4ae-5739d97b6d5a">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available-for-sale marketable securities measured at fair value on a recurring basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;688.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;682.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;206.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;200.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,005.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;993.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;793.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;196.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;61.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(19.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,124.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifd2c16269e704252a73fa8151a039fbe_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMi02LTEtMS02NTQzMQ_f1cd76f2-d5e1-4266-a458-3fbe8949b660"
      unitRef="usd">688800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifd2c16269e704252a73fa8151a039fbe_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMi04LTEtMS02NTQzMQ_7b9c08bd-4c4b-4a92-a00b-2845dd3d68e7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifd2c16269e704252a73fa8151a039fbe_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMi0xMC0xLTEtNjU0MzE_3442a8c5-9444-427f-be64-af04bd4e4b07"
      unitRef="usd">6400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifd2c16269e704252a73fa8151a039fbe_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMi0xMi0xLTEtNjU0MzE_856ee08f-3d6b-4ca1-add6-b3f060febd60"
      unitRef="usd">682400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie9a393896693451891e7d053aeeb18be_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMy02LTEtMS02NTQzMQ_b658b138-f4df-4831-8a58-44ad33c6e766"
      unitRef="usd">206300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie9a393896693451891e7d053aeeb18be_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMy04LTEtMS02NTQzMQ_6bdf8e57-256e-4247-9afa-9df737a0db29"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie9a393896693451891e7d053aeeb18be_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMy0xMC0xLTEtNjU0MzE_ffe495c3-7f85-49d9-a120-e6ec69f88c15"
      unitRef="usd">6000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie9a393896693451891e7d053aeeb18be_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfMy0xMi0xLTEtNjU0MzE_a95f44de-daa7-4283-83aa-2e1bf68199f0"
      unitRef="usd">200400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2e55fd027b044723af517c59364224f0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNC02LTEtMS02NTQzMQ_af1f0ce1-e0a3-42d2-8427-5114c0b32726"
      unitRef="usd">56100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2e55fd027b044723af517c59364224f0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNC04LTEtMS02NTQzMQ_c7028ca5-1b65-4599-8697-40244c547027"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2e55fd027b044723af517c59364224f0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNC0xMC0xLTEtNjU0MzE_aecf3b2c-480d-4bb5-8924-4a3130bc3bbe"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2e55fd027b044723af517c59364224f0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNC0xMi0xLTEtNjU0MzE_b83430d9-78e8-4168-af34-9da31c1a9955"
      unitRef="usd">56000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNS02LTEtMS02NTQzMQ_dd2e1244-b02e-4f94-b4d5-07a1c02d7de3"
      unitRef="usd">54700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNS04LTEtMS02NTQzMQ_74847c9e-768f-40fe-adda-a4e8ef8bea1f"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNS0xMC0xLTEtNjU0MzE_23717a9a-f951-4269-aeed-aaee7683c56b"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i562f5fa9ea854e28ae1979f7fc2b0e1b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNS0xMi0xLTEtNjU0MzE_d8ac0914-515f-4c24-9832-7e7de6c43a0d"
      unitRef="usd">54500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i57e3228d892b4e7db62595d4014c6676_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNi02LTEtMS02NTQzMQ_bc73c7de-5c28-4e89-b460-b2686d0f611d"
      unitRef="usd">1005900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i57e3228d892b4e7db62595d4014c6676_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNi04LTEtMS02NTQzMQ_fec863df-3221-4207-8c68-b118c11f0ba8"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i57e3228d892b4e7db62595d4014c6676_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNi0xMC0xLTEtNjU0MzE_59fdb16d-7917-48db-9ee0-d05506a63209"
      unitRef="usd">12800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57e3228d892b4e7db62595d4014c6676_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOmYwMzhkZTIyNGRjNjQ5OGQ5ZDYwYmEyODg5Zjg2MjcxL3RhYmxlcmFuZ2U6ZjAzOGRlMjI0ZGM2NDk4ZDlkNjBiYTI4ODlmODYyNzFfNi0xMi0xLTEtNjU0MzE_19ebb094-929f-4800-a3c1-6d283eb23dfe"
      unitRef="usd">993300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic4888c9b0c614731bbdccc05e61bd058_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMi02LTEtMS02NTQzMQ_db78cc81-77a9-4272-a4ab-027f27db855c"
      unitRef="usd">802700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic4888c9b0c614731bbdccc05e61bd058_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMi04LTEtMS02NTQzMQ_427eff1b-91df-4190-a63f-5a8303dd68b4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic4888c9b0c614731bbdccc05e61bd058_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMi0xMC0xLTEtNjU0MzE_84bb2117-8a27-4f99-8796-0fc0b1aa45a4"
      unitRef="usd">9300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic4888c9b0c614731bbdccc05e61bd058_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMi0xMi0xLTEtNjU0MzE_cad8ddd7-b1d8-4c2c-8268-889f6f8c0b4a"
      unitRef="usd">793400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1de7a0ae0b92460dad81ea74516f18bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMy02LTEtMS02NTQzMQ_33752c20-bdbe-42cc-9f2f-af9ad6cd324e"
      unitRef="usd">205300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1de7a0ae0b92460dad81ea74516f18bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMy04LTEtMS02NTQzMQ_5dbde017-84c6-4d8c-8fcc-49b39763655b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1de7a0ae0b92460dad81ea74516f18bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMy0xMC0xLTEtNjU0MzE_25339c9a-8bcc-4a0a-a2e7-f3f25e5d0d3e"
      unitRef="usd">9200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1de7a0ae0b92460dad81ea74516f18bd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfMy0xMi0xLTEtNjU0MzE_351a50ef-b9b8-4b96-8a19-c5dd01cb3472"
      unitRef="usd">196100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC02LTEtMS02NzQ2OQ_008e70e5-5087-4235-9989-853e6980a0c5"
      unitRef="usd">61900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC04LTEtMS02Nzg5NA_52463b48-c9d7-48ae-9f2c-494d46938c1f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC0xMC0xLTEtNjc0Njk_c096aef7-07f7-4012-88c1-2b3a2367e2bf"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaee5c6017eb344e5aef26fd2bfd18f72_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC0xMi0xLTEtNjc0Njk_2dea2ced-c22e-4dec-844d-fe0574e31ad4"
      unitRef="usd">61500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i43b0f02819274e57b2bf846e659c640e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC02LTEtMS02NTQzMQ_983cc49b-b92e-4ace-97d8-99e76f851753"
      unitRef="usd">73300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i43b0f02819274e57b2bf846e659c640e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC04LTEtMS02NTQzMQ_872150f8-82b9-4315-850a-5fdd628221da"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i43b0f02819274e57b2bf846e659c640e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC0xMC0xLTEtNjU0MzE_185879ee-d23a-4835-a828-7c12110bbabf"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i43b0f02819274e57b2bf846e659c640e_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNC0xMi0xLTEtNjU0MzE_128fc417-3787-45c5-98f2-cb5d78c1ffe2"
      unitRef="usd">73000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i75559e9dfb844d268302204b2976b7f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNS02LTEtMS02NTQzMQ_083ad3df-f7e5-4d19-93c3-bce2834b52b4"
      unitRef="usd">1143200000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i75559e9dfb844d268302204b2976b7f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNS04LTEtMS02NTQzMQ_ed363f65-9ada-444c-bc94-b84d9d7f426a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i75559e9dfb844d268302204b2976b7f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNS0xMC0xLTEtNjU0MzE_7bd5861f-a552-4a24-97bd-4d016e1e8e7e"
      unitRef="usd">19200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75559e9dfb844d268302204b2976b7f5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF80OS9mcmFnOjA3NGQ2ZGM2MjJmNjQ0ZWU4MWRlMjM3NjNiMTM1YTA0L3RhYmxlOjkyY2VhYTRkNzI4MjQ3ODc5ZjcxNzY2MTljMWZlNThiL3RhYmxlcmFuZ2U6OTJjZWFhNGQ3MjgyNDc4NzlmNzE3NjYxOWMxZmU1OGJfNS0xMi0xLTEtNjU0MzE_f1cbbeed-1d0f-4095-876b-b175cacca2fe"
      unitRef="usd">1124000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RleHRyZWdpb246ZjAxYTY0Mzc4OGJkNDg5MjgwNzIxZTcyNjIzMDUzYzVfMzAz_b58a4b80-9f46-4a1e-830b-c2b3124230c0">Property, Equipment and Leasehold Improvements &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation and amortization expense totaled $1.2 million and $1.5 million for the three months ended March&#160;31, 2023 and 2022, respectively</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RleHRyZWdpb246ZjAxYTY0Mzc4OGJkNDg5MjgwNzIxZTcyNjIzMDUzYzVfMzA0_d4d21279-ae41-4c55-9db3-b00fde5d7882">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;31.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(17.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7b2563537aad4601938c78056cfd46bb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMS0xLTEtMS02NTQzMQ_f15bbdb6-54d0-45d3-adb4-4d2b4fe18f24"
      unitRef="usd">17400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i870416186c7946d69aba9f21340eedf7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMS0zLTEtMS02NTQzMQ_06c4aaea-4981-4140-b138-9ed982fd86dc"
      unitRef="usd">17100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7c0acd6e5355425eb14e8f4f51b13bc2_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMi0xLTEtMS02NTQzMQ_e843ffe8-aaff-4629-a8d4-0957a3bce01f"
      unitRef="usd">11400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i43c92c58dac14ec68b6636151c731626_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMi0zLTEtMS02NTQzMQ_3f31a7ac-5358-4a5a-b105-f5e89a42df3a"
      unitRef="usd">10900000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i32031c903a404074b539bf9f44fb8502_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMy0xLTEtMS02NTQzMQ_f9e9e0f8-43c6-45c7-96e2-73a0c99b0c23"
      unitRef="usd">2200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i79f9dcb9a8e74e788892552ed47ce8d1_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfMy0zLTEtMS02NTQzMQ_72ca8413-8af8-436b-b8b4-d99412953741"
      unitRef="usd">2000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNC0xLTEtMS02NTQzMQ_fc76550f-8aac-4c88-94c8-90ef08c0796e"
      unitRef="usd">31000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNC0zLTEtMS02NTQzMQ_d8082c67-4400-4390-a2d3-99333527b9d3"
      unitRef="usd">30000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNS0xLTEtMS02NTQzMQ_2128eea9-1148-4bb9-a019-c8908e7a7e0c"
      unitRef="usd">17600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNS0zLTEtMS02NTQzMQ_4db5ff5b-25eb-46a6-b986-96c1e2af7cf5"
      unitRef="usd">16600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNi0xLTEtMS02NTQzMQ_e01b6b60-dfd2-47ae-9dc8-ece631620dd0"
      unitRef="usd">13400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RhYmxlOjdmM2E4ZDU5YjBiYTQ5OGNiOTNhZTdlNzhhNGE1ZTg3L3RhYmxlcmFuZ2U6N2YzYThkNTliMGJhNDk4Y2I5M2FlN2U3OGE0YTVlODdfNi0zLTEtMS02NTQzMQ_1ad98752-e70f-4f88-8623-4f197f89ce7d"
      unitRef="usd">13400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RleHRyZWdpb246ZjAxYTY0Mzc4OGJkNDg5MjgwNzIxZTcyNjIzMDUzYzVfMTgw_44b4b0c7-d8b3-4fed-a573-c6b664b3c942"
      unitRef="usd">1200000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81Mi9mcmFnOmYwMWE2NDM3ODhiZDQ4OTI4MDcyMWU3MjYyMzA1M2M1L3RleHRyZWdpb246ZjAxYTY0Mzc4OGJkNDg5MjgwNzIxZTcyNjIzMDUzYzVfMTg3_20b599d3-c8c5-4fe5-b3a8-5d378215a088"
      unitRef="usd">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4OA_ded363b4-a38a-4e99-91a1-690bc0233d16">Right-of-Use Assets and LiabilitiesThe Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the condensed consolidated balance sheets.&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments, which ranges from 3.0% - 4.1%. Lease expense is recognized on a straight-line basis over the lease term. The Company considers options to extend or terminate leases in recognizing ROU assets and lease liabilities when it is reasonably certain that such options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Company entered into a lease arrangement, which was amended in August 2022, for approximately 160,000 square feet of laboratory and office space, expected to be occupied in 2025. In connection with the signing of the lease and the related amendment, and at the Company&#x2019;s election to increase the landlord&#x2019;s contribution to the tenant improvement allowance, the Company initially issued a letter of credit totaling $4.5&#160;million, which was subsequently increased to $5.5 million, collateralized by a certificate of deposit in the same amount, which is presented as restricted cash in the consolidated balance sheets. Once occupied, the base rent will range from $7.7 million to $8.8 million annually over a ten-year lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for its corporate office, laboratories and certain equipment, which expire no later than January 2026. The leases have a weighted average remaining term of 2.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of March&#160;31, 2023, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <arvn:PercentageOfIncrementalBorrowingForLeasePayments
      contextRef="i57728ffde72e4b07b7b3bc9db63630f8_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfODY2_a4c36e98-4602-462b-8c9d-9261370e7f09"
      unitRef="number">0.030</arvn:PercentageOfIncrementalBorrowingForLeasePayments>
    <arvn:PercentageOfIncrementalBorrowingForLeasePayments
      contextRef="i90241bd38fea438fb4cc4148142c1b17_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfODcx_43d53000-8af8-4db9-971d-13cda34ba0f4"
      unitRef="number">0.041</arvn:PercentageOfIncrementalBorrowingForLeasePayments>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="if3420f377cc5416b93dcea5b7709551a_I20210531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTMwNg_4908e6be-3d87-4aaf-ae4e-0627fc8ee151"
      unitRef="sqft">160000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:DebtSecurities
      contextRef="ic584b3416c774aeca2c48f904781e806_I20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTA5OTUxMTYzMDM1MA_24e37a47-a5b8-4ace-97bc-281a44db419d"
      unitRef="usd">4500000</us-gaap:DebtSecurities>
    <us-gaap:DebtSecurities
      contextRef="i2a4cff069a1143b88d3a8e8910d7959f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTU5Ng_abc203f1-beb4-4e37-8fb8-25c7930bedb0"
      unitRef="usd">5500000</us-gaap:DebtSecurities>
    <us-gaap:LeaseCost
      contextRef="i6a4ae741e33e4f4fa646fc2cce479c2d_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTc1Ng_21438633-3982-4eff-a240-65ae551a7549"
      unitRef="usd">7700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0c9b7a41f6414722ac66b829dfd54b50_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTc2Mg_7e023099-4c2b-4c5e-8b34-9df61838ea10"
      unitRef="usd">8800000</us-gaap:LeaseCost>
    <arvn:BaseLeaseRentPeriod
      contextRef="if6dcdbc12c344074b65cede1612dc7bc_D20210501-20210531"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4OQ_cc92f66e-e04a-4c59-9845-e48c829521de">P10Y</arvn:BaseLeaseRentPeriod>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMTk4MA_4dd939fa-6740-4a62-b6b7-3c7416f33a09">P2Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4NQ_c09c6939-24d0-4c88-a5ac-cafa3daaf25c">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOjg2N2Y4ODIyOTQ3YjQ5YjY5ZmU4MWMxMzYzODc0YzFiL3RhYmxlcmFuZ2U6ODY3Zjg4MjI5NDdiNDliNjlmZTgxYzEzNjM4NzRjMWJfMi0xLTEtMS02NTQzMQ_62b066f7-8403-4933-8c53-32795016e947"
      unitRef="usd">500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOjg2N2Y4ODIyOTQ3YjQ5YjY5ZmU4MWMxMzYzODc0YzFiL3RhYmxlcmFuZ2U6ODY3Zjg4MjI5NDdiNDliNjlmZTgxYzEzNjM4NzRjMWJfMi0zLTEtMS02NTQzMQ_8bc405ab-8846-450c-bae5-a7c13d030de8"
      unitRef="usd">600000</us-gaap:OperatingLeaseCost>
    <arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4Ng_965f2ce9-b2d9-4fb0-b2b5-c9eeec981313">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmJkMTgwZDA5YmEwYTQwNGFiOWY3YWI5NjI1NDZhMWI5L3RhYmxlcmFuZ2U6YmQxODBkMDliYTBhNDA0YWI5ZjdhYjk2MjU0NmExYjlfMy0xLTEtMS02NTQzMQ_47f24a94-4214-4a15-a028-ac47c1130488"
      unitRef="usd">500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmJkMTgwZDA5YmEwYTQwNGFiOWY3YWI5NjI1NDZhMWI5L3RhYmxlcmFuZ2U6YmQxODBkMDliYTBhNDA0YWI5ZjdhYjk2MjU0NmExYjlfMy0zLTEtMS02NTQzMQ_96e05af7-b486-4059-a08f-ee788aa6dc54"
      unitRef="usd">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmJkMTgwZDA5YmEwYTQwNGFiOWY3YWI5NjI1NDZhMWI5L3RhYmxlcmFuZ2U6YmQxODBkMDliYTBhNDA0YWI5ZjdhYjk2MjU0NmExYjlfNS0xLTEtMS02NTQzMQ_ad25a848-33ff-4d36-93b9-bbf94956c3d8"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmJkMTgwZDA5YmEwYTQwNGFiOWY3YWI5NjI1NDZhMWI5L3RhYmxlcmFuZ2U6YmQxODBkMDliYTBhNDA0YWI5ZjdhYjk2MjU0NmExYjlfNS0zLTEtMS02NTQzMQ_f636b2ce-bc79-4e5f-a59f-a735c927a351"
      unitRef="usd">2400000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RleHRyZWdpb246MzY2OGE5OGIwYTJhNGY3MzllYzJhYzFkNDQ0OTE4ZGRfMjE4Nw_dab988f3-1613-4786-a2ad-d6d7c7fce80a">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of March&#160;31, 2023, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfMS0xLTEtMS02NTQzMQ_2675e33a-fc0b-431b-99b5-5c095348975c"
      unitRef="usd">1500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfMi0xLTEtMS02NTQzMQ_611086d2-c2e2-4dec-829d-78e46a1370bb"
      unitRef="usd">2200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfMy0xLTEtMS02NTQzMQ_0d224203-c192-4ef0-af17-8f42cd29a452"
      unitRef="usd">500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfNC0xLTEtMS02NTQzMQ_1b45314f-1d05-49a0-9feb-0a7779ccfce3"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfOC0xLTEtMS02NTQzMQ_fa7cdd3e-91a8-4785-b78b-a15ba9675774"
      unitRef="usd">4200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfOS0xLTEtMS02NTQzMQ_d88fe2a8-166b-4ed4-beee-f83a28921b9d"
      unitRef="usd">200000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF81NS9mcmFnOjM2NjhhOThiMGEyYTRmNzM5ZWMyYWMxZDQ0NDkxOGRkL3RhYmxlOmE4NjBmZDNlN2E5YzQ5YzI4YWE1ZTExYmNmMjI3ZTJmL3RhYmxlcmFuZ2U6YTg2MGZkM2U3YTljNDljMjhhYTVlMTFiY2YyMjdlMmZfMTAtMS0xLTEtNjU0MzE_dae3711b-9188-468f-9b8b-07c6ee002585"
      unitRef="usd">4000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RleHRyZWdpb246MmYwODIxZmUyMTliNDQ3M2EyZWRhMTYyYmRjYWVkYjJfMTIw_669ea728-8974-4449-9057-61f30e570654">Accounts Payable and Accrued Liabilities &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RleHRyZWdpb246MmYwODIxZmUyMTliNDQ3M2EyZWRhMTYyYmRjYWVkYjJfMTE5_5180df01-b42f-4567-9277-1d3c5f927633">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;35.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;66.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;74.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfMS0xLTEtMS02NTQzMQ_103ee4fb-ccbc-428b-8b8c-cb82e76df6be"
      unitRef="usd">12300000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfMS0zLTEtMS02NTQzMQ_876892b0-97df-4d6a-82b4-676ef77e6102"
      unitRef="usd">5700000</us-gaap:AccountsPayableCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfMy0xLTEtMS02NTQzMQ_fb8d5830-e843-4619-a1c9-0c8ef6017c7d"
      unitRef="usd">34900000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfMy0zLTEtMS02NTQzMQ_2a268752-30d3-4223-8953-e9468af81986"
      unitRef="usd">35900000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0xLTEtMS03MjY4OA_b83fe317-5724-4480-9f45-13e575e7ac67"
      unitRef="usd">10100000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0zLTEtMS03MjY4OA_899085b7-459b-4aa7-9b17-eec68f76bf0e"
      unitRef="usd">10300000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0xLTEtMS03MjY3Mw_89b60071-e58a-417d-bb39-544189dc2e18"
      unitRef="usd">7200000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0zLTEtMS03MjY3Mw_25b05abd-7e1e-4b5f-acc8-be585c8b6953"
      unitRef="usd">18700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0xLTEtMS02ODQxOQ_709ef257-175f-46f4-9bee-7cd91d6e0780"
      unitRef="usd">1500000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNC0zLTEtMS02ODQxOQ_10c549b7-d1a4-4cbb-8dc7-2e1fdbb413ee"
      unitRef="usd">4100000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNy0xLTEtMS02NTQzMQ_cb0e01b7-b68a-4949-82ef-230984f410a3"
      unitRef="usd">66000000.0</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82MS9mcmFnOjJmMDgyMWZlMjE5YjQ0NzNhMmVkYTE2MmJkY2FlZGIyL3RhYmxlOmUwMjJhZGZkMjQxNzQ3ZTRiMzUwMmI3ZjFkYWY3NDRjL3RhYmxlcmFuZ2U6ZTAyMmFkZmQyNDE3NDdlNGIzNTAyYjdmMWRhZjc0NGNfNy0zLTEtMS02NTQzMQ_4171c662-5aa6-4065-8367-816cc7674b90"
      unitRef="usd">74700000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMTM5Mg_a3b7e6a0-c29d-49fc-8586-da4529c87263">Long-Term Debt&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2018 Assistance Agreement Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: current installments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into an additional assistance agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. The Company borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028, with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with an assistance agreement with the State of Connecticut entered into in 2014 under which all the borrowings by the Company were forgiven, the Company is required to be located in the State of Connecticut through January 2024, with a default penalty of repayment of the full original funding amount of $2.5 million plus liquidated damages of 7.5%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, interest expense was immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMjc0ODc3OTA3MTA0Mw_d819ebfe-dcdf-49b5-b137-ba31c15f2edc">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.475%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2018 Assistance Agreement Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: current installments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2e5965f2e88e4a6da0dccbe7de98fca3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMS0zLTEtMS02ODIyMQ_eae5ea4b-d1dc-4b6b-b5ff-797a015a3397"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i2e5965f2e88e4a6da0dccbe7de98fca3_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMS01LTEtMS02ODIzNQ_faf885fe-1a00-4099-82fa-8335b6cb9996"
      unitRef="usd">1000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i4017a9b524ac448cb97651cbacb79c29_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMS03LTEtMS02ODIzNQ_7242be6e-1351-4569-b451-35b1c9e762d0"
      unitRef="usd">1000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMi01LTEtMS02ODMyNw_48688e16-8084-4477-bbb7-fb06f3c376b9"
      unitRef="usd">100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMi03LTEtMS02ODMyNw_f55eb59d-24b3-4f1d-855d-64661b14ad4f"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMy01LTEtMS02ODMyNw_36795747-cc1e-4235-8d30-46c02f34d994"
      unitRef="usd">900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia9c824c6990342a0943fa8aa395e6afd_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOjVmNGU4NTA2ODczMDQ1OGE4YjRmMTU5Nzk1M2Q2MzFjL3RhYmxlcmFuZ2U6NWY0ZTg1MDY4NzMwNDU4YThiNGYxNTk3OTUzZDYzMWNfMy03LTEtMS02ODMyNw_2200554b-11c1-448c-bb75-69908880417e"
      unitRef="usd">1000000.0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i33ef3273b7a642339a52f317c1217bf0_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMjY2_5685d212-c8c7-4a0a-b680-77df244bfa34"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:DebtInstrumentLoanForgiveness
      contextRef="i9efa444c10024282a78558891448955e_D20180901-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMzMz_d50e726b-c121-49ef-8813-53fb8a1fa967"
      unitRef="usd">1000000</arvn:DebtInstrumentLoanForgiveness>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i33ef3273b7a642339a52f317c1217bf0_I20180630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNDQ5_31f8baf4-0593-41e8-92d7-9492556460c1"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arvn:DebtInstrumentInterestPaymentsTerm
      contextRef="i9efa444c10024282a78558891448955e_D20180901-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNTE0_134675d1-d40c-4b72-9ec1-7126e935f627">P60M</arvn:DebtInstrumentInterestPaymentsTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3aed769f8e3c49e5b63cbed7fce3cc16_I20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNzMy_e9fc7885-5ee2-43ea-9631-022f281adf29"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="i9efa444c10024282a78558891448955e_D20180901-20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNzYy_ae9d9de9-b7b5-412b-8d88-6a029c86c7bd"
      unitRef="number">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i50005b9bf68d4708a6d599e4e722b8e3_I20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMTE5NA_56ee54f5-0635-45f7-b2d8-62c09c3f8030"
      unitRef="usd">2500000</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="i4511588e1c85470592130c5c36ee5bfb_D20140101-20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMTIyNA_11f01b9e-68ca-4aad-95ad-ed7cc6506ff4"
      unitRef="number">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfMTM5Mw_d83d4d56-59c0-42a8-9531-5b477505d440">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt for the years ending December&#160;31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:83.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfMS0xLTEtMS02NTQzMQ_c7cf9f2d-c833-4cc8-a8d1-a77d3691fd89"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfMi0xLTEtMS02NTQzMQ_33d0c7d3-2903-4d17-859c-85028c126ee3"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfMy0xLTEtMS02NTQzMQ_8c5f25c2-347f-4939-bedf-9320772cf1af"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfNC0xLTEtMS02NTQzMQ_9b3a3c41-fb3a-410e-9781-8d01c8f119a5"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfNS0xLTEtMS02NTQzMQ_c0dbf468-b5cb-48a9-b31e-185b026eea29"
      unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <arvn:LongTermDebtMaturityYearSix
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfNi0xLTEtMS02NTQzMQ_406ac45e-1b8b-4c3a-906c-f019a51c28d3"
      unitRef="usd">200000</arvn:LongTermDebtMaturityYearSix>
    <us-gaap:LongTermDebt
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RhYmxlOmRkZmFjMWQ4OTVkNTQxNjhhMWY5ZDFmMTY2OWRhOThiL3RhYmxlcmFuZ2U6ZGRmYWMxZDg5NWQ1NDE2OGExZjlkMWYxNjY5ZGE5OGJfNy0xLTEtMS02NTQzMQ_b22a0d83-e355-4642-b815-d5aa586b3776"
      unitRef="usd">1000000.0</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNTQ5NzU1ODE1Mjgy_c3849ffd-e7df-49cc-b65e-43c34605495f"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82NC9mcmFnOjcyZjhhNDQyZTNlZTQ3ZDU5MjNhZDE2NzgzNmYwN2ZjL3RleHRyZWdpb246NzJmOGE0NDJlM2VlNDdkNTkyM2FkMTY3ODM2ZjA3ZmNfNTQ5NzU1ODE1Mjgy_dc750cea-8b99-4443-8bb8-bfe0eb276556"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTMzNw_845a243b-a6ac-48d7-809b-a9c5eb809b77">Equity&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Distribution Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp;amp; Company (&#x201c;Piper Sandler&#x201d;) and Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $300.0 million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the common stock registered under the Company's universal shelf registration statement pursuant to one or more &#x201c;at-the-market" offerings. During the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; March&#160;31, 2023, no shares were issued under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the &#x201c;2018 ESPP&#x201d;), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company&#x2019;s common stock. The number of shares of the Company&#x2019;s common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#x2019;s then-outstanding common stock, effective as of January 1 of each year. As of March&#160;31, 2023, 2,495,756 shares remained available for purchase. During the three months ended March&#160;31, 2023 and 2022, the Company issued 23,206 and 5,749 shares of common stock, respectively, of common stock under the 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Incentive Share Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Fourth Amendment to the Company&#x2019;s Incentive Share Plan (the &#x201c;Incentive Plan&#x201d;) adopted in March 2018, the Company was authorized to issue up to an aggregate of 6,199,477 incentive units pursuant to the terms of the Incentive Plan. Generally, incentive units were granted at no less than fair value as determined by the board of managers and had vesting periods ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTczMw_e1a2df49-e8a5-4fa7-9eb4-8efbc048bb75"&gt;one&lt;/span&gt; to four years. The Incentive Plan was terminated in September 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2018 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s stockholders approved, the 2018 Stock Incentive Plan (the &#x201c;2018 Plan&#x201d;), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#x2019;s initial public offering. The number of shares of common stock initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each fiscal year beginning with the fiscal year ended December 31, 2019 and continuing to, and including, the fiscal year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#x2019;s common stock, 4% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of the year or an amount determined by the Company&#x2019;s board of directors. As of March&#160;31, 2023, 2,115,004 shares remained available for issuance under the 2018 Plan. Shares of common stock subject to outstanding equity awards that expire or are terminated, surrendered, or canceled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, the Company recognized compensation expense of $19.9 million and $16.6 million, respectively, related to the issuance of incentive awards, including $0.3 million and $0.1 million, respectively, related to the 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, there was $97.7 million of total unrecognized compensation expense that is expected to be amortized over a weighted average period of approximately 1.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during the three months ended March&#160;31, 2023 and 2022 was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.6 - 74.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.2 - 76.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.6 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.6 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.4% - 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5% - 2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$30.40 - $36.27&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$64.19 - $78.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given the Company&#x2019;s common stock has not been trading for a sufficient period of time, the Company calculates volatility of its common stock by utilizing a weighted average of a collection of peer company volatilities and its own common stock volatility. The expected term is calculated utilizing the simplified method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include stock options granted to employees and directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,814,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,470,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(46,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(41,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,196,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Exercisable as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,114,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value per share of options granted during the three months ended March&#160;31, 2023 was $23.38. The total intrinsic value of options exercised during the three months ended March&#160;31, 2023 was $0.5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, there was $67.9 million of unrecognized stock option compensation expense that is expected to be amortized over a weighted average period of approximately 1.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, there were 7,743,483 stock options under the 2018 Plan that have vested or are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include RSUs granted to employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested RSUs as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;489,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;702,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(81,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested RSUs as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,107,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of RSUs vested during the three months ended March&#160;31, 2023 was $2.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, there was $29.8 million of unrecognized RSU compensation expense that is expected to be amortized over a weighted average period of approximately 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, there were 916,138 RSUs under the 2018 Plan that have vested or are expected to vest.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <arvn:MaximumAggregateOfferingPriceOfCommonStock
      contextRef="i7bf0fb8e4f384b26bc23d6ceb6be7d53_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzEy_38ec67e5-6c9d-4ce5-9aac-db9f5b7dfac4"
      unitRef="usd">300000000</arvn:MaximumAggregateOfferingPriceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i6b0bcf64028344e6af483706f401290e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNDg2_51346eef-81eb-4769-8735-82716c28ca96"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib28dd8ea2b9a41c2971d1c69a31155e1_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfODYz_9d1885a9-6f77-46ff-9b3c-b6f0f1b9a96f"
      unitRef="shares">311850</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock
      contextRef="i4a71274815094838ab3c597fb2f26a9a_D20200101-20200101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA3Nw_77c7930d-fdcd-4c77-9d47-c783c2bbf4fa"
      unitRef="number">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ib9aec8988f694ff0bdcb13df74a26b2b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTE3OA_627eb118-8b85-47a4-b97d-95dc15338afd"
      unitRef="shares">2495756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="id759bd76e92c4ede87b28afc4a41b568_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTI3OA_2217032b-35f3-4257-83a8-a9185911d0d5"
      unitRef="shares">23206</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i92f1e3b8a73c406baaa7a7de9b0f3308_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTI4NQ_dc45c735-ca11-4ff3-aa83-d6eb0d4d9ff7"
      unitRef="shares">5749</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i9dc4b7a143d749d3b66e3a8d62fc9739_I20180331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTUyNg_0cf08321-cef3-461d-ad80-09c5af023a5a"
      unitRef="shares">6199477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i4bbe490912764883b0d0a04c6f91955c_D20180301-20180331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTczOQ_6a3bb014-9c2c-480e-8596-1d86b14ea948">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id11bdfbfc5664070828281a7fc7b86c7_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMjE4NQ_7f59c2f7-14cb-4af0-8841-565c198210b9"
      unitRef="shares">4067007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ibd1b3df3c405457383f5264958d864d2_I20180930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMjI2NQ_8fabb737-a9d5-4f57-8f73-03666353cbb9"
      unitRef="shares">1277181</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="id5f5df6145fa4e158ed350838e5a7e21_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMjgzNQ_e3e2bfd3-55c5-4ca2-8c86-c07e32f64421"
      unitRef="shares">4989593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="ib1a047b63716450a86e6886de00be9f1_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMjg3Ng_8c24360a-9c4c-4661-9073-89c5df7f69c0"
      unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i10eede6b30cc414dbf22a74b29deb8c6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzA0NQ_a066cd39-1685-4fcc-9be0-7fdb21fb3d5e"
      unitRef="shares">2115004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ca05a3c3aa44683a1997583823075d6_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzQ0MA_3dcfb208-6d84-4911-aca9-c8d0c7c72549"
      unitRef="usd">19900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie10a2301e42b4cbb841833dc0c008446_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzQ0Nw_8507246c-d883-481f-b162-2b3a77ab41f8"
      unitRef="usd">16600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iabfae107724143078681007be335943e_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzMzQ0MQ_b26f61a0-8a51-467f-82c2-9dcbb3fa0a76"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibbf44409a8a841bf993b6c95041b34d7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzMzQ1Ng_7d7557b3-1fc7-4766-8df7-cb49ed8495b3"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ied3d963eb80c4cf0821da8185cb0c1b4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzY4OA_3dab7b3c-ab76-442c-8970-1ba472b08ef8"
      unitRef="usd">97700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i5ca05a3c3aa44683a1997583823075d6_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMzgwOQ_79b7e098-9358-4a44-b134-66fef2d6b976">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTMzOA_91dbb67a-ca57-489d-b9fc-86a59a2c1bce">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during the three months ended March&#160;31, 2023 and 2022 was determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.6 - 74.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;73.2 - 76.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.6 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.6 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.4% - 4.2%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5% - 2.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$30.40 - $36.27&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$64.19 - $78.91&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMS0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOjM2NmZiMjRkMDVmYjQwZGZhMmExNjZlNjhhZTI4MmJmXzQ_18bbe872-b169-4aef-936d-c8d5de5b4a1c"
      unitRef="number">0.726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMS0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOjM2NmZiMjRkMDVmYjQwZGZhMmExNjZlNjhhZTI4MmJmXzk_ded94561-2fee-42b6-ac65-11aa32b8718c"
      unitRef="number">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMS0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOmRkNzQ5ZDVjMjU5MTRmZGZhOTdkMjg5NjE4YzE0NjQxXzQ_3d94c525-5f7c-4aeb-a5c8-e53c3d5436c3"
      unitRef="number">0.732</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMS0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOmRkNzQ5ZDVjMjU5MTRmZGZhOTdkMjg5NjE4YzE0NjQxXzk_f836ca32-7de7-4f0e-a9b2-11d52f4b8cb9"
      unitRef="number">0.760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1dc82bdb7f3249e3a8fa6593ba2f1e2f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMi0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOjgwMzAyZmE1ZjgwZDQzZDVhODc0MGEzNmVlN2UyN2QyXzQ_302dfa49-5f09-468d-b145-163304faf5fc">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i349c99c38fd24411a3098e192d5bb289_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMi0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOjgwMzAyZmE1ZjgwZDQzZDVhODc0MGEzNmVlN2UyN2QyXzk_12df1f9b-4462-4265-87f3-dfbe31e02342">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i12c09bc9792f4d4d82779a6ecdfd5cd4_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMi0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjJiMjY1OTUyMDMzMjQzOGU4YzUyMmVmMjNjMmQ5YmQ5XzQ_80631b43-1cbb-4964-a1cd-5112e4709868">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia907332b480c40519a54ef9abc49ebf1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMi0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjJiMjY1OTUyMDMzMjQzOGU4YzUyMmVmMjNjMmQ5YmQ5Xzk_dec8849f-618e-4257-9c56-053ab7094d21">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMy0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOmI2MjI1YjJmYzNkZDQxZjhhNjY3ODAxNmNiMDY2NDI1XzQ_73091f41-87ca-42dc-9c75-a81e2c3b3d6c"
      unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMy0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOmI2MjI1YjJmYzNkZDQxZjhhNjY3ODAxNmNiMDY2NDI1Xzk_14a66fd4-6cea-423b-ac8e-735dfdc44d86"
      unitRef="number">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMy0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjU0NDNmYjQzZTUwOTRiYWE5NmM3MWE0MDE3MWNhNTk5XzQ_e8921e5a-8da7-4e56-a889-53b8fc59dcc3"
      unitRef="number">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfMy0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjU0NDNmYjQzZTUwOTRiYWE5NmM3MWE0MDE3MWNhNTk5Xzk_81674d46-ff9b-4ae5-8b68-ad106acafb34"
      unitRef="number">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNC0xLTEtMS02NTQzMQ_bfa2c15d-e0a3-4600-adbb-0551552eca23"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i4ebed6fd34514ba48ad08a948cd68eab_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNC0zLTEtMS02NTQzMQ_f8d4b3ab-37b7-44b6-9db4-494736dd650c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="id992f35185d74bae9954007b9459fa21_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNS0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOmEwYTFlZmNkNTcxODRhZTJiY2EzNjE2MTQ5MTA0OTc0XzQ_95e80405-7b2b-4400-9d99-925e33c8ea2f"
      unitRef="usdPerShare">30.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i34c0d5650542472988dfa8a33538b992_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNS0xLTEtMS02NTQzMS90ZXh0cmVnaW9uOmEwYTFlZmNkNTcxODRhZTJiY2EzNjE2MTQ5MTA0OTc0Xzk_3dafa15b-8901-4f72-aba4-29a41040e6c9"
      unitRef="usdPerShare">36.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i1f3f89b30e484ddb9d12fd481d56197e_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNS0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjU0YjI4OTVmYTYzMjQ4ZTBiOWZkNjAwNmQ1MGI1ZTRiXzQ_2c62ef2b-9ceb-4125-9d7e-e0fcd041e714"
      unitRef="usdPerShare">64.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i15fe088644044a698fa4be67f06f4289_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmZkYzhhYWRlYmU1ZjQwYmFiNTllNzE5Njk3NDFhNWQ0L3RhYmxlcmFuZ2U6ZmRjOGFhZGViZTVmNDBiYWI1OWU3MTk2OTc0MWE1ZDRfNS0zLTEtMS02NTQzMS90ZXh0cmVnaW9uOjU0YjI4OTVmYTYzMjQ4ZTBiOWZkNjAwNmQ1MGI1ZTRiXzk_53f3a8f8-e6f3-4da2-9baf-0097e4aefaf3"
      unitRef="usdPerShare">78.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTMzOQ_6b2072e4-a9f1-4458-83e4-12e0b320d0bc">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include stock options granted to employees and directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.718%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.054%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;br/&gt;except weighted average exercise price)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Options &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6,814,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,470,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(46,982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(41,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;63.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Outstanding as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8,196,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Exercisable as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4,114,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;40.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMS0yLTEtMS02NTQzMQ_6d565028-c698-4ab1-a0de-1b16a93c8280"
      unitRef="shares">6814634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMS00LTEtMS02NTQzMQ_06127d19-5b38-40b3-985e-007c6b97740a"
      unitRef="usdPerShare">49.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i6b701e816ca846fca1f71db5b8b65b28_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMS02LTEtMS03NDM2MQ_972f6476-10d3-47bf-92a6-d9476fb7e107">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMS04LTEtMS03NDM0OA_033efd42-c97f-411c-a00f-890842c7e732"
      unitRef="usd">34500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMi0yLTEtMS02NTQzMQ_2f02b872-ee38-4f62-863b-b08b3b9fb010"
      unitRef="shares">1470003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMi00LTEtMS02NTQzMQ_ccd957e2-edb7-4ad0-8bf1-5676ab7159db"
      unitRef="usdPerShare">34.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMy0yLTEtMS02NTQzMQ_688050f7-bb28-4c21-a03b-4251e27e438e"
      unitRef="shares">46982</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfMy00LTEtMS02NTQzMQ_1c01f52e-fa3f-41ab-a441-8d3af34e5f98"
      unitRef="usdPerShare">17.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNC0yLTEtMS02NTQzMQ_f80a71a7-59c6-47a9-80b1-81c915cd2c1e"
      unitRef="shares">41416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNC00LTEtMS02NTQzMQ_4a885b14-e882-4288-93b4-2911b0d3790a"
      unitRef="usdPerShare">63.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNS0yLTEtMS02NTQzMQ_da765ac3-6f4b-471d-9bb1-de9e57f234d5"
      unitRef="shares">8196239</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNS00LTEtMS02NTQzMQ_f6a8f875-9ac4-43ed-b623-de3ab95ff5d9"
      unitRef="usdPerShare">46.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNS02LTEtMS02NTQzMQ_2a3bf235-c948-4ef5-ab52-fc4fef06dc9c">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNS04LTEtMS02NTQzMQ_2582034b-52dc-461a-8c67-adeb9a5181c2"
      unitRef="usd">19100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNi0yLTEtMS02NTQzMQ_323c563b-b280-45ae-b702-9f8cb94147d6"
      unitRef="shares">4114735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNi00LTEtMS02NTQzMQ_20a6bff6-4d8a-489d-b903-3cf7d20ef9b8"
      unitRef="usdPerShare">40.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNi02LTEtMS02NTQzMQ_a4ceca18-8e1a-49c5-8e52-c2fadbe50e53">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id05b975a531b4a769c53cd848058ea5a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOmViZjk5NGI3ZTZhYzRmOTNiMjQ3NTY3YjU4ODc4NDU1L3RhYmxlcmFuZ2U6ZWJmOTk0YjdlNmFjNGY5M2IyNDc1NjdiNTg4Nzg0NTVfNi04LTEtMS02NTQzMQ_08734aad-6e48-44ee-b385-46a7315b0ccf"
      unitRef="usd">18900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNDYxMg_538f6eb3-4c39-4bf4-bed7-b29a699fa565"
      unitRef="usdPerShare">23.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNDY5Nw_f4f9739b-24b6-4a0c-aab4-a7eb66054109"
      unitRef="usd">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i10eede6b30cc414dbf22a74b29deb8c6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzMzkwNA_e4eafce6-6a66-4ae0-a30a-e840ab9c363b"
      unitRef="usd">67900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8313eb035f2049c096523de984254655_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzMzkxMg_2ebc59d8-a4e5-472c-a5ce-38aeb3edc895">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i10eede6b30cc414dbf22a74b29deb8c6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNDcyMw_6d008cac-ec05-47e3-8a13-b088224f69ed"
      unitRef="shares">7743483</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTM0MQ_19a95008-6acc-463f-afea-8e6fccd1a2ce">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity under the 2018 Plan during the three months ended March&#160;31, 2023 is presented below. These amounts include RSUs granted to employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted Average&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Grant Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested RSUs as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;489,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;51.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;702,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;34.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(81,223)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;43.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(2,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;58.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Unvested RSUs as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1,107,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;41.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4397b2ab6c394deebbeeccdb3d6ef0f9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMS0yLTEtMS02NTQzMQ_fcae7026-e808-4a91-881e-f0cc3d13cf2b"
      unitRef="shares">489216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i4397b2ab6c394deebbeeccdb3d6ef0f9_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMS00LTEtMS02NTQzMQ_36ecde2f-f313-4045-bca0-7a494856c3d4"
      unitRef="usdPerShare">51.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMi0yLTEtMS02NTQzMQ_1db9c82f-104d-43a4-80cb-404ec3bb1e70"
      unitRef="shares">702206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMi00LTEtMS02NTQzMQ_135f4b0a-1612-4498-88fd-1cd19f92c3e9"
      unitRef="usdPerShare">34.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMy0yLTEtMS02NTQzMQ_eb26f6a7-aedb-485a-a038-31ef8d029901"
      unitRef="shares">81223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfMy00LTEtMS02NTQzMQ_62f74853-53b4-4aaa-ae9a-8da9fb72c41e"
      unitRef="usdPerShare">43.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfNC0yLTEtMS02NTQzMQ_eddd6f8c-b501-4a4f-8477-659e1509e1f4"
      unitRef="shares">2925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ia34e3af1f742406e870bd99006c8999b_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfNC00LTEtMS02NTQzMQ_34167c1f-950f-4978-80a7-6fb8d3449044"
      unitRef="usdPerShare">58.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i398833cc0cbe482ca635f3baea15a579_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfNS0yLTEtMS02NTQzMQ_a328cbfc-f284-42c6-b588-ec8f363f0fca"
      unitRef="shares">1107274</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i398833cc0cbe482ca635f3baea15a579_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RhYmxlOjQ1ZjQxNGEyMTcyOTRmMjViNjM1ZGYwNzA2MDQ3NGRiL3RhYmxlcmFuZ2U6NDVmNDE0YTIxNzI5NGYyNWI2MzVkZjA3MDYwNDc0ZGJfNS00LTEtMS02NTQzMQ_0124e24d-24df-4a68-b1c3-e127d2ca99a5"
      unitRef="usdPerShare">41.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ib19aa9edf1fe4cdebd33b4a75c81c3a7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzNDc4OQ_24b4c0fb-e8b7-42ad-9ffa-49783003711b"
      unitRef="usd">2600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ie0298f75c6f440a58c57320fb61d4a0a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzNDMwMA_2837160c-2e07-46d2-9346-c6d6e1ec6536"
      unitRef="usd">29800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i2256dbf3cc9e4c8aab20a9ac4ed1d1c6_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfMTA5OTUxMTYzNDI5Mg_6dd74b57-f517-41c0-80b2-3d955427436d">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber
      contextRef="i10eede6b30cc414dbf22a74b29deb8c6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF82Ny9mcmFnOjljOGJiMDc3NWU0OTQ5YThhZjE5N2RmOGI2ODRhMTM5L3RleHRyZWdpb246OWM4YmIwNzc1ZTQ5NDlhOGFmMTk3ZGY4YjY4NGExMzlfNTI1MQ_1c645d3f-1d46-497b-aa30-58f8a919a802"
      unitRef="shares">916138</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMzIwNw_d4d07908-d749-4eb1-861b-8103c82bef85">Income Taxes For the three months ended March&#160;31, 2023, the Company recognized income tax benefit of $0.4 million resulting in an effective tax rate of 0.5%, as compared to income tax expense of $4.5 million resulting in an effective tax rate of (7.9)% in the same period for 2022. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended March&#160;31, 2023 and the Company&#x2019;s overall effective tax rate of 0.5% was the effect of expected benefits from state net operating loss carryback claims offset by equity compensation and the valuation allowance recorded against the full amount of its net deferred tax assets. The primary reconciling items between the federal statutory rate of 21.0% for the three months ended March&#160;31, 2022 and the Company&#x2019;s overall effective tax rate of (7.9)% was the effect of equity compensation, deferred state income taxes and the valuation allowance recorded against the full amount of its net deferred tax assets.A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company continues to establish a full valuation allowance against the Company&#x2019;s net deferred tax assets since it is more likely than not that benefits will not be realized, including those benefits created in the current year. This assessment is based on the Company's historical cumulative losses which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfOTk_4fc76848-c502-442b-a20c-b9b4357e127b"
      unitRef="usd">-400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMTQw_54362728-e79d-4634-bd43-0646d32a50ec"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMTgx_b4395eb0-031f-47ae-a9a6-c62a2e23743f"
      unitRef="usd">4500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMjIy_7d3056f4-8102-4c39-9c1d-d89d7e35629a"
      unitRef="number">0.079</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfMzIw_b15429cd-39fa-4b57-b89f-80f0651ae4cb"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfNDAx_fe13398b-2f2f-4a2f-8ca9-42bdd8eeb61a"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfNjg0_60cce8c5-23cc-4beb-9adf-73d19a19a0b6"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83My9mcmFnOjNkNWJiODE1M2UwNjRlMWM5OTgzZjU1NWZiM2M1OTc1L3RleHRyZWdpb246M2Q1YmI4MTUzZTA2NGUxYzk5ODNmNTU1ZmIzYzU5NzVfNzY1_e052a326-6803-419f-8bab-4d89725a3b20"
      unitRef="number">0.079</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RleHRyZWdpb246MjA3YTA4YmI4OTlmNDBhZDhiMjZkZDgyZWRmMmQ5MGVfNDA2_0eba5d99-9daf-44dc-8aac-fa1135191690">Net Loss Per Share &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(81.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(63.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net loss per common share &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;-  basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported net losses for each of the three months ended March&#160;31, 2023 and 2022, and, therefore, excluded all stock options and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RleHRyZWdpb246MjA3YTA4YmI4OTlmNDBhZDhiMjZkZDgyZWRmMmQ5MGVfNDA3_d49161c1-94d5-4a33-920e-a741ae94d571">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(81.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(63.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;53.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Net loss per common share &lt;/span&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;-  basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMi0xLTEtMS02NTQzMQ_d372fac0-4cf9-4894-896e-ffeb1c10f9c5"
      unitRef="usd">-81900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMi0zLTEtMS02NTQzMQ_abdf8abb-c81b-4874-bc2e-dc07ff624a32"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMy0xLTEtMS02NTQzMQ_6fb8b296-b8b5-4f5a-9d44-4af7da8d0ddc"
      unitRef="shares">53300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMy0xLTEtMS02NTQzMQ_f2adb9f5-7468-4a95-8e5a-a5d82f3bcf93"
      unitRef="shares">53300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMy0zLTEtMS02NTQzMQ_791efd23-494b-4019-b1d7-c7917128858d"
      unitRef="shares">53000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfMy0zLTEtMS02NTQzMQ_a9caa776-2cd3-4840-b305-939cba75f45f"
      unitRef="shares">53000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfNC0xLTEtMS02NTQzMQ_2863a3c7-7cd1-4c7a-8e69-0c385817a3c5"
      unitRef="usdPerShare">-1.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfNC0xLTEtMS02NTQzMQ_d8855081-a7a4-41f3-a6eb-c64e3e441efb"
      unitRef="usdPerShare">-1.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfNC0zLTEtMS02NTQzMQ_64b6f744-3d35-4064-b855-1b6162e66767"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjgzMzQ3NTFhYWNlOTRiMGY4MmJmMWJiNzlhOWFiNDAwL3RhYmxlcmFuZ2U6ODMzNDc1MWFhY2U5NGIwZjgyYmYxYmI3OWE5YWI0MDBfNC0zLTEtMS02NTQzMQ_9d67e743-1041-4703-886c-88c319d0c3b3"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RleHRyZWdpb246MjA3YTA4YmI4OTlmNDBhZDhiMjZkZDgyZWRmMmQ5MGVfNDA4_6c63fc2e-298b-45a4-b879-5dbde9d160e5">&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported net losses for each of the three months ended March&#160;31, 2023 and 2022, and, therefore, excluded all stock options and restricted stock units from the calculation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;For the Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i11a56379c5434b73ac2a8a2184bf2b26_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfMi0xLTEtMS02NTQzMQ_6a2a1f6f-074a-41ae-b36e-c5496af7786e"
      unitRef="shares">8200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i11a56379c5434b73ac2a8a2184bf2b26_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfMi0xLTEtMS02NTQzMQ_c8eadaed-2414-4cb6-8ba4-c136a3e1d7ce"
      unitRef="shares">8200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ice51fdd252534ce4910cdfd6c31f0453_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfMi0zLTEtMS02NTQzMQ_90942dc7-cdad-4dec-b9ed-521a1454bc70"
      unitRef="shares">6400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ice51fdd252534ce4910cdfd6c31f0453_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfMi0zLTEtMS02NTQzMQ_b03bbc20-f373-4102-95a4-d3fc3d9949bf"
      unitRef="shares">6400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i79495c5a256b4d7db64470507e85fdaf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNC0xLTEtMS02NTQzMQ_1a4157aa-b0ce-4e0f-914b-e701db68835b"
      unitRef="shares">1100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i79495c5a256b4d7db64470507e85fdaf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNC0xLTEtMS02NTQzMQ_c22ee5af-b759-4394-86c3-00173af4e1f0"
      unitRef="shares">1100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec101bcd50d841439204bb45185f462f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNC0zLTEtMS02NTQzMQ_3e65deb9-4c4f-436b-a8a5-f54bc8ffd2ad"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec101bcd50d841439204bb45185f462f_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNC0zLTEtMS02NTQzMQ_6a063680-3b41-470e-be6d-742b03e36e8b"
      unitRef="shares">200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNS0xLTEtMS02NTQzMQ_581faf11-4686-48d0-8e60-fc36a6edad02"
      unitRef="shares">9300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNS0xLTEtMS02NTQzMQ_b5a24498-d1f9-4223-9a65-e0eef43a7030"
      unitRef="shares">9300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNS0zLTEtMS02NTQzMQ_7fbbcd23-2094-452d-b469-26a737e9aa8f"
      unitRef="shares">6600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF83Ni9mcmFnOjIwN2EwOGJiODk5ZjQwYWQ4YjI2ZGQ4MmVkZjJkOTBlL3RhYmxlOjg1YmNhOTQ5YWU1MzRlYzRhOGJjNTZiODYyNjE5NzA3L3RhYmxlcmFuZ2U6ODViY2E5NDlhZTUzNGVjNGE4YmM1NmI4NjI2MTk3MDdfNS0zLTEtMS02NTQzMQ_e425b696-5883-4c33-adc8-f507e38d0f3e"
      unitRef="shares">6600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA1MA_249b1651-b7a6-4759-a4b8-51a8160888f5">Equity Method Investments&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company and Bayer CropScience LP (&#x201c;Bayer LP&#x201d;) formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. The Company and Bayer LP each held an initial ownership interest in Oerth Bio of 50%. A 15% ownership interest of Oerth Bio was reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 46.0% and 47.7% as of March&#160;31, 2023 and 2022, respectively, as a result of vested incentive units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In connection with the preparation of the Company's consolidated financial statements for the yea&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;r ended December 31, 2022, the Company identified a prior period error related to the accounting of its investment in Oerth Bio in 2019. Previously, the Company disclosed that revenue of $24.7&#160;million was deferred and would be recognized if and when Oerth Bio recognized revenue associated with the license. The Company has determined that the consideration received for the amounts associated with the deferred revenue should have been constrained, because at the time Bayer LP had contributed only a portion of its full cash commitment to Oerth Bio, and Bayer LP had the right to all the cash contributed, but not yet spent, upon liquidation of Oerth Bio. The constrained revenue should have been recognized upon both cash being contributed by Bayer LP and the related cash spent by Oerth Bio on research and development activities. As such, for each period presented, the revenue recognized is accompanied by corresponding equity method losses of the same amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company ev&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;aluated the error&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd determined that the related impact did not materially misstate the previously issued unaudited condensed consoli&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;dated financial statements for the three months ended March&#160;31, 2022. Although the Company concluded that the error was not material to its previously issued unaudited condensed consolidated financial statements, the Company has&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; determined it is appropriate to adjust its previously issued unaudited condensed consolidated financial statements for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to correct&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the error and improve comparability&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in stockholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as previously reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss of Oerth Bio for the three months ended March&#160;31, 2023 and 2022 totaled $2.4 million&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $4.9 million, respectively. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized equity method losses of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.1 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March&#160;31, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;carrying value of t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he investment was zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also provides Oerth Bio with compensated research, development and administrative services through a separate agreement. The services rendered by the Company during the three months ended March&#160;31, 2023 and 2022 were immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia79bc328db4a4707a837e784c470a1b4_I20190731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMzU2_6e2a5637-31d3-428f-a1aa-08775aec001a"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage
      contextRef="i97cfc9c7c575435c98bd43efeb5fb152_I20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYzMDU3OQ_6e83ceb9-a756-4c26-b576-c79601f71cf7"
      unitRef="number">0.15</arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1a7e68f89e4c4b938c8c387fb7a06158_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYzMTM5MA_624d521d-4080-4c0b-a4c2-100751a6cbe1"
      unitRef="number">0.460</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib401d1efe8db4e449e1330c66a20922b_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYzMTM5NA_8a398fcc-ec73-4f87-b6e7-42208050c98b"
      unitRef="number">0.477</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ie9edfe32c55049d6b67f5d1ff33010d6_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYzMzg1Ng_20f0cc4a-00a9-471d-906e-cb169fef7efb"
      unitRef="usd">24700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfNjA0NzMxMzk1OTA0OA_f8f695d0-b676-43ab-933f-7b495babb45e">The following illustrates the effect of the correction of the immaterial error for the period presented. There was no impact to the balance sheets, net loss per common share, statements of cash flows or changes in stockholders&#x2019; equity.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as previously reported&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;as adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per common share - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:Revenues
      contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMi0xLTEtMS03MDYyNg_0adff91a-8085-494a-9545-cdb0510667ac"
      unitRef="usd">24200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMi0zLTEtMS03MDYyNg_a830a444-346d-48b6-8001-586af9261b95"
      unitRef="usd">2300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMi01LTEtMS03MDYyNg_e594f583-96e3-41f1-8a65-79ad3e008d5b"
      unitRef="usd">26500000</us-gaap:Revenues>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMy0xLTEtMS03MDYyNg_d3e9bf3c-22fa-4fcf-95e6-96c62cfcd569"
      unitRef="usd">-60000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMy0zLTEtMS03MDYyNg_a6eff5ab-5d59-4b5d-86ec-d1747b6d881e"
      unitRef="usd">2300000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfMy01LTEtMS03MDc0NA_9b3cb4be-65e8-43b5-8719-5c712ef49d16"
      unitRef="usd">-57700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNC0xLTEtMS03MDYyNg_bc6bc3e6-1e59-45bd-b69a-5b527f3fbbc4"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNC0zLTEtMS03MDYyNg_fb674f9a-f663-4f18-b0fe-f88747d2b883"
      unitRef="usd">-2300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNC01LTEtMS03MDYyNg_61e779ab-cff7-4f7a-88ab-e2a11514eb92"
      unitRef="usd">-2300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNS0xLTEtMS03MDYyNg_7db36e1f-2cb3-4873-87f2-5bb487634d7d"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNS0zLTEtMS03MDYyNg_df72f6f5-3b9b-4bae-99bf-6d0d4b3d980a"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNS01LTEtMS03MDYyNg_dc9cfaaf-c363-47d2-856b-2932c881da78"
      unitRef="usd">-63400000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi0xLTEtMS03MDYyNg_c211f1c6-49c7-4943-8c11-962369ac5179"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi0xLTEtMS03MDYyNg_e450988d-8201-4087-a07a-f4bfc01afa15"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi0zLTEtMS03MDYyNg_3576c47b-6fd5-45eb-8894-4753856f05b7"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi0zLTEtMS03MDYyNg_af9b65cc-e484-4676-9d2e-02cac40b910f"
      unitRef="usdPerShare">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi01LTEtMS03MDYyNg_d91bcedc-de5b-427e-8c6e-e3d723ab3c25"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNi01LTEtMS03MDYyNg_e8c864cd-21f9-4e6a-8c06-f1ed8a30af78"
      unitRef="usdPerShare">-1.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNy0xLTEtMS03MDYyNg_ee00e2b2-c7e1-4455-aa7a-b4e54debd1df"
      unitRef="usd">-77500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i505224e29c3b4722980f2901ed0c0550_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNy0zLTEtMS03MDYyNg_7d2bc362-d232-4b36-ba27-58acafeb9127"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RhYmxlOmJjMzA1OTEyMDE2MTQ3ZmNiNzFmZjhlYmI5ZjJkMmZhL3RhYmxlcmFuZ2U6YmMzMDU5MTIwMTYxNDdmY2I3MWZmOGViYjlmMmQyZmFfNy01LTEtMS03MDYyNg_24736a2a-e19c-4f0b-b91c-68924699c5f5"
      unitRef="usd">-77500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i1dcee608cf2542be9ac23c358b3e4eae_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfNzIz_a55bd68f-e214-4022-a41d-da2a3f5cac8e"
      unitRef="usd">-2400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i50b1538561114837a04b610d8fb7d5df_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfNzMw_eb0a798f-c558-41c7-af34-a1c52b4c061d"
      unitRef="usd">-4900000</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYyOTk0Mw_a3a8a387-8602-4ca5-927e-9d8b447e8255"
      unitRef="usd">-1100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia5c91740aadf40b7b22ed35825cffab6_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfMTA5OTUxMTYyOTk1OA_d6d26d39-8057-486e-aa58-8f8d09708b9a"
      unitRef="usd">-2300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i7c7ac62b86294b8d8b81d6270bdf4b43_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfOTEz_9b6b932d-cb0b-4afb-9aeb-5b2bd5c1943b"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i5b3f861bb3b64d2eb62b4fffd96d22d2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84Mi9mcmFnOjRlYjU3ZWQ5YWNmMjQ0NjI5Zjc1YmM0ODdiNTE2NGJkL3RleHRyZWdpb246NGViNTdlZDlhY2YyNDQ2MjlmNzViYzQ4N2I1MTY0YmRfOTEz_f3ed14ca-79b0-4c60-994f-ba17331338a5"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84NS9mcmFnOmZmMWU0ZWMwYTM1ZDRjZjZhM2QxNTAzYjM4ZmI5NWE0L3RleHRyZWdpb246ZmYxZTRlYzBhMzVkNGNmNmEzZDE1MDNiMzhmYjk1YTRfNDAzOA_d855c0bc-cad3-4c22-b19a-14589acd55db">Commitments and Contingencies&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;The Company's accrual for such matters totaled $7.0&#160;million as of March&#160;31, 2023, primarily related to a contract dispute that is in early stages. Due to the early stage of the dispute, the means of resolution are unknown and could involve contract modification and, or payment of consideration.&#160;An estimate of the possible range of loss associated with the dispute cannot be made at this time and the Company has accrued its best estimate as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Clinical and Preclinical Development and Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies, and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;FMI Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a Master In Vitro Diagnostics Agreement (the "FMI Agreement") with Foundation Medicine, Inc. ("Foundation Medicine") for the development and commercialization of one or more of Foundation Medicine&#x2019;s companion in vitro diagnostic assays for use with one or more of the Company's therapeutic products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FMI Agreement does not have a fixed duration, and the Company may terminate the FMI Agreement for convenience by providing adequate written notice to Foundation Medicine, Inc., subject to payment of applicable termination fees. Either party may terminate the FMI Agreement in its entirety for an uncured material breach by the other party, upon the bankruptcy or insolvency of the other party or by the mutual written agreement of both parties. Additionally, Foundation Medicine may terminate the FMI Agreement with respect to an applicable program, if (a) a reasonably necessary third party license is not secured by Foundation Medicine or if the Company does not consent to payments for such license (b) Foundation Medicine &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reasonably determines that further development of the applicable assay is not technically feasible or (c) following a certain number of years after the first commercial launch of the applicable assay for use with the applicable therapeutic product. Certain license and other rights and certain obligations of Foundation Medicine survive termination of the FMI Agreement. If the FMI Agreement is terminated in its entirety or with respect to any program, the Company has certain payment obligations remaining to Foundation Medicine and may also be required to pay a termination fee, if applicable.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bavdegalutamide&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the development of FoundationOne&#xae; Liquid CDx as a companion diagnostic for use with bavdegalutamide for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low to mid tens of millions of dollars, in addition to certain validation fees per sample and related pass-through costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ARV-766&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the development of FoundationOne&#xae; Liquid CDx as a companion diagnostic for use with ARV-766 for AR mCRPC in the United States and European Union, pursuant to the terms of the FMI Agreement, the Company is subject to success-based milestone payments of up to low tens of millions of dollars in addition to certain validation fees per sample and related pass-through costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i09295186e9a140a3bc02f7ddae9c7af0_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84NS9mcmFnOmZmMWU0ZWMwYTM1ZDRjZjZhM2QxNTAzYjM4ZmI5NWE0L3RleHRyZWdpb246ZmYxZTRlYzBhMzVkNGNmNmEzZDE1MDNiMzhmYjk1YTRfMTA5OTUxMTYzMjI5Ng_d6ef0106-b25f-4e05-8250-0b48d46adec9"
      unitRef="usd">7000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i86e8d060431b44969048abce12f5e513_D20220604-20220604"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjg4NGNmODVmMDdiZTQzMjBiNWU0ODU3YjFkYTEyMGVkL3NlYzo4ODRjZjg1ZjA3YmU0MzIwYjVlNDg1N2IxZGExMjBlZF84NS9mcmFnOmZmMWU0ZWMwYTM1ZDRjZjZhM2QxNTAzYjM4ZmI5NWE0L3RleHRyZWdpb246ZmYxZTRlYzBhMzVkNGNmNmEzZDE1MDNiMzhmYjk1YTRfMjYxOQ_48db7dc2-7823-46fe-a7c9-c116bb084c3e"
      unitRef="usd">10000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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ML(Z YQ7@.5JHVT2%ZH7<A1$G]WF\X-($AFM8EMUWSD=GU 2'AG:$NZC@+MK
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MU<>IBL=I*_26X3067:<+?1>=3C#O"N]]309K],Q*>F:=]#PE<-Y@T3] Q(;
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MT2V1&_0%(B[1QR(G1<) YA/JHQ_+._3QPR?T ;$<W;,TA<C(RZ$"8%K],*Y
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M[.LO)^ I_L*6'J)K^:O6QL7H&OY98^95GC;@/=V4^@=2,'SF//T#4$L#!!0
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M=)D%%R&M)00D+M2']9HQ28JESF1&$4:L[K4SMN_ADE)_-!H/KMJ#((J,C;%
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MW4$@Q\HK1/.>UI5J*X\E[2S ?%0<4M 7QN5E*,.@>*^RXE VL 4X+]YC3YX
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M+$#W2TW<O]NP@V;TG?\+4$L#!!0    ( $I'I58\KL=NM0(  *@&   9
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M):7&X7@8@&[EK#6L:KR$K)4E0?+3BOX J%T K9=*V4?#%>C_*?,_4$L#!!0
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M'^0:<5TCV02A. R]V3CH,M&"J@T..19.7U9[(//%+UA1-!Q/K/_ZG:*M3:E
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M^>50A6I5P(23<.[/^U,3B3D))_ZD>W(X_EB5R=K-#*2H3]]>,71N>3L>B9/
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M1'T\)VPO,]J%_Z*+LK-9(K+6>5/URD!0J3K^RON>ASV%L\DC"FFOD ;<T5%
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M<9KA2V!8"2\K$*:&6JH^8 V*!3H2J*S6U#4^RFV%ATJHJE>"A6C76$7][*^
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M%$TI:KF-I81&"'I5D(L",W%M^FIUGM36>\6]YJ1)_H%.OBW$P&EN*F/#KOV
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MM#N%:HRT9OEF_7(J)*H5(4(9]48/!3N[9^)"^0BB_L;4K7/1NJA$H4-N7&B
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M^IDR%,20TL -5@KB'<^-'1IS'G,. >90 QJ+_YL^_F]&@W8A0SD5]"LNT;
ME'ZVNT9!@OFIWNG]H83\OW0/;G,21[M+(PNDA5$X6#"IY3B<:&HZQE#4N/@P
MT0+DW%+3,,4U5Z!?!HBVO!9PO.I:IPQ=;RX&9S2HJ\)7U8I!W,C,^;:0J)5M
ML074T5< V"6I=] YLIN-L-T'^4@X6::6WI[J\'S3['#^X,'V8-[F@V] H)8=
M?^GBEF5C^AS4/^T_IFW2-Z2]>/H2!\#N<'"%@5LL7<R.,)CZ]'4KW417\Q>E
MS,7H*KXL<290G@3PGHZ3W0UMT']B//L+4$L#!!0    ( $I'I58!BECY"@,
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M>(4;!?I0EDP]KU'(XR*(@F;CCN\+8S=&RWG-]GB/YO=ZHV@U:E%R7F*EN:Q
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MNU\X-+J#B0?93AM9'L'$H.15\V4_CWGH ,;A&X#X"(@=[\:18WG+#)M/E3R
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M-'#ZR#8"S=DRMJ31R<79'OTJH*>OH$_@5DE;&O@H<\R/Y6-BVM)-7^A>I8.
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MD0T\4BA6P8VT4B,G)'P2A88G439.]]ZJ[!F^;K1_QU#M^\JTP1T^_F$A84;
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M8-]I15I;D;Y9(U='!>*J1K[M4MI2-*E_?>#3,:K7]7L'1AV#ND>@4<M\4=Q
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M"\A4>?)J@X.^14!U3 Z(:2-(0V8'I([A 3'M!:EQ?$ *Y@=^V9R*F.I/FC!
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MP8M3^;C&NRTH&X#OEU*:AX&]/36WY?@_4$L#!!0    ( $I'I5;_@K: ? (
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M;W)K<VAE971S+W-H965T-# N>&ULK51=;],P%/TK5IC0)K$F3;J"1AJI[89
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M=4?F9<\N)Y+E1=M;,JF::#%,U&<.<!V@GJ\8DX>)[J3UAU/X'U!+ P04
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M0E-R)[A>*A+S%-(._=2M[QW2QP?BAPZ ;^:QF<SP93*O0R?Q 5:GI!?\0L*
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MN5(\S8M3H#$(4T%_'W.NU@^F@?+>=?@_4$L#!!0    ( $I'I5:QLN;K2@,
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MH!R6=,/-C=Q]A=JAOM.72:[]$^WJLU& LHTVLJB%+4'!1/6FO^I ' C$Y(0
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M0>?<=%=5*5Q-4)8NR*8232RZX=Q<7*!L@7F?2XG;B=V@O@J3/U!+ P04
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M14"PA@+#6H%AJP*/A,NEJ?M;W<X=2I"P !(60L(B(%A#2-?9+2B==TBA52%
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M&M.E5! $_FSH@L:Q0@(>7TM0JUI3!3:O=^B_Y^)!S!L1=,'BOZ- AC-K8J&
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !*1Z56J,G'L(T$  "!)0  #P
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M:X8B:X8B:X8B:_:?LKX;L_SK-_GM-:UUV1SR6?>YQ.034$L! A0#%     @
M2D>E5@=!36*!    L0   !               ( !     &1O8U!R;W!S+V%P
M<"YX;6Q02P$"% ,4    " !*1Z56BKQUNN\    K @  $0
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M965T-"YX;6Q02P$"% ,4    " !*1Z56 ,>RE< %   K)0  &
M    @('+'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @
M2D>E5KF_I.R0!@  ?QP  !@              ("!P2(  'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $I'I59?4QC9@P@  /(4   8
M          " @8<I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M    " !*1Z5618 !O.8#  "$"0  &               @(% ,@  >&PO=V]R
M:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 2D>E5I(#M 4:"P  M",
M !@              ("!7#8  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+
M 0(4 Q0    ( $I'I58%:<TZ? 0   8+   9              " @:Q!  !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 2D>E5CRNQVZU
M @  J 8  !D              ("!7T8  'AL+W=O<FMS:&5E=',O<VAE970Q
M,2YX;6Q02P$"% ,4    " !*1Z56!_Q\&E<&  "?#P  &0
M@(%+20  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $I'
MI5;J&]0NM0(  %\&   9              " @=E/  !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&UL4$L! A0#%     @ 2D>E5M9-P6>K!   4PL  !D
M         ("!Q5(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M    " !*1Z56V4H3L\@*   :'P  &0              @(&G5P  >&PO=V]R
M:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $I'I5:[Z*C@?00  (8+
M   9              " @:9B  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL
M4$L! A0#%     @ 2D>E5C<I9%]6 P  JP<  !D              ("!6F<
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !*1Z56+8S4
MQ$4'  ".$@  &0              @('G:@  >&PO=V]R:W-H965T<R]S:&5E
M=#$X+GAM;%!+ 0(4 Q0    ( $I'I5:G1QN"- @  -\5   9
M  " @6-R  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @
M2D>E5L;=,JG;!P  ;A0  !D              ("!SGH  'AL+W=O<FMS:&5E
M=',O<VAE970R,"YX;6Q02P$"% ,4    " !*1Z56 8I8^0H#   ;"0  &0
M            @('@@@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4
M Q0    ( $I'I5;N=C^.,@0  & *   9              " @2&&  !X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 2D>E5CWT8#E_ P
M? @  !D              ("!BHH  'AL+W=O<FMS:&5E=',O<VAE970R,RYX
M;6Q02P$"% ,4    " !*1Z560S6?]\0"  ".!@  &0              @(%
MC@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $I'I5;E
MWVS5D ,  !8)   9              " @3N1  !X;"]W;W)K<VAE971S+W-H
M965T,C4N>&UL4$L! A0#%     @ 2D>E5L3/.@_% @  308  !D
M     ("! I4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $I'I5:O!?B&1@(  ) $   9              "
M@;2G  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 2D>E
M5F$[N%#) @  /@D  !D              ("!,:H  'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"% ,4    " !*1Z56KSZ$FE4.   QX   &0
M        @($QK0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0
M   ( $I'I58=R[+R2P0  &<2   9              " @;V[  !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 2D>E5K)TU9HJ!   A!L
M !D              ("!/\   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q0
M2P$"% ,4    " !*1Z565-=XE(X&  #>,@  &0              @(&@Q
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( $I'I59P>A5L
M80,  #D/   9              " @67+  !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&UL4$L! A0#%     @ 2D>E5O^"MH!\ @  [P4  !D
M ("!_<X  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !*
M1Z56E+_\GCX$  !'$@  &0              @(&PT0  >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $I'I583W-KP; (  ,$%   9
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M970T-"YX;6Q02P$"% ,4    " !*1Z56ET1WWL $  ##(@  &0
M    @($5Y0  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    (
M $I'I5:*8$-?; (  +D&   9              " @0SJ  !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&UL4$L! A0#%     @ 2D>E5J+B!5NR"P  .XH  !D
M             ("!K^P  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"
M% ,4    " !*1Z564*1GZ_,#   M$   &0              @(&8^   >&PO
M=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $I'I59DZ &_I 0
M (,5   9              " @<+\  !X;"]W;W)K<VAE971S+W-H965T-#DN
M>&UL4$L! A0#%     @ 2D>E5K&RYNM* P  UPH  !D              ("!
MG0$! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !*1Z56
M7G,'\:D"   6!P  &0              @($>!0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4Q+GAM;%!+ 0(4 Q0    ( $I'I59;GI<I$ ,  "H)   9
M      " @?X' 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%
M  @ 2D>E5MLZ;O(S P  K0P  !D              ("!10L! 'AL+W=O<FMS
M:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !*1Z56,$SD6<0$   Z'@
M&0              @(&O#@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+
M 0(4 Q0    ( $I'I58$:@BMQ00  !L9   9              " @:H3 0!X
M;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 2D>E5N<[WR.<
M @  ,@@  !D              ("!IA@! 'AL+W=O<FMS:&5E=',O<VAE970U
M-BYX;6Q02P$"% ,4    " !*1Z56'6<$?T0#  #*%   #0
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:+GAM;%!+!08     0 !  '<1  "L* $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>153</ContextCount>
  <ElementCount>255</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Accounting Pronouncements and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies</Role>
      <ShortName>Accounting Pronouncements and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Research Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</Role>
      <ShortName>Research Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Property, Equipment and Leasehold Improvements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</Role>
      <ShortName>Property, Equipment and Leasehold Improvements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Right-of-Use Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</Role>
      <ShortName>Right-of-Use Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestments</Role>
      <ShortName>Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Accounting Pronouncements and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Accounting Pronouncements and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Accounting Pronouncements and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesTables</Role>
      <ShortName>Accounting Pronouncements and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Research Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables</Role>
      <ShortName>Research Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables</Role>
      <ShortName>Property, Equipment and Leasehold Improvements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Right-of-Use Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables</Role>
      <ShortName>Right-of-Use Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/LongTermDebt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/Equity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Equity Method Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsTables</Role>
      <ShortName>Equity Method Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/EquityMethodInvestments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails</Role>
      <ShortName>Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Summary of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails</Role>
      <ShortName>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails</Role>
      <ShortName>Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails</Role>
      <ShortName>Equity - Summary of Restricted Stock Grant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/IncomeTaxes</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Equity Method Investments- Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Equity Method Investments- Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails</Role>
      <ShortName>Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arvn-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/CommitmentsandContingencies</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 7 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  arvn-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 -  arvn-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="arvn-20230331.htm">arvn-20230331.htm</File>
    <File>arvn-20230331.xsd</File>
    <File>arvn-20230331_cal.xml</File>
    <File>arvn-20230331_def.xml</File>
    <File>arvn-20230331_lab.xml</File>
    <File>arvn-20230331_pre.xml</File>
    <File>arvn-20230331x10qex311.htm</File>
    <File>arvn-20230331x10qex312.htm</File>
    <File>arvn-20230331x10qex321.htm</File>
    <File>arvn-20230331x10qex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="519">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>74
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arvn-20230331.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 519,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 153,
   "dts": {
    "calculationLink": {
     "local": [
      "arvn-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arvn-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "arvn-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arvn-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arvn-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "arvn-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 430,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 13
   },
   "keyCustom": 27,
   "keyStandard": 228,
   "memberCustom": 34,
   "memberStandard": 23,
   "nsprefix": "arvn",
   "nsuri": "http://www.arvinas.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.arvinas.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Marketable Securities and Fair Value Measurements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Property, Equipment and Leasehold Improvements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements",
     "shortName": "Property, Equipment and Leasehold Improvements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Right-of-Use Assets and Liabilities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilities",
     "shortName": "Right-of-Use Assets and Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Accounts Payable and Accrued Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Long-Term Debt",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.arvinas.com/role/LongTermDebt",
     "shortName": "Long-Term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.arvinas.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.arvinas.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.arvinas.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Equity Method Investments",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.arvinas.com/role/EquityMethodInvestments",
     "shortName": "Equity Method Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.arvinas.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Accounting Pronouncements and Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies",
     "shortName": "Accounting Pronouncements and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Accounting Pronouncements and Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesTables",
     "shortName": "Accounting Pronouncements and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Research Collaboration and License Agreements (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables",
     "shortName": "Research Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables",
     "shortName": "Property, Equipment and Leasehold Improvements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Right-of-Use Assets and Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables",
     "shortName": "Right-of-Use Assets and Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Long-Term Debt (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.arvinas.com/role/LongTermDebtTables",
     "shortName": "Long-Term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Equity (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.arvinas.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.arvinas.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Equity Method Investments (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsTables",
     "shortName": "Equity Method Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails",
     "shortName": "Accounting Pronouncements and Significant Accounting Policies - Cash Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "if4c84844e17f4bfd94a9daafad1c7718_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Research Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ia9c824c6990342a0943fa8aa395e6afd_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Research Collaboration and License Agreements - Summary of Contract Balances (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails",
     "shortName": "Research Collaboration and License Agreements - Summary of Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ie409a5e399c34fbda3e5ab2b0eefc4e7_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails",
     "shortName": "Research Collaboration and License Agreements - Transaction Price Allocated to Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i57e3228d892b4e7db62595d4014c6676_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails",
     "shortName": "Marketable Securities and Fair Value Measurements - Summary of Available-for-Sale Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i57e3228d892b4e7db62595d4014c6676_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
     "shortName": "Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
     "shortName": "Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "if3420f377cc5416b93dcea5b7709551a_I20210531",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LandSubjectToGroundLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Right-of-Use Assets and Liabilities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
     "shortName": "Right-of-Use Assets and Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "if3420f377cc5416b93dcea5b7709551a_I20210531",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LandSubjectToGroundLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails",
     "shortName": "Right-of-Use Assets and Liabilities - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails",
     "shortName": "Right-of-Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Right-of-Use Assets and Liabilities - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i2e5965f2e88e4a6da0dccbe7de98fca3_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails",
     "shortName": "Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
     "shortName": "Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i5ec16c9157c34cd3a52fd00046806080_D20230101-20230331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i6a30a9b9dd1b46fc8fd038e0d8ae9920_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Equity - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails",
     "shortName": "Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i41a6542d7f8a43298525f5a021278bd9_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "id6273a26513740c895cd8fe246ea1135_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "id6273a26513740c895cd8fe246ea1135_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i4397b2ab6c394deebbeeccdb3d6ef0f9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Equity - Summary of Restricted Stock Grant Activity (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
     "shortName": "Equity - Summary of Restricted Stock Grant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i4397b2ab6c394deebbeeccdb3d6ef0f9_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.arvinas.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails",
     "shortName": "Net Loss Per Share - Basic and Diluted Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Securities Excluded From Computation of Diluted Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Equity Method Investments- Additional Information (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
     "shortName": "Equity Method Investments- Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i1dcee608cf2542be9ac23c358b3e4eae_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails",
     "shortName": "Equity Method Investments - Schedule of Correction of Immaterial Error for the Period (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i3f333a553e4a4ca0a448443beed9c165_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "i09295186e9a140a3bc02f7ddae9c7af0_I20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Nature of Business and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Accounting Pronouncements and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies",
     "shortName": "Accounting Pronouncements and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Research Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements",
     "shortName": "Research Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arvn-20230331.htm",
      "contextRef": "ida6954d043d344c6bf4d087a9236adcf_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "arvn_AccountsPayableContractBalancesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable, Contract Balances, Current",
        "label": "Accounts Payable, Contract Balances, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "AccountsPayableContractBalancesCurrent",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccountsPayableContractBalancesCurrentAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable, Contract Balances, Current Additions",
        "label": "Accounts Payable, Contract Balances, Current Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AccountsPayableContractBalancesCurrentAdditions",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccountsPayableContractBalancesCurrentPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable, Contract Balances, Current Payments",
        "label": "Accounts Payable, Contract Balances, Current Payments",
        "negatedTerseLabel": "Payments made"
       }
      }
     },
     "localname": "AccountsPayableContractBalancesCurrentPayments",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Additions",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received",
        "negatedTerseLabel": "Payments received"
       }
      }
     },
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional upfront non-refundable amount received under previous agreement.",
        "label": "Additional Upfront Non Refundable Amount Received Under Previous Agreement",
        "terseLabel": "Additional upfront non-refundable amount received under previous agreement"
       }
      }
     },
     "localname": "AdditionalUpfrontNonRefundableAmountReceivedUnderPreviousAgreement",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_AggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "AggregateIntrinsicValueAbstract",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-the-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_BaseLeaseRentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base lease rent period.",
        "label": "Base Lease Rent Period",
        "terseLabel": "Base rent lease term (in years)"
       }
      }
     },
     "localname": "BaseLeaseRentPeriod",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_BayerAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer AG.",
        "label": "Bayer A G [Member]",
        "terseLabel": "Bayer Collaboration Agreement"
       }
      }
     },
     "localname": "BayerAGMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_BayerCropScienceLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer CropScience LP.",
        "label": "Bayer Crop Science L P [Member]",
        "terseLabel": "Bayer LP"
       }
      }
     },
     "localname": "BayerCropScienceLPMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CapitalizedContractCostAmortizationDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Contract Cost, Amortization During Period",
        "label": "Capitalized Contract Cost, Amortization During Period",
        "negatedLabel": "Amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationDuringPeriod",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Accounts Payable, after Allowance for Credit Loss",
        "label": "Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts payable related to collaborations"
       }
      }
     },
     "localname": "ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Accounts Receivable, after Allowance for Credit Loss",
        "label": "Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts receivable related to collaborations"
       }
      }
     },
     "localname": "ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Collaboration Contract Asset And Other Assets",
        "label": "Change in Collaboration Contract Asset And Other Assets [Roll Forward]",
        "terseLabel": "Contract assets: Collaboration contract asset"
       }
      }
     },
     "localname": "ChangeInCollaborationContractAssetAndOtherAssetsRollForward",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract with Customer, Liability",
        "label": "Change in Contract with Customer, Liability [Roll Forward]",
        "terseLabel": "Contract liabilities: Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CollaborationContractAssetAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration contract asset and other assets.",
        "label": "Collaboration Contract Asset And Other Assets",
        "terseLabel": "Collaboration contract asset and other assets"
       }
      }
     },
     "localname": "CollaborationContractAssetAndOtherAssets",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments And Contingencies",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements",
        "label": "Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements",
        "label": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements",
        "terseLabel": "Additions to collaboration agreements"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Five",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Five [Member]",
        "terseLabel": "Corporate Bonds Maturing 2024-2025"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentyFiveMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Six",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Four Through Two Thousand Twenty Six [Member]",
        "terseLabel": "Corporate Bonds Maturing 2024-2026"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyFourThroughTwoThousandTwentySixMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Three",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Three [Member]",
        "terseLabel": "Corporate Bonds Maturing 2023"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyThreeMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four",
        "label": "Corporate Bonds Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]",
        "terseLabel": "Corporate Bonds Maturing 2023-2024"
       }
      }
     },
     "localname": "CorporateBondsMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_DebtInstrumentInterestPaymentsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest payments term.",
        "label": "Debt Instrument Interest Payments Term",
        "terseLabel": "Debt instrument interest payments term (in months)"
       }
      }
     },
     "localname": "DebtInstrumentInterestPaymentsTerm",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "arvn_DebtInstrumentLoanForgiveness": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument loan forgiveness.",
        "label": "Debt Instrument Loan Forgiveness",
        "terseLabel": "Loan forgiveness"
       }
      }
     },
     "localname": "DebtInstrumentLoanForgiveness",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_DevelopmentMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestone payments.",
        "label": "Development Milestone Payments [Member]",
        "terseLabel": "Development Milestone Payments"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_DirectAndIncrementalCostsIncurredToObtainTheContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct and incremental costs incurred to obtain the contract.",
        "label": "Direct And Incremental Costs Incurred To Obtain The Contract",
        "terseLabel": "Collaboration agreement direct and incremental costs incurred"
       }
      }
     },
     "localname": "DirectAndIncrementalCostsIncurredToObtainTheContract",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees And Directors",
        "label": "Employees And Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees.",
        "label": "Employees [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_EquityDistributionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity distribution agreement.",
        "label": "Equity Distribution Agreement [Member]",
        "terseLabel": "Equity Distribution Agreement"
       }
      }
     },
     "localname": "EquityDistributionAgreementMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_FoundationMedicineIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foundation Medicine, Inc.",
        "label": "Foundation Medicine, Inc. [Member]",
        "terseLabel": "Foundation Medicine, Inc."
       }
      }
     },
     "localname": "FoundationMedicineIncMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future grant of incentive units to service providers, percentage.",
        "label": "Future Grant Of Incentive Units To Service Providers Percentage",
        "terseLabel": "Future grant of incentive units to service providers percentage"
       }
      }
     },
     "localname": "FutureGrantOfIncentiveUnitsToServiceProvidersPercentage",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genentech, Incorporation. and F. Hoffman-La Roche Limited.",
        "label": "Genentech Incorporation And F Hoffman La Roche Limited [Member]",
        "terseLabel": "Genentech, Inc. and F. Hoffman-La Roche Ltd."
       }
      }
     },
     "localname": "GenentechIncorporationAndFHoffmanLaRocheLimitedMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Four",
        "label": "Government Securities Maturing Two Thousand Twenty Four [Member]",
        "terseLabel": "Government Securities Maturing 2024"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyFourMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Three",
        "label": "Government Securities Maturing Two Thousand Twenty Three [Member]",
        "terseLabel": "Government Securities Maturing 2023"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyThreeMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Three One",
        "label": "Government Securities Maturing Two Thousand Twenty Three One [Member]",
        "terseLabel": "Government Securities Maturing 2023"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyThreeOneMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four",
        "label": "Government Securities Maturing Two Thousand Twenty Three Through Two Thousand Twenty Four [Member]",
        "terseLabel": "Government Securities Maturing 2023-2024"
       }
      }
     },
     "localname": "GovernmentSecuritiesMaturingTwoThousandTwentyThreeThroughTwoThousandTwentyFourMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Statement And Statement Of Comprehensive Income",
        "label": "Income Statement And Statement Of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAndStatementOfComprehensiveIncomeAbstract",
     "nsuri": "http://www.arvinas.com/20230331",
     "xbrltype": "stringItemType"
    },
    "arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.",
        "label": "Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock",
        "terseLabel": "Common stock reserved for issuance represented as percentage on outstanding common stock"
       }
      }
     },
     "localname": "IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_LongTermDebtMaturityYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, Year Six",
        "label": "Long-Term Debt, Maturity, Year Six",
        "terseLabel": "2028"
       }
      }
     },
     "localname": "LongTermDebtMaturityYearSix",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_MaximumAggregateOfferingPriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate offering price of common stock.",
        "label": "Maximum Aggregate Offering Price Of Common Stock",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfCommonStock",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_OerthBioLimitedLiabilityCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oerth Bio LLC.",
        "label": "Oerth Bio Limited Liability Corporation [Member]",
        "terseLabel": "Oerth"
       }
      }
     },
     "localname": "OerthBioLimitedLiabilityCorporationMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_OptionPaymentsToLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option payments to license agreement.",
        "label": "Option Payments To License Agreement [Member]",
        "terseLabel": "Option Payments To License Agreement"
       }
      }
     },
     "localname": "OptionPaymentsToLicenseAgreementMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PercentageOfIncrementalBorrowingForLeasePayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of incremental borrowing for lease payments.",
        "label": "Percentage Of Incremental Borrowing For Lease Payments",
        "terseLabel": "Percentage of incremental borrowing for lease payments"
       }
      }
     },
     "localname": "PercentageOfIncrementalBorrowingForLeasePayments",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PercentageOfLiquidatedDamages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of liquidated damages.",
        "label": "Percentage Of Liquidated Damages",
        "terseLabel": "Percentage of liquidated damages"
       }
      }
     },
     "localname": "PercentageOfLiquidatedDamages",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "arvn_PfizerIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer, Incorporation.",
        "label": "Pfizer Incorporation [Member]",
        "terseLabel": "Pfizer, Inc."
       }
      }
     },
     "localname": "PfizerIncorporationMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_PiperSandlerAndCantorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Piper sandler and cantor.",
        "label": "Piper Sandler And Cantor [Member]",
        "terseLabel": "Piper Sandler and Cantor"
       }
      }
     },
     "localname": "PiperSandlerAndCantorMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares",
        "label": "Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares",
        "terseLabel": "Proceeds from exercise of stock options and issuance of ESPP shares"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ProceedsFromMaturitiesOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from maturities of marketable securities.",
        "label": "Proceeds From Maturities Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesOfMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_ProceedsFromSaleOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sale of marketable securities.",
        "label": "Proceeds From Sale Of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arvn_RegulatoryAndSalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and sales-based milestones.",
        "label": "Regulatory And Sales Based Milestones [Member]",
        "terseLabel": "Regulatory and Sales-Based Milestones"
       }
      }
     },
     "localname": "RegulatoryAndSalesBasedMilestonesMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_RegulatoryMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payments.",
        "label": "Regulatory Milestone Payments [Member]",
        "terseLabel": "Regulatory Milestone Related to Marketing Approvals"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Collaboration And License Agreements",
        "label": "Research Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arvinas.com/20230331",
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Line Items]",
        "terseLabel": "Research Collaboration And License Agreements [Line Items]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsLineItems",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research collaboration and license agreements.",
        "label": "Research Collaboration And License Agreements [Table]",
        "terseLabel": "Research Collaboration And License Agreements [Table]"
       }
      }
     },
     "localname": "ResearchCollaborationAndLicenseAgreementsTable",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_ResearchFundingPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research funding payments.",
        "label": "Research Funding Payments [Member]",
        "terseLabel": "Research Funding Payments"
       }
      }
     },
     "localname": "ResearchFundingPaymentsMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SalesBasedMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestone payments.",
        "label": "Sales Based Milestone Payments [Member]",
        "terseLabel": "Sales Based Milestone Payments"
       }
      }
     },
     "localname": "SalesBasedMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SalesBasedMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based milestones.",
        "label": "Sales Based Milestones [Member]",
        "terseLabel": "Sales-Based Milestones"
       }
      }
     },
     "localname": "SalesBasedMilestonesMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental cash flow information related to leases.",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award restricted stock units vested and expected to vest exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Restricted stock units vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "arvn_StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock incentive plan.",
        "label": "Stock Incentive Plan [Member]",
        "terseLabel": "Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SuccessBasedMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success-Based Milestone Payments",
        "label": "Success-Based Milestone Payments [Member]",
        "terseLabel": "Success-Based Milestone Payments"
       }
      }
     },
     "localname": "SuccessBasedMilestonePaymentsMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_SupplementalNonCashInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental non-cash information related to leases.",
        "label": "Supplemental Non Cash Information Related To Leases [Abstract]",
        "terseLabel": "Supplemental non-cash information:"
       }
      }
     },
     "localname": "SupplementalNonCashInformationRelatedToLeasesAbstract",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "arvn_TwoThousandAndEighteenAssistanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and eighteen assistance agreement.",
        "label": "Two Thousand And Eighteen Assistance Agreement [Member]",
        "terseLabel": "2018 Assistance Agreement"
       }
      }
     },
     "localname": "TwoThousandAndEighteenAssistanceAgreementMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandAndFourteenAssistanceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen assistance agreement.",
        "label": "Two Thousand And Fourteen Assistance Agreement [Member]",
        "terseLabel": "2014 Assistance Agreement"
       }
      }
     },
     "localname": "TwoThousandAndFourteenAssistanceAgreementMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "arvn_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Plan",
        "verboseLabel": "2018 Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://www.arvinas.com/20230331",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.arvinas.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r248",
      "r273",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r290",
      "r425",
      "r437",
      "r462",
      "r463",
      "r477",
      "r483",
      "r493",
      "r538",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r290",
      "r425",
      "r437",
      "r462",
      "r463",
      "r477",
      "r483",
      "r493",
      "r538",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r283",
      "r290",
      "r318",
      "r319",
      "r320",
      "r400",
      "r425",
      "r437",
      "r462",
      "r463",
      "r477",
      "r483",
      "r493",
      "r534",
      "r538",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r283",
      "r290",
      "r318",
      "r319",
      "r320",
      "r400",
      "r425",
      "r437",
      "r462",
      "r463",
      "r477",
      "r483",
      "r493",
      "r534",
      "r538",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r248",
      "r273",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r121",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r179",
      "r217",
      "r218",
      "r337",
      "r358",
      "r359",
      "r360",
      "r361",
      "r379",
      "r391",
      "r392",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r121",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r179",
      "r217",
      "r218",
      "r337",
      "r358",
      "r359",
      "r360",
      "r361",
      "r379",
      "r391",
      "r392",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Error Correction, Adjustment [Member]",
        "terseLabel": "adjustments"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r291",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r121",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r167",
      "r179",
      "r337",
      "r358",
      "r359",
      "r360",
      "r379",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r532",
      "r533",
      "r573",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]",
        "terseLabel": "as previously reported"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r168",
      "r291",
      "r500",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r204",
      "r205",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r479",
      "r492",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r448",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r479",
      "r492",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r168",
      "r291",
      "r500",
      "r501",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r526",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONNECTICUT",
        "terseLabel": "State of Connecticut"
       }
      }
     },
     "localname": "CT",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Total accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r490"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net accretion of bond discounts/premiums"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r2",
      "r99",
      "r110"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities [Abstract]",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees and other"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r65",
      "r127"
     ],
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r130",
      "r433",
      "r443",
      "r447"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r90",
      "r392",
      "r438",
      "r439",
      "r507",
      "r508",
      "r509",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r490"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r327",
      "r328",
      "r329",
      "r516",
      "r517",
      "r518",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r84",
      "r85",
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per common share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetPledgedAsCollateralMember": {
     "auth_ref": [
      "r351",
      "r486",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset pledged as collateral.",
        "label": "Asset Pledged as Collateral [Member]",
        "terseLabel": "Asset Pledged as Collateral"
       }
      }
     },
     "localname": "AssetPledgedAsCollateralMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r109",
      "r128",
      "r147",
      "r193",
      "r197",
      "r201",
      "r214",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r351",
      "r355",
      "r369",
      "r490",
      "r536",
      "r537",
      "r581"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r123",
      "r131",
      "r147",
      "r214",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r351",
      "r355",
      "r369",
      "r490",
      "r536",
      "r537",
      "r581"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r210",
      "r224"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r57",
      "r209",
      "r224",
      "r428"
     ],
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r46",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, equipment and leasehold improvements unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r228"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of collaboration contract asset"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r40",
      "r125",
      "r464"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails",
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r41",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r34",
      "r40",
      "r45"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r91"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r347",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Research Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r19",
      "r102",
      "r116"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r68",
      "r229",
      "r230",
      "r449",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r516",
      "r517",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r490"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 53.4 and 53.2 shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r26",
      "r133",
      "r135",
      "r141",
      "r429",
      "r434"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "negatedTerseLabel": "Comprehensive loss",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r107",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Contract Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r276",
      "r278",
      "r281"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contract revenue receivable if milestones achieved"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r276",
      "r277",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Revenue adjustments arising from contract modifications"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r276",
      "r277",
      "r281"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r276",
      "r277",
      "r281"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r282"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from balances held at the beginning of the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsSummaryofContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r146",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r261",
      "r268",
      "r269",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r98",
      "r100",
      "r108",
      "r152",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r378",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r93",
      "r95",
      "r245",
      "r378",
      "r473",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r17",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument bearing interest rate",
        "verboseLabel": "Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r18",
      "r152",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r378",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r74",
      "r75",
      "r92",
      "r93",
      "r95",
      "r106",
      "r152",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r251",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r378",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities",
        "terseLabel": "Letter of credit for collateralized by certificate of deposit"
       }
      }
     },
     "localname": "DebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Gain (Loss)",
        "negatedTerseLabel": "Loss on sale of marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Summary of Available-for-Sale Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r38",
      "r63"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r295",
      "r323",
      "r324",
      "r326",
      "r330",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r142",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r169",
      "r171",
      "r173",
      "r174",
      "r175",
      "r179",
      "r360",
      "r361",
      "r430",
      "r435",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic (in dollars per share)",
        "verboseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r142",
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r171",
      "r173",
      "r174",
      "r175",
      "r179",
      "r360",
      "r361",
      "r430",
      "r435",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r176",
      "r177",
      "r178",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "negatedTerseLabel": "Effective tax rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r148",
      "r332",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expense not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense not yet recognized, period of recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation expense on options not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "2018 ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r71",
      "r120",
      "r136",
      "r137",
      "r138",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r167",
      "r181",
      "r216",
      "r275",
      "r327",
      "r328",
      "r329",
      "r336",
      "r337",
      "r359",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r392",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r122",
      "r147",
      "r214",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r122",
      "r147",
      "r214",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember": {
     "auth_ref": [
      "r503",
      "r514",
      "r531",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee or group of nonconsolidated investees. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee or Group of Investees [Member]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee or Group of Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest in joint venture (percentage)"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r60",
      "r194",
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r362",
      "r363",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r259",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r363",
      "r397",
      "r398",
      "r399",
      "r473",
      "r474",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Marketable Securities and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r259",
      "r284",
      "r289",
      "r363",
      "r398",
      "r473",
      "r474",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r259",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r397",
      "r398",
      "r399",
      "r473",
      "r474",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r211",
      "r212",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r270",
      "r274",
      "r357",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r471",
      "r528",
      "r529",
      "r530",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r193",
      "r196",
      "r200",
      "r202",
      "r470"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes and loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r27",
      "r38",
      "r60",
      "r103",
      "r117",
      "r191"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss from equity method investment",
        "terseLabel": "Loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r333",
      "r334",
      "r335",
      "r338",
      "r341",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r149",
      "r166",
      "r167",
      "r192",
      "r331",
      "r339",
      "r342",
      "r436"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income tax benefit (expense)",
        "terseLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r426",
      "r510"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r510",
      "r575"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r94",
      "r105",
      "r139",
      "r190",
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r30",
      "r189"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Lease for laboratory and office space"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r388",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Base rent"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r577"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Right-of-Use Assets and Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r147",
      "r214",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r352",
      "r355",
      "r356",
      "r369",
      "r469",
      "r536",
      "r581",
      "r582"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r101",
      "r114",
      "r490",
      "r514",
      "r531",
      "r574"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r124",
      "r147",
      "r214",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r352",
      "r355",
      "r356",
      "r369",
      "r490",
      "r536",
      "r581",
      "r582"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r100",
      "r111",
      "r258",
      "r272",
      "r473",
      "r474"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedLabel": "Less: current installments",
        "terseLabel": "Current portion of long term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r69",
      "r152",
      "r263"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r69",
      "r152",
      "r263"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r69",
      "r152",
      "r263"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r69",
      "r152",
      "r263"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r69",
      "r152",
      "r263"
     ],
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r231",
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss contingency"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r34",
      "r36",
      "r39"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r28",
      "r39",
      "r104",
      "r118",
      "r122",
      "r132",
      "r134",
      "r138",
      "r147",
      "r156",
      "r158",
      "r159",
      "r161",
      "r162",
      "r166",
      "r167",
      "r172",
      "r193",
      "r196",
      "r200",
      "r202",
      "r214",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r361",
      "r369",
      "r470",
      "r536"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Grant Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r193",
      "r196",
      "r200",
      "r202",
      "r470"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r384",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r382",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r511"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r387",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r87",
      "r88",
      "r89"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expenses)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and leasehold improvements"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgedStatusAxis": {
     "auth_ref": [
      "r351",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by pledged or not pledged status of asset owned by entity.",
        "label": "Pledged Status [Axis]",
        "terseLabel": "Pledged Status [Axis]"
       }
      }
     },
     "localname": "PledgedStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PledgedStatusDomain": {
     "auth_ref": [
      "r351",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledged or not pledged status of asset owned by entity.",
        "label": "Pledged Status [Domain]",
        "terseLabel": "Pledged Status [Domain]"
       }
      }
     },
     "localname": "PledgedStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PledgingPurposeAxis": {
     "auth_ref": [
      "r408",
      "r486",
      "r491",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Axis]",
        "terseLabel": "Pledging Purpose [Axis]"
       }
      }
     },
     "localname": "PledgingPurposeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PledgingPurposeDomain": {
     "auth_ref": [
      "r408",
      "r486",
      "r491",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pledging purpose of pledged asset owned.",
        "label": "Pledging Purpose [Domain]",
        "terseLabel": "Pledging Purpose [Domain]"
       }
      }
     },
     "localname": "PledgingPurposeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r506"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Payments received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r122",
      "r132",
      "r134",
      "r143",
      "r147",
      "r156",
      "r166",
      "r167",
      "r193",
      "r196",
      "r200",
      "r202",
      "r214",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r350",
      "r353",
      "r354",
      "r361",
      "r369",
      "r431",
      "r470",
      "r487",
      "r488",
      "r509",
      "r536"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Equipment and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r64",
      "r126"
     ],
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, equipment and leasehold improvements, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r66",
      "r115",
      "r432",
      "r490"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and leasehold improvements, net",
        "totalLabel": "Property, equipment and leasehold improvements, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, Equipment and Leasehold Improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r86",
      "r119",
      "r590"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r504",
      "r512"
     ],
     "calculation": {
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesCashReconciliationDetails",
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r76",
      "r113",
      "r442",
      "r447",
      "r490"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r120",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r167",
      "r216",
      "r327",
      "r328",
      "r329",
      "r336",
      "r337",
      "r359",
      "r438",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r346",
      "r569"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Milestone payments (up to low)"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "terseLabel": "Transaction Price Allocated to Performance Obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r140",
      "r147",
      "r187",
      "r188",
      "r195",
      "r198",
      "r199",
      "r203",
      "r204",
      "r206",
      "r214",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r369",
      "r431",
      "r536"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r386",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedFromComputationofDilutedNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Securities Excluded From Computation of Diluted Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r18",
      "r72",
      "r73",
      "r74",
      "r75",
      "r92",
      "r93",
      "r95",
      "r106",
      "r473",
      "r475",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Loss per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r62",
      "r122",
      "r147",
      "r214",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r163",
      "r164",
      "r166",
      "r167",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsScheduleofCorrectionofImmaterialErrorforthePeriodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.",
        "label": "Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]",
        "terseLabel": "Schedule of Correction of the Immaterial Error for the Period"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Minimum Future Payments on Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r45",
      "r96",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r292",
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r78",
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Share-based award, vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Incentive units authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common stock, shares remained available for purchase (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable, ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period",
        "terseLabel": "Annual increase in reserved shares of common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Stock options vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Annual increase in reserved shares as percentage of outstanding common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquitySummaryofRestrictedStockGrantActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r294",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Intrinsic value of options, vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r46",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Accounting Pronouncements and Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r71",
      "r120",
      "r136",
      "r137",
      "r138",
      "r153",
      "r154",
      "r155",
      "r157",
      "r164",
      "r167",
      "r181",
      "r216",
      "r275",
      "r327",
      "r328",
      "r329",
      "r336",
      "r337",
      "r359",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r392",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r181",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued and sold (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r71",
      "r76",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise/ vesting of stock-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited",
      "http://www.arvinas.com/role/EquitySummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r71",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise/ vesting of stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r55",
      "r490",
      "r514",
      "r531",
      "r574"
     ],
     "calculation": {
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited",
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityunaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedBalanceSheetsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r376",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r376",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r376",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r211",
      "r212",
      "r270",
      "r274",
      "r357",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r528",
      "r529",
      "r530",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsSummaryofAvailableforSaleMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r182",
      "r183",
      "r185",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/AccountingPronouncementsandSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r170",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r169",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted average number of common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.arvinas.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossunaudited",
      "http://www.arvinas.com/role/NetLossPerShareBasicandDilutedLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=126928961&loc=SL5834089-161433",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r495": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r496": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r497": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r498": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r499": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001655759-23-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001655759-23-000041-xbrl.zip
M4$L#!!0    ( $I'I5843J--[H$! ,J##P 1    87)V;BTR,#(S,#,S,2YH
M=&WLO6E7&\F2/_Q^/H4>[BS=Y[AP[@O=S?_0!G.Y8PD;L#WPQB=75*"%6Y(
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M?E%??QM'3%(R"VFD\7_X G)O! .9I)[YC!&",^NX!@L8W&5+HU04+:T^" @
M0[B2$H&RT(QA<.C!,M!6*&6<C43,B$F&@"D5C_R81_);/(*EM(&8D/"# X]P
MFMDH<*:LM"P('"@".'D0D%!*8X@4@<&HF/;&VH1) 6MKJ6/>5SPRUSPRO,4C
M!%-.&#A^/'J4L4AL9E1D&?A\V/I L>'^@3PB6)#4!69(M,RK8)CGVG$:I!:2
M(UKQR#SS2./-+1[Q1%!NJ0=S,P*/&.U!URB3 7[$P+R(6L<'\@BW1D>GD?(
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ME0XB,%:S5,=><T&U%4H99R.9N<'^XKB.3;#E5^8Z"NHR1(J<%(II;ZR-'/.
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M.'8B@C?G%X"EG]I;>9N?_HB:E?PM!K>;$+@3",M@*6.!FQ")B)[8Z+&*DBP
MM_^:##0SWW)!&)M1BR(B"FLB@:^E!9963 3!4WXH"A5C5XQ]G;&W.XO"VY)S
MKH/VT2K&/!&*IHUVS!(MA9615[P]I[P]-PQD"4^GQDEC?%D8B2HG%>+"1?AN
M%R">];[HPGC[P_<MF(*UCD\G7I7[H_X>?BUL6@+!NU%]X6XQO'QF09QK)1'#
M BOAI&;""VU2YA+!%-17\%'.OYC/+Y6F*$L.&>=%X)1S1GBPF 456>388FH=
M>2&R-'GX'6!P:'9;?JM]4H".7:1=98PZ31Q7WC@@DA/*"D$%YFG[>LI7>"$"
M-3M234^J*$$4.XVH88@AR2RGVD8=&0.CAZ.7)E7;,>8N+)J"DCIJ[ZPV*H"/
M)952FG!.@F?2!>7Q"Y.GYR32]"0I%;I4,?H@T^DY2%II02UI;P'Z*(IS7L+L
M9@6 O'./"@ SE(]!)Q_->V>0^G(YI>V1Z[(Z;@,^3AJ8W)E\3RW<24B-",/6
M4Q6#8?"O9<XQS!1FQ(&M(1>+D/<JY3 O0!<I(RA2*9WC8));3;T+AMNT3X]S
M/#EEE<_;.;,X0_SQK-S[=^S?8N1!OUA)-Q[,QF!_,4MA%IV4S 1GB&,J:L2D
MPD$A\7QS^=-*HQ7\84KE'10GW=XMHZO?#\5V?%,$G_](1SSLE<&GXS0&-T]S
M[O5"?WQ_K5<>J ,=>.)3MQ_%6-?SR0QS,2)P;C%FU"KE*9@32F/DI>8ZSB^J
M5>SP)-MD !,DPX'2P,"+-H*)Z(AS@4GM2%DY-Z'#J*+#7,+$<YHMUZHDE$)Y
MORH)-^3W$542D--6&H:C %M$$F*<$%81[:/GX+6A!2784YDGLR=8%-YYZS!Q
ME)6>M>#E(8@"$^_D^!2AYR780LP;"5P+'DE0*C CO$'>.1ND#UI%9V:^6?G'
M6F,]V/Z=:V57UL.2#YP?-OLA=$"3Y G'W<(5468(2Z,M)RP5'%7.:BDX=M8X
MFY2(GO^XQ)R3:HIQ/AHB)9*"#A&,4*H-)Y%B"?B$I1UM)\!J7H^ N3S>;C-T
M#PMSTLR=&2\3]OHGQ<J;O<?;>O/-"JDL_Y1.:]$A&L:8PP@11A0Q4G&NP!,
M$08O.XP/3=#C0Q.0KGABGGCBYF$-^MZ'-<"C4ZEU2DWP4NBH G5,!VX%!07M
M971PP6$QQI**;^:*;ZYCB9X.EG"@#[?:1J$\DTB!O<:U#BR AV*!/TI68"_
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M?="8,YG]I[<4T[R\2 Q^U'+0V1>#C-?6B4P1 %*&9<P,3AL\#6,R&"HD0\D
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M*=\1O;$TI-,\>N&R^?*\IL0F]SN@@<P>A[[']O<3]+&<!YB_=C?)]1A24EK
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MB:";?N#Z-9>.SDE%$LKR">T0^J QP,HI1UU\-2D.!^".=HMA[?(LO3ED,K)
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MGH6E5;8LY\C;J&(%\Z3U*]F<EFS>U/G>.<8M-5GP065,P#\:]'VFC?**BD1
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M\4%S18//72COU(?^P<'C$=# C8ON.ACS/V"$G9A:@W%TX?7!A8\H<F2->!Q
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M!'96&;+>>$%<9,@P8Q&/BB'M%4:*Z<@B-8(97P[X9JNXWB7E?WVCKVK >IJ
MM3K"6@/6<HAI!5@L86.)L$CQ".:D 4O2<2^09Y1%IFB0.FSM2#;'/;X1@/4(
M..O&197EMLH@H"> $*6[\K.&L_V6K_H-M=IG@QCN<![-8'^$[EEN8?^$.A_>
M]-:;IBY>Q]Z[O#>6RW/IM5KCA>UU8++ZH^?^F7?D6'O@6GO<0GM\F*&[3+ED
MJ+>(1)H0=U(@0QP07\^\]49YGT-2UGD?[%=X5.^$.^X$924.AC&$DX:=$+E!
MVL#J>.9"HE'(:(I;6LSRB*5&*]V DYO3XK=6<X]8S=W1.JKA;>7P-IV PWF@
M7#A$0LB9==HBDXQ'TA(EJ"9&8/I+BN[>=D)->):R#Z(P3B6"-+4&<4H=<LQ+
M,)P-L\0*RG@H6?VSW>LV5\T] AOZCN<^H?5M=.\3V_O<ZDQ$1H]NBO(=BLXH
M=VUU0NP,GB-3","]&.$"M-'?Y1\Q-"R\B_T<KQCB_4;W;- ?@!T.X_V950[O
M>Z<$VFKBYNW2.S*<-='YUP)]-<VKSJ ?+?)NM<:'9R<N]EZE@O/]5Y=+?!7S
M:Q?I;3#?SQJY6N:,6XZBEB8G;470_0D(@"">X&B\IWQ=M\20_\WLC'I3W'%3
M""H5B88C$K49AF%%3Y&Q'$<@ 5@1MK4CV)R(CN7F:"\#:C<H3+U6,'/09.EQ
M[K6"62F63!D5*L1<SX\B94"M\'S\YHSFR MCG-.,,&W7=4O4"F9%FR)12PR6
M%B62'.)1<&2D)4@Z(Z7TW.O,.D#!W,+2?&0*9DWMT=\'%MY_9#UED[%L?*VY
M3UHDK%SDC&(G(M=".1(LH3B&3U1L37YIULXDM*C+<OOQJE5S#^-KV]-^?#[Z
MY8_1\%J=HE7*E_X8WFRXE-EHG9KVLBS5QW]\;X7!\7."\38L8]9%0T-[^.3A
MQ]OEHZF]5'TFU;8QUW^,M\FUG_WLMH1O8W']5W]VVY]_QK%<S6#9;6^[.9O\
M>J?+C>S.W,D_XV.N-[!*9J9OY6!YV>TU!L>Q<73<B['1A.N/^XT7G1##/UWO
M]YVF[?GC!B//;M&4Y5Z6XP&.B<8366[SO#6 1_C;G*2$#&*]?J/5:<!3VKG\
MQ*V:VRQ6K&#==E5^]6SD+_%-;].)YU%,&EVYF*V%^WK30L!666[DD9Y\W_S>
M:^BFJ%,8KC<\#]\-#<^3]^<?OAS@P_T7['#?4S \Z<<O7T7SY..7C_O_.6[N
M?VPW_WI!/UP<MBX-SZ_\XU'S^\?]ER<?_W[;.CQZ(YH7G\7AR<LO8'1^A\\N
M/A[!/>G[\VG#\]71<1N,V:_-OS^VP< EA_M?+\!HI1_^;H+1^2=\!L;LES=@
MG/XK-6>[M^=@'4N$0%@:C+@T 8'QHA ER;B@3'(1WSF#X<&K#*TR<J=&L$>*
M8$\MIV%#$&RZ1Y0!#>.<E,B;%!&'=4":8(LLT=@+S*EWZ<XI#0^.8(^ U6Y*
M,F[5_!+$\[07CV.GW_H6"\M]_DN-5V][&+9^]W@$6V[C"MR\[_0B//LBAL9G
MV^HT?LL;[Q\-4%3VFVVULW<7I6X/]6WV#4=_UFL-6G'& 'N,]3,>LH=%@82]
M242H]/?N:%%@3?*2O!NOR&[X<E95TP!E_RH=V1^ON[T\[MW!H-=R9\51?]1]
M;7MP24T!%J  AWLS1HQ@.!"J V*46L2UHTACAI&ET0N'J37:Y488=8.TC9#T
M]2#IM<ROE<Q/TW[N@H["<T1YH(@SK)#Q6*-H72 14\."V=HA?+TK8ST"CK4I
MM'YOAM"O,D+B:7B%5C(Q&ZZ15N?XGJ.,1HJFUB:+:)-W,PS2$,Z5D@XE0576
M)@19*WENNR1U$BQ)S[9VE+A3Q;952,MFU/NI(;.&S <A\35D+@TRIPFX,,XI
M12EBG@,!)]P!6BJ-F%"4:>6%=!(@4RVCBO<:0^::,OC9Z-3Y@::S@3[+ 0F"
M%X\*HSF^\EV,#>NS]]UVSF')&IWN(/8;@VX)PP/8"+D2?YZ,3EEBF[,?4ZMC
M.QY& Z.&/Y0BME>S&R=F8/@X7I(YN_U6WI+/>[%M!X 1E^&P_\_51-#AWL.7
M7[$.!G VN/XK*Y_::P$X1RZRJ?3.B9\+!"OK<;#R<>\RUO!S1*X7[5=D$[S6
M<]O^;L_[6[]?W6BPRR:G>GJ6KIV+E)8\%]4>!WW1K9I</0> B;U\%8S$/O (
M&L>]K /_Z^:U4%L[1R4FO/O/W^V&#3PU<K.Q2BQA['-VYC40I>\#HJ[S&Q1
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MCYAP2I!A4B,>@'I9$0+2D3I@S)SZ1+=VA.1SRO6M+_%:4LKY@Y3UN9WT%5%
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M&=2AMP_-((9KM!]3A!4)PP"^W4XH&%4"_&IX6@R>9AO%<YVH=M$A3 @&>!+
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M$:P:1E88@BPU6#K/$Z-D:X>)NQ=]J)T.:R:OJR,0/Y/7NF?B<N3X?#H#T-+
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M,2'F,H81;KWO#4YO[L#V61\6\<]BB'(%.O<K81N!#F74$P^.1DH9=(*.2/N
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MI#Z5=?MK*F6$-;,A3_1+*@K$ S'(,,^0\Y%JQIV@F4>%K!/.GF6JW]V$DB^
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M>_[[\YI14F\-S6B>'?[M VULU\$4'K7VMS_SW2:8QFU_4?_V%4S=WD7]<HN
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M1(57AF$7@\.9;/[VDXSU6L&/?)J'1Q1^D@/8+)R/%N!F]FH +4(L\FFC9-\
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M0=CKF"0FRJNPMLGXAEFA-II[XLVM /A&=?6A?E^EJX^KJY.>(+54:B4H8CB
MKE+*D#:"H6BXU#9I8K0$714KI:O+K&)>42=AI^M[G5@[M3_OZ0^\M-KEYTF=
M99@IE[J95[H"E<5!Y49/&ZL?[_'=K0.G68J,*"04S>4!.O>T<8$(BT*)J*R7
M:FV3X VR0@UMRXZ WJAR+C'Q4RGG,I3S<D(Y->R,%DXA+HQ#W%J%C -=C=%+
MG91T"<=".1^<VE[1#H(5M?@?.B?MWD6,51K@D<W^:*&'XTEO5%Y5"/-@\\_J
MYX P3F*L"(I"6\2)"L@Y9I#@G&@3/(U$YX+.9;5,5N'_RNCHLJQ_I:./Z 5D
M':7"Y>G= :E((N(N4T![KY$#G15>.VD$ R] +^T(J(K[Y]*U/_N]% <#6&?;
MKJ68"8>[H=8[/8K]*@WPJ&F FRO_,59 \T!G@.YN?_ZY^_E 81,3%0H1!1C#
M9>(0;L2(E ^&!!FQTG@I;*!5*F#5%'3)J8!*09?J"8P4E& ON'$*!6(YXMXY
MI(-7"+ST%)SCA,68NU=7*5>WS'3 L].8W,6R9.?L'GG,%N)%29E6Q)-Z5,Z!
MN];DA:/V(Q4FSVRGK"#\'A ^77#A'8Z8 (0[F1,NAAND:4P(MLEHGCB!;5S;
ME/)9& @>@<5J2<F:"B0KD'Q^U[8"R<<!R<E*%TX4\5)2)*S-TX2E0)I)A321
MWBNIN#,0B"J^[*+GYP+)>Q.TS$E)PJ\H25:6,T(_.F?$=G2GJ\<)T7@_TE!_
ML7]\=-38_GRQWVRTX7O8_O9743]N'.UO?Z"-R\/+1F?OO$'WCR>;]AN7?W1V
M/WW C>T_VG6:OR=\;S2_7]3IQ^_UYA[;W:[3?"_[G4:J-^NB?G@ OJ("],/(
MYV$,W"2/M- 2A4R;#H"IJ&23K!#@5UJ)G2.2"IX'>WO*F2=<8I4G$9K)-O]_
M][J'J!G[G5I>^GM0/_SR"Y^.^B$_P4YW  ]6D+6^6>D!S-[=]FRWN<7JS2U<
M/S\(FICH4D3!Y_Z4/#W($0;^K67$$Y%H#/ZE$$#D7;XY+_NA1 _R9?$\,+G!
ME:AX'JJ;?;2;Y16#QNMCT"@'[=:V[>D4?\*K)\_8&9)6U[Z\Q:>OV%-6D#WE
M3M*IIW.F*":ZMC7(_I/M^EC;.NS'6#1/EN' &*'APS@/[@[)GU9JYIR0B\T_
MJ;Y7:_"\96VO?@EOS0%VS[)"3J0!:11&YG!$Z\BM#!8'[UU4(1J=O&6SSTIV
M&A]GY1&N0\$1_F?X_^LT%\#]&?MYB>SA]3P/1%]FG%CF 8__TVE\^LH;S2T*
ML=]E??LS@7B1[QU_Z=2;7T7C\CNIT\^T?OEQ*@_8^+:']YN'I+Z]QQN7]?/&
M]E>^USQJ-3[M_808$^+(KY?[VWN7]6_CW >[VSL7]<\'T481+7<HD. 1=](A
M)U)"RBB+B;",&;6VR3;H=$7*WQY#MRJZE(HNY9Y ,F,:1Z][F+-C&4]6YL#@
MA0 %N0$4EXT\^2=I+5)$Q&*,.#;Y5#59I!D33GIGC)&Y<FW)AZH5!52%::\"
MTS@FRAHG*+>><PT*HZ0@'M;&*>.IF?>,M,*T^V,:F\ T13EU40*F,4$RL[)!
MCL-O@&C$FZ@D#?BE8=H;Z HH9YKYLA"@UH) P;;;=P]>?.E$4%4-]AV)W^>8
M\W8#A5>M(N5%@''KIH-9OVB<'W MP=TG$FFL,TV"4B@/(4#)89F89THZDZ>X
M35=>/\L4MTHC5ZIT;*9"KO:,[I>BJ&Q"49,0T0D3$.6.(9Y(0%J(@"27DCC"
M;>#I!<[H?CUM$NU<%72:JX+"S6. 9\J K_HU'E2X6!4]WW-!7KC9>@P_LM'K
M^LJ57-Q"74RYDDPJ(Q17R/O<SD^90#HPC+C,V\1X,(9G5W)9+'[+T(B7W/U1
MH>#;1,''<-XK%+PO"D[ZZ91B+ 1WB!!/,N^@AX!:"92W2VN-.5'Q$;*;SX*"
M<[1WW%ZS\[P5T3O=VA]GW5C+Q3SK107T^UX'OOVB5E2!Q%!K=4][-;B=O$ZG
M)1>*O2[ZL5=%/^>MTZ/B D651*ZG?M_K=B/LJ3\[K?T]O[)V:\G0VC]J\"TG
M_=Z/5HBU!-L+>Y(CZ.**\2?<428;*%JN03M[/\HN OB2MG5Y$&NO?U&RLZ34
M@@O# OJX46O>>!YX6[]W#@_TOPM@#&,Q,:J84U:")6?&"C#A1'E"B7*EIT4T
ME@S?C3'C-24?X>:V.KG9;#Q+T#WKH- KALOF*[UT"'I %\(>/1!2BP#PC;SV
M"G&+;6ZIQ4BID"CG+ED&;A2= 2"C MQ:,9FWD*#;:]5:W=I?\>2T+/$KM0"D
MZORHY8\6DA03D^6<>X(QY513J[006AL"T&>$B+D;!23%%-TH^9?;1*9@W1Z7
MEW_W;/=C#U#C1^S&P: 2FIE"<UF_/ @"1T6E0UE!$8=-05H3A@1+3EN2K"G8
M;N\2FG,[R.M;+';M[ 3^THGQ-,.1!QM@05YB08A62 ^(0(F*@XW:[P7 P!L'
M-P3O&A]=M/V,HZU107%_").+E;G=#Y'>=IG;O64*KB\.&$G:V<01%H8A3J)&
MA@:%##=4",DE]N2V(K7:2<R;#CNY7AK(T>ZC7K=]D9E$BI-#L&G_/6ME:SLR
M>:G5!Q&YJ_WM7H!S*\2,]O_/X1UEAW@,9\#!\._"6;\#]W#TUL2@^0$?$,:E
M$H&@P'&N5504F0BNK2)41L-$DA2@1>))UZ]6K-A@O7!/.KF7(DX:':I+5^5V
M*S64CP'(ACT=<]-<K+5[/BMLONJM_M?I$3C-AT<37SL42@M(D>Q9^Q3$%?R[
MTXO\Z7X<2N=5:]Q9NUWK@3O<*OCPACZ:+?R8_)Z%_"H;@Y(FZ<@\H+1PDGD'
M?TH>_N")'*+8K4:R\JON)<>7]8N#:))76@LD8J2(LVB1D8P@B)43U<2"=V5^
MX5>=M,\&M78+1#(4@A=L!\S$8'%C]D"GZ895*R#MVF3MIG]?W=YV>7=OV(I=
M[ET<V&B""=$@IYP *T8SM9C62%J<^\&E5RYD(N!91FP( *<E#=:5PH\@H!]]
M!&\I;,P[&_W90UX_1,;L[A4 V+U/3#L6(0/X@HCRH>M7Q@\6 #-_VEU[ANYB
M#+W/X0)7WN9X_-VZX17 ]1?$^3]L]\Q"3 PHSY\-Y05LGW#&):D#5UA;&80Q
MD8.+3AU ?X'R_-<9N@KE%V. ^" :6Q _QRAX$@AB 5!XD11R-(#"4X^-9TEC
M %/ ^6F%7S[.<T&(R/4U7@L0!&$H8=@+S_(]NN0*G.=#JH9IB:AP?LZ-W[F
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M_9T3U_=UJA@E,HE2PCQ/@N[FIA@S&C,J(QWY=&/;9PV)U<LKGKS?Y-G?;"#
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M6,*#,CCL MX_'L/<77B0-/Z0>(27LPD\4JS[ %]A0(I9H3_[6E:?=Z=D\C]
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M@EI=5K,[>EE=%XGN/FST(I=:5>&KP>K!?]87ARINKOVAEG-N-RY_<?JLL^X
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M'".;Y:-L_%=NZV7L&A--FIX8-;I'],*<_0=C]DH'FE&M?E$F1*T/(GJCA9G
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MC>9M%9'9\'V7:3FEYH0)PUD!C$<:Y$&4W18JDPD#TS;DGDOP/'<$.ZI/#Y/
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MR^49EFSJ0JC0F;$Y_?C3_P!02P,$%     @ 2D>E5LL6'3UI&   LNH  !4
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M70;K"T/&<O),MT]0; =N2#[,@4C6C^!ZY-6=9P1']6I%A<*"T-Z"\E9#S-9
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M>PILR\S!^>OU2PQS_.6'_P=02P,$%     @ 2D>E5G>LGT7U10  ?AX# !4
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MJ-WAEP!N6 J4^/+L4=J8B8\HIS;22 G4F]#K ?E]60FK 1_KO<3N6JWHY%^
M6#*L#XR:"4J70Q\^!6E'Y:^;;P_-U<XLN@(G>70,,N.$,E=NR&U$=R%B[. 4
MB^@T.MVO/O2Q#7A'=E!=^VVCL,IV^]7_.3Z?GZ].=D.,4C-%J"@E 7%TXJR1
MY;0'4"J3(?3JMW&/Y:X->N#\@%W5WM306<73\ +DHH#01]P9?#MN%HQ,BBEC
M+!&I/"MDQA-/@R8@N5&)4:UHKR(;]QCQUL$?\X:YO[8K'I1T@)8X?I],OT(<
MYS&D96Y+'U 5M]*-0 Z_L58P4C.4ABLOW9O!8>B%[CIGA!I<SJ3/DC@1&$DL
M)BUP/7*IAIM\8+/?L1T?RNK;*'8@:[]N6HA^N@K#H^$8<%M9=I_N+I9BT%>R
M S  S,XQ0$DKFOKZZ(?=NBN9Y19#[Z'3 8JG?9R'*?S7O-0%_%;B>_QG"SH[
MC;X&\C> %$2*!,32K$D2@J5$!9>^>N>"VZ$\UEV^I@6&Z$)P$]9J-^H!;*#4
MO(V@CE1=M8;I[J?#'GH?HO/79H L20?,$J1\)C);0:SRGF"$&A1/%,%7KS)^
M6$+<5V/UL'S80MW#\V#UWD31DJ-3SFM+CQY#([$I&1*"Q\V12LC5:^S>"N0(
M72/K&.IN\^^@Y8U.PU&JYEVY0'C?X@]?G'5,@S1KWD/;U7";1'@7SL:?N\^8
M'J*BWLZ@#EAMKX[BUBKQ@5-4L&"SXUE:S8*T&3*#*!5Z,L+VK\2W,[Q]:_]V
MU1<^0)EHB[8[-\?ZY4]TX1'*I_$Y_LJ[_!&_.\T+L&\O'ORGF$ !-80[Z8BD
MMKO"4L1Y8RCZ]=&*VKM7/?3[UU#N@60D<PY>1D:<+6ZN<!CCEF=%SH<0>$;Z
MT*.HZ/"+_9%X=[,L<VVS#5*?>T]=+7IIL9$%'TP40((HC1_+@U:G0B(LH& *
M=U09:C_=J(7]F:&'-/X WN[><BP."F14BFFJ"+ILADB)^O3,HE.HLV?"2)7X
MR6TR!VUV]%AHN[VYCUW<IYKH'V>^G;U"WV_QA$Q =E0+PEF@&*J4/H<6 M&.
MN<2B,%F;4V/\-0F.U;[I&!2L/0MVI\+&)?Q!1:TC=I)QZX@]A,AU77EKL:MV
M@AH-GAL7I,C)RL -DJK4R.'"PO"Q*P)\CEZ?H]?GZ/4Y>GV.7I\N0Y^CU^?H
M]9'1]MC1:TTG_U??_@NZ9N27O<O1"WSMQ^T__-D<?@4_G2_::$P_SL_/??N]
MR5?;GI<G:[=]R!XW4X-CVM^]/ZS:UGS[X*-W7'C%/9/)(]V2URH+;;S.V=K1
MX.CV6V\O<"Q:;'2)0XMBXN/RQJG#EMY-/I1A6YQ]BW=6[>JO/_OI^$HI:J71
M!TJ6$BLB;AZ)H?,3M"2!&9-$ELJ'VG?J5078N\33RFZO%W9[!6%V:;$7YTT[
M&_\WI-("IQMX%(T$J[4F)IC2ZIIJXF+$U4M8RW7(0'GU]GY;8CR\2W4\3MZH
M##6D/0<( >[!>]GK\.]M,YW^CCKS9T6 OZ-9?BZ+#7SR?X[ 0I Z*.*EI$0"
M2-28%82R$ ./'G?:7@^5ZI&R'_!GIA[2\D-4R-M1B+?XMTLA?+ T9DCE<:\I
M'<(]?D5+OU^=@K;.A%"[>F<5X,_T/:3EAZ@<NB;$55_MJCBC;#7W0>#>X+)&
MG*5C1U+EA9U,7-ND682!&;H)VS,)*]NOXLOPFAI;Q,U196VXY01HE.BNR$A<
MDIPPG"M,@V<^UNY;5PW\H4Y*3H>?Q['[J=SV7TC_\_>++__/&-IR<?;];2G9
MU%W=>@].I*R(M>4HR.I$7&GTSHS'Z-Q2%W@>BM)W(CO6[?R16+.)N_6L-X #
M>NNIS$V\RVSY/F '>EZT%=#C/#D:PN*;2#68N8[.,5?J"Y5+F. UNAK<>N)+
MZ4'&4)S$C=+57S>> +?N>;UT<M3:QDI#4NK-Y.M\-NTTP%?%[]'/")VOJH,@
MTCE+/,^6"!%C#MZ*' 9S\6[".6)X4=^0FRBSIQ4&.!>\,F&NJ.%UV[W7BM^[
MV<*T<$X82VARY:46<\1"$@2_&[U7BAE:^RBZ!ZQGKZFFW08X]+AM?ET 7,ZJ
M/A /Z"BMP3NZ>U3'M#TVL!IV.9!'M [52Y84R$R<[]H3:XYQ<[+$\IP,SP L
M\L="G?[>S]&8LXTY#N5#7ZS%J_)_&F2(*1%*/;I_-(K2$@:($A248\+*X3:T
M.W"=A@NTET'[^,K[6&,(#V@\\9-2P?7-9#IKYQ=]@Y+T-@ONB X4Y<X\D<!2
M)DPGECB3W.?J)+D=RA/W="K89X"C]B[A/D-;U/(1VF_CV&6@W8)V6LHH3&__
MT7*.]9%E(#>HIAQ'\I=J$&2]_^"QK3O UEA5)IE8#L9'0IG&1=MD0:S/E"2A
M&0\*::9JYW.=/E/O<\].G:C;&+5VQZJ7R\ZP\',S2=-?_6Q>]I!/?S2?OC3S
MDA?YZ0]$^OT3D@GPCV;^^<N-'[YNYNW*J9#6<>T%24H .A4<'9;2E8.J+)4-
MFL7UDLH;R]K7Q'5X%^]X!&E.P[KU&^KU$J6@W23)Q_&?JZY!5 K%(B5"8 PF
M?=!%$(8AF6?19Z TYIHT[87JF:0'MFSMM?3OS3=H)UUYUXO4E+WG'.<J,Q=*
M:HLI==NU(X$;1804AK*H <#WHNH0Z)XJ98]NZ=H]"[<2Z IF"=8@K$2 XQ_2
ME<YK% 3Q64-D0)TUJCX[GPEX"'O5[I.XC3.R@INB]8H+ M[0TM6M5+_$*>%2
M!!ID]%3U:Y^W_=A/E5D#6ZEV#\8*SL/K\;>5)#9IG;7VQ$C/46N0B5?.$TV%
MY%0IE9T]E%]X">N9BH>V;>T.D=O["TO0V6G*K!%$98%3RRI'G,1%6R2;#3.>
M&2D'\OZ>-O<.8K':/2BW!_UN<M&;RXIL#<^(6R-NWMT\42#*LA@@T<C7:TQ4
M8]H%B&>R#6NWC?TM:SZ:?]\V7Z&=??_EO^;CKF5OJ9L$?@I?FK/TYOQKB\(N
M'E?'+Y#F9]#DWO]DCW?SAX"U_]/Y@RMO[?6\2*J\B$V)1RZ%UC9HQ<"YR*+$
MO5..#@%PO_N6U7#OS_QDAM/Z8MBW%V\^(K62V](LVC!5KKXYL58'(@P/S@.#
M)&L7([D?U;[W3!M'Z%[HC8)0(J7,B'/2$ZEP<W)::>*X5<$%;:5UAY*Y0W3X
MQ;XR,];OA"H:8(B7Z)=/-E_!UQ9P"RO:QJ_/8-FA9OE\WB^JV6T09F24\BR*
MTI(@)")E,,1F&8A* C2&@32G7KT7MWDK60G[HZ/<48PZP!WY1F"_P6Q$C4V9
M9DY,S*6"D-#$>R$(52Y0&C(S4+L,[%UX'AV)JBE_@&3FE1?Q+F]$N4AU,MY[
MFS#8BH$S(G&A)5Y;1D*.*FC!I#6U2=(7VZ'>Q0Y,DT%,<2IO63>*]//WBU9,
M$(3V7@K"6"FKYI4A 84A$9UFQ;USS-6NPM@#UK&R%(>A0]^E:4>S''+KNM+%
MJ0_$@?(,>\ [3OI@==/VI<Z>=CD2A9S-*0%D H9C]."I);[,)\>C4YGA#UGM
M9Z='H\X]^7RGP)QMS%$[S>3MHB)YTUZ>J"S/ GU@7'7>&3KLB,HQ8AFGA#J%
M&@B /UV+\3><X6X<XH2<WUVMT517Y0#1^JWG8ZL\$:=C\M(3'[E!:,"(%\63
M,UF'J)A2HO8+B3O@/!Y&U-;] #O%NYS'$=:Y6B[9L\R&"$4ID<PKXH1(1 A5
M2B%1[]:S)/8FQ*U 'A\5]M?WQIBX:C.2\><OLR;_/ET^&?+7G@R]2*D;H%Q9
M=;6<%T=$N_?&W'VT"JU#*HFZ=N_!+$Y<Y;0(,LE,L[,6V1)C"HIEX>UHCW'W
MW0EP/.C6I%<PC>WXZ_5BWU)S*90!(ISD1')3NAU@<!^I\5(;&J!Z]XY[(.WE
MW+S'"+1<$7W&P/+-)"[>+OJSGYNV;?X83SZ_;MINX/?^>[<NCS+E@(MQ)"PR
MG(RAE'X3L>N0JWBR')COER&Q[<B'7^UJ4N&:&S2HTH?PCG#V?9R'_X0X^]3\
MO6WFRPO% LR!!UZ>\V1%9'*)!*HST91[G-DB"%G[C&8CF,=!D+HZ'\ G6BL%
MR0 @!B>)M;XX[IP3%X/%0%#KY%%(RFHSX-@%.X<T^Q[:'> ZH).Q%/<>)1HL
MY2:1I"D&^ J9YSD#DEDT'CT[&0;8]I:#/RX+[Z;3VLGA/R.(#LD'W& 6K6]&
MU$/(QG($0!.1IMR8)U/N*+TP+'%A=.BUM=_RX8_#AE545S$E^R)NPJ@,?>#)
MYP[7/Z$XSY!>?,/O?K[L+=/]\!.TY^49=E)1VDRB0S="&A-1^,@(*!HP>#/9
M5#_3V!;CXV#,02Q4,7WZ;ETL;IA*U\98SF.T5()(&Q/Q3&22F,K44US#6.W4
MICO@'.JZ=]@]H8ZVCWV].VUGHP]^\GEQ*1 M^J:"XWI8BJ#($K!XFC,QJ!8,
M^EDPJ=<B@Y]ZA2/XMTM^7!OP6%>SU:S7[*O%BN[^!8CE(5P?&-O<J?8Q:OUC
MSOOO2_=0_KKY]M#<@(;TW">>F" T&4-DU*4\K'?$,,=2"L:[?BVJCFW #;>6
M]>VWC<(JV^U7U-3Y_'QU#NY8T#8Q$A6N(%(%1H)!-!18\M0EE6VOKAGW6.[:
MH(?SPO92>U-#9Q5/SCH@_L\K0+2SE'%%2108XDDC/0E620(8*P@6,P7H5;_Q
M/N-='?0!&F]GG0V1)W(&Z7/IR3EOOZ+OU"TH@G/)&(;K-N=(I+.EOQF+)%/K
MLN+<:U4[<+H%QF/Q=&II>H"CKS5(R\O-/J"&RBR[#="1<LGV-=?=YM]#U\.O
M JM4MM+K7%M/&!,EL]<Y$A25I:$-I2PK2.MG90^) /=EA!W$_MNH> "[OX79
M#-IW^64+:;Q*19!6Q)B,((XF="I#"?(%8X0GSZ++X%WU:JFWX3A"YL?^)KIQ
MYK&G?@>XZ.RDA/1QYF?S:4?K;+5E1@BB79"+3F<A)$.R5S&E&!WSU9_QK8-X
ME+O]SEH>H,CM-4!+:O>!-.1.?QW.$??YW0UUE]GWT/)0>_P:-%X2DKAU)$M;
M#N!=)MYJ1G0PE&FG)*Y+#]7P??;W0>V^C7('L'>74[;$]6+ZLCDK3SI;?W91
MJEVSE%- 7X8'1*=]>9TIB7*@LI5:15J[9=#=B(ZTW^]CM/67L_4TOG'?KYGB
M^;:9?"X7<5T^QD5IA:O?W2.CL_^'[Y_ N:,@:_F:"KQ 1UZ%DJ\96; )! T1
M$N-H&IY&_8?9/_OHLA+,VXO;-]#.1OP?L8[9\FZ6$D^11;Z\]>?1!9-KMT?9
M *5&?M7EQ[Z9X#2!Z>P#3I<R&2%=)@^.-/?4</26C5(.O65E2?#.8N!E&<1H
M.*M>G;P_NL.O636X<5L^U@#6&"))\\I<&T%PN)(Z],RUQ?54F*Y*D2)"*2UC
M2,'ZVD4CKH[_.&R_LT:'.(VX@N7EO&U+$0FOC?7.&.(]ZSK* +'2:9(9QLF*
M!IJS']#(2QB/S]:[Z'>(Y,LKD'YK)G&)JF3Y.M""@,O(1B$IL<9:=,6B-2(G
M9LNN/9C5+Y$\/L/OJ.4!3B2N2[HX<F$L9F\<(UZ6"VT.MM2KIAB2L>A]8D[P
MVE')+3 .E6XU_&:^O5:/G5YUNQQ=@!ZB#!!2)%EG5 L%36STI19F B4R"JA[
MY0;L3(YC'E3N;=<[>;*U?@=Z='&)Z#=_OCJ![X-KH&/*39B.<U:YK\WNI,">
M"C\D(90SBCLH]5Y*)CJ80 *CE@BP2NNLT%T5#YH(]YQ='HH'V^BY=D6**S5J
MRR/L+I<<)B^FT_%TYB<17GQN :X\H.9"4U<:!X$J3;V=E\2*5*[IJ+*@3>2I
M7ZWA+0<^MH>XJ[F: ^GZX">9M9^F]_[LNN>8.S\[1\. ,2!-"EYZYD-*WH'7
M'%0&;M6H]RC#G&):E8S*UA%A2Q-:1M&OE0Q]&/#):BH4M;5CNX.<8K[V.%'.
MFSD&5MK%",ES8H.+1)I2*0C0S0,+PJ%C[\5Z?Z7*(EYB.?;RM)O=[]ZA=M1T
M[>YQ:X(V?O(:U3;^!A.88@QG;6)!)^*#*]6BC"!!,H$1-J76*^!BO1[TAOWH
MSF$>MGDKJW%P%_3NHW$=2FL:]+L4*VD]*J,'9H $H2-*KY2,SQ<5-9>!:M:H
MW?CL=IBK0A=EZQV%I)#5/)!L2\\LW*:)IZ@*L-X&1750T*_'V?UC/6S3#Z'0
MVN_,KY8Z>3O^K_DX=<6S_3E^IY0WL%18HX@J>*3)@5C)-%$V4X5N=,#8K)>I
M[QSF$5BYGAH'>'V^(MTO?W[%(!U&"D0&%Q!.1-FDC91XK3B*JIQPRDBG:]_%
MKT%XV!:OH=<!GH3?=LJ*KD8"ER71P@4B.44?DP='-(:Y-D2F J^=)'>"=Q+U
M]NWMM7K"=Q+,*\X\+P6K2I.#:!-Q&@S!2-L(2QECHG82PFG?26QEU_OO)+;1
M[R&/H/O@>JIW$EO9K.]9]"X*/R0A# ^6AY1)LKF<A$J% 8?V"-*+% +3U@R[
M2YS>G<0@/-A&S\>^DW ^XW^2)"%IA6MAQO@S8SCJ.4\F&9: WWO\_,#O)+8R
MUSYW$MOHNO9)X'6LI7?LW5@#3@ > (AARA )Q8U2/I"DK$@T&.59WH$7]P[\
M^'A15]>5*UMTAU(%RM^A^=SZKU_&T9\M;FM#R"9R3HPMY2U5R;JC6A#'=18<
MDJ;K!-BI4,)&  _=8:RGW8IG?QVH1:!Q%=(JIZ('J(JUA38".7REH4J&:H;2
M<NU9OQ&<,$DQ)G&FE.;-4N(^%:+/Q*8LLZ.>AGXU]4_+]'?4*#JDY;=1;DV+
MS[ZVHY>?1E8GFJ&\$#8QEM1Y=#]*)_@0M,PQ213KKMJQ4XA_^=Q\^ZE\W,*V
MY:LK=ET,<]AB-Y64W>RNJ8,DCY16#+/OM=-&>GSJ_@DCVT)?2Q6)0? @&3C+
ME4R!.<HB*)65$=X8KD8]/G_/7HQ?? NEV&QZV9R7$V"_H'-;ZBP5\OW\_?)7
MEA<^+_[P;;H\F$S<<V8X<I&7MDRZ:S.*? *9O.;9^LAJ5VW>'_5>X<:R@-2+
MS^CJ?L85]EW.4-JZOV_'$?^"F,Z;R<=9$_\U H$3BFM'& =9;DT4<=%D8JCF
M/ L:;#*](HW^8QX^R#@PB:Z%(P/98H"W<QV(-]/I'-*K>0>Q*^O<:6;Z&_S1
M_6@Z<DKA,@ >-8'RX]*>""[HEIBDHRU=JBBOG9[5#]F3X=6 !AO@0/0*PU_Z
MK^.9/UL _ !3:+\!1NCMZ_ELWD*!6P+TD8)L0GE8SS*&>9)QC/I3R$1&I4WT
M!A34+C>S-<@G1[9AS5@[PZ9K*(.*>#/I!_9#:60^18V5P@Q7\@PF[^:S<FR4
M<'9=6ZJ]!V>X)AE*14V9(G$H%*%1):HC!XB\U[8Y,- G0].3L_H [R%W5NUO
M\V*S=WFACA??T"\O)VNHC[_COYV-N,&IRC#88IZ5=YX^D #E86'4WE$!8$3M
M7)6A9'DRA#\I4@R03W6G<_,+!MC-=X#NE][/V_BE- H[\Y,I[CH)N,F6> BT
MG!:7O$[!2$05<\>HIM#KY+R6>[H9ZM.CZ@%,.D#*5ZT9-I]]:=KQ?T,::<V9
MUY23TKD5/:/DB$TEI4V$Y#. K%^RIKH03X^]1Z7!35[KH_&Z^^,?,)U=3&$V
M4C:'F*(FSBA-I"V582)G)&7AE'8N>5;[15--_,]L/I3Q;Q+9'(W([[I:KM-W
MLR_0KF*'Z2M8?O%FLNQKQFG$/:8X^P'0[4\>B&..$VHC5Y%''=:S=(['[7XB
M/=/]B!2Y.0/LT6; U2<55X+>S@E;GER/J#$JBYR(!IY+JEXI;ZZ ,$:I#\HD
MGN6IT+^'/,_</Q8Y;A+?[5W#]JS['4BW"[EZ-**S1T/S2&*B&,MRE8GGVA*F
M?=0R*!ZJ!X7]D#TY,@Y@L%ON+/:^"[N(1J']-HYP.]C?FLDW=(1@X1--/S4S
M?W;UYZ6_[6_-[/_![ /$YO.D<_IY]$8S*X@PI<AO2HR$I"))3COP+#*<,I6I
M.)@P3XZ]IT&+6PB_]RW=8)(M'*373;O\5OD]-O(RF"2E+8U2#"E%!DE 'XD
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MXI+K"(DF(X46UD;#M I),)FYM:,!\!RI-//;BW)U$%44&("7VBPXR[(7Q(F
M"RR \LD[Z67MA6M_U$<K:7UAURNF7U60_$=SAA]SA@SYX&>P3!\:)>HU+C+H
MA@G.,7!UG-A25@FT=R[["."KEZT[F'0GN-/497RULM;#$F>(8@,'D'39LM Q
M7&8ERX2RTEM.IDR<\XP8JISG('RD^@%.D0?<W?+4I\@.Q!GJ*&27.MUW2?H)
M'0@VDF 3ESH1[6+)A,!@Q\:2&*&9<< 2*%W[VGDX:9[F%#@^,08HE%9U<G\8
M3__UNH52C!Y:#/NO[GY!&- Z9*+!&@S^>"3.2DJRYP(UD!3PDVFOMJ5L3W,Z
MG!IIABBQ,[B<JWU/BIPD:C_*7$Y&O$8[<"",2Q538('JDVF4LZ5LSY/C%$A3
ML5C H&[AJ_&W<8))*G*.!*/66L^)Z00$XTBP&# E9X2D5@K%3WI6W";4\W0X
M*DTJOH,=2,!%4\7W[3C"2(/*,F1&<!ND1!H,C"RWB0BEF%/2J%R]>.APTCPS
M_SC$&."E4[TL(.:"!H^JU30%G+O.$DMQ*H/F5%"EN<VY-L.?8 N;O6A\%&.?
M2@N;Z\D8K$0C/!<)%,Z[2 VQPB22E(>D#80@JE=S?EQI?UMQX,ZTOVUL\5#2
MIOK(])SVMU7:WU8T.43^U"XV?BC\-5%P9HPD3(12BRAZXHWA!-UQ9K-ET>OG
MM+^'2=MM3#M$NZ>-^3^2<1%Y$,2('(D,CI.0%$=7)PL&+B7-:]=?>.R)6EO9
MNG>BUC:&&JY0F<P\NE+&U4"I%U)JKV;J"9>&>N%LS*I7P/%T"I7MXK'MKO.*
M5UPWRFWU@/$("Y5MH_Q-A<IVT-R A<JHM"[1& F+6N/>*!EQ4F8"U IE!(:S
M_9YF'MN _0J55;#?-@H;M%!9]C8$7/D)%]R4<RM.G+.9>+#>&A>RHKTN@1]&
MH;*MU+ZQ4-DV.ANT4)D!'Q10')E[7;HS26+!6Y)-3E[K)+BM,>U.I%#9SL;;
M66>'3$Z?GY_[]GN3KWAI+^)L_*WT2]H[Y[S'AU=+)=]6D+4,<:ZR+Z^4@[=9
M4FU]-"'B'RIF*U@RH_[#'#WQ.R=&P60@3 H@TLM(O/">!"45I<(I,">38?/V
MZ(G?R^S]=_/9=.8G:3SY_*$Y.WO=M.6'(QHX3G2+07=T.&^UR*2LPH0RKG7V
MB8*UIZ++.R4YP8BT+I.KW;K5(\0I)6_?E.JW^<*G9S&PI!)QNK@5W"AB2W#.
M$F4>O#!*5+]YJRW$ R)W178-1_@=J'&,D^E[!.H>9$W?3-Y#.V[2W]MF.ATY
M#F 4$\09X4J6K4"/#/\(D$*F2ELM!TF_KBO&,]]/@!Y#)&%WU?.FTSFD5_/2
M)FR!K1-C>O6MX2H+)(TXE=E!*9RL%".2&4N"Q+]23YU+S&6 ZKEQ6Z-\YNOP
MQCVEM.>E(*BU#./9'.5;3;.10W5YJC-1E"<BK:?$J@A$&8R"F07@U6]I!A#C
MF= G0(]3RF7>[$.)R"%%BB%,B.7@!XA'->-D3JAZK@4+P]6-&\2]/KQ6EPMB
MN85::M4QCL$?I\3QB)XIDQ)W;%P=DW3@8NG1F$XF(WR3$ ]H#3F-B'P_&IS2
M,]&E0+\UDV\PG4'Z)W3ED].+;]#ZS]!YIJ_\[++8Q(LPG;4^SD8\424"4$(I
MLT2"#L0REXC/2AOM P]JD+.]@TKY-&?&Z1+IE)Z;WMRCUF1>2Y!/FB9.'1&2
MHP?-+1J$14Z\#S1JSA1E)U,$93O1CC1)3IBEPYV'5:/82>5OWGH.<J>H,@G@
M/GM<V7!YD]RA=^Z8(TQK+] S]ZY?=\>#I'5N+=[SC-IW1AV):L?8G^X3=25-
M/VF5\"D%X"19P# \8P!L93;$.VD=-^70Y^"7,%4E?)Y;0\^MX0AWC)/%^Z2]
MY>SH3GE%AJ @,Q*H#"6361/KM2 ,M^L<>+;:'?S8L;*,SU-LZ"DV).E.^S#S
M;C$=Y2%206*RF4@E'0G19\*-=<I(AS_KU2_XU&.LHQY\WAV"N)"4CI1P!>74
M/"KBC9<$A(Z.6Z:-Z-4Z]CC'H2>XJ#V*0])JE#G!J\47*74\\&>OQM/R#KPL
MRA>[A/<TI\ \KK2^! \TEQ0612!JD")[=D(9D'T$>IX%1Z/'4/OR'F[3YLWK
M Q3CXO=?-I-.U+D_*]4%^0@%<SKE0 (HCL:@B5CABD6TM=P:H&R0DYO#BOF
MYDE]HE:^4QB:92=X'[=Y[]PD,AL!RR%J%HB.995S IU?GS@)'+UB[[(6:9#
M\K!B/D^LA\.RBJ>A79??%Y\_M_ 9H_$W"&H\F8[C]9 \^22<X!XU2&U)4I/$
M1QM)2$8I@=$@9_WZ8=\ST /BX'Y.4'6MGU*QNYN[RW4!1](D%5WF)*L0B#1!
M$T]5)N!-]B'2+.FIQ;(;A3D<9>MS9KC;U#T,?MI.PW7!V,A$SH)1GNB<2NY?
MSL1:CSZ1#4)[A=\T@U!Y$&D>&Y>/;_(AKBVK5?M(P62NA"&&FUPJ!9970 X(
MYQ"H$3RY^I6HGV!!QKT.28YB[%,IR+@J5=05QS#H"$=F&&$BBU(<@^*,<X&
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MF:&-F$#">0HC3$F8$$1);%418&_<J?&#,:[S:IES_6!O%U!Q,\#VP3O/!E=
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M=4M0=11@:FR^W0W]UWR1/ZX>P=O5TE0;[<([34.DW7X+?=O/6ZZ1'1</B?S
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M(Q_QD4=[JJ16_4=#!^$LB6(212*!$0GTWHVYWKMQPB!.LDRE*D*1LNISU%>
MJ>WJ'W<3:V_ UZX('VV+\)7K(GQ-ZNWZP-6GIJ/S>MDQQI"K,#"M'"3IGJF"
M6'_"<_W#OM -DLEK,?T+YO;:@W,^V]=AG"$2RW[1LYF^/;-4A8(&'$$:4J3/
M,1F&&6$93#.2<8&S((S#[F+ASE=F63=[CPN#NQ'XT(@&B@6H:'/Y][A))JL&
M229;KX8=TWD$=S()9#? R U^,)*?WD\\IX[M0S5*TMAZT@FEB^T#X98H=O#M
MD>]-UQ>WLU1BGB9! $,:$1-#&$.2"%.Y+<Q8BFD<QDX)LM>+-#5;KPD)NW#M
M]G-[[0:.7+M=$U9R_0(/?'/::]FF?E$Z5(B*-Y!?^A+T_0N%M'@#T-L5Y^'(
M;E1>E<M-3[=?9'%?TJ>'G--Y71A2*&U94A[ITW88091R#C.N JCMSQ@1R0@6
M5JU9SLXR-<+=EL^IN.9Y+,\3H3>$!N8V%W"L"<I*^7.<HP?8XAO]VX9KSH\]
M"GU8J=<Q@MV'O9;A;"+J=@KEK3N*)@GA)$P$C&6,(0HB"JGB%#*I"!><9XHX
M]5MS%V%J]%!7CE1U)](ZG#_O1-^JROF3E[*<Y];%SJP:%NV!J>9"F<ZU$EME
M.@?I#=L?Q&$K=YX38 H5/"T LJSD:3-2KT"N9SDOG@S1_IK/]0S%0G9Q"&V=
M!IZ)* OU\321VNQ!@F>0I"R&J0HP"BA21 0.@5R7YIL:UVU)#-8BKZ..G *.
M+D)]GM$& '!P%]HY[/I4&[$ T2EJRR>8HT5M;4!]7(/:A6SYB]:RA>9"M-;%
M8<:,UK+5:2]:R_IK([<.;')"-I%DU<?E@RSO'NBB#?N]O;\OZRN(=XMEF2^J
MG/^5SE?RKUH)*6:4TY@F--9GV=@4JDH(S)AD,(@Y$C%C";(+T7UA/::V8ZQE
M!,]&R*8*=!OT_UQ+/%([P2L?#P>WY;07?>J^SILN4V\+#%"C 98:CDW*R!H1
ML'G&:DQNP%_//UCC=1?TLZPOW6'P2BW^&%T&_2R5MTZ#GL3I<0IJ9GZ=ZYES
MMJK%[<J-M$8EPRE)LD#"%!$&$0TY9$+_JC@/61+(3$JKO@9VTTUM1VOI:5OB
M7M63+N-L<0+RBM[ 6\-9X/J<?RXCZ'#\\8KD2*>?%E&QC:CW@E#6P)P]^UP>
M9;RCC[5&.R<?^V^YD:Z0^>S-8EE7)G]\+!9U%_9Z4]CN,SL+0\)I1@44H4 0
M(1/F)44"E8AQEG&62;N05[OI)D>ZM<2@$1G4,M\T-F2UW7W:CCPL$3]/O_YQ
M')I^KX30FC7<D#EBW%:2_^6^>/Y1#]38M?J'C3EK.?PH=.*F:D<GCM_JYT=Y
M2_.RM@A_E;1:E35/5>M__-^Y+/60#]]?%R9L=28XCE,1A3#+8FW2"53?Z6=0
M9"A10I$D1K&+]\-I]JF1C9&S.4J"M:3 U"#^</M7\'LCLV/@E-MJV#D;!L-X
M8"*Z#E[GPWLOF#P=N=WF'O6@W N6_>-MOT'Z$=JGTK2/6W[_I!^FY>VB/B'7
M?NA-#P_):<I$&L* 4LUB3$J8<93 -.4B"Q(BH\C)AWMYRJE1UW;%JT[ZQJ/6
MW)&8UZQ.4'@HY@*\>WPJBV?I<'GGL!AV).87XH&9:X-H+6Z-Y@;;(1NHV,/D
MB;DL)AR5KNP!V.<HAV_V\):]>C">O'>+KJ'YW_+EPZM5M2P>9;EN.?6YF,_?
M%J7QZ\U$&#'.PQ R'NMSG* !9$D80TP802HCG 7VI6!<9Y\:775R;^<E_P1>
M2R7+4@I0RF>Y6)UN]^!A.2Q\;$."/#!A-:*;BEIKI+]JZ4$G_E8S4?"[40&T
M.KBXX=Q? 7NOW)#8C^2D<U@#3QZ[OJ"==> Y#SJ>/Z^OOCONO=Z#N'O[7K</
MWIW^Z@QSEH4J$U %F6E 0C!D<4A@J"U7I*U6S(C5R7M_X*E1?2<;,,+9^^EV
ML+KLD>N+P, \;*>\DX?MF*:]?&D[ XWF-3LF_K9_[.C?^]AG]"E?TGG^#W,#
MV[S9KXIJ>?MHNI+_HZ;^UW6/HK:P9\*9C*B,(0F%U.99%)K4PP1&. S2*!(J
MDY9E6OM,;_7(CEI_=5M2%YO $78;,VP *$>RPC:2;VP (_L-V)8>-.)?*GYZ
M/=@N]M=PH(]E?GD%W]$0ZX?>>3O,<<P1S;!^VNY:83W'Z+$SF-BSVA7V63^$
M'?N+( P"D4"J9 @1S4QDBV9_*3$B:<*33-IW@SLRP=2,,B,BJ*O:75$5Z"2:
M%J1^)48#$W<-3U.NQ\CGSLS'4'%@WRO1&8EA:Y2:YZ=^E)YJ07V%GYS!X"Q/
M'OO>>%QX1NH=OCOWN9[E#>E"?%FQ_Y1\>5?\4A:KA:@GJ&8\CF*E4 !#95HQ
M(QY!$H<Q#%1 9!B25"/H5/#TU$Q38[GF#59%";3X16F>MN;"L5 JYQ+4WW,L
MAW@29;MK#R_8#<Q^1D;0"@F6!6C$;/C09_'$2U#X*J5X<IYQ"RM>4O>@S.+%
M+XQ<K.=B:/*'8M&D=FP[?;&2*,I2 C$QI581B;1IA?5/5'#*8LU 43I*89]>
MXD^-TIIHH9&*]_1;<#LBG.XR#LRNXR7*K('0/ZY,H*H)#F@#_RPO?<8K+735
MLKYT&:)^PO\Q2A9=M3#>RAM=)\5D-\J]6J*_Z*&7K^E2KD.I9HHG61J%4F^?
M(88((P(ICCD,PT@S3<9#PJ-9<_+ZLJ3E<C*;Z$757#AY7\$!#[7R/E_4Y7H9
MU7_0IP3C%A'ZH:)E98ZX32^RL5J1^7R41!P0)I(8$N/I0K$,("&80QXQG')$
MPPPG[:/T9C%T+[H7?9 Z]89[C-[4H=S__9ZAR1AW7I^*_XXFWT$A\AHB8# "
MFTCL/Y3E9[WF?QQ[\+)*_]VL1.M%? ';T5ZV_I7=7^<5GQ<F:'X3,LT13W"8
M<ABG40:1C!+(4)I &DN"<)*&66256'UAGJDY,W9[+KF793\&I=T&Y0&@H2.'
M3.'UC8C@]T'"RR_@X+&J^K%91B^C?D;58W73SWV\3TA243Z96PCY<[$05=-.
M;'%_][6X>RA6%5V(NZ^:G;Z_U<_0W4-9K.X?#O^6/\LVQ3U#+ A#0B$72IB<
MEQC2A&GB"*F2*HX93D+[>'*?HDV-9M;*@5H[T*D'](.*S-.*76)NO"ZB3?C3
M2RW-T,%1IU9%BP\Z^4&C ##:@5:]XQ_0*O8I)>%W.5T"K%YJ6<<*O_*^O+YB
MLX8 _GSDEM<91XSK&@*IW:BO06;H6X;CRX.<S\W9@BZ^SX(XX3P6!(H 88AB
M'L",:..<ZM_3D 1I&%EMK\>'G]H6V4@(:A%!*Z-K38T=^,YO;->#,O#FY(1'
MCP(9Q]2^HB#&SG C%\ XILIAP8NCG^IA0V]WAFT;\G[_#TG++_FW6:@2$[XI
M8,)X!!%A(60J$% 1D9*$1Y1$5DTJ+DTTM9=7/Q"9@\ES#D(+>]03,$/',.VU
M<^XDO0%&5J"%]828@\GG";F1#+@K$'0SR"Q@.6M>G?O^>,:2A18[IH_-YWL&
M@LJJDG*W9^4ZD;$KV?QZ)3_(;TMM0\VU_50LE@_5#".DI,(,!HPF)DX4F3A1
MK/F3)02QE,2Q4Q6-OH),D%^18Y1HWR6P\UZ. >S0_%RK< ,.^N>N];@QH:?,
M%,K/1<LY'Q<>[ZNN!=%7=&I?,<8-7KT2K(/8UFO'ZUD;+5_0!<_I?',95+?D
M2JC J2 !3--,0A2B&#*"0YA1%?& 21$QJ_2?"_-,C=C68F[=*SLU.KN$JQV=
M>4!K8+;J Y1[O;+S,/BJ3'9BEG%KD)U7]:#:V(6/][23#BVP7%:?9==$Y*/Z
M5.9ZVB<SK]E_[O02R!EF299$:0(ED@*BC&BN2%,$XTBQ*),$D80Z64F]Q)@:
ME=C?HEP)OZ6%-#BH+WM^K<7U: M=!9<O2ZB?$./:05<!=6 %73=:SZCF%:OD
M?ZWT^&^>Y;I@>IJE-&4F1Y"1#"+SGPP3!D,1H%CH<V%H5XWF["Q3(ZV-D*"6
MTC$>\RB0=OQT-3P#T\\^,I>O5MWC!<]!X"N [^@<XT;4G5/S(,3M[(?[O>_'
MZEK=ZM.7*8FX/G+5%2PW051AQ"+"L8"84*1MG""$#(D(DE1A)BB5S.T\U$.&
MZ7'%XR,MOYL4JG4UD9^;Z&['=+P^"V+'*@/#/##GG*J2M_[W6I6MW[=<1294
MX+/D,G^N2[$.69'U"I ]L5H?"4;EO"L@VF?$:X;J7Z#O4Y<E8H)_9U1$@20L
M@$E*C%]<)C +> JQE#(6J?Y73%PK]>W,,#6N6U>M:Z0$6LPZ;\"]>M\ND.=9
MS L\ W.4,S*]2OL=U?ZJ&G^[(XY>[.^H0L>J_AW_X'"QMO6!JK7<@U@F6!($
MN1)8O^:80T:E,7](BD+,]1')OKN9^_Q3(X%S4;.Q_PC+[94XSQ,CX#NXI>,0
M&UFK,&!HZS;P_N-7>R[ %(-4/?G<KD3/1Z3I]K"3"R<]HG.?F-%CP_381S[E
M3[+\HD>=:[MS(5[1A5[5KAVFMOY"$:<PC *J-XS09%8K"0,N0H4)(8$(K#>,
M,Q--;6>H106MK/71JY'6@9O.P6K!_I[ &ICF=W&Z7>/4A\S/ >; VIZ &XF>
M&P"KK0>-UP+[*C%H@<99NCWW_?%XU4*+'0*U^7P_5V-],*]FH>)244FAH(I!
M)(,8,IQDD#.DB#XMQS@.9\MB2>=VWL-F6"<67 \^W,-Y9^8 M);-S0'8PF3G
MTW-7?F!6NSVOL;,_;5=!3RZR=M!1O5Z[BNP[LO;^ZB-__)95M6]L%D8TB^M#
MJV *(J822!.4P(0B)A*"@R3+^J>/=]-,S0PYR)#N!'4,7CH!JMWK>3U40WNL
MW%&Z,HM\'X1!DLC7D[Q@#OF^HN=3R \^W8\"WM#25*>J/ND]W%2[6#^O<8)Q
MFD088H0#B+!(8:9X"&4:11AGB$>A4_3VJ8FF1@.=G,8EVU30Z<T$)[&UXP(?
MB W,!OW <B:$2TAXHH23TXQ*"I>4W:>%BY]_F=(27_)O:[]&FH6(95!@%D$4
M!J8:C="_AAD.0XFPI Z="CU*-C7JN5A8(AFW$L%F"?UYT+TOS)1\ZQ?K#F@-
M7ZBJQ&8MQRTJT6M-I^BNMUG;Z924.(!]Z(H2FPDG=P/@A)/O>A*'$_3TA2V6
MN<CGJV7^++](WL;VOOG&YRLAQ5L-C,F&7S6OS$>U;Q3\_/WX '5:31J0F&-,
M(8F,@RWF E(6!I 3E A"A8C3R,74'U#6J6W9VY*"C:B]LIZ&7&)+Y^ T%FYH
MCV._-7/W1 Z/IB_WYH"2CNLS'1[R T?L"%->GY#V:E6:GEJSA"H1)Q&!5*0$
M(ID(R#+,8!+%#!.>!8CTSC9KYY@:1;=B@2?3^J]8F(CKN9:ZZ5$GG N%'D,U
M0(QPRDQ NU00&==Y%H8$RABE%%$51B*S:_9Z+:ZC]G0U6=<_ =[BFR^J)9W/
MZTRCZR&UV["N?/P&WFCVD^ZZ)W&3FS5,RMT>$@/DTW4SO%BRW)Z*YS+A]C\Z
M4/..ZE2YZ+8H])MOLN1Y):MWBR8J=:\X=/?W3V7.Y0Q+GG$D&*18&^*(R10R
M%# H5)B$2),+RYR\[^.*/[4MH!-.C-,XP>^C8,>$TUW@@4G6IAE"=:$;PKK?
MP1H$O9NU,?E'.A]TGP(U%B.V/!AD#<=J;N!7^&FU,1AD89P;%@PC1;_]\H-<
MOJ+5PZ>R>,[U.>CG[[]IF=XMVM(;B_M;KL\[M0TTDSQB&2$I#(($F_BN &9)
MF,)4_WL0R%!%(G:)[[*?>FHQ8%IRP+7HX*F5W?"6ZN0&="VXVX;EL!9VF\TP
M" ^\41APC=3@TQ:X/QC)-=G_&:R%![>787:F=G?$/-&RP\2C4JH[(/MTV&.$
MGJYWSHO5PM05^U3,<VZ<,UT@!U,(H4"E&O>4041"!DD2:_X*XS2)!=+\Y53F
MXO144S.I-Y*"3M3><3)G +;T6WN!;6BW<S_$W-W.%\'PY34^/=&X3M^+"A_X
M;"]_HV<TW>/3O/@NY6<YK_UO;4:YGJ#S:RFD.(K2%(HXE/I@GX20I?H_2$F4
M9#BB26*5Y&,]X]2(HQ,8R&_&AG6U92XC;$<97G$;F#DZ66'9" NVI%U[%3U&
MV]E"XROL[N)\X\;?V:I_$(AG_<6>+LAEP?_^4,SU-ZJF!]UZFT0QEW&F$DTH
M@?Y/0A)( TE@)#&+$D3#1#G=X)^>:FITLBWI__CG+ K3_PED+?%/CEZ]T^A:
M>N"\8#:TMVQ+R'_INH#>+I=ESE;+NLC-L@"?:-D4)/5OG%P&R9<[ZO1$X[J.
M+BI\X.:Y_(U^_/&IE$\T%V^:??=V(>J^E4TB4;=YQH'*B&D/'E,60!0$"E*D
M]*E&_X>&)$L"[%2IRV+.J3%**_+:/JD318NZ.6YWU=DG2\\&?3NB\8SIP(S3
MP=F*6Z/9M!IN)![ @'$ R!/;V,PX*NTX0+#//RY?[9%:\$OQ+,N%<4UO@EW.
M5UTXV:I+/Z-M3#,-&68LP5!AI6DK#KBF+4U@4L@4ATPBHH1UBL$0$DZ-Y#8Z
M;D? [=3D@?9]*H9;V/.,.(GE&I@_+ZS4Z1(_9_L?FF#V'HD(@ZRQ0T+"2Z_U
M2(D)@ZVYIP2%(9?A;*+"(!./E[ P)&X[B0N#3M1CTW^=EY*;&IOO%KRL[ZKI
M_%51+2O]NS$IQ%WQD2UIOKA[D%V)SED0ASA4*8-A%J<0R5A &B0Q3 (5JB1E
M44#M^^_UD6!JF_8K$[C$3$**B6^A]WK9:HX0M6ZU99UOM /<J&?^I=;/@>5[
MK9;%3CWT&@R\$S?BUX67MA0 M0:@4P'<%:!10A.P7!<7'AI]ASUTZ%48:8]\
M;?/0&V]6T:R&/L3H/S;J^"KX= V49_>Y7@./MX]=H_?./G750#WVH=M[39HF
M-/Z='BM?5#G_*YVO-H49,A5*2I,((AYAJ$^-TGB^"%0Q(TF2IE)RJ]+,-I--
M;7=9BPO6\H):8 ?NNH2OQ2;A$;6A+_1/ >8<"&&%G0/%>\1P)#9W?_C<F-H2
MD;.D?&F,\?C74IL=JK7]CI\R0IM6$T$JDYAB"@5).40HSB#)B("2$<VG@>95
M.RO^XDQ3XU,3;_B^J+9JXUQ7/<BU>X<7H(:.;#A2/VB0+AL7P1BHA- +=<RX
MJ.ZE(D+7=K]87V;R!RE6<_E1'8],KR\[V_!TPT=-2'M5K1Z;?]OK6Q.E@@68
M)S#+4 91E@4P$[&$+ J%2HA /$R=XAR\BC<U!NJT,RFO6T*#.N99GXQ>2Y,#
MFR\D>$OSLK5=]&=KK;ND&/!+21=+6__!0.MN&8'Q8JLY=-3&UD*>26/:6;<;
ML%9Q9_&'[&4TS +XB@CQ*]RX422# 'L0>3+,+/UVCMHCH"5X+9O_?;<XT=Y[
MQM*,A+%4D.E3NMX4(E.NEDD8B81'22 ))HG+IF ]\]3X?BTFF!LYP;P3U(V[
M[9&WH^5!\!R8<3N9P0^=U'\V*:$;A&O)-RWC_'&H,UJ>Z-%^WE&9SQF.?5)S
M'Z!/O4Q:/9C_,_%ZSW1N<C$_2WVPSKFVG,P?;A?B5UK^7=8QEIL[N1EB2G&<
M(-,=5T$4(@$IYA(B',2Q(CA-B%7@[E523(W'C*@W32*DW*AR \JU,LT?C>__
M<:T/J-8*N916[+MR%J[,,=9C8!YLEJ).FWRSO10;/9H_FJ78J+(5M3#&4KA4
MM!QA2<:J7CG8TCA6J[P2TO.5*?L./F(5RBOUWZTX>>U@8U>WJ?]SIV?5@GW2
MS^<'_<2^+AYIOI@)%"=1$IN]3200$6*<-2G2&UPL$>,JDZ%5 \0AA9S:UE=+
M"HRHX/=&0L=<VD%6TM+]\L+K,_1UG\/2C%CZY3)V+U[@Y8R(?Y R+I=!]E>L
MQ6*N?B3?.'+E%VV8K)JJL"CC6,4"0\H)@TCA&)(P-;'S))-9:AH.2A>&/IAA
M:O3:"@@:"7M5Z3U$T8X=K\)F8&IS@\69W$ZJ[HF9#L<?E59.JK?/":<_>%VU
M@2^R?,ZY/$XY'XK%L[8@9<,K5=UF;OOO)MSJ0['\#[G\+'EQO\C_H>FHK@[U
MMBC;?S*?"V<T(D2$D8 \-%5.L=1L$4D$24+"*",93I%3;N"XXD^-BG9JU;6Y
MAF!1+,%WN03E6I<;4Z;0M(8O5/>O]3=,(</ODI:58_'"D9\9RU"%R3X)0U_L
M';O,V]@(-V"M='?'9[34_]H\)I^W'I-&5:"*$FPIZ[\JQ+AKY+G$Q$C"OTB]
MBG$7YE3QBY&EN,+=P<X8YZUMSLX74C0NF+T2BI^E,=3SQ7T7K;RB<U.(.)SQ
M.,*81XFI]*-M;81#F.G'%'*9H2!1VMS&3DTU7T"'J6VA6RKTW@]?XE%P<*=,
M=X%'W!E/E?5UK.IKD#A2S7>-!MB" Q@\/+MW7F8M?7I_1M9@?.?0RRS14=_1
M"XGBMJ$*F<_>+);Y\OMG>9^;2/+%TOBK9B@0<4@#!>/ZK!@%&:1)$$*,]"$Q
MB8,HQ%:^_U,33&XKJF4$&R&!D=)N*SH)XOE]P@<T Y.X(RK6M'I)]2.<5TG^
ME_OB^4?]U8;N] \;ECLYX"@4=$F=CA\N?NZ*NG+OJFHEQ>LZ0[PQN6N*J3[(
MK_6?JAD-$HG2F,&,AL99+!-(I(I@$C"5JC#6#T,XTS3#"J<J<Q<G=GF>MZ<?
MV#:I0%Y+7M^O5\6\Z2U1]Y-PMD'M%L#2;/0.ZM"67AVUW$@,&I'7K1<:J6^
MEKOYA,>2W&Y ^2Q+=WG2\4O460-QM%R=_;<'BD\X=9EF$AN:/+=-F+*I;&7"
M*5[GIG#X0GRF2SFC/.0LU,=SA9-4LQL2,$NC0)LN"2%8G\Y%;)7Y.YK$D[.
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M:]VW\*:A.(^6.WG]F<][(5>Y%BRG!4B)@5PD'%#3WDU"SHJ8T#BFF7OG@E#
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M@(_VC(H90NZ:BOO-\ZHF^3>]:JL(S-O'I_GRIY3512VEVV?] :QG-*.2%Z@
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MEU$C>+25W,$D60)O8>W#PSGX4<5E)'VB"):0.ACX\-".9-L;B)]:B#?+:-Y
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M2I11CWI#@'9X[AODF2%M\.WF-5VM?I:+AXJ\:*;M+$1$,,!XD@$4LP3@F I
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M@_R[?L#FC?:?WM%R5<4?MNQ"D--"Q(D"2B%##A<SP&)H\@ (1S%##!>9'6G
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MT'$KIYR .*JD<KO;SQ29DZRRYM6_78B=]U9*TU!,4<)1Q7IO.@BA!-!,I:!
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M>:K_C129<F+L[1EK:J:WDBU*W(QF'Y9VUC 00@.;.2-E5(EI$L>,H#=1 UC
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MDB2I= H,7AYR:K;;2&R2 6IR3;]:=0N@[0Q%6/@&MAF.R+GG1%B#$2KGX?*
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MSV @P?0 ,*E.^A/T7![/:*E/%0_O@R_ZN[__;?L;_<6$@__];_\'4$L#!!0
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MG(5BR%JKZ"0$Y1!,Y!I39**$QVI/]@'.(^2,TVAE./BTDGP'('J64BWS7GW
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MD]%9996723-4"HRA_:""">#")CA6.F3CZ'!N_=[@-@UC5]:VT>T]AFAO07<
ME ^X#M,YYE=A.2<3NGJ6TNG)Z:P6P+_$,DW3]416@[H)006O34T"'=$H+3#I
MA75!NLP?:WB^7SW;SZ@:^PW"(&!JK(P.X/4LY\W#C#!['Z;YS?Q%^#HEAVQB
MN42NT='>,/7UC['@DA7@N#,A>"9E>FS^UEY7P?>3,FY&8" @M1![#^BYPO_F
MQ5_MW[C$+SA?3;]AG7UZ@F\7JUH^\ZY\"M\GGIL2-7K0F%*=DTLB<]:"=M$Y
MGY)VLK4;OB.)XR8(AD+;@&KJ (5WI39)0A:1@P=F,-7)NHFD)30$$;%PCC;&
MUI6Z=ZD8-UTP$)8.%'8'>8*?12H3DS,*S6NVHX8IV1$_12,$IQ7W%KW4 R:9
M[J5IG!''8V6>#E=+,YB-UI;K_48S7W ]3>0#W6"K>8^NFVL=N6'7(XP>LWN7
M- &9)*NE7."U>W"MU"/\,FM<4)YQ^VB#_UZ[=UT+?TG0[Y:;-?,F$GZ/RTT3
MY4GA0AK+#&!R6!OH(3BEZ+C/4L2,G*?<_@W>3\D:.QO1&#./Y"6:**8#/^Q.
M=^XWJ]4IYHGRFGDK U@CZY-"+B&*.DF.EV(9:E^:5TH\0,K828GC86IO!?2(
MH^M=WB4JI7AEPV^F4BI.\DD*M! \"B>RQ-;.V<&-]0?,3AP;4?NJXBGU2;V4
MZFI1SF_3Z:>A7F-=BYMKQ-R^B>H^:P_FL!TLB ,=N$V=Z5E^XI*436QPB?I[
M,AF7N,]T:$JC?9U<3!@U3D%4*(!+:5220J3B?J:C@R@XU [>7O=R0R>;;!$2
MN$JL/KA.$#*26^ 3]SI*)F+KW.P#I(SCHQT/%K?-80N-='# ?L!O.#_%U22@
MRY9Y P4C"43K6MEK*,*FF)I1,(\EM?;,+M8>U[UOHL@[ET-[2+4#-%P^&#MO
M3715_<V-%2*P C;48< 4@("O!4'D3EH?=69!#/:"[S8QX[KN0^"EC=P[ - '
MT@414-O'OJ0],%ML>LZ<<S6)BFF;N:-H(P507"CP*A?0UAEA0\KM&]4]2M"X
MAJ>1TN]V7FVD@0[@]#><DXQFM10VGTSGTRJ?.E7V@AU>O ZF./#6)E!U[%,4
MU@#)B(*.R"+*UNU[?T+2N+9I&$BUU$('H+HCI$G)P06?*5Q%I%/:9PZ.FP*N
M9*5%=BSDUJ]F[A Q;O9@&. <)ND.[@<O&;BZ&9_PZ(VNW?>\J].+M2!9D-T$
M85 449+E;#"P7)$Q+EP&]8'VE'4/<*DO*GY?S!<W6;GH\WEYYXZ1HPG$1I*Y
MEO=$"%XJ8%C(5H80HVB.H*TH&_?%RR"@:J^1'DZP1[F:2"V"#"4#\U& "LI"
MM$D"*P8+1:,AN=:A_.,4C>QG#X"!G6"VDT(Z@->;^3=<;0HVSMAX,Z?/IN],
M:AUK3LR"P]K>H00#@:$!&:SE(1>E0NMFK0_1,K*?/3RDFBBA S ]O"NB=@R9
M\A"BHEC442P:A(WU_9E.JA0KFK=5/,Q"#>=]#P^G-FKHP,>Z\@Y?DQS/JLE.
MB:FK2ZGG6!;+\U3_I_ =5[]-YXOE=/WC8@M1('OS4\Y>E?V&ZR^+?+7O5A/F
MG5<4E(!0/M;9\PZ<HF@EN((F.<=*;IU>.")[X[Y)'<+;ZQ4;W6P;8OE\VS_'
M.98IG2;D@0AR1D"'5-^#5-?$"0<ZIV0S(O>Y]1N*!T@9MQ)V.#@>)O/=H>//
MH#/'S_7>_E-#KW";;:&]3\G4=)&M;<&3XA"XE"!S=L6BT3&V[AO9SM@-5A$[
MO+%KH8\>O$5<7TO_I,A"2;0]C!8%5"V&BG58$\F&R9")_-"Z1N@& >,^M1\"
M-/O+MX,S[*+4\N)1[/.PFJ8)]U)D:0M$<H-!*9> ,!\A8Z#8VOC,FC]<N)>0
MK<#BGQ)8#I=W!Q;E-A,OI[-3.A<G%$)'*ZT!S,'5YJ81O-8*2O"(R)A-KO5+
M]P=(V2X[QIXR<O81>@?8^3O6H2>8GWVC^.$S_GYZ$G'YKMQY_GJV,:)#6Y(L
MX)4@@9E@P 4>@+OL-C(SKO7LM)T(W YG3^J=U7 *ZA=]YWOI[AMLI=#ZE.DT
M5[+V!(\!/*L-O9AR%J-.H;3.5NQ(XG8(?%(OMX944@<8O/:0]OSM[*T7W[=>
MU/K@I YDX+TB'LDY4.#JA$SCBM-<HHBF]0W!CB2.<W$PWCOE(378 4!O!C1.
MVJA+T!3!<(IV;:A>*@M@D4GG?$[DNXX>,!ZC4+&]JA\-)'>1>P>!Y#:=+]XO
MEAN]K=?+:3S=S"+_M#@K4+X48$3CN4 )FEE1WT8I"H4VI4^AN!RM8&F0P<N'
MD]Y-]>/@0!U#UQW8Q8?8?O8M3&>5P;)8KL(,/V(Z79YU6LC_Z_0L:[B%6":Z
M))U8"I"=1%#",O!HTF:RF_(1B^;-ZP&&9:F#1RK'ANF66V4,S'2PA>Z1Q&5;
M))N"CR%X<L$"'7A.FSKZO>;6R2 %CM:%UK'^(^1T4WD\N#5OI9.GU!3F>NGM
MBR]A_AE7T_G=ICC#%B!OM?!1JH]W%T'[WC&/]#V*H<@HDP(A1:C/L\CVELWK
MFA@-!N$I\!\N MZV)? !W'^J-GV2=2PY:@EU2!BQ*22X(CR8P+0(04J,K9--
M-RGH)M1JA(4'X_;=Y=W!V7E)_9E$JME>S.O^??9]NIKXR+FWSH*IM1]*UB>,
MJA00&)U*,H5D6I^>CQ+4"9;VT/1#H#E8[!U@Z!8/+Q<G83J?%.ME--F#XH6\
MAQS)P;5" =,^.U$OD53KP.->0CK!S.&*OGUU=[#4.X#.M5XUOV'-R$]TMM9R
M%4 J5<O80H0H:&L%X21W: KJ 1M/G1$Q+F0:*/;ACD![2+D#F-SNX7W.A2-J
MK:436UA#,;2-$9PD5FS@1F>IBA:MFZK<3\FX6;KV@&D@[PY0\T##[G-F%$?!
ME=6@'3>@8B'TTQX QU61J$.4S1-CCQ(T;FZ@/8;:2;\'*/V\&_<Y8R485"0W
M$)Z198UD7B,3!7A*4J!R63<? +DU<>.6C0X L4&TT@'<+KW&MV2%W]!?R54,
MC'GE$9+7C#B@K1-J.W F L><?$#-&N/J+A6=W$8UC+_V$W '$"%X+^NPP)=X
M]M\W]Z39/BQFL]>+Y9]AF2>N)FQ]DI!3HAV@/0//; ;IBN?!%NV;/]'>D<1.
M K4]$7'WT?]@ZND ?2\>ZS&::B?1S8RF*"-L:J\BK].:)**W6;'0_'WE8_2,
MWK5N."#LTOEU%ZWLC;"ON)PNZBW <CW4F!#O7& 4=H#Q49+7( W$: 4$Q;(2
M:"66UH9LS]D.0[Z//!JF#M1 -TBZN@%??5H\$)ML-DT,FSNMDUH)N-'H!R2V
M5],U?L3EMVFJK=Z)L@^8%I_GFT\YFU'GDDE,NT0132!WA'L+/B.=%HD^DL?
M2%#-X\EA>1J]=]'14-X5.CHXWV^^&I2RR!QD!JXB!Y6PU*;A=)(XA=JG1-N^
M]62FW5]K#MGNZ&@XW%_N>X/F&R[CHN54K[,!!B]/E^1UG.V&,V=D\\-W7S?E
M_:^^XS)-:2M-O$AH,5,4%Y4FMT32QC#,@@XH= [&,&R=P]V=RM$[,!SWN!].
M@QV8M@<XW)CI^QGDHD[<J Y.0 L*@X>H0WW?CP91*_*G6U])[4SDZ$T9QD9H
M(_UU -"A7W>Z^K34*@LI%@K_LM<053;@DS8^.9ME:%U0V\.+X"%[1AP-_#UA
MHX.M\FC"@_E@36$&G"^Y5@O2ME?&@"Y:I<*0.=<Z47!P&FK('A5]I*%VT<J!
MR8-7\SQ4$DIS9[Q3!5R0'I32!6+R'&)AP02+F%WKSK![)J&&;&0Q9A)J%PTT
MQ=&Q'Y*'U9?7L\6? \^MNF>9XSP2_PE[[9^$7ZYX5>>08BY,$QZ3QSK O3;(
MQP2%)Q9*D4SYUJVP'J.G0>ZF?N;[Y>+;E"3W_,<?)/\W\\NVW<_2>OKMS#>X
M?/], HC"!"A%./*+!0-7F !C5/26>=JQK8/PW:GLY'[P4 3=D_(94ET=>&FW
M2I"#94HS!2SK.B"5_A:L(#^S1)T3UPQ+Z_"CH]+OH;7]>/7W#J+O #<WDO(U
MHSY/TQG>8.G38E=I:IFCM$8!JCHFPYC:0-<*2"YXC8RSPEK7PPS!Q[@7D$=&
M\>A Z& SO$1:.4W/5#S/STYJ%/^?FR\GT4<FHDF0.?&C>&80:O,NK9604?!L
M9.O>L(^0,ZZ!'1\KBV$4UP$&GR4*]39\7&.B]E!:I<5IK6F9Y_=+/)F>GJQN
M=&#64I@8!5A9DTI8ZWV#-,"YL!2J,<-$ZQ-_/TK'-:K=(?<(ZCZT:W(CTQK7
MUQ*F%ZG4UXOEQS##OX7I?.,]"331.)] VU2O\),%9V4$:S@*S%HJW=[*;D/9
MN,\TNH/M .KLI[GWI=#>UIS;A]K3[ETA>3Y;K7!]?9]>3(W(Q@8?,$!$'4 Q
MK(46!H$X5,R9@-FV;O2V*XWC/N_H#K^#JK@#+^+\.=7T/S=9P8V\7BQ6-SB;
M"$^!*0I/H6FFS6EL@LA%!)V1S@_T/NG6531;D#7N,Y#N@-I:D1U@\Z)]]LTW
M?I,LI#&BD'<>;0&EB &GM >OO5=%9E9L:SC>3\FXSSRZ0V #=74 NKLW:9?R
M.M]BE\*JG6>+M1$P%N)," ;1N0(N*IL2>=U&MA_LMBUUXS[#Z Z< ZFU2\!2
MJ+@)"4GN./UV5IXG0Y8),UA7JZ=$S."-<H!&*9V,TMRT?@^_#5V]50.UP<1/
MH7>@@KJ(T^\17GT.=<72:N)5DBY+![D.:U+". C6&_!<EKI9E2NM2\]^3E5O
MQ4)'@MQ!RND4<.^7^#5,\\MSBBX&/\[/ZL\W$=IJX@1M'H$>S.9!= H6/ MU
ME)/EWA0C?/-YF?M1VEM]SY& V5R)G8+UPN:_#S_J!JR7#RDM3VF]:8C3V<;3
MF3CI?5#)0RF,@]*91%M"@4Q16\HLZ>2&!^LVE/96!'3D@[N9$KOT'V_FO"Y8
M^S')P8ID<P+&2BTU3<18SB1+I9A,W%HO6W>]V)JXWHJ"CG6L-U!5EQB\R&']
M?;K^\H)"20H:EU?L<:^0!V9 ;MBC;04..:^/O9C((?I86J> =B2QMQ*@(^&Q
MG=HZ0.7V#VLFF9N B24(6!] RUJ%+VUM(,\$YY)SA@/,W-R2NG$]R^,_LAM"
M:1W,7WF L[/;_@<R9L%JS3RQ)%,B5X3\YL"" 44,>Z9L<<TK(W:GLI,^5D=Z
M2MQ*71W81_*"+YHTI/\XG2[QM[#\!VYJV*ZN_">(KA1E&0AA:9>A,Q XS_2'
M5X4(%SFUS@)M15B73X^;H6,QM*I&#;,W@^%(=@DQ;P9Y_Q;6YTR\*_>R1A%8
M<)QL/8N>U8(G 3%H R4S1KXR_8??ZIIQMVYGYU6[?!?<&F+#ZF)$,W>'L?IB
MZ0&6&/G*,N9 41;204'' D0E ICDI' ^<VGESO!Z>+TN/;K!@=5(_CV>G,0F
M.:CK'^]G83/BLM95?JV_0KYP*5$E#E:RVN:Y<E;(1*?$B%_G.&\^J'U[ZL9-
M XY]AK916A?YZNU%.7$4J3MO+0A#\;LJ!L'I2$Y"#%XE$J(P1RI/O(>Z<=.
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M#++#FFOU!4*H=TX4:25C0]38VBYN1UFW=7F[H.1. 7)[I730/N3]<KI8GK5
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MII :M6O]7JAU%SOZM%I>?SLY7G217 O:-,J08U 0(C%%(!<NI1*$LJUGTCY
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M?V[6>4%06LRF^:+T\3H-[\IK(GV>IF'VD;YSJQ12QB)$<!9*5+41$>/@A++
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MUQ\FSF16L#8PM"G5Y#8=J]H'B-&HDK(B,3S5YFB)Z3\^SK_^9_VX#2CJ5[<
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M:5[&\?RL1HX+VZC_/JC:ZF+L$_'5ZL,G_'M8_!-7;PL-/YU]W&[+V>7"DBB
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MM+8F&#WWV4D+F+!V^(X4!W@*!HS1M>=W=B:W+GYY8!KC'F!'*O8IF!P@Y0Z
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M=Q^S\R.^,13FP^NEA\UUG5=?+B\Q_WBY7A(M;)[7DES^BO]:_XA\>?+6&<=
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MAZK!:KV8W9#_4N]S^\#(2S:6C1?X\WRQ_5;]/3X)*MI<Z5!<*1:41P.1'$%
M)GW6S$5I!ZMB/,D*=S.KEWKWW#&:.K"U8R.N];7+=8#U#UP_V,VOON*"7,KU
M#W^DP_SG,%W\$2XNZ=S67*/R$;APE5B<CNSH+0-#_F56QD==6I=JG'B)NUG;
M2[L&/P<\O0!S^^E/BM>FMU(:ZYWJS6RUF,Z6T[21B4O)98\22JA/;U1,X 4S
M(+3,PJ,51G93[[S'NG8SK']?F9\(.1U8TV!'^ZU7$\L)LY'90!M+*<:0UJ0!
M)Y,$KY.BO8:77%J;TTD6MIL]O=2[^?ZPTX%!';O)_+$1UBS7-$U]_O9A7K^U
MW7MJI<[F?G>B:9MQ'.G89C4BE59#+)5"/>=D15$Y[D;<>L(C:M>U[696_[[X
M/R&">K&L^+Q<XGVY;'HUO9DM5XO+]7.K]1W7AT]AMI78];.4NV?Y1I 3C,A9
M$8XD9!(H)QGX0M&I%P:S59[Q,$CIP.F7NIO=O>@R@\[Q-7:=_L$J>N@Y]\X;
M%><H),\)2GW*JS!FB"Y8D"EYD4L.5N]&!#?*]'>SJI=6CW F<&EF4/_K/[]3
M+PGPG^L?K7]2_Z]W6/YG_>_O[][<^7P2UG06EO^1YI\WG[[94JZ>$,_+J^7R
M\O-F,_F=1+6:_X@T@<^DH>L\SKR$V1W/><.OE.DWP_1B>7?!RRGY[OB<S0PP
MB_^\$<A]46TG\QWX3RX<_'.%LTS'X7'^RH_39;J8+R\7FP>NU_!_AQ?U<K8&
M/LOO#I3EJTC(#VDU24(&ES*O%!<*E.((3AN$F$(JV85Z8=O8[3ANQD?[=\T>
MS',?#0:MP+!,CBUZ!XX% 6@$DTP;X4KSVOY6DQ_WC?@),?N=^S6*^CN(:^Z2
M/G$T)E+P19/7#%1B=-9*FR'K@-E8C%$V[PR]-[O;<)4SXX#@27:W?332 9P.
M%]P3/#HV2?( K0(N8VUME ($:P6XQ+DKCJ=@_LWNMA^[VUZP.@6[VSXZ[@#G
MC],S*2YD$E&"E84"ZNA%K=41P&R1''W.1@Q6SW40I]9YL;KMA9.=.;7V45H/
MW; V7:%4$<G7/J@6:U>7VKRTL !"61:D=ZGLYJ,W;9XV7''?J(?SX9+O 2Y;
ME#/E?&;U<76JEUE)D:NL5 %D3FHK@U>[T8F?6?.T?93U2/.T?20W=@^M.\V_
M2G QTGX&0@I+$N "O'<% KK@K(]%LYW*M<ZO>=I>*GNT>=H^\AM;\7>:?UD,
M42.K5?6!EF^5 H?!0;$E!V.R%*Z%K7?8/.U@Q1\LO_-^J7F3:<>D$VV/F=R>
MVCBV! E>1@L>48=,@@NJ=2'U\;,>F9>KBY3!B77?0?QU\(JOD_*W\O975SI_
MS"_H8RZFJV_OP@JW!\$DLV!\"(KD(2CB2!0;N)PX*29X7T)"#,W)$T^VNLXC
MQ,:X;64VPX+H+V)>V\>IGEMN%"_ >'T(J'(A#RMPL$S[(%"&Q,P9FM<>CYI[
M?@_7NWD= *)>S.N08I^G)/,!%Y_Y1*'+HG+$&I]J.T:6P*7:G=%PZY%GU*9U
M/[KA5G/VG*M'F\_X(.G%7%IM).^FRW_^O,!:#8<$J-7M4SI*6^]%"AAT%.T;
MD< [Q: $(4EB6:/HYG';GFL[>V[7;DZB5@#Z2QC6U?FL9,F*M)54J9U0@B&]
M"00NE$XY\LA,-\\%]ES;V?/ ]FU8!P#HI1G6U=G]X_3K-.,L5[E,)&?.N2#
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MYZ3S0/;U2?G(@E%CX1"9JAT;DP$7C*R=NT.)HCCC3Y[$;[S&#C+\?R'S'!*
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M4>I[& 8'R'+TTE&<!;*/WQ;X=3J_7%Y\>X=?R$'!O+V>XU$DR5EU6F,!)9.
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MW;&T/#Q7P_8']8](WL/__A__'U!+ P04    " !*1Z56Y&"D7V\(   :*
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M#DF"S1? /Y1,X D5)1$-X94B<@)ART@GMR&0\I!K3=4<12;TCD._*VUJ>,=
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MN1+__OX*']%K$PD6%DA)2!J) KTB]9)>0M2[3T]F[04K9KUG>R&\O_[-V$N
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M5C)384?@H$EYY Q$O2F8IABX.8%NC QFR]/PNO%6VWF\<1+#XDXB!,<B@D4
M&XA#LUYJ%TD,O$"QTH7?D<P8Z 24+(6K" @3R"4I!!GQB;B5<@' //;FWM"
M<>9*Z")*9!($ '4*H.&&,\Z>B)H1B:6:FCDD-1\*8Z'^MH3B36\W6%E<0I:9
M&[-F[>L&5WU7P-5?B<1;DP,G3^"X[%4<"[ATT>D1JKG# <15#"3'>!$.X!M(
M848HCF)CH#RD/;QFPD12F0SZ(1EJ)3T@4JTBSN"V(?L0?\8!4#[(W=MH1),A
M)RW@F<M,@H2K%0_W^8'KZFI%O/*7 BN\Q ,1]1,DHR5\>KR@+5L/%*\,%,-
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M\N< F_[!_H2OG8U;E!Z^3EETH0. <&;7NSQRG"[_]B?[W!G#L_\!4$L#!!0
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M,C R,S S,S$N:'1M4$L! A0#%     @ 2D>E5@4T? 2W$0  %L,  !$
M         ( !'8(! &%R=FXM,C R,S S,S$N>'-D4$L! A0#%     @ 2D>E
M5LL6'3UI&   LNH  !4              ( ! Y0! &%R=FXM,C R,S S,S%?
M8V%L+GAM;%!+ 0(4 Q0    ( $I'I59WK)]%]44  'X> P 5
M  "  9^L 0!A<G9N+3(P,C,P,S,Q7V1E9BYX;6Q02P$"% ,4    " !*1Z56
MLTN^-#S.   MN @ %0              @ ''\@$ 87)V;BTR,#(S,#,S,5]L
M86(N>&UL4$L! A0#%     @ 2D>E5BA,C\/R>@  0XT% !4
M ( !-L$" &%R=FXM,C R,S S,S%?<')E+GAM;%!+ 0(4 Q0    ( $I'I5;D
M8*1?;P@  !HH   :              "  5L\ P!A<G9N+3(P,C,P,S,Q>#$P
M<65X,S$Q+FAT;5!+ 0(4 Q0    ( $I'I58._H<M;P@  +XH   :
M      "  0)% P!A<G9N+3(P,C,P,S,Q>#$P<65X,S$R+FAT;5!+ 0(4 Q0
M   ( $I'I58:A3\_ZP0  ((3   :              "  :E- P!A<G9N+3(P
M,C,P,S,Q>#$P<65X,S(Q+FAT;5!+ 0(4 Q0    ( $I'I58^=OACUP0  -@2
M   :              "  <Q2 P!A<G9N+3(P,C,P,S,Q>#$P<65X,S(R+FAT
7;5!+!08     "@ * *H"  #;5P,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
